Quinazolines as potassium ion channel inhibitors

ABSTRACT

A compound of formula I 
     
       
         
         
             
             
         
       
     
     wherein A, X, Y, Z, R 1  and R 24  are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, I Kur -associated disorders, and other disorders mediated by ion channel function.

RELATED APPLICATION

This application is a continuation of U.S. application Ser. No.15/249,710, filed Aug. 29, 2016 (now allowed) which is a continuation ofU.S. application Ser. No. 14/038,814, filed Sep. 27, 2013, U.S. Pat. No.9,458,114, which is a continuation of U.S. application Ser. No.13/393,328 filed Feb. 29, 2012, which was the National Stage ofInternational Application No. PCT/US2010/047430, filed on Sep. 1, 2010,which claims the benefit of U.S. Provisional Application No. 61/239,452,filed on Sep. 3, 2009, each incorporated herein by reference in itsentirety.

FIELD OF THE INVENTION

The present invention provides for quinazolines useful as inhibitors ofpotassium channel function (especially inhibitors of the K_(v)1subfamily of voltage gated K⁺ channels, more especially inhibitors ofK_(v)1.5 (which have been linked to the ultra-rapidly activating delayedrectifier K⁺ current I_(Kur)), and/or K_(v)1.3 channels, and/or K_(v)1.1channels) and to pharmaceutical compositions containing such compounds.The present invention further provides for methods of using suchcompounds in the treatment and prevention of arrhythmia,I_(Kur)-associated disorders, and other disorders mediated by ionchannel function.

BACKGROUND OF THE INVENTION

The ultra-rapidly activating delayed rectifier K⁺ current (I_(Kur)) isbelieved to represent the native counterpart to a cloned potassiumchannel designated K_(v)1.5 and, while present in human atrium, itappears to be absent in human ventricle. Furthermore, because of itsrapidity of activation and limited slow inactivation, I_(Kur) isbelieved to contribute significantly to repolarization in human atrium.Consequently, a specific blocker of I_(Kur), that is a compound whichblocks K_(v)1.5, would overcome the short coming of other compounds byprolonging refractoriness by retarding repolarization in the humanatrium without causing the delays in ventricular repolarization thatunderlie arrhythmogenic after depolarizations and acquired long QTsyndrome observed during treatment with current Class III antiarrhythmicagents. (Antiarrhythmic agents of Class III are drugs that cause aselective prolongation of the duration of the action potential withoutsignificant cardiac depression.)

Immunoregulatory abnormalities have been shown to exist in a widevariety of autoimmune and chronic inflammatory diseases, includingsystemic lupus erythematosis, chronic rheumatoid arthritis, type I andII diabetes mellitus, inflammatory bowel disease, biliary cirrhosis,uveitis, multiple sclerosis and other disorders such as Crohn's disease,ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis,ichthyosis, Graves ophthalmopathy and asthma. Although the underlyingpathogenesis of each of these conditions may vary, they have in commonthe appearance of a variety of auto-antibodies and self-reactivelymphocytes. Such self-reactivity may be due, in part, to a loss of thehomeostatic controls under which the normal immune system operates.Similarly, following a bone-marrow or an organ transplantation,lymphocytes recognize the foreign tissue antigens and begin to produceimmune mediators which lead to graft rejection or graft-vs-hostrejection.

One end result of an autoimmune or a rejection process is tissuedestruction caused by inflammatory cells and the mediators they release.Anti-inflammatory agents such as NSAIDs act principally by blocking theeffect or secretion of these mediators but do nothing to modify theimmunologic basis of the disease. On the other hand, cytotoxic agents,such as cyclophosphamide, act in such a nonspecific fashion in whichboth the normal and autoimmune responses are shut off. Indeed, patientstreated with such nonspecific immunosuppressive agents are as likely tosuccumb to infection as they are to their autoimmune disease.

Cyclosporin A, which was approved by the US FDA in 1983 is currently theleading drug used to prevent rejection of transplanted organs. In 1993,FK-506 (PROGRAF®) was approved by the US FDA for the prevention ofrejection in liver transplantation. Cyclosporin A and FK-506 act byinhibiting the body's immune system from mobilizing its vast arsenal ofnatural protecting agents to reject the transplant's foreign protein. In1994, Cyclosporin A was approved by the US FDA for the treatment ofsevere psoriasis and has been approved by European regulatory agenciesfor the treatment of atopic dermatitis. Though these agents areeffective in fighting transplant rejection, Cyclosporin A and FK-506 areknown to cause several undesirable side effects includingnephrotoxicity, neurotoxicity, and gastrointestinal discomfort.Therefore, a selective immunosuppressant without these side effectsstill remains to be developed. Potassium channel inhibitors as describedhere promise to be the solution to this problem, since inhibitors ofK_(v)1.3, for example, are immunosuppressive. See Wulff et al.,“Potassium channels as therapeutic targets for autoimmune disorders,”Curr. Opin. Drug Discov. Devel., 6(5):640-647 (September 2003); Shah etal., “Immunosuppressive effects of a K_(v)1.3 inhibitor,” Cell Immunol.,221(2):100-106 (February 2003); Hanson et al., “UK-78,282, a novelpiperidine compound that potently blocks the K_(v)1.3 voltage-gatedpotassium channel and inhibits human T cell activation,” Br. J.Pharmacol., 126(8):1707-1716 (April 1999).

Inhibitors of K_(v)1.5 and other K_(v)1.x channels stimulategastrointestinal motility. Thus, the compounds of the invention arebelieved to be useful in treating motility disorders such as refluxesophagitis. See Frey et al., “Blocking of cloned and native delayedrectifier K channels from visceral smooth muscles by phencyclidine,”Neurogastroenterol. Motil., 12(6):509-516 (December 2000); Hatton etal., “Functional and molecular expression of a voltage-dependent K(+)channel (K_(v)1.1) in interstitial cells of Cajal,” J Physiol., 533 (Pt2):315-327 (Jun. 1, 2001); Vianna-Jorge et al., “Shaker-type K_(v)1channel blockers increase the peristaltic activity of guinea-pig ileumby stimulating acetylcholine and tachykinins release by the entericnervous system,” Br. J. Pharmacol., 138(1):57-62 (January 2003); Koh etal., “Contribution of delayed rectifier potassium currents to theelectrical activity of murine colonic smooth muscle,” J. Physiol., 515(Pt. 2):475-487 (Mar. 1, 1999).

Inhibitors of K_(v)1.5 relax pulmonary artery smooth muscle. Thus, thecompounds of the invention are believed to be useful in treatinghypertension and otherwise improving vascular health. See Davies et al.,“K_(v) channel subunit expression in rat pulmonary arteries,” Lung,179(3):147-161 (2001), Epub. Feb. 4, 2002; Pozeg et al., “In vivo genetransfer of the O2-sensitive potassium channel K_(v)1.5 reducespulmonary hypertension and restores hypoxic pulmonary vasoconstrictionin chronically hypoxic rats,” Circulation, 107(15):2037-2044 (Apr. 22,2003), Epub. Apr. 14, 2003.

Inhibitors of K_(v)1.3 increase insulin sensitivity. Hence, thecompounds of the invention are believed to be useful in treatingdiabetes. See Xu et al., “The voltage-gated potassium channel K_(v)1.3regulates peripheral insulin sensitivity,” Proc. Natl. Acad. Sci.U.S.A., 101(9):3112-3117 (Mar. 2, 2004), Epub. Feb. 23, 2004; MacDonaldet al., “Members of the K_(v)1 and K_(v)2 voltage-dependent K(+) channelfamilies regulate insulin secretion,” Mol. Endocrinol., 15(8):1423-1435(August 2001); MacDonald et al., “Voltage-dependent K(+) channels inpancreatic beta cells: role, regulation and potential as therapeutictargets,” Diabetologia, 46(8):1046-1062 (August 2003), Epub. Jun. 27,2003.

Stimulation of K_(v)1.1 is believed to reduce seizure activity byhyperpolarizing neurons. Thus, the compounds of the invention arebelieved to be useful in treating seizures, including seizuresassociated with epilepsy and other neurological diseases. See Rho etal., “Developmental seizure susceptibility of kv1.1 potassium channelknockout mice,” Dev. Neurosci., 21(3-5):320-327 (November 1999); Colemanet al., “Subunit composition of K_(v)1 channels in human CNS,” J.Neurochem., 73(2):849-858 (August 1999); Lopantsev et al.,“Hyperexcitability of CA3 pyramidal cells in mice lacking the potassiumchannel subunit K_(v)1.1,” Epilepsia, 44(12):1506-1512 (December 2003);Wickenden, “Potassium channels as anti-epileptic drug targets,”Neuropharmacology, 43(7): 1055-1060 (December 2002).

Inhibition of K_(v)1.x channels improves cognition in animal models.Thus, the compounds of the invention are believed to be useful inimproving cognition and/or treating cognitive disorders. See Cochran etal., “Regionally selective alterations in local cerebral glucoseutilization evoked by charybdotoxin, a blocker of centralvoltage-activated K+-channels,” Eur. J. Neurosci., 14(9): 1455-1463(November 2001); Kourrich et al., “Kaliotoxin, a K_(v)1.1 and K_(v)1.3channel blocker, improves associative learning in rats,” Behav. BrainRes., 120(1):35-46 (Apr. 8, 2001).

SUMMARY OF THE INVENTION

In accordance with the present invention, acyclic compounds and relatedcompounds are provided that have the general structure of formula I:

wherein A, X, Y, Z, R₁ and R₂₄ are defined below.

By use of a respective effective amount of at least one compounddescribed herein, provided are methods of treating (includingameliorating) or preventing arrhythmias, atrial fibrillation, atrialflutter, supraventricular arrhythmias, gastrointestinal disorders (suchas reflux esauphagitis or a motility disorder), inflammatory orimmunological disease (such as chronic obstructive pulmonary disease),diabetes, cognitive disorders, migraine, epilepsy, hypertension, ortreating I_(Kur)-associated conditions, or controlling heart rate.

Also provided are pharmaceutical compositions comprising atherapeutically effective amount of at least one compound describedherein and a pharmaceutically acceptable vehicle or carrier thereof.Such compositions can further comprise one or more other agent(s). Forexample, at least one other anti-arrhythmic agent (such as sotalol,dofetilide, diltiazem or Verapamil), or at least one calcium channelblocker, or at least one anti-platelet agent (such as clopidogrel,cangrelor, ticlopidine, CS-747, ifetroban and aspirin), or at least oneanti-hypertensive agent (such as a beta adrenergic blocker, ACEinhibitor (e.g., captopril, zofenopril, fosinopril, enalapril,ceranopril, cilazopril, delapril, pentopril, quinapril, ramipril, orlisinopril), A II antagonist, ET antagonist, Dual ET/A II antagonist, orvasopepsidase inhibitor (e.g., omapatrilat or gemopatrilat)), or atleast one anti thrombotic/anti thrombolytic agent (such as tPA,recombinant tPA, TNK, nPA, factor VIIa inhibitors, factor Xa inhibitors(such as razaxaban), factor XIa inhibitors or thrombin inhibitors), orat least one anti coagulant (such as warfarin or a heparin), or at leastone HMG-CoA reductase inhibitor (pravastatin, lovastatin, atorvastatin,simvastatin, NK-104 or ZD-4522), or at least one anti diabetic agent(such as a biguanide or a biguanide/glyburide combination), or at leastone thyroid mimetic, or at least one mineralocorticoid receptorantagonist (such as spironolactone or eplerinone), or at least onecardiac glycoside (such as digitalis or ouabain).

Definitions

The terms “alk” or “alkyl” refer to straight or branched chainhydrocarbon groups having 1 to 12 carbon atoms, or 1 to 8 carbon atoms,such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl,pentyl, hexyl, heptyl, octyl, or any subset of the foregoing. The term“substituted alkyl” refers to alkyl groups substituted with one or moregroups (such as by groups described above in the definition of R¹⁰),such as selected from aryl, substituted aryl, heterocyclo, substitutedheterocyclo, carbocyclo, substituted carbocyclo, halo, hydroxy, alkoxy(optionally substituted), aryloxy (optionally substituted), alkylester(optionally substituted), arylester (optionally substituted), alkanoyl(optionally substituted), aryol (optionally substituted), cyano, nitro,amino, substituted amino, amido, lactam, urea, urethane and sulfonyl, orany subset of the foregoing.

The term “alkenyl” refers to straight or branched chain hydrocarbongroups having 2 to 12 carbon atoms, or 2 to 4 carbon atoms, and at leastone double carbon to carbon bond (either cis or trans), such as ethenyl.The term “substituted alkenyl” refers to alkenyl groups substituted withone or more groups (such as by groups described above in the definitionof R¹⁰), such as selected from aryl, substituted aryl, heterocyclo,substituted heterocyclo, carbocyclo, substituted carbocyclo, halo,hydroxy, alkoxy (optionally substituted), aryloxy (optionallysubstituted), alkylester (optionally substituted), arylester (optionallysubstituted), alkanoyl (optionally substituted), aryol (optionallysubstituted), cyano, nitro, amino, substituted amino, amido, lactam,urea, urethane and sulfonyl, or any subset of the foregoing.

The term “alkynyl” refers to straight or branched chain hydrocarbongroups having 2 to 12 carbon atoms, or 2 to 4 carbon atoms, and at leastone triple carbon to carbon bond, such as ethynyl. The term “substitutedalkynyl” refers to alkynyl groups substituted with one or more groups(such as by groups described above in the definition of R¹⁰), such asselected from aryl, substituted aryl, heterocyclo, substitutedheterocyclo, carbocyclo, substituted carbocyclo, halo, hydroxy, alkoxy(optionally substituted), aryloxy (optionally substituted), alkylester(optionally substituted), arylester (optionally substituted), alkanoyl(optionally substituted), aryol (optionally substituted), cyano, nitro,amino, substituted amino, amido, lactam, urea, urethane and sulfonyl, orany subset of the foregoing.

The term “aryl” refers to aromatic homocyclic (i.e., hydrocarbon) mono-,bi- or tricyclic ring-containing groups such as having 6 to 12 memberssuch as phenyl, naphthyl and biphenyl. Phenyl is an example of an arylgroup. The term “substituted aryl” refers to aryl groups substitutedwith one or more groups (such as by groups described above in thedefinition of R¹⁰), such as selected from alkyl, substituted alkyl,alkenyl (optionally substituted), aryl (optionally substituted),heterocyclo (optionally substituted), halo, hydroxy, alkoxy (optionallysubstituted), aryloxy (optionally substituted), alkanoyl (optionallysubstituted), aroyl, (optionally substituted), alkylester (optionallysubstituted), arylester (optionally substituted), cyano, nitro, amino,substituted amino, amido, lactam, urea, urethane and sulfonyl, or anysubset of the foregoing, where optionally one or more pair ofsubstituents together with the atoms to which they are bonded form a 3to 7 member ring.

The term “cycloalkyl” refers to mono-, bi- or tri homocyclic ring groupsof 3 to 15 carbon atoms which are, respectively, fully saturated andpartially unsaturated. The rings of multi-ring cycloalkyl groups may befused, bridged and/or joined through one or more spiro unions. The term“substituted cycloalkyl” refers to a cycloalkyl group substituted withone or more groups (such as by groups described above in the definitionof R¹⁰), such as selected from aryl, substituted aryl, heterocyclo,substituted heterocyclo, carbocyclo, substituted carbocyclo, halo,hydroxy, alkoxy (optionally substituted), aryloxy (optionallysubstituted), alkylester (optionally substituted), arylester (optionallysubstituted), alkanoyl (optionally substituted), aryol (optionallysubstituted), cyano, nitro, amino, substituted amino, amido, lactam,urea, urethane and sulfonyl, or any subset of the foregoing.

The terms “halogen” and “halo” refer to fluorine, chlorine, bromine andiodine.

The terms “heterocycle”, “heterocyclic”, “heterocyclic group” or“heterocyclo” refer to fully saturated or partially or completelyunsaturated, including aromatic (“heteroaryl”) or nonaromatic cyclicgroups (for example, 3 to 13 ring member monocyclic, 7 to 17 ring memberbicyclic, or 10 to 20 ring member tricyclic ring systems, such as, incertain embodiments, a monocyclic or bicyclic ring containing a total of3 to 10 ring atoms) which have at least one heteroatom in at least onecarbon atom-containing ring. Each ring of the heterocyclic groupcontaining a heteroatom may have 1, 2, 3 or 4 heteroatoms selected fromnitrogen atoms, oxygen atoms and/or sulfur atoms, where the nitrogen andsulfur heteroatoms may optionally be oxidized and the nitrogenheteroatoms may optionally be quaternized. The heterocyclic group may beattached at any heteroatom or carbon atom of the ring or ring system.The rings of multi-ring heterocycles may be fused, bridged and/or joinedthrough one or more spiro unions.

Exemplary monocyclic heterocyclic groups include azetidinyl,pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl,imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl,isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl,isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl,piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl,2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, pyridyl,pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, tetrahydropyranyl,tetrazoyl, triazolyl, morpholinyl, thiamorpholinyl, thiamorpholinylsulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane andtetrahydro-1,1-dioxothienyl,

and the like.

Exemplary bicyclic heterocyclic groups include indolyl, benzothiazolyl,benzoxazolyl, benzothienyl, quinuclidinyl, quinolinyl,tetra-hydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl,indolizinyl, benzofuryl, benzofuranyl, dihydrobenzofuranyl, chromonyl,coumarinyl, benzodioxolyl, dihydrobenzodioxolyl, benzodioxinyl,cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (suchas furo[2,3-c]pyridinyl, furo[3,2-b]pyridinyl] or furo[2,3-b]pyridinyl),dihydroisoindolyl, dihydroquinazolinyl (such as3,4-dihydro-4-oxo-quinazolinyl), tetrahydroquinolinyl, azabicycloalkyls(such as 6-azabicyclo[3.2.1]octane), azaspiroalkyls (such as 1,4dioxa-8-azaspiro[4.5]decane), imidazopyridinyl (such asimidazo[1,5-a]pyridin-3-yl), triazolopyridinyl (such as1,2,4-triazolo[4,3-a]pyridin-3-yl), and hexahydroimidazopyridinyl (suchas 1,5,6,7,8,8a-hexahydroimidazo[1,5-a]pyridin-3-yl),

and the like.

Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl,phenanthrolinyl, acridinyl, phenanthridinyl, xanthenyl and the like.

The terms “substituted heterocycle”, “substituted heterocyclic”,“substituted heterocyclic group” and “substituted heterocyclo” refer toheterocycle, heterocyclic and heterocyclo groups substituted with one ormore groups (such as by groups described above in the definition ofR¹⁰), such as selected from alkyl, substituted alkyl, alkenyl, oxo,aryl, substituted aryl, heterocyclo, substituted heterocyclo, carbocyclo(optionally substituted), halo, hydroxy, alkoxy (optionallysubstituted), aryloxy (optionally substituted), alkanoyl (optionallysubstituted), aroyl (optionally substituted), alkylester (optionallysubstituted), arylester (optionally substituted), cyano, nitro, amido,amino, substituted amino, lactam, urea, urethane, sulfonyl, or anysubset of the foregoing, where optionally one or more pair ofsubstituents together with the atoms to which they are bonded form a 3to 7 member ring.

The term “alkanoyl” refers to alkyl group (which may be optionallysubstituted as described above) linked to a carbonyl group (i.e.,—C(O)-alkyl). Similarly, the term “aroyl” refers to an aryl group (whichmay be optionally substituted as described above) linked to a carbonylgroup (i.e., —C(O)-aryl).

Throughout the specification, groups and substituents thereof may bechosen to provide stable moieties and compounds.

The compounds described herein form salts or solvates which are alsowithin the scope of this invention. Reference to a compound describedherein is understood to include reference to salts thereof, unlessotherwise indicated. The term “salt(s)”, as employed herein, denotesacidic and/or basic salts formed with inorganic and/or organic acids andbases. In addition, when a compound described herein contains both abasic moiety and an acidic moiety, zwitterions (“inner salts”) may beformed and are included within the term “salt(s)” as used herein.Pharmaceutically acceptable (i.e., non-toxic, physiologicallyacceptable) salts are preferred, although other salts are also useful,e.g., in isolation or purification steps which may be employed duringpreparation. Salts of the compounds described herein may be formed, forexample, by reacting a compound with an amount of acid or base, such asan equivalent amount, in a medium such as one in which the saltprecipitates or in an aqueous medium followed by lyophilization.

The compounds described herein which contain a basic moiety may formsalts with a variety of organic and inorganic acids. Exemplary acidaddition salts include acetates (such as those formed with acetic acidor trihaloacetic acid, for example, trifluoroacetic acid), adipates,alginates, ascorbates, aspartates, benzoates, benzenesulfonates,bisulfates, borates, butyrates, citrates, camphorates,camphorsulfonates, cyclopentanepropionates, digluconates,dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates,glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides(formed with hydrochloric acid), hydrobromides (formed with hydrogenbromide), hydroiodides, 2-hydroxyethanesulfonates, lactates, maleates(formed with maleic acid), methanesulfonates (formed withmethanesulfonic acid), 2-naphthalenesulfonates, nicotinates, nitrates,oxalates, pectinates, persulfates, 3-phenylpropionates, phosphates,picrates, pivalates, propionates, salicylates, succinates, sulfates(such as those formed with sulfuric acid), sulfonates (such as thosementioned herein), tartrates, thiocyanates, toluenesulfonates such astosylates, undecanoates, and the like.

The compounds described herein which contain an acidic moiety may formsalts with a variety of organic and inorganic bases. Exemplary basicsalts include ammonium salts, alkali metal salts such as sodium,lithium, and potassium salts, alkaline earth metal salts such as calciumand magnesium salts, salts with organic bases (for example, organicamines) such as benzathines, dicyclohexylamines, hydrabamines (formedwith N,N-bis(dehydroabietyl)ethylenediamine), N-methyl-D-glucamines,N-methyl-D-glucamides, t-butyl amines, and salts with amino acids suchas arginine, lysine and the like.

Basic nitrogen-containing groups may be quaternized with agents such aslower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides,bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl,dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl,myristyl and stearyl chlorides, bromides and iodides), aralkyl halides(e.g., benzyl and phenethyl bromides), and others.

Any compound that can be converted in vivo to provide the bioactiveagent (i.e., the compound of formula I) is a prodrug within the scopeand spirit of the invention.

The term “prodrugs” as employed herein includes esters and carbonatesformed by reacting one or more hydroxyls of compounds of formula I withalkyl, alkoxy, or aryl substituted acylating agents employing proceduresknown to those skilled in the art to generate acetates, pivalates,methylcarbonates, benzoates, and the like.

Various forms of prodrugs are well known in the art and are describedin:

-   a) Wermuth, C. G. et al., The Practice of Medicinal Chemistry,    Chapter 31, Academic Press (1996);-   b) Design of Prodrugs, H. Bundgaard, ed., Elsevier (1985);-   c) Bundgaard, H., Chapter 5, “Design and Application of Prodrugs,” A    Textbook of Drug Design and Development, pp. 113-191, P.    Krosgaard-Larsen et al., eds., Harwood Academic Publishers (1991);    and-   d) Testa, B. et al., Hydrolysis in Drug and Prodrug Metabolism,    Wiley-VCH (2003).

In addition, compounds described herein are, subsequent to theirpreparation, preferably isolated and purified to obtain a compositioncontaining an amount by weight equal to or greater than 99% of thecompound described herein (“substantially pure” compound), which is thenused or formulated as described herein. Such “substantially pure”compounds described herein are also contemplated herein as part of thepresent invention.

To the extent that compounds described herein, and salts thereof, mayexist in their tautomeric form, all such tautomeric forms arecontemplated herein as part of the present invention.

All stereoisomers of the present compounds, such as those which mayexist due to asymmetric carbons on the various substituents, includingenantiomeric forms (which may exist even in the absence of asymmetriccarbons) and diastereomeric forms are contemplated within the scope ofthis invention. Individual stereoisomers of the compounds of theinvention may, for example, be substantially free of other isomers, ormay be admixed, for example, as racemates or with all other, or otherselected, stereoisomers.

The terms “including”, “such as”, “for example” and the like areintended to refer to exemplary embodiments and not to limit the scope ofthe present invention.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, compounds of formula I areprovided

or enantiomers, diastereomers, tautomers, prodrugs or salts thereofwherein:

X is H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl,C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₁₀ cycloalkyl, a 4- to 12-memberedheteroaryl, 4- to 12-membered heterocyclyl, —CN, —NO₂, —NR₁₁SO₂R₁₂,—SO₂NR₁₁R₁₂, —CONR₁₁R₁₂, —NR₁₁CONR₁₁R₁₂, —NCOR₁₁, —NR₁₁SO₂NR₁₁R₁₂,—OCONR₁₁R₁₂, —CO₂R₁₁ or —NR₁₁R₁₂;

Y is H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl,C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₁₀ cycloalkyl, a 4- to 12-memberedheteroaryl, 4- to 12-membered heterocyclyl, —CN, —NO₂, —NR₁₁SO₂R₁₂,—SO₂NR₁₁R₁₂, —CONR₁₁R₁₂, —NR₁₁CONR₁₁R₁₂, —NCOR₁₁, —NR₁₁SO₂NR₁₁R₁₂,—OCONR₁₁R₁₂, —CO₂R₁₁ or —NR₁₁R₁₂;

Z is H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl,C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₁₀ cycloalkyl, a 4- to 12-memberedheteroaryl, 4- to 12-membered heterocyclyl, —CN, —NO₂, —NR₁₁SO₂R₁₂,—SO₂NR₁₁R₁₂, —CONR₁₁R₁₂, —NR₁₁CONR₁₁R₁₂, —NCOR₁₁, —NR₁₁SO₂NR₁₁R₁₂,—OCONR₁₁R₁₂, —CO₂R₁₁ or —NR₁₁R₁₂;

A is —(CH₂)_(m)—R₂, —CH(R₂₅)(R₂₆), —(CH₂)_(m)—C(O)—R_(2a),—CH(R₂₆)—CO₂—R_(2a) or —(CH₂)_(n-1)—NR₂₅—CO₂—R₂₄;

m is 0 to 4;

n is 1 to 4;

n−1 is 2 to 4;

R₁ is —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, haloC₁₋₁₀ alkyl, C₂₋₁₂ alkenyl,C₃₋₁₀ cycloalkyl, —CN, —(CH₂)_(m)—SO₂R₁₁, —(CH₂)_(n)—SO₂NR₁₁R₁₂,—(CH₂)_(n)—CO₂R₁₁ or —(CH₂)_(n)—NR₁₁SO₂R₁₂, wherein the alkenyl andcycloalkyl may be optionally substituted with one or more R₁₃'s; or

R₁ is a 4- to 12-membered heteroaryl or 4- to 12-membered heterocyclyl,wherein: (i) the heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(13a), R_(13b), R_(13c), R_(13d),R_(13e), R_(13f), R_(13g), R_(13h), R_(13hh), R_(13j), R_(13m),R_(13m-1), R_(13n-1), R_(13p), R_(13p-1), R_(13q) and R_(13q-1); (ii)the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or4 heteroatoms independently selected from the group consisting of N, S,or O; and (iii) the heteroaryl and heterocyclyl are connected to thequinazolinyl ring via a carbon atom; or

R₁ is phenyl, which may be optionally substituted with one or moreR_(13aa), R_(13bb), R_(13cc), R_(13dd), and R_(13ee);

R₂ is C₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ cycloalkenyl or —NR₁₄R₁₄,wherein the cycloalkyl may be optionally substituted with one or moreR₁₃'s or R_(13bb)'s and the cycloalkenyl may be optionally substitutedwith one or more R_(13b)'s; provided that R₂ is not —NR₁₄R₁₄ when m is0, 1 or 3; or

R₂ is C₆₋₁₀ aryl, which is optionally substituted with one or moreR_(13a-1), R_(13b-1), R_(13c-1), R_(13d-1) and R_(13e-1); or

R₂ is a 4- to 12-membered heteroaryl or 4- to 12-membered heterocyclyl,both of which are optionally substituted with one or more R_(13a-2),R_(13b-2), R_(13c-2), R_(13d-2), R_(13e-2), R_(13g-2), R_(13a-4),R_(13b-4), R_(13c-4), R_(13d-4), R_(13b-5), R_(13c-5), R_(13h-1),R_(13hh-1), R_(13hh-2), R_(13m-1), R_(13n-1), R_(13n-2), R_(13p-1),R_(13p-2), R_(13q-1), and R_(13q-2S); and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(2a) is C₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, —NR₁₄R₁₄, a 4- to12-membered heteroaryl or 4- to 12-membered heterocyclyl, any of whichis optionally substituted with one or more R₁₃'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₁₁ and R₁₂, at each occurrence, are independently selected from H,C₁₋₁₀ alkyl, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl and a 4- to 12-membered heterocyclyl, wherein thealkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R₁₃'s and the heteroaryl and heterocyclylconsist of carbon atoms and 1, 2, 3, or 4 heteroatoms independentlyselected from the group consisting of N, S, or O; or

R₁₁ and R₁₂ are taken together with the nitrogen to which they areattached to form a 4- to 12-membered heterocyclyl, wherein theheterocyclyl may be optionally substituted with one or more R₁₃'s andthe heterocyclyl consists of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₁₃, at each occurrence, is independently H, —OH, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO; provided that when R₁₃ is alkyl substituted with one R_(14a), R_(14a)is not —OH;

R_(13a), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13aa), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13a-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13a-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13a-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13b), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13bb), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13b-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13b-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13b-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13b-5), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13c), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(n)—OCONR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₂₆, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄,—CONR₁₄OR₁₄ or —NCOR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy,aryl, heteroaryl and heterocyclyl may be optionally substituted with oneor more R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13cc), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄, or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13c-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13c-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13c-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13c-5), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13d), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13dd), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13d-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13d-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13d-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13e), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13ee), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13e-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13e-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13f), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13g), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13g-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13h), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13h-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13hh), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13hh-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13hh-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13j), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13m), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13m-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13n-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13p), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13p-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13p-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13q), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13q-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13q-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R₁₄, at each occurrence, is independently selected from hydrogen, C₁₋₁₀alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, a 4- to 12-membered heteroaryl or a4- to 12-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with beoptionally substituted with 0-3 R_(14a) and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; or

two R₁₄'s are taken together with the atoms to which they are attachedto form a cyclic ring, wherein the cyclic ring may be optionallysubstituted with one or more R_(24a)'s and optionally contain 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(14a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, F, Cl, Br, I,—CN, —NO₂, —CO₂H, —CO₂R₂₆, —OCONR₂₄R₂₄, —CO₂NR₂₄R₂₄, —OCF₃, —OR₂₅, ═O,—CONR₂₄R₂₄, —COR₂₄, —SO₂R₂₄, —NR₂₄R₂₄, —NR₂₄CO₂R₂₄, —SO₂NR₂₄R₂₄, orC₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consist ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, S, or O;

R₂₄, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the alkyl, aryl, heteroaryland heterocyclyl may be optionally substituted with one or moreR_(24a)'s and the heteroaryl and heterocyclyl consist of carbon atomsand 1, 2, 3, or 4 heteroatoms independently selected from the groupconsisting of N, S, or O; or

two R₂₄'s are taken together with the atoms to which they are attachedto form a cyclic ring, wherein the cyclic ring may be optionallysubstituted with one or more R_(24a)'s and optionally contain 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(24a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, —CN, —NO₂,—CO₂R₂₅, —OCF₃, —OR₂₅, ═O, —CONR₂₅R₂₅, —COR₂₅, —NR₂₅R₂₅, —NR₂₅CO₂R₂₅, orC₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consist ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, S, or O;

R₂₅, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; and

R₂₆, at each occurrence, is independently selected from C₁₋₁₀alkyl,haloC₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-memberedheteroaryl or 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O.

In one embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula I, are provided wherein R₁ is a 4-to 12-membered heteroaryl or 4- to 12-membered heterocyclyl, wherein:(i) the heteroaryl and heterocyclyl may be optionally substituted withone or more R_(13a), R_(13b), R_(13c), R_(13d), R_(13e), R_(13f),R_(13g), R_(13h), R_(13hh), R_(13j), R_(13m), R_(13m-1), R_(13n-1),R_(13p), R_(13p-1), R_(13q) and R_(13q-1); (ii) the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; and(iii) the heteroaryl and heterocyclyl are connected to the quinazolinylring via a carbon atom.

In another embodiments of the invention, compounds, enantiomers,diastereomers, tautomers, prodrugs or salts thereof, of formula I, areprovided wherein R₁ is —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, haloC₁₋₁₀ alkyl,C₂₋₁₂ alkenyl, C₃₋₁₀ cycloalkyl, —CN, —(CH₂)_(m)—SO₂R₁₁,—(CH₂)_(n)—SO₂NR₁₁R₁₂, —(CH₂)_(n)—CO₂R₁₁ or —(CH₂)_(n)—NR₁₁SO₂R₁₂,wherein the alkenyl and cycloalkyl may be optionally substituted withone or more R₁₃'s.

In yet another embodiment, compounds, enantiomers, diastereomers,tautomers, prodrugs or salts thereof, of formula I, are provided whereinR₂ is C₆₋₁₀ aryl, which is optionally substituted with one or moreR_(13a-1), R_(13b-1), R_(13c-1), R_(13d-1) and R_(13e-1).

In still yet another embodiment, compounds, enantiomers, diastereomers,tautomers, prodrugs or salts thereof, of formula I, are provided whereinR₂ is a 4- to 12-membered heteroaryl or 4- to 12-membered heterocyclyl,both of which are optionally substituted with one or more R_(13a-2),R_(13b-2), R_(13c-2), R_(13d-2), R_(13e-2), R_(13g-2), R_(13a-4),R_(13b-4), R_(13c-4), R_(13d-4), R_(13b-5), R_(13c-5), R_(13h-1),R_(13hh-1), R_(13hh-2), R_(13m-1), R_(13n-1), R_(13n-2), R_(13p-1),R_(13p-2), R_(13q-1), and R_(13q-2S); and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O.

In one embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula I, are provided wherein R₂ is a 4-to 12-membered heteroaryl or 4- to 12-membered heterocyclyl, both ofwhich are optionally substituted with one or more R_(13a-2), R_(13b-2),R_(13c-2), R_(13d-2), R_(13e-2), R_(13g-2), R_(13a-4), R_(13b-4),R_(13c-4), R_(13d-4), R_(13b-5), R_(13c-5), R_(13h-1), R_(13hh-1),R_(13hh-2), R_(13m-1), R_(13n-1), R_(13n-2), R_(13p-1), R_(13p-2),R_(13q-1), and R_(13q-2S); and the heteroaryl and heterocyclyl consistof carbon atoms and at least one N heteroatom.

In yet another embodiment, compounds, enantiomers, diastereomers,tautomers, prodrugs or salts thereof, of formula I, are providedwherein:

X is H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl,C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₁₀ cycloalkyl, a 4- to 12-memberedheteroaryl, 4- to 12-membered heterocyclyl, —CN, —NO₂, —NR₁₁SO₂R₁₂,—SO₂NR₁₁R₁₂, —CONR₁₁R₁₂, —NR₁₁CONR₁₁R₁₂, —NCOR₁₁, —NR₁₁SO₂NR₁₁R₁₂,—OCONR₁₁R₁₂, —CO₂R₁₁ or —NR₁₁R₁₂;

Y is H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl,C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₁₀ cycloalkyl, a 4- to 12-memberedheteroaryl, 4- to 12-membered heterocyclyl, —CN, —NO₂, —NR₁₁SO₂R₁₂,—SO₂NR₁₁R₁₂, —CONR₁₁R₁₂, —NR₁₁CONR₁₁R₁₂, —NCOR₁₁, —NR₁₁SO₂NR₁₁R₁₂,—OCONR₁₁R₁₂, —CO₂R₁₁ or —NR₁₁R₁₂;

Z is H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl,C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₁₀ cycloalkyl, a 6- to 12-memberedheteroaryl, 4- to 12-membered heterocyclyl, —CN, —NO₂, —NR₁₁SO₂R₁₂,—SO₂NR₁₁R₁₂, —CONR₁₁R₁₂, —NR₁₁CONR₁₁R₁₂, —NCOR₁₁, —NR₁₁SO₂NR₁₁R₁₂,—OCONR₁₁R₁₂, —CO₂R₁₁ or —NR₁₁R₁₂;

A is —(CH₂)_(m)—R₂, —CH(R₂₅)(R₂₆), —(CH₂)_(m)—C(O)—R_(2a),—CH(R₂₆)—CO₂—R_(2a) or —(CH₂)_(n-1)—NR₂₅—CO₂—R₂₄;

m is 0 to 4;

n is 1 to 4;

n−1 is 2 to 4;

R₁ is —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, haloC₁₋₁₀ alkyl, C₂₋₁₂ alkenyl,C₃₋₁₀ cycloalkyl, —CN, —(CH₂)_(m)—SO₂R₁₁, —(CH₂)_(n)—SO₂NR₁₁R₁₂,—(CH₂)_(n)—CO₂R₁₁ or —(CH₂)_(n)—NR₁₁SO₂R₁₂, wherein the alkenyl andcycloalkyl may be optionally substituted with one or more R₁₃'s; or

R₁ is selected from the group consisting of:

or

R₁ is

R₂ is C₁₋₁₀ alkyl, cyclopropyl optionally substituted with one or moreR₁₃'s; C₄₋₁₀ cycloalkyl optionally substituted with one or moreR_(13bb)'s; C₃₋₁₀ cycloalkenyl optionally substituted with one or moreR_(13b)'s; or —NR₁₄R₁₄; provided that R₂ is not —NR₁₄R₁₄ when m is 0, 1or 3; or

R₂ is

or

R₂ is selected from the group consisting of:

R_(2a) is C₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, —NR₁₄R₁₄, a 4- to12-membered heteroaryl or 4- to 12-membered heterocyclyl, any of whichis optionally substituted with one or more R₁₃'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₁₁ and R₁₂, at each occurrence, are independently selected from H,C₁₋₁₀ alkyl, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl and a 4- to 12-membered heterocyclyl, wherein thealkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R₁₃'s and the heteroaryl and heterocyclylconsist of carbon atoms and 1, 2, 3, or 4 heteroatoms independentlyselected from the group consisting of N, S, or O; or

R₁₁ and R₁₂ are taken together with the nitrogen to which they areattached to form a 4- to 12-membered heterocyclyl, wherein theheterocyclyl may be optionally substituted with one or more R₁₃'s andthe heterocyclyl consists of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₁₃, at each occurrence, is independently H, —OH, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO; provided that when R₁₃ is alkyl substituted with one R_(14a), R_(14a)is not —OH;

R_(13a), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13aa), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13a-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13a-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13a-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13b), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13bb), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13b-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13b-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13b-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13b-5), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13c), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —(CH₂)_(n)—OCONR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄,—NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₂₆,—NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13cc), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄, or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13c-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 6- to 12-membered heteroaryl, a 6-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13c-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13c-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13c-5), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13d), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₂₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13dd), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13d-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13d-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13d-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13e), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13ee), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13e-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13e-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13f), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₂₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13g), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13g-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13h), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13h-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₇₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13hh), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13hh-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13hh-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13j), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13m), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13m-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13n-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13p), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13p-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13p-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13q), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13q-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13q-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R₁₄, at each occurrence, is independently selected from hydrogen, C₁₋₁₀alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, a 4- to 12-membered heteroaryl or a4- to 12-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with beoptionally substituted with 0-3 R_(14a) and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; or

two R₁₄'s are taken together with the atoms to which they are attachedto form a cyclic ring, wherein the cyclic ring may be optionallysubstituted with one or more R_(24a)'s and optionally contain 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(14a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, F, Cl, Br, I,—CN, —NO₂, —CO₂H, —CO₂R₂₆, —OCONR₂₄R₂₄, —CO₂NR₂₄R₂₄, —OCF₃, —OR₂₅, ═O,—CONR₂₄R₂₄, —COR₂₄, —SO₂R₂₄, —NR₂₄R₂₄, —NR₂₄CO₂R₂₄, —SO₂NR₂₄R₂₄, orC₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consist ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, S, or O;

R₂₄, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the alkyl, aryl, heteroaryland heterocyclyl may be optionally substituted with one or moreR_(24a)'S and the heteroaryl and heterocyclyl consist of carbon atomsand 1, 2, 3, or 4 heteroatoms independently selected from the groupconsisting of N, S, or O; or

two R₂₄'s are taken together with the atoms to which they are attachedto form a cyclic ring, wherein the cyclic ring may be optionallysubstituted with one or more R_(24a)'s and optionally contain 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(24a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, —CN, —NO₂,—CO₂R₂₅, —OCF₃, —OR₂₅, ═O, —CONR₂₅R₂₅, —COR₂₅, —NR₂₅R₂₅, —NR₂₅CO₂R₂₅, orC₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consist ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, S, or O;

R_(24b), at each occurrence, is independently selected from C₁₋₁₀ alkyl,C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, —CO₂R₂₅, —SO₂NR₂₅R₂₅, —COR₂₅ orC₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consist ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, S, or O;

R₂₅, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; and

R₂₆, at each occurrence, is independently selected from C₁₋₁₀alkyl,haloC₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-memberedheteroaryl or 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

provide that:

(i) R₁ is not Cl when m is 0, 1 or 2; R_(13a-1) is H, —CF₃, or methoxy;R_(13c-1) is H, OH, methoxy or dimethylamino; X, Y, Z, R_(13b-1),R_(13d-1), R_(13a-2), R_(13b-2), R_(13c-2), R_(13d-2), R_(13e-2),R_(13g-2), R_(13a-4), R_(13b-4), R_(13c-4), R_(13d-4), R_(13b-5),R_(13c-5), R_(13m-1), R_(13n-1), R_(13p-1), and R_(13q-1) are H; and

(ii) m is not 0 or 1 when X, Y, R_(13a), R_(13d), R_(13e), R_(13g),R_(13a-2), R_(13b-2), R_(13c-2), R_(13d-2), R_(13a-4), R_(13b-4),R_(13c-4), R_(13d-4) R_(13b-5), R_(13c-5), R_(13h-1) and R_(13hh-1) areH; R_(13b) is H or —SO₂NH₂; R_(13c) is H, —CONH₂, —SO₂N(C₂H₄OH)₂,—SO₂NHCOCH₃, —SO₂NH₂, -tetrazolyl or (4-aminopiperidinyl)sulfonyl;R_(13f) is H or —NHC₂H₄OCH₃; and Z is H, —CO₂H, or —CO₂CH₃.

In still yet another embodiment, compounds, enantiomers, diastereomers,tautomers, prodrugs or salts thereof, of formula I, are providedwherein:

X is H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl,C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₁₀ cycloalkyl, a 4- to 12-memberedheteroaryl, 4- to 12-membered heterocyclyl, —CN, —NO₂, —NR₁₁SO₂R₁₂,—SO₂NR₁₁R₁₂, —CONR₁₁R₁₂, —NR₁₁CONR₁₁R₁₂, —NCOR₁₁, —NR₁₁SO₂NR₁₁R₁₂,—OCONR₁₁R₁₂, —CO₂R₁₁ or —NR₁₁R₁₂;

Y is H, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₃₋₁₀ cycloalkyl, a 4- to 12-memberedheteroaryl, 4- to 12-membered heterocyclyl, —CN, —NO₂, —SO₂NR₁₁R₁₂,—CONR₁₁R₁₂, —NR₁₁CONR₁₁R₁₂, —NCOR₁₁, —NR₁₁SO₂NR₁₁R₁₂, —OCONR₁₁R₁₂,—CO₂R₁₁ or —NR₁₁R₁₂;

Z is H, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₃₋₁₀ cycloalkyl, a 6- to 12-memberedheteroaryl, 4- to 12-membered heterocyclyl, —NO₂, —NR₁₁SO₂R₁₂,—SO₂NR₁₁R₁₂, —NR₁₁CONR₁₁R₁₂, —NCOR₁₁, —NR₁₁SO₂NR₁₁R₁₂, —OCONR₁₁R₁₂,—CO₂R₁₁ or —NR₁₁R₁₂;

A is —(CH₂)_(m)—R₂, —CH(R₂₅)(R₂₆), —CH(R₂₆)—CO₂—R_(2a) or—(CH₂)_(n-1)—NR₂₅—CO₂—R₂₄;

m is 0 to 4;

n is 1 to 4;

n−1 is 2 to 4;

R₁ is —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, haloC₁₋₁₀ alkyl, C₂₋₁₂ alkenyl,C₃₋₁₀ cycloalkyl, —CN, —(CH₂)_(n)—SO₂NR₁₁R₁₂, —(CH₂)_(n)—CO₂R₁₁ or—(CH₂)_(n)—NR₁₁SO₂R₁₂, wherein the alkenyl and cycloalkyl may beoptionally substituted with one or more R₁₃'s; or

R₁ is selected from the group consisting of:

or

R₁ is

R₂ is C₁₋₁₀ alkyl, cyclopropyl optionally substituted with one or moreR₁₃'s C₄₋₁₀ cycloalkyl optionally substituted with one or moreR_(13bb)'s; C₃₋₁₀ cycloalkenyl optionally substituted with one or moreR_(13b)'s; or —NR₁₄R₁₄; provided that R₂ is not —NR₁₄R₁₄ when m is 0, 1or 3 or

R₂ is

or

R₂ is selected from the group consisting of:

R_(2a) is C₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, —NR₁₄R₁₄, a 4- to12-membered heteroaryl or 4- to 12-membered heterocyclyl, any of whichis optionally substituted with one or more R₁₃'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₁₁ and R₁₂, at each occurrence, are independently selected from H,C₁₋₁₀ alkyl, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl and a 4- to 12-membered heterocyclyl, wherein thealkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R₁₃'s and the heteroaryl and heterocyclylconsist of carbon atoms and 1, 2, 3, or 4 heteroatoms independentlyselected from the group consisting of N, S, or O; or

R₁₁ and R₁₂ are taken together with the nitrogen to which they areattached to form a 4- to 12-membered heterocyclyl, wherein theheterocyclyl may be optionally substituted with one or more R₁₃'s andthe heterocyclyl consists of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₁₃, at each occurrence, is independently H, —OH, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO; provided that when R₁₃ is alkyl substituted with one R_(14a), R_(14a)is not —OH;

R_(13a), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄,—C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13aa), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13a-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13a-2), at each occurrence, is independently H, —OH, F, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13a-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13b), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄,—C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13bb), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄,—C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b-2), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄,—C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄,—CONR₁₄OR₁₄ or —NCOR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy,aryl, heteroaryl and heterocyclyl may be optionally substituted with oneor more R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13b-5), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13c), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, —CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,═O, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —(CH₂)_(n)—OCONR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —NR₁₄CO₂R₁₄,—CO₂R₂₆, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or—NCOR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'S and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13cc), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄, or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13c-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 6- to 12-membered heteroaryl, a 6-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—NO₂, —NR₁₄SO₂R₁₄, ═O, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —NR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄or —NCOR₁₄, wherein the alkyl, cycloalkyl, alkenyl, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13c-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13c-4), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13c-5), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13d), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₂₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13dd), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13d-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄CONR₁₄R₁₄,—C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein the alkyl,cycloalkyl, alkenyl, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13d-2), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13d-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13e), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, ═O, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄,—C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13ee), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13e-1), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄,—CONR₁₄OR₁₄ or —NCOR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy,aryl, heteroaryl and heterocyclyl may be optionally substituted with oneor more R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13e-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13f), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₂₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄,—NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄,—CONR₁₄OR₁₄ or —NCOR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy,aryl, heteroaryl and heterocyclyl may be optionally substituted with oneor more R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13g), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13g-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13h), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13h-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₇₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13hh), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13hh-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13hh-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13j), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, ═O, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄,—C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13m), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13m-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13n-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13p), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13p-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13p-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13q), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13q-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13q-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄, —CONR₁₄OR₁₄ or —NCOR₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R₁₄, at each occurrence, is independently selected from hydrogen, C₁₋₁₀alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, a 4- to 12-membered heteroaryl or a4- to 12-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with beoptionally substituted with 0-3 R_(14a) and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; or

two R₁₄'s are taken together with the atoms to which they are attachedto form a cyclic ring, wherein the cyclic ring may be optionallysubstituted with one or more R_(24a)'s and optionally contain 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(14a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, F, Cl, Br, I,—CN, —NO₂, —CO₂R₂₆, —CO₂NR₂₄R₂₄, —OCF₃, —OR₂₅, ═O, —CONR₂₄R₂₄, —COR₂₄,—SO₂R₂₄, —NR₂₄R₂₄, —NR₂₄CO₂R₂₄, —SO₂NR₂₄R₂₄, or C₆₋₁₀arylC₁₋₁₀alkyl,wherein the heteroaryl and heterocyclyl consist of carbon atoms and 1,2, 3, or 4 heteroatoms independently selected from the group consistingof N, S, or O;

R₂₄, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the alkyl, aryl, heteroaryland heterocyclyl may be optionally substituted with one or moreR_(24a)'S and the heteroaryl and heterocyclyl consist of carbon atomsand 1, 2, 3, or 4 heteroatoms independently selected from the groupconsisting of N, S, or O; or

two R₂₄'s are taken together with the atoms to which they are attachedto form a cyclic ring, wherein the cyclic ring may be optionallysubstituted with one or more R_(24a)'s and optionally contain 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(24a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, —CN, —NO₂,—CO₂R₂₅, —OCF₃, —OR₂₅, ═O, —CONR₂₅R₂₅, —COR₂₅, —NR₂₅R₂₅, —NR₂₅CO₂R₂₅, orC₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consist ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, S, or O;

R_(24b), at each occurrence, is independently selected from C₁₋₁₀ alkyl,C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, —CO₂R₂₅, —SO₂NR₂₅R₂₅, —COR₂₅ orC₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consist ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, S, or O;

R₂₅, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; and

R₂₆, at each occurrence, is independently selected from C₁₋₁₀alkyl,haloC₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-memberedheteroaryl or 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

provide that:

(i) R₁ is not Cl when m is 0, 1 or 2; R_(13a-1) is H, —CF₃, or methoxy;R_(13c-1) is H, OH, methoxy or dimethylamino; X, Y, Z, R_(13b-1),R_(13d-1), R_(13a-2), R_(13b-2), R_(13c-2), R_(13d-2), R_(13e-2),R_(13g-2), R_(13a-4), R_(13b-4), R_(13c-4), R_(13d-4), R_(13b-5),R_(13c-5), R_(13m-1), R_(13n-1), R_(13p-1), and R_(13q-1) are H; and

(ii) m is not 0 or 1 when X, Y, R_(13a), R_(13d), R_(13e), R_(13g),R_(13a-2), R_(13b-2), R_(13c-2), R_(13d-2), R_(13a-4), R_(13b-4),R_(13c-4), R_(13d-4) R_(13b-5), R_(13c-5), R_(13h-1) and R_(13hh-1) areH; R_(13b) is H or —SO₂NH₂, R_(13c) is H, —CONH₂, —SO₂N(C₂H₄OH)₂,—SO₂NHCOCH₃, —SO₂NH₂, -tetrazolyl or (4-aminopiperidinyl)sulfonyl;R_(13f) is H or —NHC₂H₄OCH₃; and Z is H, —CO₂H, or —CO₂CH₃.

In one embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula I, are provided wherein X is H.

In another embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula I, are provided wherein X and Yare H.

In yet another embodiment, compounds, enantiomers, diastereomers,tautomers, prodrugs or salts thereof, of formula I, are provided whereinX, Y and Z are H.

In one embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula I, are provided wherein R₁ is F,Cl, Br or I.

In one embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula I, are provided wherein R₁ is Cl.

In one embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula I, are provided wherein R₁ isselected from the group consisting of:

In another embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula I, are provided wherein R₁ isselected from the group consisting of:

In yet another embodiment, compounds, enantiomers, diastereomers,tautomers, prodrugs or salts thereof, of formula I, are provided whereinR₁ is selected from the group consisting of:

In one embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula I, are provided wherein R₁ isselected from the group consisting of:

In one embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula I, are provided wherein R₁ is

In one embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula I, are provided wherein R₁ is

In one embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula I, are provided wherein:

X is H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl,C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₁₀ cycloalkyl, a 4- to 12-memberedheteroaryl, 4- to 12-membered heterocyclyl, —CN, —NO₂, —SO₂NR₁₁R₁₂,—CONR₁₁R₁₂, —NR₁₁CONR₁₁R₁₂, —NCOR₁₁, —CO₂R₁₁ or —NR₁₁R₁₂;

Y is H, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₃₋₁₀ cycloalkyl, a 4- to 12-memberedheteroaryl, 4- to 12-membered heterocyclyl, —CN, —NO₂, —SO₂NR₁₁R₁₂,—CONR₁₁R₁₂, —NR₁₁CONR₁₁R₁₂, —NCOR₁₁, —CO₂R₁₁ or —NR₁₁R₁₂;

Z is H, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₃₋₁₀ cycloalkyl, a 6- to 12-memberedheteroaryl, 4- to 12-membered heterocyclyl, —NO₂, —SO₂NR₁₁R₁₂, —NCOR₁₁,—NR₁₁SO₂NR₁₁R₁₂, —OCONR₁₁R₁₂ or —NR₁₁R₁₂;

A is —(CH₂)_(m)—R₂, —CH(R₂₅)(R₂₆) or —CH(R₂₆)—CO₂—R_(2a);

m is 0 to 4;

n is 1 to 4;

R₁ is —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, haloC₁₋₁₀ alkyl, C₂₋₁₂ alkenyl,C₃₋₁₀ cycloalkyl, —CN, —(CH₂)_(n)—SO₂NR₁₁R₁₂ or —(CH₂)_(n)—NR₁₁SO₂R₁₂,wherein the alkenyl and cycloalkyl may be optionally substituted withone or more R₁₃'s; or

R₁ is selected from the group consisting of:

R₁ is

R₂ is C₁₋₁₀ alkyl, cyclopropyl optionally substituted with one or moreR₁₃'s; C₄₋₁₀ cycloalkyl optionally substituted with one or moreR_(13bb)'s; or —NR₁₄R₁₄; provided that R₂ is not —NR₁₄R₁₄ when m is 0, 1or 3; or

R₂ is

or

R₂ is selected from the group consisting of:

R_(2a) is C₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, —NR₁₄R₁₄, a 4- to12-membered heteroaryl or 4- to 12-membered heterocyclyl, any of whichis optionally substituted with one or more R₁₃'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₁₁ and R₁₂, at each occurrence, are independently selected from H,C₁₋₁₀ alkyl, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl and a 4- to 12-membered heterocyclyl, wherein thealkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R₁₃'s and the heteroaryl and heterocyclylconsist of carbon atoms and 1, 2, 3, or 4 heteroatoms independentlyselected from the group consisting of N, S, or O; or

R₁₁ and R₁₂ are taken together with the nitrogen to which they areattached to form a 4- to 12-membered heterocyclyl, wherein theheterocyclyl may be optionally substituted with one or more R₁₃'s andthe heterocyclyl consists of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₁₃, at each occurrence, is independently H, —OH, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O; provided that when R₁₃ is alkylsubstituted with one R_(14a), R_(14a) is not —OH;

R_(13a), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or—CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13aa), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13a-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13a-2), at each occurrence, is independently H, —OH, F, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13a-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13b), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or—CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13bb), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or—CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13b-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,aryl, heteroaryl and heterocyclyl may be optionally substituted with oneor more R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13b-2), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or—CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13b-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, whereinthe alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13b-5), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13c), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, —CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,═O, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —NR₁₄CO₂R₁₄, —CO₂R₂₆,—NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl,alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13cc), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13c-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 6- to 12-membered heteroaryl, a 6-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—NO₂, —NR₁₄SO₂R₁₄, ═O, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄,wherein the alkyl, cycloalkyl, alkenyl, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13c-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13c-4), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13c-5), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13d), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₂₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13dd), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13d-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄,wherein the alkyl, cycloalkyl, alkenyl, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13d-2), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13d-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13e), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, ═O, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or—CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13ee), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13e-1), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, whereinthe alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13e-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13f), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₂₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄,—NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, whereinthe alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13g), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13g-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13h), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13h-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₇₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13hh), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13hh-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13hh-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13j), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, ═O, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or—CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13m), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13m-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13n-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13p), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13p-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13p-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13q), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13q-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13q-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R₁₄, at each occurrence, is independently selected from hydrogen, C₁₋₁₀alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, a 4- to 12-membered heteroaryl or a4- to 12-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with beoptionally substituted with 0-3 R_(14a) and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; or

two R₁₄'s are taken together with the atoms to which they are attachedto form a cyclic ring, wherein the cyclic ring may be optionallysubstituted with one or more R_(24a)'s and optionally contain 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(14a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, F, Cl, Br, I,—CN, —NO₂, —CO₂R₂₆, —OCONR₂₄R₂₄, —CO₂NR₂₄R₂₄, —OCF₃, —OR₂₅, —CONR₂₄R₂₄,—COR₂₄, —SO₂R₂₄, —NR₂₄R₂₄, —NR₂₄CO₂R₂₄, —SO₂NR₂₄R₂₄, orC₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consist ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, S, or O;

R₂₄, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the alkyl, aryl, heteroaryland heterocyclyl may be optionally substituted with one or moreR_(24a)'S and the heteroaryl and heterocyclyl consist of carbon atomsand 1, 2, 3, or 4 heteroatoms independently selected from the groupconsisting of N, S, or O; or

two R₂₄'s are taken together with the atoms to which they are attachedto form a cyclic ring, wherein the cyclic ring may be optionallysubstituted with one or more R_(24a)'s and optionally contain 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(24a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, —CN, —NO₂,—CO₂R₂₅, —OCF₃, —OR₂₅, —CONR₂₅R₂₅, —COR₂₅, —NR₂₅R₂₅, —NR₂₅CO₂R₂₅, orC₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consist ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, S, or O;

R_(24b), at each occurrence, is independently selected from C₁₋₁₀ alkyl,C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, —CO₂R₂₅, —SO₂NR₂₅R₂₅ or C₆₋₁₀arylC₁₋₁₀alkyl,wherein the heteroaryl and heterocyclyl consist of carbon atoms and 1,2, 3, or 4 heteroatoms independently selected from the group consistingof N, S, or O;

R₂₅, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; and

R₂₆, at each occurrence, is independently selected from C₁₋₁₀alkyl,haloC₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-memberedheteroaryl or 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O.

In one embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula I, are provided wherein:

X is H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl,C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₃₋₁₀ cycloalkyl, a 4- to 12-memberedheteroaryl, 4- to 12-membered heterocyclyl, —CN, —NO₂, —CO₂R₁₁ or—NR₁₁R₁₂;

Y is H, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₂₋₁₂alkenyl, C₂-12 alkynyl, C₃₋₁₀ cycloalkyl, a 4- to 12-memberedheteroaryl, 4- to 12-membered heterocyclyl, —CN, —NO₂, —CO₂R₁₁ or—NR₁₁R₁₂;

Z is H, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₃₋₁₀ cycloalkyl, a 6- to 12-memberedheteroaryl, 4- to 12-membered heterocyclyl, —NO₂ or —NR₁₁R₁₂;

A is —(CH₂)_(m)—R₂ or —CH(R₂₅)(R₂₆);

m is 0 to 4;

n is 1 to 4;

R₁ is F, Cl, Br, I, C₁₋₁₀ alkyl, haloC₁₋₁₀ alkyl, C₂₋₁₂ alkenyl, C₃₋₁₀cycloalkyl, —(CH₂)_(n)—SO₂NR₁₁R₁₂ or —(CH₂)_(n)—NR₁₁SO₂R₁₂, wherein thealkenyl and cycloalkyl may be optionally substituted with one or moreR₁₃'S; or

R₁ is selected from the group consisting of:

R₁ is

R₂ is C₁₋₁₀ alkyl, cyclopropyl optionally substituted with one or moreR₁₃'s; or C₄₋₁₀ cycloalkyl optionally substituted with one or moreR_(13bb)'s; or

R₂ is

R₂ is selected from the group consisting of:

R₁₁ and R₁₂, at each occurrence, are independently selected from H,C₁₋₁₀ alkyl, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl and a 4- to 12-membered heterocyclyl, wherein thealkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R₁₃'s and the heteroaryl and heterocyclylconsist of carbon atoms and 1, 2, 3, or 4 heteroatoms independentlyselected from the group consisting of N, S, or O; or

R₁₁ and R₁₂ are taken together with the nitrogen to which they areattached to form a 4- to 12-membered heterocyclyl, wherein theheterocyclyl may be optionally substituted with one or more R₁₃'s andthe heterocyclyl consists of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₁₃, at each occurrence, is independently H, —OH, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O; provided that when R₁₃ is alkylsubstituted with one R_(14a), R_(14a) is not —OH;

R_(13a), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or—CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13aa), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13a-1), at each occurrence, is independently —OH, F, Cl, Br, I, C₁₋₁₀alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4-to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄,—NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄, or —CONR₁₄OR₁₄, whereinthe alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13a-2), at each occurrence, is independently H, —OH, F, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13a-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13b), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, whereinthe alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13bb), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or—CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13b-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,aryl, heteroaryl and heterocyclyl may be optionally substituted with oneor more R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13b-2), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or—CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13b-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, whereinthe alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13b-5), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13c), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, —CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,═O, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —NR₁₄CO₂R₁₄, —CO₂R₂₆,—NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl,alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13cc), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13c-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 6- to 12-membered heteroaryl, a 6-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—NO₂, —NR₁₄SO₂R₁₄, ═O, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄,wherein the alkyl, cycloalkyl, alkenyl, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13c-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13c-4), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13c-5), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13d), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₂₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13dd), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13d-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄,wherein the alkyl, cycloalkyl, alkenyl, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13d-2), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13d-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13e), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, ═O, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or—CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13ee), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13e-1), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, whereinthe alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13e-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13f), at each occurrence, is independently —OH, F, Cl, Br, I, C₁₋₁₀alkyl, C₂₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄,—NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13g), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13g-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13h), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13h-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₇₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13hh), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13hh-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13hh-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13j), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, ═O, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄ or—CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13m), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13p), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13q), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, ═O, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R₁₄, at each occurrence, is independently selected from hydrogen, C₁₋₁₀alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, a 4- to 12-membered heteroaryl or a4- to 12-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with beoptionally substituted with 0-3 R_(14a) and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; or

two R₁₄'s are taken together with the atoms to which they are attachedto form a cyclic ring, wherein the cyclic ring may be optionallysubstituted with one or more R_(24a)'s and optionally contain 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(14a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, F, Cl, Br, I,—CN, —NO₂, —CO₂R₂₆, —CO₂NR₂₄R₂₄, —OCF₃, —OR₂₅, —CONR₂₄R₂₄, —COR₂₄,—SO₂R₂₄, —NR₂₄R₂₄, —NR₂₄CO₂R₂₄, —SO₂NR₂₄R₂₄, or C₆₋₁₀arylC₁₋₁₀alkyl,wherein the heteroaryl and heterocyclyl consist of carbon atoms and 1,2, 3, or 4 heteroatoms independently selected from the group consistingof N, S, or O;

R₂₄, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the alkyl, aryl, heteroaryland heterocyclyl may be optionally substituted with one or moreR_(24a)'s and the heteroaryl and heterocyclyl consist of carbon atomsand 1, 2, 3, or 4 heteroatoms independently selected from the groupconsisting of N, S, or O; or

two R₂₄'s are taken together with the atoms to which they are attachedto form a cyclic ring, wherein the cyclic ring may be optionallysubstituted with one or more R_(24a)'s and optionally contain 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(24a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, —CN, —NO₂,—CO₂R₂₅, —OCF₃, —OR₂₅, —CONR₂₅R₂₅, —COR₂₅, —NR₂₅CO₂R₂₅, orC₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consist ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, S, or O;

R_(24b), at each occurrence, is independently selected from C₁₋₁₀ alkyl,C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, —CO₂R₂₅, —SO₂NR₂₅R₂₅ or C₆₋₁₀arylC₁₋₁₀alkyl,wherein the heteroaryl and heterocyclyl consist of carbon atoms and 1,2, 3, or 4 heteroatoms independently selected from the group consistingof N, S, or O;

R₂₅, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; and

R₂₆, at each occurrence, is independently selected from C₁₋₁₀alkyl,haloC₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-memberedheteroaryl or 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O.

In one embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula I, are provided wherein:

X is H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl,C₃₋₁₀ cycloalkyl, a 4- to 12-membered heteroaryl, 4- to 12-memberedheterocyclyl, —CO₂R₁₁ or —NR₁₁R₁₂;

Y is H, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀cycloalkyl, a 4- to 12-membered heteroaryl, 4- to 12-memberedheterocyclyl, —CO₂R₁₁ or —NR₁₁R₁₂;

Z is H, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀cycloalkyl, a 6- to 12-membered heteroaryl, 4- to 12-memberedheterocyclyl or —NR₁₁R₁₂;

A is —(CH₂)_(m)—R₂ or —CH(R₂₅)(R₂₆);

m is 0 to 3;

n is 1 to 3;

R₁ is F, Cl, Br, I, C₁₋₁₀ alkyl, C₂₋₁₂ alkenyl, C₃₋₁₀ cycloalkyl,—(CH₂)_(n)—SO₂NR₁₁R₁₂ or —(CH₂)_(n)—NR₁₁SO₂R₁₂, wherein the alkenyl andcycloalkyl may be optionally substituted with one or more R₁₃'s; or R₁is selected from the group consisting of:

or

R₁ is

R₂ is C₁₋₁₀ alkyl, cyclopropyl optionally substituted with one or moreR₁₃'s; or C₄₋₁₀ cycloalkyl optionally substituted with one or moreR_(13bb)'s; or

R₂ is

or

R₂ is selected from the group consisting of:

R₁₁ and R₁₂, at each occurrence, are independently selected from H,C₁₋₁₀ alkyl, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl and a 4- to 12-membered heterocyclyl, wherein thealkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R₁₃'s and the heteroaryl and heterocyclylconsist of carbon atoms and 1, 2, 3, or 4 heteroatoms independentlyselected from the group consisting of N, S, or O; or

R₁₁ and R₁₂ are taken together with the nitrogen to which they areattached to form a 4- to 12-membered heterocyclyl, wherein theheterocyclyl may be optionally substituted with one or more R₁₃'s andthe heterocyclyl consists of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₁₃, at each occurrence, is independently H, —OH, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; providedthat when R₁₃ is alkyl substituted with one R_(14a), R_(14a) is not —OH;

R_(13a), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'S and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13aa), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13a-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄, or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13a-2), at each occurrence, is independently H, —OH, F, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13a-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13b), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13bb), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13b-2), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl, cycloalkyl,alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b-5), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13c), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, —CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —NR₁₄CO₂R₁₄, —CO₂R₂₆ or—NR₁₄R₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13cc), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13c-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 6- to 12-membered heteroaryl, a 6-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—NO₂, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl, cycloalkyl, alkenyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13c-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13c-4), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13c-5), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13d), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₂₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13dd), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13d-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄ or —CO₂R₁₄, wherein the alkyl,cycloalkyl, alkenyl, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'S and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13d-2), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13d-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13e), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13ee), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13e-1), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl, cycloalkyl,alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13e-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13f), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₂₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄,—NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl, cycloalkyl,alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13g), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13g-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13h), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13h-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₇₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,—NR₁₄CONR₁₄R₁₄ or —CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13hh), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13hh-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13hh-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13m), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13p), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13q), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₂₋₁₂ alkynyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4-to 12-membered heterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl,—CN, —NO₂, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R₁₄, at each occurrence, is independently selected from hydrogen, C₁₋₁₀alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, a 4- to 12-membered heteroaryl or a4- to 12-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with beoptionally substituted with 0-3 R_(14a) and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; or

two R₁₄'s are taken together with the atoms to which they are attachedto form a cyclic ring, wherein the cyclic ring may be optionallysubstituted with one or more R_(24a)'s and optionally contain 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(14a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, F, Cl, Br, I,—CN, —NO₂, —CO₂R₂₆, —CO₂NR₂₄R₂₄, —OCF₃, —OR₂₅, —CONR₂₄R₂₄, —COR₂₄,—SO₂R₂₄, —NR₂₄R₂₄ or C₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₂₄, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the alkyl, aryl, heteroaryland heterocyclyl may be optionally substituted with one or moreR_(24a)'S and the heteroaryl and heterocyclyl consist of carbon atomsand 1, 2, 3, or 4 heteroatoms independently selected from the groupconsisting of N, S, or O; or

two R₂₄'s are taken together with the atoms to which they are attachedto form a cyclic ring, wherein the cyclic ring may be optionallysubstituted with one or more R_(24a)'s and optionally contain 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(24a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, —CN, —NO₂,—CO₂R₂₅, —OCF₃, —OR₂₅, —CONR₂₅R₂₅, —COR₂₅, —NR₂₅R₂₅ orC₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consist ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, S, or O;

R₂₅, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; and

R₂₆, at each occurrence, is independently selected from C₁₋₁₀alkyl,haloC₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-memberedheteroaryl or 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O.

In one embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula I, are provided wherein:

X is H, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, 4- to12-membered heterocyclyl, —CO₂R₁₁ or —NR₁₁R₁₂;

Y is H, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, 4- to12-membered heterocyclyl, —CO₂R₁₁ or —NR₁₁R₁₂;

Z is H, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, 4- to12-membered heterocyclyl or —NR₁₁R₁₂;

A is —(CH₂)_(m)—R₂;

m is 0 to 3;

n is 1 to 3;

R₁ is F, Cl, Br, I, C₁₋₁₀ alkyl, C₂₋₁₂ alkenyl, C₃₋₁₀ cycloalkyl,wherein the alkenyl and cycloalkyl may be optionally substituted withone or more R₁₃'s; or

R₁ is selected from the group consisting of:

R₁ is

R₂ is cyclopropyl optionally substituted with one or more R₁₃'S; orC₄₋₁₀ cycloalkyl optionally substituted with one or more R_(13bb)'s; or

R₂ is

R₂ is selected from the group consisting of:

R₁₁ and R₁₂, at each occurrence, are independently selected from H,C₁₋₁₀ alkyl, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl and a 4- to 12-membered heterocyclyl, wherein thealkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R₁₃'s and the heteroaryl and heterocyclylconsist of carbon atoms and 1, 2, 3, or 4 heteroatoms independentlyselected from the group consisting of N, S, or O; or

R₁₁ and R₁₂ are taken together with the nitrogen to which they areattached to form a 4- to 12-membered heterocyclyl, wherein theheterocyclyl may be optionally substituted with one or more R₁₃'s andthe heterocyclyl consists of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₁₃, at each occurrence, is independently H, —OH, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; providedthat when R₁₃ is alkyl substituted with one R_(14a), R_(14a) is not —OH;

R_(13a), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl, cycloalkyl,alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13aa), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13a-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄, or—CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13a-2), at each occurrence, is independently H, —OH, F, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13a-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13bb), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b-2), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13b-5), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13c), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —NR₁₄CO₂R₁₄, —CO₂R₂₆ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13cc), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13c-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 6- to 12-membered heteroaryl, a 6- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —NR₁₄SO₂R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄,—NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13c-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13c-4), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13c-5), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13d), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₂₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13dd), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13d-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄ or —CO₂R₁₄, wherein the alkyl, cycloalkyl, alkenyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13d-2), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13d-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13e), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13ee), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13e-1), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl, cycloalkyl,alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13e-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13f), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₂₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13g), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13g-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13h), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13hh), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13m), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₁₄, at each occurrence, is independently selected from hydrogen, C₁₋₁₀alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, a 4- to 12-membered heteroaryl or a4- to 12-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with beoptionally substituted with 0-3 R_(14a) and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(14a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, F, Cl, Br, I,—CN, —CO₂R₂₆, —CO₂NR₂₄R₂₄, —OCF₃, —OR₂₅, —CONR₂₄R₂₄, —SO₂R₂₄, —NR₂₄R₂₄or C₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R₂₄, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the alkyl, aryl, heteroaryland heterocyclyl may be optionally substituted with one or moreR_(24a)'S and the heteroaryl and heterocyclyl consist of carbon atomsand 1, 2, 3, or 4 heteroatoms independently selected from the groupconsisting of N, S, or O;

R_(24a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, —CN, —CO₂R₂₅,—OCF₃, —OR₂₅, —CONR₂₅R₂₅, —NR₂₅R₂₅ or C₆₋₁₀arylC₁₋₁₀alkyl, wherein theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R₂₅, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; and

R₂₆, at each occurrence, is independently selected from C₁₋₁₀alkyl,haloC₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-memberedheteroaryl or 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O.

In yet another embodiment, compounds, enantiomers, diastereomers,tautomers, prodrugs or salts thereof, of formula I, are providedwherein:

X is H, F, Cl, Br, I, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, 4- to 12-memberedheterocyclyl, —CO₂R₁₁ or —NR₁₁R₁₂;

Y is H, F, Cl, Br, I, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, 4- to 12-memberedheterocyclyl, —CO₂R₁₁ or —NR₁₁R₁₂;

Z is H, Cl, Br, I, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, 4- to 12-memberedheterocyclyl or —NR₁₁R₁₂;

A is —(CH₂)_(m)—R₂;

m is 0 to 3;

n is 1 to 3;

R₁ is C₁, C₂₋₁₂ alkenyl, C₃₋₁₀ cycloalkyl, wherein the alkenyl andcycloalkyl may be optionally substituted with one or more R₁₃'s; or

R₁ is selected from the group consisting of:

or

R₁ is

R₂ is cyclopropyl optionally substituted with one or more R₁₃'s; or

R₂ is

or

R₂ is selected from the group consisting of:

R₁₁ and R₁₂, at each occurrence, are independently selected from H,C₁₋₁₀ alkyl, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl and a 4- to 12-membered heterocyclyl, wherein thealkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R₁₃'s and the heteroaryl and heterocyclylconsist of carbon atoms and 1, 2, 3, or 4 heteroatoms independentlyselected from the group consisting of N, S, or O;

R₁₃, at each occurrence, is independently H, —OH, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; providedthat when R₁₃ is alkyl substituted with one R_(14a), R_(14a) is not —OH;

R_(13a), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl, cycloalkyl,alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13aa), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13a-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄, —NR₁₄CONR₁₄R₁₄, or—CONR₁₄OR₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13a-2), at each occurrence, is independently H, —OH, F, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13a-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13bb), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b-2), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13b-5), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13c), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —NR₁₄CO₂R₁₄,—CO₂R₂₆ or —NR₁₄R₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy,aryl, heteroaryl and heterocyclyl may be optionally substituted with oneor more R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13cc), at each occurrence, is independently H, F, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13c-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 6- to 12-membered heteroaryl, a 6- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —NR₁₄SO₂R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄,—NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13c-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13c-4), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13c-5), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13d), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₂₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13dd), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13d-1), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄ or —CO₂R₁₄, wherein the alkyl, cycloalkyl, alkenyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13d-2), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13d-4), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13e), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13ee), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13e-1), at each occurrence, is independently H, —OH, Cl, Br, I, C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, haloC₂₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl,C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl, cycloalkyl,alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13e-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13f), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₂₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13g), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13g-2), at each occurrence, is independently H, —OH, F, Cl, Br, I,C₂₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, a 4- to 12-membered heteroaryl-C₁₋₁₀ alkyl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₁₄, at each occurrence, is independently selected from hydrogen, C₁₋₁₀alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, a 4- to 12-membered heteroaryl or a4- to 12-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with beoptionally substituted with 0-3 R_(14a) and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(14a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, F, Cl, Br, I,—CN, —CO₂R₂₆, —CO₂NR₂₄R₂₄, —OCF₃, —OR₂₅, —CONR₂₄R₂₄, —SO₂R₂₄, —NR₂₄R₂₄or C₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R₂₄, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the alkyl, aryl, heteroaryland heterocyclyl may be optionally substituted with one or moreR_(24a)'S and the heteroaryl and heterocyclyl consist of carbon atomsand 1, 2, 3, or 4 heteroatoms independently selected from the groupconsisting of N, S, or O;

R_(24a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, —CN, —CO₂R₂₅,—OCF₃, —OR₂₅, —CONR₂₅R₂₅, —NR₂₅R₂₅ or C₆₋₁₀arylC₁₋₁₀alkyl, wherein theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R₂₅, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; and

R₂₆, at each occurrence, is independently selected from C₁₋₁₀alkyl,haloC₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-memberedheteroaryl or 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O.

In yet another embodiment, compounds, enantiomers, diastereomers,tautomers, prodrugs or salts thereof, of formula I, are provided whereinthe compounds are compounds of formula Ia:

In yet another embodiment, compounds, enantiomers, diastereomers,tautomers, prodrugs or salts thereof, of formula I, are provided whereinthe compounds are compounds of formula Ib or Ic:

wherein:

X is H, F, Cl, Br, I, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, 4- to 12-memberedheterocyclyl, —CO₂R₁₁ or —NR₁₁R₁₂;

Y is H, F, Cl, Br, I, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, 4- to 12-memberedheterocyclyl, —CO₂R₁₁ or —NR₁₁R₁₂;

Z is H, Cl, Br, I, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, 4- to 12-memberedheterocyclyl or —NR₁₁R₁₂;

R₁₁ and R₁₂, at each occurrence, are independently selected from H,C₁₋₁₀ alkyl, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl and a 4- to 12-membered heterocyclyl, wherein thealkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R₁₃'s and the heteroaryl and heterocyclylconsist of carbon atoms and 1, 2, 3, or 4 heteroatoms independentlyselected from the group consisting of N, S, or O;

R_(13a) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₂₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13a-2) is independently H, —OH, F, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy,haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl, cycloalkyl,alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b) is independently H, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy,haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —CONR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄, —NR₁₄R₁₄ or —NR₁₄CONR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13b-2) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄,—SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13c) is independently H, —OH, Cl, Br, I, C₁₋₁₀ alkyl, hydroxyC₁₋₁₀alkyl, cyanoC₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a4- to 12-membered heterocyclyl, —CN, —(CH₂)_(m)—SO₂R₁₄,—(CH₂)_(n)—OCONR₁₄R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —NR₁₄CO₂R₁₄,—CO₂R₂₆, —NR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄ or —NR₁₄CONR₁₄R₁₄, wherein thecycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, or 3 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13c-2) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl, cycloalkyl,alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13d) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₂₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄,—NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or—NR₁₄R₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13d-2) is independently H, —OH, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy,haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —SO₂NR₁₄CONR₁₄R₁₄,—NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl, cycloalkyl,alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₁₄, at each occurrence, is independently selected from hydrogen, C₁₋₁₀alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, a 4- to 12-membered heteroaryl or a4- to 12-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with beoptionally substituted with 0-3 R_(14a) and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(14a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, F, Cl, Br, I,—CN, —CO₂H, —CO₂R₂₆, —OCONR₂₄R₂₄, —CO₂NR₂₄R₂₄, —OCF₃, —OR₂₅, —CONR₂₄R₂₄,—SO₂R₂₄, —NR₂₄R₂₄ or C₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₂₄, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the alkyl, aryl, heteroaryland heterocyclyl may be optionally substituted with one or moreR_(24a)'S and the heteroaryl and heterocyclyl consist of carbon atomsand 1, 2, 3, or 4 heteroatoms independently selected from the groupconsisting of N, S, or O; or

two R₂₄'s are taken together with the atoms to which they are attachedto form a cyclic ring, wherein the cyclic ring may be optionallysubstituted with one or more R_(24a)'S and optionally contain 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(24a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, —CN, —CO₂R₂₅,—OCF₃, —OR₂₅, —CONR₂₅R₂₅, —NR₂₅R₂₅ or C₆₋₁₀arylC₁₋₁₀alkyl, wherein theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R₂₅, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; and

R₂₆, at each occurrence, is independently selected from C₁₋₁₀alkyl,haloC₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-memberedheteroaryl or 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

provided that X, Y, Z, R_(13a), R_(13b), R_(13d), R_(13a-2), R_(13b-2),R_(13c-2) and R_(13d-2) is not all H when R_(13c) is —C(═O)N(C₂H₄OCH₃)₂,—SO₂N(C₂H₄OH)₂.

In yet another embodiment, compounds, enantiomers, diastereomers,tautomers, prodrugs or salts thereof, of formula Ib are provided.

In still yet another embodiment, compounds, enantiomers, diastereomers,tautomers, prodrugs or salts thereof, of formula Ib or Ic, are providedwherein:

X is H, F, Cl, Br, I, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, —CO₂R₁₁ or—NR₁₁R₁₂;

Y is H, F, Cl, Br, I, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, —CO₂R₁₁ or—NR₁₁R₁₂;

Z is H, Cl, Br, I, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl or —NR₁₁R₁₂;

R₁₁ and R₁₂, at each occurrence, are independently selected from H,C₁₋₁₀ alkyl, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl and a 4- to 12-membered heterocyclyl, wherein thealkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R₁₃'s and the heteroaryl and heterocyclylconsist of carbon atoms and 1, 2, 3, or 4 heteroatoms independentlyselected from the group consisting of N, S, or O;

R_(13a) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₂₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —CO₂R₁₄ or—NR₁₄R₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13a-2) is independently H, —OH, F, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy,haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, whereinthe alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13b) is independently H, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy,haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄,—NR₁₄R₁₄, or —NR₁₄CONR₁₄R₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13b-2) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or—NR₁₄R₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13c) is independently H, —OH, Cl, Br, I, C₁₋₁₀ alkyl, hydroxyC₁₋₁₀alkyl, cyanoC₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a4- to 12-membered heterocyclyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —SO₂NR₁₄COR₁₄, —NR₁₄CO₂R₁₄,—CO₂R₂₆, —NR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄ or —NR₁₄CONR₁₄R₁₄, wherein thecycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2 or 3 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13c-2) is independently H, —OH, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy,haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, whereinthe alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13d) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₂₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —NR₁₄CO₂R₁₄,—CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy,aryl, heteroaryl and heterocyclyl may be optionally substituted with oneor more R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13d-2) is independently H, —OH, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy,haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂NR₁₄R₁₄,—NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, whereinthe alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R₁₄, at each occurrence, is independently selected from hydrogen, C₁₋₁₀alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, a 4- to 12-membered heteroaryl or a4- to 12-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with beoptionally substituted with 0-3 R_(14a) and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(14a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, F, Cl, Br, I,—CN, —CO₂R₂₆, —CO₂NR₂₄R₂₄, —OCF₃, —OR₂₅, —CONR₂₄R₂₄, —SO₂R₂₄, —NR₂₄R₂₄or C₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R₂₄, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the alkyl, aryl, heteroaryland heterocyclyl may be optionally substituted with one or moreR_(24a)'S and the heteroaryl and heterocyclyl consist of carbon atomsand 1, 2, 3, or 4 heteroatoms independently selected from the groupconsisting of N, S, or O;

R_(24a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, —CN, —CO₂R₂₅,—OCF₃, —OR₂₅, —CONR₂₅R₂₅, —NR₂₅R₂₅ or C₆₋₁₀arylC₁₋₁₀alkyl, wherein theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R₂₅, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; and

R₂₆, at each occurrence, is independently selected from C₁₋₁₀alkyl,haloC₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-memberedheteroaryl or 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O.

In one embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula Ib or Ic, are provided wherein:

X is H, F, Cl, Br, I, C₁₋₁₀ alkoxy or haloC₁₋₁₀ alkyl;

Y is H, F, Cl, Br, I, C₁₋₁₀ alkoxy or haloC₁₋₁₀ alkyl;

Z is H, Cl, Br, I, C₁₋₁₀ alkoxy or haloC₁₋₁₀ alkyl;

R_(13a) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₂₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —CO₂R₁₄ or—NR₁₄R₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13a-2) is independently H, —OH, F, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy,haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, whereinthe alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13b) is independently H, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy,haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CO₂NR₁₄R₁₄, —NR₁₄CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —NR₁₄CO₂R₁₄, —CO₂R₁₄,—NR₁₄R₁₄, or —NR₁₄CONR₁₄R₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13b-2) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13c) is independently H, —OH, Cl, Br, I, C₁₋₁₀ alkyl, hydroxyC₁₋₁₀alkyl, cyanoC₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a4- to 12-membered heterocyclyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —NR₁₄CO₂R₁₄, —NR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄ or—NR₁₄CONR₁₄R₁₄, wherein the cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2 or 3 heteroatoms independently selected from the groupconsisting of N, S, or O;

R_(13c-2) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄,—(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, whereinthe alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13d) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₂₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄, wherein thealkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclylmay be optionally substituted with one or more R_(14a)'s and theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R_(13d-2) is independently H, —OH, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy,haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄,—CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —CO₂R₁₄ or—NR₁₄R₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R₁₄ is independently selected from hydrogen, C₁₋₁₀ alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀ aryl, a 4- to 12-membered heteroaryl or a 4- to12-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with beoptionally substituted with 0-3 R_(14a) and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(14a) is independently selected from F, Cl, Br, I, C₁₋₁₀ alkyl,haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to 12-memberedheteroaryl, a 4- to 12-membered heterocyclyl, F, Cl, Br, I, —CN,—CO₂R₂₆, —CO₂NR₂₄R₂₄, —OCF₃, —OR₂₅, —SO₂R₂₄, —NR₂₄R₂₄ orC₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consist ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, S, or O;

R₂₄ is independently selected from hydrogen, C₁₋₁₀alkyl,C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl or 4- to12-membered heterocyclyl, wherein the alkyl, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(24a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(24a) is independently selected from F, Cl, Br, I, C₁₋₁₀ alkyl,haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to 12-memberedheteroaryl, a 4- to 12-membered heterocyclyl, —CN, —CO₂R₂₅, —OCF₃,—OR₂₅, —CONR₂₅R₂₅, —NR₂₅R₂₅ or C₆₋₁₀arylC₁₋₁₀alkyl, wherein theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R₂₅ is independently selected from hydrogen, C₁₋₁₀alkyl,C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl or 4- to12-membered heterocyclyl, wherein the heteroaryl and heterocyclylconsist of carbon atoms and 1, 2, 3, or 4 heteroatoms independentlyselected from the group consisting of N, S, or O; and

R₂₆ is independently selected from C₁₋₁₀alkyl, haloC₁₋₁₀alkyl,C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl or 4- to12-membered heterocyclyl, wherein the heteroaryl and heterocyclylconsist of carbon atoms and 1, 2, 3, or 4 heteroatoms independentlyselected from the group consisting of N, S, or O.

In another embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula Ib or Ic, are provided wherein:

X is H, F, Cl, Br, I, or C₁₋₁₀ alkoxy;

Y is H, F, Cl, Br, I, or C₁₋₁₀ alkoxy;

Z is H, Cl, Br, I, C₁₋₁₀ alkoxy or haloC₁₋₁₀ alkyl;

R_(13a) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₂₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —CONR₁₄R₁₄, —CO₂R₁₄ or—NR₁₄R₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13a-2) is independently H, —OH, F, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy,haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CONR₁₄R₁₄, —CO₂R₁₄ or —NR₁₄R₁₄,wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13b) is independently H, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy,haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—CO₂R₁₄, —NR₁₄R₁₄, or —NR₁₄CONR₁₄R₁₄, wherein the alkyl, cycloalkyl,alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b-2) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —CO₂R₁₄ or —NR₁₄R₁₄, whereinthe alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13c) is independently H, Cl, Br, I, C₁₋₁₀ alkyl, hydroxyC₁₋₁₀ alkyl,cyanoC₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, a 4- to 12-memberedheterocyclyl, —CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄,—(CH₂)_(m)—SO₂NR₁₄R₁₄, —(CH₂)_(m)—NR₁₄SO₂R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—NR₁₄COR₁₄, —NR₁₄CO₂R₁₄, —NR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄ or —NR₁₄CONR₁₄R₁₄,wherein the cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, or3 heteroatoms independently selected from the group consisting of N, S,or O;

R_(13c-2) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —(CH₂)_(n)—NR₁₄SO₂NR₁₄R₁₄, —NR₁₄SO₂NR₁₄R₁₄,—CO₂R₁₄ or —NR₁₄R₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy,aryl, heteroaryl and heterocyclyl may be optionally substituted with oneor more R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13d) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₂₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —CONR₁₄R₁₄, —CO₂R₁₄ or—NR₁₄R₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R_(13d-2) is independently H, —OH, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy,haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —CONR₁₄R₁₄, —CO₂R₁₄ or—NR₁₄R₁₄, wherein the alkyl, cycloalkyl, alkenyl, alkoxy, aryl,heteroaryl and heterocyclyl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl and heterocyclyl consist of carbonatoms and 1, 2, 3, or 4 heteroatoms independently selected from thegroup consisting of N, S, or O;

R₁₄ is independently selected from hydrogen, C₁₋₁₀ alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀ aryl, a 4- to 12-membered heteroaryl or a 4- to12-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with beoptionally substituted with 0-3 R_(14a) and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(14a) is independently selected from F, Cl, Br, I, C₁₋₁₀ alkyl,haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to 12-memberedheteroaryl, a 4- to 12-membered heterocyclyl, F, Cl, Br, I, —CN,—CO₂R₂₆, —CO₂NR₂₄R₂₄, —OCF₃, —OR₂₅, —SO₂R₂₄, —NR₂₄R₂₄ orC₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consist ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, S, or O;

R₂₄, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the alkyl, aryl, heteroaryland heterocyclyl may be optionally substituted with one or moreR_(24a)'S and the heteroaryl and heterocyclyl consist of carbon atomsand 1, 2, 3, or 4 heteroatoms independently selected from the groupconsisting of N, S, or O;

R_(24a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, —CN, —CO₂R₂₅,—OCF₃, —OR₂₅, —CONR₂₅R₂₅, —NR₂₅R₂₅ or C₆₋₁₀arylC₁₋₁₀alkyl, wherein theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R₂₅, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; and

R₂₆, at each occurrence, is independently selected from C₁₋₁₀alkyl,haloC₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-memberedheteroaryl or 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O.

In still yet another embodiment, compounds, enantiomers, diastereomers,tautomers, prodrugs or salts thereof, of formula Ib or Ic, are providedwherein:

X is H, F, Cl, Br, I or C₁₋₁₀ alkoxy;

Y is H, F, Cl, Br, I or C₁₋₁₀ alkoxy;

Z is H, Cl, Br, I or C₁₋₁₀ alkoxy;

R_(13a) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₂₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl or —CN, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13a-2) is independently H, —OH, F, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy,haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl or a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, wherein the alkyl, cycloalkyl,alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'S and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13b) is independently H, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy,haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —CO₂NR₁₄R₁₄, —NR₁₄COR₁₄,—NR₁₄R₁₄, or —NR₁₄CONR₁₄R₁₄, wherein the alkyl, cycloalkyl, alkenyl,alkoxy, aryl, heteroaryl and heterocyclyl may be optionally substitutedwith one or more R_(14a)'s and the heteroaryl and heterocyclyl consistof carbon atoms and 1, 2, 3, or 4 heteroatoms independently selectedfrom the group consisting of N, S, or O;

R_(13b-2) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₂₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl or a 4-to 12-membered heteroaryl-C₁₋₁₀ alkyl, wherein the alkyl, cycloalkyl,alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13c) is independently H, Cl, Br, I, C₁₋₁₀ alkyl, hydroxyC₁₋₁₀ alkyl,cyanoC₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂alkenyl, C₆₋₁₀aryl, a 4- to 12-membered heteroaryl, —CN,—(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —NR₁₄CO₂R₁₄,—NR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄ or —NR₁₄CONR₁₄R₁₄, wherein the cycloalkyl,alkenyl, alkoxy, aryl and heteroaryl may be optionally substituted withone or more R_(14a)'s and the heteroaryl consists of carbon atoms and 1,2 or 3 heteroatoms independently selected from the group consisting ofN, S, or O;

R_(13c-2) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN, —CO₂R₁₄ or —NR₁₄R₁₄, whereinthe alkyl, cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl andheterocyclyl may be optionally substituted with one or more R_(14a)'sand the heteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3,or 4 heteroatoms independently selected from the group consisting of N,S, or O;

R_(13d) is independently H, —OH, F, Cl, Br, I, C₁₋₁₀ alkyl, C₂₋₁₀alkoxy, haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a4- to 12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl, —CN or —NR₁₄R₁₄, wherein the alkyl,cycloalkyl, alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may beoptionally substituted with one or more R_(14a)'S and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(13d-2) is independently H, —OH, Cl, Br, I, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy,haloC₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, C₆₋₁₀aryl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, a 4- to12-membered heteroaryl-C₁₋₁₀ alkyl or —CN wherein the alkyl, cycloalkyl,alkenyl, alkoxy, aryl, heteroaryl and heterocyclyl may be optionallysubstituted with one or more R_(14a)'s and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R₁₄, at each occurrence, is independently selected from hydrogen, C₁₋₁₀alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, a 4- to 12-membered heteroaryl or a4- to 12-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with beoptionally substituted with 0-3 R_(14a) and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(14a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, F, Cl, Br, I,—CN, —CO₂R₂₆, —CO₂NR₂₄R₂₄, —OCF₃, —OR₂₅, —SO₂R₂₄, —NR₂₄R₂₄ orC₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consist ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, S, or O;

R₂₄, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the alkyl, aryl, heteroaryland heterocyclyl may be optionally substituted with one or moreR_(24a)'S and the heteroaryl and heterocyclyl consist of carbon atomsand 1, 2, 3, or 4 heteroatoms independently selected from the groupconsisting of N, S, or O;

R_(24a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, —CN, —CO₂R₂₅,—OCF₃, —OR₂₅, —CONR₂₅R₂₅, —NR₂₅R₂₅ or C₆₋₁₀arylC₁₋₁₀alkyl, wherein theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R₂₅, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; and

R₂₆, at each occurrence, is independently selected from C₁₋₁₀alkyl,haloC₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-memberedheteroaryl or 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O.

In one embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula Ib or Ic, are provided wherein:

X is H or C₁₋₁₀ alkoxy;

Y is H or C₁₋₁₀ alkoxy;

Z is H or C₁₋₁₀ alkoxy;

R_(13a), at each occurrence, is independently H or —CN;

R_(13a-2), at each occurrence, is independently H, F, C₁₋₁₀ alkyl, C₁₋₁₀alkoxy, haloC₁₋₁₀ alkyl or C₃₋₁₀ cycloalkyl, wherein the alkyl,cycloalkyl and alkoxy may be optionally substituted with one or moreR_(14a)'s;

R_(13b), at each occurrence, is independently H, C₁₋₁₀ alkoxy, —CN,—CO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —NR₁₄R₁₄, or —NR₁₄CONR₁₄R₁₄;

R_(13b-2), at each occurrence, is independently H or F;

R_(13c), at each occurrence, is independently H, C₁₋₁₀ alkyl, C₁₋₁₀alkoxy, C₃₋₁₀ cycloalkyl, C₂₋₁₂ alkenyl, a 4- to 12-membered heteroaryl,—CN, —(CH₂)_(m)—SO₂R₁₄, —NR₁₄SO₂R₁₄, —CONR₁₄R₁₄, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—(CH₂)_(m)—NR₁₄SO₂R₁₄, —NR₁₄SO₂NR₁₄R₁₄, —NR₁₄COR₁₄, —NR₁₄CO₂R₁₄,—NR₁₄R₁₄, —C(═NOR₁₄)NR₁₄R₁₄ or —NR₁₄CONR₁₄R₁₄, wherein the cycloalkyl,alkenyl, alkoxy and heteroaryl may be optionally substituted with one ormore R_(14a)'s and the heteroaryl consists of carbon atoms and 1, 2 or 3heteroatoms independently selected from the group consisting of N, S, orO;

R_(13c-2), R_(13d), and R_(13d-2) are H;

R₁₄, at each occurrence, is independently selected from hydrogen, C₁₋₁₀alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, a 4- to 12-membered heteroaryl or a4- to 12-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with beoptionally substituted with 0-3 R_(14a) and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(14a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, F, Cl, Br, I,—CN, —CO₂R₂₆, —CO₂NR₂₄R₂₄, —OCF₃, —OR₂₅, —SO₂R₂₄, —NR₂₄R₂₄ orC₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consist ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, S, or O;

R₂₄, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the alkyl, aryl, heteroaryland heterocyclyl may be optionally substituted with one or moreR_(24a)'S and the heteroaryl and heterocyclyl consist of carbon atomsand 1, 2, 3, or 4 heteroatoms independently selected from the groupconsisting of N, S, or O;

R_(24a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, —CN, —CO₂R₂₅,—OCF₃, —OR₂₅, —CONR₂₅R₂₅, —NR₂₅R₂₅ or C₆₋₁₀arylC₁₋₁₀alkyl, wherein theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R₂₅, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; and

R₂₆, at each occurrence, is independently selected from C₁₋₁₀alkyl,haloC₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-memberedheteroaryl or 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O.

In another embodiment, compounds, enantiomers, diastereomers, tautomers,prodrugs or salts thereof, of formula Ib or Ic, are provided wherein:

X, Y, Z, R_(13a), R_(13a-2), R_(13b-2), R_(13c-2), R_(13d) and R_(13d-2)are H;

R_(13b), at each occurrence, is independently H, C₁₋₁₀ alkoxy, or—NR₁₄R₁₄;

R_(13c), at each occurrence, is independently H, C₁₋₁₀ alkyl, C₃₋₁₀cycloalkyl, a 4- to 12-membered heteroaryl, —(CH₂)_(m)—SO₂NR₁₄R₁₄,—CONR₁₄R₁₄ or —NR₁₄R₁₄, wherein the cycloalkyl, and heteroaryl may beoptionally substituted with one or more R_(14a)'s and the heteroarylconsists of carbon atoms and 1, 2 or 3 heteroatoms independentlyselected from the group consisting of N, S, or O;

R₁₄, at each occurrence, is independently selected from hydrogen, C₁₋₁₀alkyl, C₃₋₁₀ cycloalkyl, C₆₋₁₀ aryl, a 4- to 12-membered heteroaryl or a4- to 12-membered heterocyclyl, wherein the alkyl, cycloalkyl, aryl,heteroaryl and heterocyclyl may be optionally substituted with beoptionally substituted with 0-3 R_(14a) and the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O;

R_(14a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, F, Cl, Br, I,—CN, —CO₂R₂₆, —CO₂NR₂₄R₂₄, —OCF₃, —OR₂₅, —SO₂R₂₄, —NR₂₄R₂₄ orC₆₋₁₀arylC₁₋₁₀alkyl, wherein the heteroaryl and heterocyclyl consist ofcarbon atoms and 1, 2, 3, or 4 heteroatoms independently selected fromthe group consisting of N, S, or O;

R₂₄, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the alkyl, aryl, heteroaryland heterocyclyl may be optionally substituted with one or moreR_(24a)'s and the heteroaryl and heterocyclyl consist of carbon atomsand 1, 2, 3, or 4 heteroatoms independently selected from the groupconsisting of N, S, or O;

R_(24a), at each occurrence, is independently selected from F, Cl, Br,I, C₁₋₁₀ alkyl, haloC₁₋₁₀alkyl, C₆₋₁₀aryl, C₃₋₁₀cycloalkyl, a 4- to12-membered heteroaryl, a 4- to 12-membered heterocyclyl, —CN, —CO₂R₂₅,—OCF₃, —OR₂₅, —CONR₂₅R₂₅, —NR₂₅R₂₅ or C₆₋₁₀arylC₁₋₁₀alkyl, wherein theheteroaryl and heterocyclyl consist of carbon atoms and 1, 2, 3, or 4heteroatoms independently selected from the group consisting of N, S, orO;

R₂₅, at each occurrence, is independently selected from hydrogen,C₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-membered heteroarylor 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O; and

R₂₆, at each occurrence, is independently selected from C₁₋₁₀alkyl,haloC₁₋₁₀alkyl, C₃₋₁₀cycloalkyl, C₆₋₁₀aryl, a 4- to 12-memberedheteroaryl or 4- to 12-membered heterocyclyl, wherein the heteroaryl andheterocyclyl consist of carbon atoms and 1, 2, 3, or 4 heteroatomsindependently selected from the group consisting of N, S, or O.

In another embodiment, compounds, enantiomers, diastereomers, tautomers,or salt thereof, of the present invention are selected from thecompounds exemplified in the examples, preferably, Examples 7, 22, 29,31, 32, 38, 40, 42, 46, 50, 97, 105, 107, 108, 110, 111, 130, 134 and137 more preferably, Examples 7, 32, and 101, even more preferably,Examples 7 and 101.

In one embodiment, pharmaceutical compositions comprising atherapeutically effective amount of at least one compound of formula I,Ia, Ib, and/or Ic, preferably compounds exemplified in the examples,more preferably, Examples 7, 22, 29, 31, 32, 38, 40, 42, 46, 50, 97,105, 107, 108, 110, 111, 130, 134 and 137, even more preferably,Examples 7, 32, and 101, still even more preferably, Examples 7 and 101,are provided.

In another embodiment, pharmaceutical compositions comprising atherapeutically effective amount of at least one compound of formula I,Ia, Ib, and/or Ic, preferably compounds exemplified in the examples,more preferably, Examples 7, 22, 29, 31, 32, 38, 40, 42, 46, 50, 97,105, 107, 108, 110, 111, 130, 134 and 137, even more preferably,Examples 7, 32, and 101, still even more preferably, Examples 7 and 101,and at least one other therapeutic agent, for example, anti-arrhythmicagents, calcium channel blockers, anti-platelet agents,anti-hypertensive agents, anti thrombotic/anti thrombolytic agents, anticoagulants, HMG-CoA reductase inhibitors, anti diabetic agents, thyroidmimetics, mineralocorticoid receptor antagonists, and cardiacglycosides, are provided.

In yet another embodiment, pharmaceutical compositions comprising atherapeutically effective amount of at least one compound of formula I,Ia, Ib, and/or Ic, preferably compounds exemplified in the examples,more preferably, Examples 7, 22, 29, 31, 32, 38, 40, 42, 46, 50, 97,105, 107, 108, 110, 111, 130, 134 and 137, even more preferably,Examples 7, 32, and 101, still even more preferably, Examples 7 and 101,and at least one other therapeutic agent, for example, sotalol,dofetilide, diltiazem, verapamil, clopidogrel, cangrelor, ticlopidine,CS-747, ifetroban, aspirin, a beta adrenergic blocker, an ACE inhibitor,an A II antagonist, an ET antagonist, a dual ET/A II antagonist, avasopepsidase inhibitor, tPA, recombinant tPA, TNK, nPA, a factor VIIainhibitor, a factor Xa inhibitor, a factor XIa inhibitor, a thrombininhibitor, warfarin, a heparin, pravastatin, lovastatin, atorvastatin,simvastatin, NK-104, ZD-4522, a biguanide, a biguanide/glyburidecombination, spironolactone, eplerinone, digitalis and ouabain, areprovided.

In still yet another embodiment, pharmaceutical compositions comprisinga therapeutically effective amount of at least one compound of formulaI, Ia, Ib, and/or Ic, preferably compounds exemplified in the examples,more preferably, Examples 7, 22, 29, 31, 32, 38, 40, 42, 46, 50, 97,105, 107, 108, 110, 111, 130, 134 and 137, even more preferably,Examples 7, 32, and 101, still even more preferably, Examples 7 and 101,and at least one other therapeutic agent, for example, captopril,zofenopril, fosinopril, enalapril, ceranopril, cilazopril, delapril,pentopril, quinapril, ramipril, lisinopril, omapatrilat, gemopatrilat,and razaxaban, are provided.

In one embodiment, methods of treating or preventing arrhythmiacomprising administering to a patient in need thereof an effectiveamount of at least one compound of formula I, Ia, Ib, and/or Ic,preferably compounds exemplified in the examples, more preferably,Examples 7, 22, 29, 31, 32, 38, 40, 42, 46, 50, 97, 105, 107, 108, 110,111, 130, 134 and 137, even more preferably, Examples 7, 32, and 101,still even more preferably, Examples 7 and 101, are provided.

In another embodiment, methods of treating or preventingsupraventricular arrhythmia, for example, atrial fibrillation and atrialflutter, comprising administering to a patient in need thereof aneffective amount of at least one compound of formula I, la, Ib, and/orIc, preferably compounds exemplified in the examples, more preferably,Examples 7, 22, 29, 31, 32, 38, 40, 42, 46, 50, 97, 105, 107, 108, 110,111, 130, 134 and 137, even more preferably, Examples 7, 32, and 101,still even more preferably, Examples 7 and 101, are provided.

In one embodiment, a method of controlling heart rate comprisingadministering to a patient in need thereof an effective amount of atleast one compound of formula I, Ia, Ib, and/or Ic, preferably compoundsexemplified in the examples, more preferably, Examples 7, 22, 29, 31,32, 38, 40, 42, 46, 50, 97, 105, 107, 108, 110, 111, 130, 134 and 137,even more preferably, Examples 7, 32, and 101, still even morepreferably, Examples 7 and 101, is provided.

In another embodiment, methods of treating an I_(Kur)-associatedconditions, for example, gastrointestinal disorders, such as refluxesauphagitis and a motility disorder; inflammatory and/or immunologicaldiseases, such as chronic obstructive pulmonary disease; diabetes;cognitive disorders; migraines; epilepsy; and hypertension, comprisingadministering to a patient in need thereof an effective amount of atleast one compound of formula I, Ia, Ib, and/or Ic, preferably compoundsexemplified in the examples, more preferably, Examples 7, 22, 29, 31,32, 38, 40, 42, 46, 50, 97, 105, 107, 108, 110, 111, 130, 134 and 137,even more preferably, Examples 7, 32, and 101, still even morepreferably, Examples 7 and 101, are provided.

The invention may be embodied in other specific forms without departingfrom the spirit or essential attributes thereof. This invention alsoencompasses all combinations of alternative aspects of the inventionnoted herein. It is understood that any and all embodiments of thepresent invention may be taken in conjunction with any other embodimentto describe additional embodiments of the present invention.Furthermore, any elements of an embodiment may be combined with any andall other elements from any of the embodiments to describe additionalembodiments.

Synthesis

The compounds of the present invention can be prepared in a number ofways known to one skilled in the art of organic synthesis. The compoundsof the present invention can be synthesized using the methods describedbelow, together with synthetic methods known in the art of syntheticorganic chemistry, or by variations thereon as appreciated by thoseskilled in the art. Preferred methods include, but are not limited to,those described below. The reactions are performed in a solvent orsolvent mixture appropriate to the reagents and materials employed andsuitable for the transformations being effected. It will be understoodby those skilled in the art of organic synthesis that the functionalitypresent on the molecule should be consistent with the transformationsproposed. This will sometimes require a judgment to modify the order ofthe synthetic steps or to select one particular process scheme overanother in order to obtain a desired compound of the invention.

The novel compounds of this invention may be prepared using thereactions and techniques described in this section. Also, in thedescription of the synthetic methods described below, it is to beunderstood that all proposed reaction conditions, including choice ofsolvent, reaction atmosphere, reaction temperature, duration of theexperiment and workup procedures, are chosen to be the conditionsstandard for that reaction, which should be readily recognized by oneskilled in the art. Restrictions to the substituents that are compatiblewith the reaction conditions will be readily apparent to one skilled inthe art and alternate methods must then be used.

The compounds of the present invention may be prepared by the exemplaryprocesses described in the following schemes and working examples, aswell as relevant published literature procedures that are used by oneskilled in the art. Exemplary reagents and procedures for thesereactions appear hereinafter and in the working examples. Protection andde-protection of functional groups in the processes below may be carriedout by procedures generally known in the art (see, for example, Greene,T. W. et al., Protecting Groups in Organic Synthesis, 3^(rd) Ed., Wiley(1999). General methods of organic synthesis and functional grouptransformations are found in: Trost, B. M. et al., eds., ComprehensiveOrganic Synthesis: Selectivity, Strategy & Efficiency in Modern OrganicChemistry, Pergamon Press, New York, N.Y. (1991); March, J., AdvancedOrganic Chemistry: Reactions, Mechanisms, and Structure, 4^(th) Ed.,Wiley & Sons, New York, N.Y. (1992); Katritzky, A. R. et al., eds.,Comprehensive Organic Functional Groups Transformations, 1^(st) Ed.,Elsevier Science Inc., Tarrytown, N.Y. (1995); Larock, R. C.,Comprehensive Organic Transformations, VCH Publishers, Inc., New York,N.Y. (1989); and references therein.

Solvents, temperatures, pressures, and other reaction conditions mayreadily be selected by one of ordinary skill in the art. Startingmaterials are commercially available or can be readily prepared by oneof ordinary skill in the art using known methods. For all of the schemesand compounds described below Y, Z, A, R₁ and R₂₄ are as described for acompound of Formula (I).

The following are the definitions of symbols used throughout Schemes 1to 3 and the examples:

Me=Methyl Et=Ethyl Pr=Propyl

i-Pr=Isopropyl

Bu=Butyl

i-Bu=Isobutylt-Bu=tert-butyl

Ph=Phenyl Bn=Benzyl

Boc=tert-butyloxycarbonylAcOH or HOAc=acetic acidAlCl₃=aluminum chlorideCH₂Cl₂=Dichloromethane

CH₃CN or CAN=Acetonitrile

CDCl₃=deutero-chloroform

CHCl₃=Chloroform

mCPBA or m-CPBA=meta-chloroperbenzoic acidCs₂CO₃=cesium carbonate

DCM=Dichloromethane DEA=Diethylamine DIC=Diisopropylcarbodiimide

dil=diluteDIPEA or Hunig's base=DiisopropylethylamineDME=1,2-dimethyoxyethane

DMF=Dimethylformamide

DMSO=dimethyl sulfoxidecDNA=complimentary DNAEDC=N-(3-dimethylaminopropyl)-N′-ethylcarbodiimideEDTA=ethylenediaminetetraacetic acid

Et₃N or TEA=Triethylamine

EtOAc=ethyl acetateEt₂O=diethyl ether

EtOH=Ethanol

eq=equivalentsHCl=hydrochloric acidHOBt=1-hydroxybenzotriazoleHAUT=(2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate)H₂SO₄=sulfuric acidK₂CO₃=potassium carbonateKOAc=potassium acetateK₃PO₄=potassium phosphateLG=leaving groupLiOH=lithium hydroxide

MeOH=Methanol

min=minute or minutesMgSO₄=magnesium sulfateMsOH or MSA=methylsulfonic acidNaCl=sodium chlorideNaH=sodium hydrideNaHCO₃=sodium bicarbonateNa₂CO₃=sodium carbonateNaOH=sodium hydroxideNa₂SO₃=sodium sulfiteNa₂SO₄=sodium sulfate

NH₃=Ammonia

NH₄C₁=ammonium chlorideNH₄OH=ammonium hydroxidePd(OAc)₂=palladium(II) acetatePd/C=palladium on carbonPd(dppf)Cl₂=[1,1′-bis(diphenylphosphino)-ferrocene]dichloropalladium(II)Ph₃PCl₂=triphenylphosphine dichloridePd(TRIPHENYLPHOSPHINE)₂Cl₂=Bis(triphenylphosphine)palladium(II)chloridePG=protecting groupPOCl₃=phosphorus oxychloridei-PrOH or IPA=Isopropanol

PS=Polystyrene

PyBOP=(benzotriazol-1-yloxy)tripyrrolidinophosphoniumhexafluorophosphatePyBrop=Bromo-tris-pyrrolidino phosphoniumhexafluorophosphateSiO₂=silica oxideSnCl₂=tin(II) chlorideTFA=trifluoroacetic acid

THF=Tetrahydrofuran

TOSMIC=Toluenesulfonylmethyl isocyanide

Compounds of formula I may be synthesized according to Scheme 1.Commercially available 4-bromoindoline-2,3-dione may be hydrolyzed to2-amino-6-bromobenzamide followed by condensation with sodium isocyanateto form 5-bromoquinazoline-2,4(1H,3H)-dione. The protocols include, butare not limited to, palladium mediated cross coupling between5-bromoquinazoline-2,4(1H,3H)-dione and the aryl boronic acid or esterto form the intermediate 5-substituted quinazoline-2,4(1H, 3H)-dione.Conversion to the corresponding dichloro quinazoline and sequentialdisplacement at the 4-position followed by transition metal mediatedcross coupling or displacement of the C₂ chloride forms compounds I asdescribed.

Alternatively, compounds of formula I may also be synthesized accordingto Scheme 2. Formation of the methyl-carbimidate from the correspondingnitrile and subsequent condensation with 2-amino-6-bromobenzamideprovides compounds of formula 8. Subsequent conversion of 8 to4-chloroquinazoline intermediate 9 and displacement of the chlorideprovides 5-bromoquinazoline 10. Compounds of formula 10 may be obtaineddirectly from 8 utilizing coupling reagents, for example but not limitedto, PyBOP in suitable solvents. The protocols include but are notlimited to palladium mediated cross coupling between quinazoline 10 anda suitable aryl boronic acid or ester to obtain compounds of formula I.

Alternatively, compounds of formula I may also be synthesized accordingto Scheme 3. Compounds of formula 8 may be subjected to cross couplingconditions, for example, but not limited to palladium mediated crosscoupling of aryl boronic acids or esters, followed by subsequentconversion to the quinazoline intermediate 12 and displacement of the C₄chloro group to obtain compounds of Formula I.

It should be recognized that the above schemes are only illustrations ofsome general synthetic routes to prepare compounds of the presentinvention. The experimental details for the synthesis of variousspecific examples of the present invention will be further described inthe examples set forth below. Additional functional group manipulationsof compounds obtained in the above schemes using methods known in theart should provide additional compounds of this invention.

EXAMPLES

The following examples are offered to illustrate, but not limit, some ofthe preferred embodiments of the present invention and are not meant tobe limiting of the scope of the invention. Abbreviations and chemicalsymbols have their usual and customary meanings unless otherwiseindicated. Unless otherwise indicated, the compounds described hereinhave been prepared, isolated and characterized using the schemes andother methods disclosed herein or may be prepared using the same.

General Methods

The following methods were used in the working Examples, except wherenoted otherwise.

Analytical HPLC and HPLC/MS Methods Employed in Characterization of theexamples are as follows:

Reverse phase analytical HPLC/MS was performed on Shimadzu LC10ASsystems coupled with Waters ZMD Mass Spectrometers (methods A-C, E andF) or Waters AQUITY® system coupled with a Waters MICROMASS® ZQ MassSpectrometer (method D). Chiral analytical LC was performed on a BergerAnalytical SFC instrument (method G).

Method A:

Linear gradient of 0 to 100% B over 2 min, with 3 min hold at 100% B;UV visualization at 220 nm;

Column: PHENOMENEX® Luna C18 4.6×30 mm;

Flow rate: 5 ml/min;Solvent A: 0.1% trifluoroacetic acid, 90% water, 10% acetonitrile;Solvent B: 0.1% trifluoroacetic acid, 90% acetonitrile, 10% water.

Method B:

Linear gradient of 0 to 100% B over 10 min, with 5 min hold at 100% B;UV visualization at 220 nm;Column: Xbridge phenyl 4.6×150 mm;Flow rate: 1 ml/min;Solvent A: 0.1% trifluoroacetic acid, 90% water, 10% acetonitrile;Solvent B: 0.1% trifluoroacetic acid, 90% acetonitrile, 10% water.

Method C:

Linear gradient of 0 to 100% B over 4 min, with 1 min hold at 100% B;UV visualization at 220 nm;

Column: PHENOMENEX® Luna C18 4.6×50 mm;

Flow rate: 4 ml/min;Solvent A: 10 mM ammonium acetate, 90% water, 10% methanol;Solvent B: 10 mM ammonium acetate, 90% methanol, 10% water.

Method D:

Linear gradient of 2 to 98% B over 1 min, with 0.5 min hold time at 98%B;UV visualization at 220 nm;

Column: Waters BEH C18 2.1×50 mm;

Flow rate: 0.8 ml/min;Solvent A: 0.05% TFA, 100% water;

Solvent B: 0.05% TFA, 100% ACN. Method E:

Linear gradient of 0 to 100% B over 4 min, with 1 min hold time at 100%B;UV visualization at 220 nm;

Column: Ascentis Express 4.6×50 C18 at 45° C.;

Flow rate: 4 ml/min;Solvent A: 10 mM ammonium acetate, 5% ACN, 95% water;Solvent B: 10 mM ammonium acetate, 95% ACN, 5% water.

Method F:

Linear gradient of 0 to 100% B over 8 min, with 1 min hold at 100% B;UV visualization at 220 nm;

Column: PHENOMENEX® Luna C18 4.6×75 mm;

Flow rate: 2.5 ml/min;Solvent A: 10 mM ammonium acetate, 90% water, 10% methanol;Solvent B: 10 mM ammonium acetate, 90% methanol, 10% water.

Method G:

Isocratic 80/20 CO₂/MeOH containing 0.1% DEA;UV visualization at 220 nm;

Column: CHIRALPAK® AC, 250×4.6 mm, 10 uM;

Flow rate: 3.0 ml/min.

Preparative HPLC methods employed in the purification of the examplesare as follows:

Method H:

Linear gradient of 0 to 100% B over 10 min, with 5 min hold time at 100%B;Shimadzu LC-8A binary pumps;Waters ZQ mass spectrometer using Waters Masslynx 4.0 SP4 MS software;UV visualization at 220 nm;

Column: Waters SunFire 19×100 mm 5 um C18;

Flow rate: 20 ml/min;Peak collection triggered by mass spectrometry;Solvent A: 0.1% TFA, 10% ACN, 90% water;Solvent B: 0.1% TFA, 90% ACN, 10% water.

Method I:

Linear gradient of 20 to 100% B over 10 min, with 5 min hold time at100% B;Shimadzu LC-8A binary pumps;Shimadzu SPD-20A UV detector;UV visualization at 220 nm;

Column: PHENOMENEX® Luna AXIA 21.1×100 mm 5 um C18;

Flow rate: 20 ml/min;Peak collection triggered by UV absorbance;Solvent A: 0.1% TFA, 10% MeOH, 90% water;Solvent B: 0.1% TFA, 90% MeOH, 10% water.

Method J:

Linear gradient of 20 to 100% B over 10 min, with 2 min hold time at100% B;Shimadzu LC-8A binary pumps;Shimadzu SPD-10A UV detector;UV visualization at 220 nm;

Column: PHENOMENEX® Luna AXIA 21.1×100 mm 5 um C18;

Flow rate: 20 ml/min;Peak collection triggered by UV absorbance;Solvent A: 0.1% TFA, 10% ACN, 90% water;Solvent B: 0.1% TFA, 90% ACN, 10% water.

Method K:

Isocratic 80/20 CO₂/CH₃OH containing 0.1% DEA;Berger Multigram II SFC instrument;UV visualization at 220 nm;

Column: CHIRALPAK® AD-H 250×21 cm ID, 5 uM;

Flow rate: 65 ml/min;Peak collection triggered by UV absorbance.

Additional Analytical HPLC and HPLC/MS Methods Employed inCharacterization of Examples are as follows:

Method L:

Solvent A-5% ACN, 95% water, 10 mM NH₄OAc;

Solvent B-95% ACN, 5% Water, 10 mM NH₄OAc;

Flow rate: 4.0 ml/min;

Column: Ascentis Express C18 (4.6×50 cm) mm, 2.7 um;

Time (min): 0-4.0 gradient % B: 0-100.

Method M:

Linear gradient of 0 to 100% B over 2 min;UV visualization at 220 nm;

Column: PHENOMENEX® Luna C18 4.6×30 mm;

Flow rate: 5 mL/min;Solvent A: 0.1% trifluoroacetic acid, 90% water, 10% methanol;Solvent B: 0.1% trifluoroacetic acid, 90% methanol, 10% water.

Method N:

-   Linear gradient of 0 to 5% B over 0.25 min then 5 to 100% B up to 2    min with 0.5 min hold at 100% B;-   UV visualization at 220 nm;-   Column: BEH C18 50×2.1 mm-1.7 μm;-   Flow rate: 0.6 mL/min;-   Solvent A: 0.1% formic acid, 95% water, 5% acetonitrile;-   Solvent B: 0.1% formic acid, 95% acetonitrile, 5% water.

Method O:

Linear gradient of 0 to 100% B over 2 min;UV visualization at 220 nm;

Column: CHROMOLITH® SpeedROD C18 4.6×30 mm;

Flow rate: 5 mL/min;Solvent A: 0.1% trifluoroacetic acid, 90% water, 10% methanol;Solvent B: 0.1% trifluoroacetic acid, 90% methanol, 10% water.

Method P:

Linear gradient of 40 to 95% B over 3 min with 3 min hold at 95% B;UV visualization at 220 nm;Column: Atlantis dC18 C18 50×4.6 mm-5 μm;Flow rate: 1.5 mL/min;Solvent A: 0.1% formic acid in water;Solvent B: acetonitrile.

Method Q:

Linear gradient of 0 to 100% B over 2 min;UV visualization at 220 nm;

Column: PHENOMENEX® Luna C18 4.6×30 mm;

Flow rate: 5 mL/min;Solvent A: 10 mM ammonium acetate, 90% water, 10% methanol;Solvent B: 10 mM ammonium acetate, 90% methanol, 10% water.

Method R:

Linear gradient of 30 to 95% B over 3 min with 1 min hold at 95% B;UV visualization at 220 nm;Column: Atlantis dC18 C18 50×4.6 mm-5 μm;Flow rate: 1 mL/min;Solvent A: 10 mM ammonium acetate in water;Solvent B: acetonitrile.

Method S:

Linear gradient of 40 to 95% B over 3 min with 1 min hold at 95% B;UV visualization at 220 nm;Column: Atlantis dC18 C18 50×4.6 mm-5 μm;Flow rate: 1.5 mL/min;Solvent A: 10 mM ammonium acetate in water;Solvent B: acetonitrile.

Method T:

Linear gradient of 0 to 100% B over 2 minAgilent 1200 series systems coupled with DADetector using Agilentchemstation & using Chemstation B.04.01 (482) software, with ESIionization source in Positive mode only.UV visualization at 220 nm;

Column: Agilent Zorbax SB C18 4.6×50 mm 5 um

Gradient Programme: Time (min)/% B: 0/0, 2/100, 3/0.Flow rate: 5.0 ml/min;Buffer: 0.1% Trifluoroacetic acid in water.

Mobile Phase A: Buffer: Methanol: 90:10 Mobile Phase B: Buffer:Methanol: 10:90 Method U:

Linear gradient of 0 to 100% B over 2 min;UV visualization at 220 nm;

Column: Chromolith SpeedROD C18 4.6×30 mm;

Flow rate: 5 mL/min;Solvent A: 0.1% trifluoroacetic acid, 90% water, 10% methanol;Solvent B: 0.1% trifluoroacetic acid, 90% methanol, 10% water.

Method V:

Linear gradient of 0 to 100% B over 1.5 min, with 1.7 min hold at 100%B;Agilent 1200 series systems coupled with DADetector using Agilentchemstation & using Chemstation B.04.01 (482) software; with ESIionization source in both Positive & Negative mode.UV visualization at 220 nm;

Column: Waters Xbridge Phenyl 4.6×30 mm 3.5 um

Gradient Programme: Time (min)/% B: 0/0, 1.5/100, 3.2/100, 3.6/0, 4.0/0Flow rate: 1.8 ml/min;Buffer: 10 mM Ammonium Formate in water.

Mobile Phase A: Buffer: Acetonitrile: 98:02 Mobile Phase B: Buffer:Acetonitrile: 02:98 Method W:

Linear gradient of 0 to 100% B over 2.50 min, with 0.5 min hold at 100%B;Agilent 1200 series systems coupled with DADetector using Agilentchemstation & Chemstation B.04.01 (482) software with Multi modeionization source in both Positive & Negative mode.UV visualization at 220 nm;

Column: Merck Puroshpere @ Star RP-18 4×5 mm, 3 u

Gradient Programme: Time (min)/% B: 0/0, 2.0/100, 2.5/100, 3.0/0, 3.5/0Flow rate: 2.5 ml/min;Buffer: 20 mM Ammonium Acetate in water.

Mobile Phase A: Buffer: Acetonitrile: 90:10 Mobile Phase B: Buffer:Acetonitrile: 10:90 Method X:

Linear gradient of 0 to 100% B over 2 min;UV visualization at 220 nm;

Column: Phenomenex Luna C18 4.6×30 mm;

Flow rate: 5 mL/min;Solvent A: 10 mM ammonium acetate, 90% water, 10% methanol;Solvent B: 10 mM ammonium acetate, 90% methanol, 10% water.

Method Y:

Reverse phase analytical HPLC/MS was performed on Agilent 1200 seriessystems coupled with DADetector, Ion-Trap 6330 Mass Spectrometer, 1200ELSD (Agilent) using Agilent chemstation & Brooker 4.0 Build 234software in both Positive & Negative mode.Linear gradient of 0 to 100% B over 1.2 min, with 1.8 min hold at 100%B;Agilent 1200 series systems coupled with DADetectorUV visualization at 220 nm;

Column: Ascentis Express C18 2.1×50 mm, 2.7 u

Gradient Programme: Time (min)/% B: 0/0, 1.2/100, 3.0/100, 3.4/0, 4.0/0Flow rate: 1.0 ml/min;Buffer: 10 mM Ammonium Formate in water.

Mobile Phase A: Buffer: Acetonitrile: 98:02 Mobile Phase B: Buffer:Acetonitrile: 02:98 Method Z:

Reverse phase analytical HPLC/MS was performed on Agilent 1200 seriessystems coupled with DADetector, Ion-Trap 6330 Mass Spectrometer, 1200ELSD (Agilent) using Agilent chemstation & Brooker 4.0 Build 234software in both Positive & Negative mode.Linear gradient of 0 to 100% B over 1.2 min, with 1.8 min hold at 100%B;Agilent 1200 series systems coupled with DADetectorUV visualization at 220 nm;

Column: Zorbax AQ C18 4.6×50 mm, 3.5 u

Gradient Programme: Time (min)/% B: 0/2, 1.5/20, 4.0/95, 4.5/2, 6/2Flow rate: 1.0 ml/min;Buffer: 0.1% Formic Acid in water.Mobile Phase A: 0.1% Formic Acid in water.

Mobile Phase B: Acetonitrile. Method Z1: Method Info:

A: Water:ACN (95:5); 10 mM ammonium acetateB: Water:ACN (5:95); 10 mM ammonium acetateFlow: 4 ml/min

Temp: 45° C. Column: Ascentis Express C18 (50×4.6), 2.7 μm

Time (min): 0-4

Method A1:

Linear gradient of 10 to 100% B over 12 min, with 3 min hold at 100% B;

Gradient Programme: T/% B: 0/10, 12/100, 15/100, 18/10, 23/10

UV visualization at 220 & 254 nm;

Waters Sunfire C18 (4.6×150 mm, 3.5 u)

Flow rate: 1 ml/minBuffer: 0.05% Trifluoroacetic acid in water pH adjusted to 2.5 with dilAmmonia

Mobile Phase A: Buffer: Acetonitrile: 95:05 Mobile Phase B: Buffer:Acetonitrile: 05:95 Method A2:

Linear gradient of 10 to 100% B over 12 min, with 3 min hold at 100% B;

Gradient Programme: T/% B: 0/10, 12/100, 15/100, 18/10, 23/10

UV visualization at 220 & 254 nm;

Waters Xbridge Phenyl (4.6×150 mm, 3.5 u)

Flow rate: 1 ml/minBuffer: 0.05% Trifluoroacetic acid in water pH adjusted to 2.5 with dilAmmonia

Mobile Phase A: Buffer: Acetonitrile: 95:05 Mobile Phase B: Buffer:Acetonitrile: 05:95 Method A3:

Linear gradient of 10 to 100% B over 12 min, with 8 min hold at 100% B;Gradient Programme: Time (min)/% B: 0/10, 12/100, 20/100, 23/10, 26/10UV visualization at 220 & 254 nm;

Waters Xbridge Phenyl (4.6×150 mm, 3.5 u)

Flow rate: 1.0 ml/min;Mobile Phase A: 10 mM Ammonium Bicarbonate in water pH adjusted to 9.5with dil Ammonia

Mobile Phase B: Methanol Method A4:

Linear gradient of 0 to 100% B over 10 min, with 5 min hold at 100% B;UV visualization at 220 nm;Column: X-bridge phenyl 4.6×150 mm;Flow rate: 1 ml/min;Solvent A: 0.1% trifluoroacetic acid, 90% water, 10% acetonitrile;Solvent B: 0.1% trifluoroacetic acid, 90% acetonitrile, 10% water.

¹H NMR spectra were obtained with Bruker or JEOL FOURIER® transformspectrometers operating at frequencies as follows: ¹H NMR: 400 MHz(Bruker or JEOL) or 500 MHz (JEOL). ¹³C NMR: 100 MHz (Bruker or JEOL).Spectra data are reported in the format: chemical shift (multiplicity,coupling constants, and number of hydrogens). Chemical shifts arespecified in ppm downfield of a tetramethylsilane internal standard (δunits, tetramethylsilane=0 ppm) and/or referenced to solvent peaks,which in ¹H NMR spectra appear at 2.49 ppm for CD₂HSOCD₃, 3.30 ppm forCD₂HOD, and 7.24 ppm for CHCl₃, and which in ¹³C NMR spectra appear at39.7 ppm for CD₃SOCD₃, 49.0 ppm for CD₃OD, and 77.0 ppm for CDCl₃. All¹³C NMR spectra were proton decoupled.

Example 15-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine

Step 1. Preparation of 2-amino-6-bromobenzoic acid

To 4-bromoindoline-2,3-dione (8.94 g, 39.6 mmol) was added 1.0 M sodiumhydroxide (40 mL, 120 mmol) to give a dark brown mixture. The mixturewas heated to 80° C. then 20% hydrogen peroxide (9 mL, 88 mmol) wasadded slowly over 15 min (caution: a strong exotherm was observed uponreagent addition). The mixture was then stirred at 80° C. for 1 h. Afterthis time, the mixture was cooled in an ice bath to ˜10° C. and thenconcentrated to a residue. HCl was added cautiously to the residue untilthe pH of the mixture was 4-5. Once at the prescribed pH, the mixturewas then concentrated to dryness and MeOH (150 ml) was added. Theresulting suspension stirred for 15 min and then filtered. The filtratewas concentrated to dryness and dried under vacuum for 14 h to yield2-amino-6-bromobenzoic acid (9.18 g) as a brown solid. ¹H NMR (400 MHz,DMSO-d₆) δ ppm 6.72 (1H, t, J=7.91 Hz), 6.60 (1H, dd, J=7.78, 1.00 Hz),6.52 (1H, dd, J=7.91, 1.13 Hz). LCMS Method D: retention time 0.68 min,[M+1] 200.0.

Step 2. Preparation of 5-bromoquinazoline-2,4(1H,3H)-dione

2-Amino-6-bromobenzoic acid (2.97 g, 13.7 mmol) was suspended in amixture of water (100 mL) and acetic acid (1.5 mL) at 35° C. then asuspension of sodium cyanate (2.23 g, 34.4 mmol) in 10 mL of water wasadded slowly to the mixture. Upon completion of addition, the resultingmixture was stirred at 35° C. for 30 minutes and then sodium hydroxide(24.7 g, 619 mmol) pellets were slowly added to the mixture to yield athick precipitate. The mixture was cooled to 5° C. in an ice bath andthe pH of the suspension was adjusted to 4 using concentrated HCl. Onceat the prescribed pH, the suspension was filtered and the solid waswashed with water and dried under vacuum while heating at 100° C. togive 5-bromo-1H-quinazoline-2,4-dione (1.91 g) as a brown solid. ¹H NMR(400 MHz, DMSO-d₆) δ ppm 11.30 (1H, br. s.), 11.26 (1H, br. s.),7.43-7.48 (1H, m), 7.40 (1H, dd, J=7.78, 1.25 Hz), 7.16 (1H, dd, J=7.91,1.13 Hz).

Step 3. Preparation of 2,4-dichloro-5-phenylquinazoline

See J. Med. Chem., 50(7):1675 (2007), 76759-011. To a mixture of5-bromoquinazoline-2,4(1H,3H)-dione (900 mg, 3.73 mmol) and Pd(Ph₃P)₄(216 mg, 0.187 mmol) in DME (90 mL) was added phenylboronic acid (683mg, 5.60 mmol) followed by a solution of sodium bicarbonate (941 mg,11.2 mmol) in water (30 mL) and the reaction heated at reflux for 40 h.At the conclusion of this period, the organic solvent was removed underreduced pressure. The resulting mixture was filtered and the solidwashed with water. The solid was concentrated under reduced pressurefrom MeOH/DCM to remove the water to yield5-phenylquinazoline-2,4(1H,3H)-dione as an off-white solid. The5-phenylquinazoline-2,4(1H,3H)-dione (9.64 g, 40.4 mmol) was added toPOCl₃ (75 mL, 810 mmol) followed by PhN(CH₃)₂ (10.3 mL, 81.0 mmol). Uponcompletion of addition, the reaction mixture was heated to reflux (105°C.) where it was stirred for 2 hours. After this time, the reactionmixture was allowed to cool to ambient temperature. Once at theprescribed temperature, the reaction mixture was concentrated underreduced pressure, diluted with DCM and then quenched by the addition ofcold 1M K₃PO₄ solution. The organic layer was separated and the aqueouslayer was extracted twice with DCM. The combined organic layers weredried over MgSO₄, filtered and concentrated under reduced pressure toyield a residue. The residue was purified by ISCO chromatography (330 gcolumn) using hexanes/EtOAc (0-25% over 20 min, flow rate 100 mL/min) togive 2,4-dichloro-5-phenylquinazoline (7.11 g, 63.9% yield) as a yellowsolid. ¹H NMR (400 MHz, chloroform-d) ppm 8.04 (1H, m) 7.96 (1H, m) 7.59(1H, dd, J=7.28, 1.25 Hz) 7.45 (3H, dd, J=5.02, 1.76 Hz) 7.32 (2H, m).

Step 4. Preparation of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine

2,4-Dichloro-5-phenylquinazoline (1.38 g, 5.03 mmol) was dissolved inTHF (80 mL) and triethylamine (1.33 mL, 9.56 mmol) was added dropwise.The mixture was stirred for 5 min at room temperature and thenpyridin-2-ylmethanamine (0.57 mL, 5.53 mmol) was added dropwise. Theresulting mixture was stirred at ambient temperature for 14 hours. Afterthis time, the mixture was filtered through a medium porosity glassfrit, concentrated to dryness under reduced pressure and then purifiedby ISCO flash column chromatography (80 g silica gel column) elutingwith 0-100% ethyl acetate/hexanes over 30 min to provide2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (1.32 g,75%). LCMS Method A [M+1] observed 347.1. HPLC Method B: Purity 99.1%retention time 6.66 min. ¹H NMR (400 MHz, chloroform-d) δ ppm 8.16 (1H,d, J=4.77 Hz), 7.79 (1H, d, J=7.28 Hz), 7.70 (1H, t, J=7.78 Hz), 7.59(1H, dt, J=7.53, 1.51 Hz), 7.40-7.55 (5H, m), 7.08-7.25 (4H, m), 4.66(2H, d, J=4.02 Hz).

Step 5. Example 1

2-Chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (225 mg,0.649 mmol), pyrimidin-5-ylboronic acid (121 mg, 0.973 mmol), and bis(triphenylphosphine)palladium (II) chloride (23 mg, 0.032 mmol) werecombined in a microwave tube which was sealed, evacuated and thenbackfilled with argon. Under argon, previously degassed dioxane (1 mL)and a sodium carbonate (0.33 mL, 0.330 mmol) in water (0.33 mL) solutionwere added to the reaction mixture. The resulting mixture was heatedunder microwave irradiation to 100° C. where it was maintained for 60min. After this time, additional pyrimidin-5-ylboronic acid (91 mg,0.7773 mmol) and bis (triphenylphosphine)palladium (II) chloride (17 mg,0.024 mmol) were added. Upon completion of addition, the resultingmixture was heated under microwave irradiation at 100° C. for 40 min andthen allowed to cool to room temperature where it stirred for 14 h. Atthe conclusion of this period, the reaction mixture was diluted with 50mL each of water and ethyl acetate. The organic layer was separated andthe aqueous portion was extracted with ethyl acetate. The combinedorganic portions were washed with 50 mL of brine, dried over Na₂SO₄,decanted and concentrated under reduced pressure to yield a cruderesidue. The crude residue was purified by ISCO (40 g silica gel column)eluting with 0-5% MeOH over 15 min and then 5% MeOH for 10 min to yieldExample 1 (212 mg, 84%). ¹H NMR (400 MHz, CDCl₃) ppm 4.74 (d, J=4.27 Hz,2H) 6.73-6.81 (m, 1H) 7.09-7.16 (m, 2H) 7.25-7.29 (m, 1H) 7.44-7.52 (m,5H) 7.58 (dt, J=7.72, 1.88 Hz, 1H) 7.73 (dd, J=8.28, 7.28 Hz, 1H) 7.93(dd, J=8.28, 1.25 Hz, 1H) 8.23-8.26 (m, 1H) 9.29 (s, 1H) 9.78 (s, 2H).LCMS Method D: retention time 0.76 min, [M+1]=391; HPLC Method B: purity99%, retention time 5.6 min.

Alternatively, Example 1 can be synthesized as follows:

Step 1. Preparation of methyl pyrimidine-5-carbimidate

To a stirred suspension of 5-cyanopyrimidine (5.0 g, 47 mmol) inmethanol (50 mL) was added 25% by weight sodium methoxide in methanol(1.2 g, 23 mmol). The mixture was stirred at room temperature for 17 hunder nitrogen atmosphere and then acetic acid (2.72 ml, 47 mmol) wasadded dropwise. The resulting mixture was stirred for 4 h and thenevaporated under reduced pressure to remove methanol and yield aresidue. The residue was dissolved in ether (150 mL) and the solids wereremoved by filtration. The filtrate was concentrated under reducedpressure to yield methyl pyrimidine-5-carbimidate (4.9 g, 75% yield).The crude product was used without further purification. ¹H NMR (400MHz, DMSO-d₆, δ): 3.83 (s, 3H); 9.18 (s, 2H); 9.30 (s, 1H); 9.54 (s,1H). ES-MS: [M⁺+1]=138.

Step 2. Preparation of 5-bromo-2-(pyrimidin-5-yl)quinazolin-4-ol

To a stirred suspension of methyl pyrimidine-5-carbimidate (2.00 g, 14.5mmol) in methanol (20 mL) was added 2-amino-6-bromobenzoic acid (3.1 g,14.5 mmol). The mixture was heated to reflux where it stirred for 16 hunder the nitrogen atmosphere. At the conclusion of this period, aceticacid (2.72 ml, 47 mmol) was added drop wise. Upon completion ofaddition, methanol was evaporated under reduced pressure to yield aresidue. The residue was triturated with ether (100 mL), ethyl acetate(50 mL) and the resulting solid was dried to yield5-bromo-2-(pyrimidin-5-yl)quinazolin-4-ol (1.2 g, 27%) as an off-whitesolid. The crude product was used without further purification. ¹H NMR(400 MHz, DMSO-d₆, δ): 7.64 (dd, J=7.2 Hz, 8.4 Hz, 1H); 7.73-7.75 (m,2H); 9.35 (s, 1H); 9.46 (s, 2H); 12.9 (br s, 1H). ES-MS: [M⁺+1]=303 and[M⁺+3]=305.

Step 3. Preparation of5-bromo-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine

To a stirred suspension of 5-bromo-2-(pyrimidin-5-yl)quinazolin-4-ol(2.0 g, 6.5 mmol) in DMF (20 mL) was added diisopropylethyl amine (3.4ml, 19 mmol) followed by PyBroP (3.7 g, 7.9 mmol). After 5 min stirringat room temperature, 2-aminomethylpyridine (1.0 mL, 9.8 mmol) was addedto the reaction. Upon completion of addition, the reaction mixture waswarmed to 80° C. where it stirred for 2 h (during which time reactionbecame a clear solution). At the conclusion of this period, the reactionmixture was quenched by the addition of cold water and then extractedinto 50% ethyl acetate and hexane mixture (200 mL). The organic extractswere dried, concentrated, purified by column chromatography using ethylacetate and hexanes as eluent to yield the crude produce. The crudeproduct was further purified by trituration with ethyl acetate andhexane to yield5-bromo-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine (0.5g, 20% yield). ¹H NMR (400 MHz, CDCl₃, δ): 5.07 (d, J=4.4 Hz, 2H); 7.26(m, 1H); 7.41 (d, J=7.6 Hz, 1H); 7.53 (t, J=8 Hz, 1H); 7.71-7.73 (m,2H); 7.86 (dd, J=0.8 Hz, 8.4 Hz, 1H); 8.65 (d, J=4 Hz, 1H); 9.30 (s,1H); 9.38 (br s, 1H); 9.75 (s, 2H). ES-MS: [M⁺+1]=393 and [M⁺+3]=395.

Step 4. Example 1

A stirred suspension of5-bromo-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine (1.0g, 2.5 mmol), phenylboronic acid (0.46 g, 3.8 mmol) and potassiumcarbonate (1.0 g, 7.6 mmol) in dimethoxyethane-water (3-1, 10 mL) wasdegassed and charged with tetrakistriphenylphosphene palladium (0.14 g,0.12 mmol). The reaction mixture was then heated to 90° C. where itstirred for 16 h under a nitrogen atmosphere. After this time, thereaction mixture was quenched with water (5 mL) and then extracted withethyl acetate (3×25 mL). The combined organic extracts were dried andthen concentrated to yield the crude product. The crude product waspurified by preparative TLC using chloroform and methanol (95:5) as thesolvent system to yield Example 1 (40 mg, 4% yield). ¹H NMR (400 MHz,DMSO-d₆, δ): 5.01 (d, J=5.6 Hz, 2H); 7.27 (t, J=4.0 Hz, 1H); 7.41-7.56(m, 5H); 7.66-7.79 (m, 4H); 7.91 (d, J=6.8 Hz, 1H); 8.42 (d, J=8 Hz,1H); 8.55 (d, J=4.8 Hz, 1H); 9.23 (s, 1H); 9.32 (t, J=6 Hz, 1H); 9.40(s, 2H). LCMS Method O: retention time 1.67 min, [M+1]=391. HPLC MethodB: purity 99%, retention time 8.5 min.

Example 1 can also be synthesized as follows:

Step 1. Preparation of 5-phenyl-2-(pyrimidin-5-yl)quinazolin-4-ol

A stirred suspension of 5-bromo-2-(pyrimidin-5-yl)quinazolin-4-ol (2.0g, 6.6 mmol), phenylboronic acid (1.2 g, 9.9 mmol) and a solution ofpotassium carbonate (2.6 g, 19.8 mmol) in dimethoxyethane and water(3:1, 15 mL) was degassed and charged with1,1′-bis(diphenylphosphino)ferrocene palladium dichloride (0.24 g, 0.33mmol). The reaction mixture was heated to 90° C. where it stirred for 24h under nitrogen atmosphere. At the conclusion of this period, thereaction mixture was concentrated to yield the crude product. The crudeproduct was purified by flash column chromatography on silica gel using2% methanol in dichloromethane as eluent to yield5-phenyl-2-(pyrimidin-5-yl)quinazolin-4-ol (800 mg, 27% yield). ¹H NMR(400 MHz, DMSO-d₆, δ): 7.29-7.40 (m, 6H); 7.79-7.87 (m, 4H); 9.37 (s,1H); 9.45 (s, 2H); 12.59 (br s, 1H). LCMS Method O: retention time 1.68min, [M+1]=301.

Step 2: Example 1

5-Phenyl-2-(pyrimidin-5-yl)quinazolin-4-ol was subsequently converted toExample 1 utilizing the reagents and conditions described for thepreparation of5-bromo-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine instep 3 above.

Example 25-Phenyl-N-(pyridin-2-ylmethyl)-2-(trifluoromethyl)quinazolin-4-amine

Step 1. Preparation of 5-chloro-2-(trifluoromethyl)quinazolin-4(3H)-one

See U.S. Pat. No. 3,843,791. To a solution of 2-amino-6-chlorobenzoicacid (1.91 g, 11.13 mmol) in a mixture of chloroform (22 mL) and drypyridine (1.5 mL) at 0° C. was added trifluoroacetic anhydride (3.52 mL,24.94 mmol). Upon completion of addition, the reaction mixture washeated to reflux where it stirred for 2 h. After this time, the reactionmixture was cooled to room temperature and concentrated to yield a crudematerial. The crude material was dissolved in chloroform (22 mL),saturated with ammonia gas and then stirred for 30 min at roomtemperature. After this time, the mixture was concentrated and theresulting solid was washed with 1N HCl (2×20 mL) and diluted with ethylacetate (100 mL) and water (100 mL). The organic layer was separated andthe aqueous layer was extracted with ethyl acetate (100 mL). The organiclayer was dried over MgSO₄, filtered and concentrated to yield the crudeproduct. The crude product was purified by flash chromatography onsilica gel eluting with 2-15% ethyl acetate/hexanes to afford5-chloro-2-(trifluoromethyl)quinazolin-4(3H)-one (1.3 g, 46%) as a whitesolid. ¹H NMR (400 MHz, chloroform-d) ppm 10.23 (1H, br. s.), 7.71-7.82(2H, m), 7.64 (1H, d, J=7.15 Hz). LCMS Method A: retention time 0.65 min[M+1]=250.

Step 2. Preparation of 5-phenyl-2-(trifluoromethyl)quinazolin-4(3H)-one

Palladium (II) acetate (19 mg, 0.085 mmol), potassium fluoride (498 mg,8.57 mmol), 2-(di-tert-butylphosphino)biphenyl (51.1 mg, 0.171 mmol),and phenylboronic acid (522 mg, 4.27 mmol) were combined in a microwavevial under an argon atmosphere. A solution of5-chloro-2-(trifluoromethyl)quinazolin-4(3H)-one (710 mg, 2.86 mmol) indry THF (9 mL) was added and the mixture was heated in the microwave at100° C. for 30 min. After this time, the reaction mixture was dilutedwith ethyl acetate (50 mL) and washed with 1N NaOH (25 mL) and saturatedNaCl (25 mL). The organic layer was separated, dried over sodium sulfateand then concentrated under reduced pressure to give the crude product(968 mg), which was used in the next step without further purification.

Step 3. Preparation of 4-chloro-5-phenyl-2-(trifluoromethyl)quinazoline

To the crude material from Step 2, Example 3, was added phosphorousoxychloride (2.86 mL, 307 mmol) and N,N-dimethylaniline (425 μL, 3.34mmol). The reaction mixture was heated to 100° C. where it stirred for10 min. After this time, the reaction mixture was cooled to roomtemperature. Once at the prescribed temperature, the solvents wereremoved under reduced pressure to yield a residue, which was thendissolved in dichloromethane (20 mL). The dichloromethane solution wasadded to 50 mL of a 1.5 M KH₂PO₄ solution. Upon completion of addition,the dichloromethane was removed under reduced pressure and the aqueouslayer was extracted with DCM (3×50 mL). The combined organic portionswere dried over sodium sulfate and concentrated under reduced pressureto yield a second residue. The second residue was purified by flashchromatography on silica gel eluting with 100% DCM to yield4-chloro-5-phenyl-2-(trifluoromethyl)quinazoline (612 mg, 59% yield) asa white solid. ¹H NMR (400 MHz, chloroform-d) ppm 8.27 (1H, d, J=8.53Hz), 8.07 (1H, t, J=7.78 Hz), 7.75 (1H, d, J=7.03 Hz), 7.42-7.54 (3H,m), 7.29-7.38 (2H, m). LCMS Method D: retention time 1.07 min [M+1]=309.

Step 4. Example 2

To a solution of 4-chloro-5-phenyl-2-(trifluoromethyl)quinazoline (200mg, 0.648 mmol) in THF (15 mL) was added triethylamine (0.172 mL, 1.231mmol). Upon completion of addition, the reaction mixture was stirred andpyridin-2-ylmethanamine was added (0.080 mL, 0.777 mmol). The resultingreaction mixture was stirred at room temperature for 1 h and thenfiltered. The filtrate was concentrated under reduced pressure to yielda residue. The residue was purified by flash chromatography on silicagel eluting with 0-75% ethyl acetate/hexanes to yield Example 2 (217 mg,88% yield) as a white solid. ¹H NMR (400 MHz, chloroform-d) ppm 8.20(1H, d, J=4.55 Hz), 7.99 (1H, d, J=8.34 Hz), 7.78 (1H, t, J=7.71 Hz),7.59 (1H, t, J=7.58 Hz), 7.42-7.54 (5H, m), 7.35 (1H, d, J=7.33 Hz),7.03-7.22 (3H, m), 4.69 (2H, d, J=4.04 Hz). LCMS Method D: retentiontime 0.90 min [M+1]=381.

Example 32-Cyclopropyl-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine

To a mixture of zinc bromide (64.9 mg, 0.288 mmol) and1,1′-bis(diphenylphosphino)ferrocene-palladium(II)dichloridedichloromethane complex (5.89 mg, 7.21 μmol) was added anhydrous THF(0.3 mL). Upon completion of addition, the mixture was cooled to −78° C.Once at the prescribed temperature, cyclopropyl magnesium bromide (0.288mL, 0.144 mmol) was added dropwise and the mixture was stirred at −78°C. for 15 min. At the conclusion of this period, a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (50 mg, 0.144mmol) in anhydrous THF (1.5 mL) was added. The resulting mixture wasstirred at −78° C. for 1 h and then allowed to warm to room temperaturewhere it stirred for 18 h. After this time, the reaction mixture wasdiluted with saturated NH₄Cl (5 mL) and the aqueous layer extracted withethyl acetate (3×20 mL). The organic portions were combined and washedwith saturated NaCl, dried over sodium sulfate and concentrated underreduced pressure to yield the crude product. The crude product waspurified by preparative HPLC (YMC Sunfire 5 u C18 30×100 mm, MobilePhase A: 10% MeOH—90% H₂O—0.1% TFA, Mobile Phase B: 90% MeOH—10%H₂O—0.1% TFA, 20-100% B over 10 min, 100% B for 2 min) to yield Example3 (3.73 mg, 7% yield) as a pale yellow solid. ¹H NMR (400 MHz,chloroform-d) ppm 8.27-8.30 (1H, m), 7.77 (1H, dd, J=8.46, 0.88 Hz),7.63 (1H, dd, J=8.34, 7.07 Hz), 7.56 (1H, td, J=7.71, 1.77 Hz),7.41-7.48 (5H, m), 7.04-7.15 (3H, m), 6.30 (1H, br. s.), 4.57 (2H, d,J=4.55 Hz), 2.11-2.20 (1H, m), 1.10-1.16 (2H, m), 0.92-0.98 (2H, m).LCMS Method D: retention time 0.76 min [M+1]=353.

Example 65-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinamide

To a solution of5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinonitrile(prepared in a similar manner to the procedures described in Example 1,200 mg, 0.48 mmol) in THF (5 mL) was slowly added a solution of sodiumhydroxide (77 mg, 1.92 mmol) in H₂O (2 mL). The resulting mixture wascooled to 0° C. and 30% H₂O₂ (0.2 mL, 1.92 mmol) was added. Uponcompletion of addition, the reaction mixture was allowed to warm to roomtemperature where it stirred for 16 h. At the conclusion of this period,the reaction mixture was filtered and purified by preparative TLC using5% chloroform in methanol to afford Example 6 (50 mg) as brown solid. ¹HNMR (400 MHz, DMSO-d₆) δ (ppm): 9.74 (d, J=1.8 Hz, 1H), 9.18-9.15 (dd,J=11.2, 1.6 Hz, 2H), 8.34 (s, 1H), 8.24 (d, J=4.4 Hz, 1H), 7.95-7.93(dd, J=8.4, 1.2 Hz, 1H), 7.88-7.84 (dt, J=7.2, 1.6 Hz, 1H), 7.76-7.71(dt, J=8.0, 1.6 Hz, 2H), 7.59-7.52 (m, 5H), 7.37-7.31 (dd, J=13.6, 8.0Hz, 2H), 7.24 (t, J=6.0 Hz, 1H), 6.94 (t, J=4.0 Hz, 1H), 4.78 (d, J=4.0Hz, 2H). LCMS Method O: retention time 1.39 min; [M+1]=433.0. HPLCMethod B: purity 97.9%, retention time 8.06 min.

Example 75-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridine-3-sulfonamide

Step 1. Preparation of 5-Bromopyridine-3-sulfonamide

See also U.S. Publication Nos. 2006/217387 and 2006/375834, and J. Org.Chem., 54:389 (1989). A mixture of pyridine-3-sulfonic acid (10.3 g,64.8 mmol), phosphorous pentachloride (20.82 g, 100 mmol) andphosphorous oxychloride (10 mL, 109 mmol) was heated to reflux where itstirred for 4 h. At the conclusion of this period, the reaction mixturewas allowed to cool to room temperature. Once at the prescribedtemperature, the reaction mixture was evaporated to dryness underreduced pressure to yield a residue. The residue was treated withbromine (6.00 mL, 116 mmol) and then heated to reflux where it stirredfor 14 h. After this time, the reaction mixture was cooled to 0° C. andthen a saturated solution of NH₄OH in H₂O (40 mL) was slowly added. Theresulting mixture was allowed to warm to room temperature where itstirred for 30 min. The reaction mixture was then filtered and thefilter cake was washed with hexane to afford5-bromopyridine-3-sulfonamide (6.0 g) as an off-white solid. The productwas used without further purification. LCMS Method Q: retention time0.75 min; [M+1]=237.0.

Step 2. Preparation of pyridine-3-sulfonamide-5-ylboronic acid pinacolester

See also WO2008/150827 A1 and WO2008/144463. A mixture of5-bromopyridine-3-sulfonamide (1.5 g, 6.33 mmol), bis(pinacolato)diboron(2.41 g, 9.5 mmol) and potassium acetate (1.86 g, 19.0 mmol) in1,4-dioxane (15 mL) was degassed with nitrogen for 15 min then(1,1′-bis(diphenylphosphino)-ferrocene)palladium (II) chloridedichloromethane complex (232 mg, 0.317 mmol) was added and the resultingmixture was degassed again with nitrogen for 10 min. At the conclusionof this period, the reaction mixture was heated in a microwave at 120°C. for 45 min. After this time, the reaction mixture was filteredthrough CELITE® and the filtrate was concentrated under reduced pressureto provide pyridine-3-sulfonamide-5-ylboronic acid pinacol ester (740mg) as a brown solid. The product was used without further purification.¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.83 (s, 1H), 8.80 (s, 1H), 8.26 (s,1H), 7.56-7.74 (bs, 2H), 1.17 (s, 12H).

Step 3. Example 7

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (150 mg, 0.43mmol) in 1,4-dioxane (6 mL) and H₂O (1 mL) under nitrogen was addedpyridine-3-sulfonamide-5-ylboronic acid pinacol ester (185 mg, 0.65mmol), and potassium carbonate (119 mg, 0.86 mmol). Upon completion ofaddition, the mixture was degassed with nitrogen for 15 minutes and then(1,1′-bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (31 mg, 0.043 mmol) was added. The resultingmixture was again degassed with nitrogen for 10 min. After this time,the mixture was heated to 90° C. where it stirred for 16 h. At theconclusion of this period, the reaction mixture was allowed to cool toroom temperature. Once at the prescribed temperature, the reactionmixture was quenched by the addition of water and then transferred to aseparation funnel. The aqueous layer was extracted with ethyl acetate.The combined organic portions were washed with water and saturated NaCl,dried over Na₂SO₄, filtered and concentrated under reduced pressure. Theresulting concentrate was purified by preparative TLC using 5% methanolin dichloromethane to afford Example 7 (50 mg) as a brown solid. ¹H NMR(400 MHz, DMSO-d₆) δ (ppm): 9.81 (s, 1H), 9.17 (s, 1H), 9.09 (s, 1H),8.24 (d, J=4.4 Hz, 1H), 7.94 (d, J=7.2 Hz, 1H), 7.86 (t, J=7.6 Hz, 1H),7.75-7.72 (t, J=7.6 Hz, 3H), 7.59-7.51 (m, 5H), 7.34 (d, J=7.2 Hz, 2H),7.24 (t, J=6.4 Hz, 1H), 6.98 (t, J=3.2 Hz, 1H), 4.77 (d, J=4.0 Hz, 2H).LCMS Method Q: retention time 1.39 min; [M+1]=469.0. HPLC Method B:purity 98.1%, retention time=8.74 min.

Alternatively, Example 7 can be synthesized as follows:

Step 1. Preparation of 5-Bromo-pyridine-3-sulfonyl chloride

PCl₅ (2.95 Kg, 14.16 moles) and POCl₃ (2.45 Kg, 15.98 moles) were addedinto pyridine-3-sulfonic acid (1.5 Kg, 9.42 mol) in 10 L RB flaskequipped with mechanical stirrer under inert atmosphere. The reactionmass was heated to 120-125° C. where it stirred for 18 h. After thistime, the reaction progress was monitored by HPLC, which indicated thereaction was complete. Excess POCl₃ was removed under vacuum to give aresidue. The residue was cooled to ambient temperature and bromine (1.2Kg, 7.5 moles) was added. Upon completion of addition, the resultingmixture was heated to 120-125° C. where it stirred for 5 h. At theconclusion of this period, the reaction progress was monitored by HPLC,which indicated the reaction was complete. The reaction mixture wascooled to ambient temperature and then poured into ice-water (10 L), andthe resulting mixture was extracted with DCM (10.5 L×2). The DCMextracts were combined and the solvent was removed under vacuum to yieldcrude product (1.8 Kg, 74.4% yield).

Step 2. Preparation of 5-bromo-N-tert-butylpyridine-3-sulfonamide

Crude 5-bromopyridine-3-sulfonyl chloride from step 1 above wasdissolved in THF (14 L, 8 vol) and then transferred to a 20 L RB flaskequipped with mechanical stirrer under inert atmosphere. The solutionwas cooled to 0-5° C. and tert-butyl amine (1.95 Kg, 26.66 moles) wasadded at 0-5° C. Upon completion of addition, the reaction mixture waswarmed to ambient temperature where it stirred for 2 h. At theconclusion of this period, the reaction progress was monitored by HPLC,which indicated that the reaction was complete. The solvent wasevaporated under vacuum to give a thick residue. The residue wasdissolved in ethyl acetate (18 L, 12 vol). The organic layer wasseparated, washed with water (9 L, 5 vol) and then concentrated undervacuum to yield a residue. Hexanes (9 L, 5 vol) were added to theresidue and the product precipitated out and was collected by filtrationto yield a free flowing yellow solid (1.5 Kg, 54.28% overall yield). ¹HNMR (DMSO-D6, 400 MHz, δ ppm); 8.99 (d, J=2 Hz, 1H), 8.81 (d, J=2 Hz,1H), 8.29 (t, J=2 Hz, 1H). [M⁺+1]=293.

Step 3. Preparation of 5-bromo-N-tert-butylpyridine-3-sulfonamide

5-Bromo-N-tert-butylpyridine-3-sulfonamide (1.5 Kg, 5.11 moles) wasdissolved in dimethylformamide (7.5 L, 5 vol) and the solution was addedto a 20 L glass-lined reactor equipped with mechanical stirrer. Thesolution was degassed with nitrogen for 30 min. After this time,potassium ferrocyanide trihydrate (867 g, 2.05 moles), sodium carbonate(1.08 Kg, 10.189 moles), copper (I) iodide (73.2 g, 0.374 moles) anddichloro-bis (triphenylphosphine) palladium (II) (71.6 g, 0.102 moles)were added. Upon completion of addition, the reaction mixture was heatedto 120-125° C. where it stirred for 4 h. At the conclusion of thisperiod, the reaction progress was monitored by HPLC, which indicated thereaction was complete. The reaction mixture was cooled to ambienttemperature and then filtered through a celite bed. Water (18 L, 12 vol)was added into the filtrate and the resulting mixture was extracted withethyl acetate (7.5 L×2). The organic layers were combined, washed withwater and then concentrated to yield a thick residue. Hexanes (7.5 L, 5vol) were added to the residue. The product precipitated out and wascollected by filtration to yield a free flowing yellow solid (1.0 Kg,82.8% yield, 89% purity by HPLC). ¹H NMR (DMSO-D6, 400 MHz, δ ppm);9.21-9.24 (d,d J=7.2 Hz, 3.2 Hz, 2H), 8.70-8.71 (m, 1H), 7.98 (s, 1H).[M⁺+1]=239.2.

Step 4. Preparation of 3-aminobiphenyl-2-carbonitrile

2-Amino-6-bromo-benzonitrile (1.0 Kg, 5.07 moles) and toluene (10 L, 10vol) were added to a 20 L glass-lined reactor equipped with mechanicalstirrer under inert atmosphere. Potassium acetate (996 g, 10.16 moles)and phenylboronic acid (866, 7.10 moles) were added into the solutionand the solution was degassed with nitrogen for 30 min. After this time,dichloro-bis (triphenylphosphine) palladium (II) (17.8 g, 0.025 moles)was added to the reaction mixture at ambient temperature. The mixturewas heated to 110° C., where it stirred for 17 h. At the conclusion ofthis period, the reaction progress was monitored by HPLC, whichindicated the reaction was completed. The reaction mixture was filteredthrough a celite bed. The filtrate was transferred back to the reactorand concentrated hydrochloric acid (˜35%, 2 L, 2 vol) was charged to thereactor at ambient temperature. The HCl salt of the title compoundprecipitated out from the reaction and was collected by filtration. TheHCl salt was transferred into the 20 L reactor and then made basic with10% NaOH solution (pH 8-9). The resulting product was extracted withethyl acetate (10 L, 10 vol). The ethyl acetate layer was washed withwater (5 L, 5 vol) and then the solvent was evaporated under vacuum togive a residue. Hexanes (5 L, 5 vol) were added to the residue at 35-40°C., and the resulting slurry was cooled to ambient temperature. Once atthe prescribed temperature, the product was collected by filtration toprovide a pale yellow solid (802 g, 81.4%, 99% by HPLC). ¹H NMR(DMSO-D6, 400 MHz, 8 ppm); 7.43-7.52 (m, 5H), 7.33-7.37 (m, 1H), 6.83(d, J=8 Hz, 1H), 6.62 (d, J=8 Hz, 1H), 6.1 (s, 2H). ES-MS:[M⁺+1]=194.23.

Step 5. Preparation of5-(4-amino-5-phenylquinazolin-2-yl)-N-tert-butylpyridine-3-sulfonamide

3-Aminobiphenyl-2-carbonitrile (1028 g, 5.30 moles),5-bromo-N-tert-butylpyridine-3-sulfonamide (1440 g, 5.55 moles) and1,4-dioxane (10 L, 10 vol) were added to a 20 L glass-lined reactorequipped with mechanical stirrer. Sodium tert-butoxide (1.275 Kg 12.870moles) was added to the solution portion-wise at 20-30° C. Uponcompletion of addition, the reaction mixture was heated to reflux whereit stirred for 2 h. At the conclusion of this period, the reactionprogress was monitored by HPLC, which indicated the reaction wascomplete. The reaction mixture was cooled to 30-35° C. and then pouredinto water (40 L, 40 vol). The resulting mixture was extracted with DCM(20 L×2). The DCM layers were combined, washed with water (10 L, 10 vol)and then dried over sodium sulfate. The solvent was evaporated undervacuum to give a residue. Isopropyl alcohol (1.2 L, 1.2 vol) was addedto the residue at 40° C. The resulting precipitate slurry was cooled to10-15° C. and then stirred for 2 h. After this time, the precipitate wascollected by filtration and dried at 50° C. for 16 h to yield theproduct (1.9 Kg, 82.9% yield, 99% purity by HPLC). ¹H NMR (DMSO-D6, 400MHz, b ppm); 9.72 (s, 1H), 9.11 (s, 2H), 7.83-7.94 (m, 4H), 7.49-7.60(m, 5H), 7.31 (d,d J=6.8 Hz, 1.2 Hz, 1H). ES-MS: [M⁺+1]=433.53.

Step 6. Preparation ofN-tert-butyl-5-(5-phenyl-4-(pyridin-2-ylmethylamino) quinazolin-2-yl)pyridine-3-sulfonamide

2-(Chloromethyl) pyridine hydrochloride (564 g, 3.44 moles) and dimethylacetamide (7 L, 7 vol) were added to a 20 L RB flask-1 equipped withmechanical stirrer under inert atmosphere. The resulting solution wascooled to 0-5° C. and triethylamine (346.3, 3.44 moles) was added at0-5° C.5-(4-Amino-5-phenylquinazolin-2-yl)-N-tert-butylpyridine-3-sulfonamide(1.0 Kg. 2.306 moles) and dimethylacetamide (4 L, 4 vol) were added to aseparate 20 L RB flask-2 equipped with mechanical stirrer under inertatmosphere. This solution was cooled to 0-5° C. and sodium tert-butoxide(884 g, 9.24 moles) was added at 0-5° C. The resulting solution wasstirred to affect dissolution and then transferred to the RB flask-1 at0-5° C. Upon completion of addition, the reaction mixture was stirred at0-5° C. for 2 h. At the conclusion of this period, the reaction progresswas monitored by HPLC, which indicated that the reaction was complete.The reaction mass was poured into water (60 L, 60 vol) with stirring.The crude product was collected by filtration and dried at 60° C. for 12h. After this time, the dried material was dissolved in THF (20 L, 20vol). Upon dissolution, 6M HCl in isopropyl alcohol (1 L, 1 vol) wasadded at 20-25° C. The crude HCL salt of the product was obtained apale-yellow free flow solid (920 g, 71% yield, 93% purity by HPLC). Thecrude HCl salt (1.345 Kg, 2.56 moles), methanol (6.7 L, 5 vol) anddichloromethane (13.5 L, 10 vol) were added to a 20 L glass-linedreactor equipped with mechanical stirrer. The slurry was stirred for20-30 min at 30° C. After this time, the solvent was distilled to 4 volwith respect to input under vacuum. The resulting slurry was cooled to20-25° C., where stirred for 2 h. At the conclusion of this period, theslurry was filtered and dried at 50° C. for 6 h to yield the product(1.1 Kg, 82% yield, 98% purity by HPLC). ¹H NMR (DMSO-D6, 400 MHz, δppm); 9.72 (s, 1H), 9.10-9.14 (m, 2H), 8.39 (s, 1H), 7.92-8.03 (m, 4H),7.56-7.58 (m, 5H), 7.43-7.49 (m, 3H), 7.1 (bs, 1H), 4.88 (s, 2H), 1.17(2, 9H).

Step 7. Example 7

N-tert-butyl-5-(5-phenyl-4-(pyridin-2-ylmethylamino) quinazolin-2-yl)pyridine-3-sulfonamide (1.0 Kg, 1.9 moles) and concentrated hydrochloricacid (7 L, 7 vol) were added to a 20 L glass-lined reactor equipped withmechanical stirrer. The reaction mixture was heated to 90-100° C. whereit stirred for 1 h. At the conclusion of this period, the reactionprogress was monitored by HPLC, which indicated the reaction wascomplete. The reaction mixture was cooled to 5-10° C. and the pH wasadjusted to 1.7 to 2.0 using 12% aqueous sodium hydroxide solution. Onceat the prescribed pH, the crude HCl salt of the product was collected byfiltration. The HCl salt filter cake and ethanol (5 L, 5 vol) were addedto 10 L glass-lined reactor equipped with a mechanical stirrer. Theresulting mixture was made basic to pH 7-8 at 20-25° C. using triethylamine (2.25 Kg, 22.23 moles). Once at the prescribed pH, the basicmixture was stirred for 2 h. After this time, the free base of productwas filtered and washed with water (10 L, 10 vol) followed by ethanol (2L, 2 vol). The resulting product was dried at 50-55° C. for 8 h to yieldExample 7 (644 g, 72% yield, 99.9% purity by HPLC). ¹H NMR (DMSO-D6, 400MHz, δ ppm); 9.81 (d, J=2.0 Hz, 1H), 9.18 (t, J=2 Hz, 1H), 9.11 (d, J=2Hz, 1H), 8.23 (d, J=4.4 Hz, 1H), 7.92-7.94 (m, 1H), 7.83-7.87 (m, 1H),7.78 (s, 2H), 7.70-7.72 (m, 1H), 7.50-7.59 (m, 5H), 7.31-7.34 (m, 2H),7.22-7.25 (m, 1H), 6.95 (t, J=4 Hz, 1H), 4.76 (d, J=4 Hz, 2H). ES-MS:[M⁺+1]=469.

Example 85-Phenyl-N-(pyridin-2-ylmethyl)-2-(2H-1,2,3-triazol-4-yl)quinazolin-4-amine

Step 1. Preparation of2-ethynyl-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (1.0 g, 2.8mmol) in DMF (10 mL) under nitrogen was added trimethylsilylacetylene(2.0 mL, 14 mmol), cupric iodide (0.11 g, 0.58 mmol) and Et₃N (1.2 mL,8.4 mmol). Upon completion of addition, the mixture was degassed withnitrogen for 15 min. Tetrakis(triphenylphosphine)palladium (0.20 g, 0.28mmol) was then added and the resulting mixture was again degassed withnitrogen for 10 min. After this time, the reaction mixture was heated ina sealed tube to 120° C. where it stirred for 16 h. At the conclusion ofthis period, the reaction mixture was allowed to cool to roomtemperature. Once at the prescribed temperature, the reaction mixturewas quenched by the addition of water. The resulting reaction mixturewas extracted with ethyl acetate and the organic layer was washedsuccessively with water and brine. The combined organic layers weredried over Na₂SO₄, filtered and concentrated under reduced pressure. Theresulting concentrate was dissolved in methanol and saturated withammonia gas. The saturated solution was stirred for 2 h at 0° C. andthen concentrated under reduced pressure to yield a residue. The residuewas purified by flash column chromatography using ethyl acetate andpetroleum ether to afford2-ethynyl-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (650 mg). ¹HNMR (400 MHz, CDCl₃) δ (ppm): 8.15 (d, J=4.0 Hz, 1H), 7.86 (dd, J=8.4,1.2 Hz, 1H), 7.69 (t, J=8.4 Hz, 1H), 7.56 (dt, J=3.6, 1.6 Hz, 1H),7.49-7.42 (m, 5H), 7.26-7.23 (m, 1H), 7.13-7.08 (m, 2H), 6.94 (bs, 1H),4.67 (d, J=10.0 Hz, 2H), 3.02 (s, 1H). LCMS Method O: retention time1.35 min, [M+1]=337.0.

Step 2. Example 8

To a suspension of2-ethynyl-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (0.17 g,0.50 mmol) in toluene (3 mL) was added trimethylsilylazide (0.20 ml, 1.5mmol). Upon completion of addition, the reaction mixture was heated insealed tube to 120° C. where it was maintained for 2 days. At theconclusion of this period, the toluene was removed under reducedpressure to yield a residue. The residue was washed with water and thenextracted with dichloromethane. The organic extracts were dried overNa₂SO₄, filtered and then concentrated. The resulting concentrate waspurified by flash column chromatography on silica gel eluting withchloroform and methanol (ratio 95:5) to afford Example 8 (90 mg) as ayellow solid. ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.42 (bs, 1H), 8.33 (d,J=10.0 Hz, 1H), 7.92 (d, J=10.0 Hz, 1H), 7.83 (t, J=11.2 Hz, 1H),7.76-7.72 (m, 2H), 7.49 (m, 5H), 7.31 (d, J=10.8 Hz, 1H), 7.30-7.25 (m,2H), 4.78 (s, 2H). LCMS Method O: retention time 1.36 min, [M+1]=380.2.HPLC Method B: purity 98.5%, retention time 10.03 min.

Example 105-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-2(1H)-one

Step 1. Preparation of2-(6-methoxypyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (200 mg, 0.58mmol) in DMF (10 mL) and H₂O (2 mL) under nitrogen was added6-methoxypyridin-3-ylboronic acid pinacol ester (202 mg, 0.86 mmol) andpotassium carbonate (160 mg, 1.16 mmol). Upon completion of addition,the mixture was degassed with nitrogen for 15 min and thentetrakis(triphenylphosphine)-palladium (66 mg, 0.0050 mmol) was added.The mixture was again degassed with nitrogen for 10 min. After thistime, the reaction mixture was heated to 90° C. where it stirred for 12h. The reaction mixture was then allowed to cool to room temperature andthen quenched by the addition of water. The reaction mixture wasextracted with ethyl acetate and the organic layer was washedsuccessively with water and brine. The combined organic layers weredried over Na₂SO₄, filtered and concentrated under reduced pressure. Theresulting concentrate was purified by flash column chromatography using16% ethyl acetate in petroleum ether to afford2-(6-methoxypyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine(140 mg) as a brown solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.26 (d,J=2.4 Hz, 1H), 8.70-8.67 (dd, J=8.8, 2.4 Hz, 1H), 8.23-8.22 (d, J=5.2Hz, 1H), 7.84-7.76 (m, 2H), 7.73-7.69 (dt, J=8.0, 2.0 Hz, 1H), 7.58-7.48(m, 5H), 7.32-7.30 (d, J=7.6 Hz, 1H), 7.25-7.23 (m, 2H), 6.95-6.93 (d,J=8.8 Hz, 1H), 6.81-6.79 (t, J=4.0 Hz, 1H), 4.72-4.71 (d, J=4.0 Hz, 2H),3.94 (s, 3H). LCMS Method S: retention time 3.96 min, [M+1]=420.2. HPLCMethod B: purity 98.9%, retention time 8.93 min.

Step 2. Example 10

To a solution of2-(6-methoxypyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine(140 mg, 0.33 mmol) in CH₂Cl₂ (2 mL) was slowly added BBr₃ (416 mg, 1.66mmol) at 0° C. The reaction mixture was stirred at room temperature for72 h before it was quenched by the addition of aqueous solution ofammonium hydroxide. The reaction mixture was then extracted with CH₂Cl₂.The organic layer was washed successively with water and brine. Thecombined organic layers were dried over Na₂SO₄, filtered andconcentrated under reduced pressure. The resulting concentrate waspurified by preparative HPLC to afford Example 10 (75 mg) as anoff-white solid. Preparative HPLC Conditions: Column: Sunfire C18(250×19 mm), Mobile Phase A: 0.1% TFA in H₂O, Mobile Phase B: CH₃CN,Gradient: 0 to 40% B over 25 min, 100% B for 10 min., Flow Rate: 14mL/min., Retention time: 20.5 min. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm):8.68 (s, 1H), 8.41-8.38 (dd, J=9.6, 2.8 Hz, 1H), 8.23 (d, J=4.4 Hz, 1H),8.09-7.94 (m, 3H), 7.84-7.79 (dt, J=7.6, 1.6 Hz, 1H), 7.65-7.54 (m, 5H),7.50-7.48 (d, J=7.2 Hz, 1H), 7.40-7.38 (d, J=8.0 HZ, 1H), 7.33-7.30 (t,J=6.8 Hz, 1H), 6.62-6.60 (d, J=9.6 Hz, 1H), 4.88 (d, J=4.0 Hz, 2H). LCMSMethod O: retention time 1.35 min, [M+1]=406.2. HPLC Method B: purity99.2%, retention time 10.26 min.

Example 115-Phenyl-N-(pyridin-2-ylmethyl)-2-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)quinazolin-4-amine

Step 1. Preparation of5-Phenyl-4-(pyridin-2-ylmethylamino)quinazoline-2-carbonitrile

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (5.0 g, 14mmol) in CH₃CN (50 mL) was added tetramethylammonium cyanide (4.5 g, 29mmol) followed by DBU (4.39 g, 28.88 mmol). Upon completion of addition,the reaction mixture was heated to 80° C. where it stirred for 12 h.After this time, the reaction mixture was quenched with water and thenextracted with ethyl acetate. The organic layer was washed successivelywith water and brine, and the combined organic layers were dried overNa₂SO₄, filtered and concentrated under reduced pressure. The resultingconcentrate was purified by flash column chromatography using 28% ethylacetate in petroleum ether to yield5-phenyl-4-(pyridin-2-ylmethylamino)quinazoline-2-carbonitrile (2.1 g)as a brown solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.15-8.14 (d, J=4.0Hz, 1H), 7.96-7.87 (m, 2H), 7.75-7.70 (dt, J=7.6, 2.0 Hz, 1H), 7.62-7.45(m, 6H), 7.34-7.29 (m, 2H), 7.25-7.22 (m, 1H), 4.60 (d, J=3.6 Hz, 2H).LCMS Method O: retention time 1.52 min, [M+1]=338.2.

Step 2. Example 11

To a solution of5-phenyl-4-(pyridin-2-ylmethylamino)quinazoline-2-carbonitrile (150 mg,0.45 mmol) in EtOH (5 mL) was added NH₂OH—HCl (62 mg, 0.90 mmol)followed by Et₃N (125 μL, 0.90 mmol). The reaction mixture was heated toreflux where it stirred for 4 h. After this time, the reaction mixturewas concentrated under reduced pressure to yield a residue. The residuewas dissolved in THF (5 mL). The resulting solution was cooled to 0° C.and pyridine (145 μL, 1.80 mmol) followed by trifluoroacetic anhydride(125 μL, 0.90 mmol) were added. Upon completion of addition, thereaction mixture was warmed to room temperature where it stirred for 16h. At the conclusion of this period, the reaction mixture wasconcentrated under reduced pressure to yield a residue. The residue waspurified by flash column chromatography using 36% ethyl acetate inpetroleum ether to afford Example 11 (65 mg) as an off-white solid. ¹HNMR (400 MHz, DMSO-d₆) δ (ppm): 8.19 (d, J=4.0 Hz, 1H), 7.99-7.91 (m,2H), 7.75-7.71 (t, J=7.2 Hz, 1H), 7.60-7.54 (m, 5H), 7.44 (d, J=6.4 Hz,1H), 7.36 (d, J=7.6 Hz, 1H), 7.26-7.23 (m, 1H), 7.19 (m, 1H), 4.68-4.67(d, J=3.6 Hz, 1H). LCMS Method O: retention time 1.71 min, [M+1]=449.0.HPLC Method B: purity 99.5%, retention time 9.66 min.

Example 124-((5-Phenyl-2-(pyrimidin-5-yl)quinazolin-4-ylamino)methyl)benzamide

Step 1. Preparation of methyl 4-(aminomethyl)benzoate

To a solution of 4-(aminomethyl)benzoic acid (1 g, 7 mmol) in MeOH (10mL) was added dropwise concentrated H₂SO₄ (1 mL). Upon completion ofaddition, the reaction mixture was heated to 60° C. where it stirred for12 h. After this time, the reaction mixture was concentrated underreduced pressure to yield a residue. The residue was dissolved in ethylacetate and then carefully neutralized with a 10% NaOH solution. Theorganic layer was separated and washed successively with water andbrine. The combined organic layers were dried over Na₂SO₄, filtered andconcentrated under reduced pressure to afford methyl4-(aminomethyl)benzoate (2.5 g) as a white solid. LCMS Method O:retention time 0.49 min, [M+1]=166.2.

Step 2. Preparation of methyl4-((2-chloro-5-phenylquinazolin-4-ylamino)-methyl)benzoate

To a solution of 2,4-dichloro-5-phenylquinazoline (1 g, 4 mmol) in THF(15 mL) was added diisopropylethyl amine (1.86 mL, 10.9 mmol) followedby methyl 4-(aminomethyl)benzoate (1.19 g, 7.21 mmol). Upon completionof addition, the reaction mixture was stirred for 12 h. At theconclusion of this period, the reaction mixture was diluted with ethylacetate and then washed successively with water and brine. The combinedorganic layers were dried over Na₂SO₄, filtered and concentrated toyield a residue. The residue was purified by flash column chromatographyusing 6% ethyl acetate in petroleum ether to afford methyl4-((2-chloro-5-phenylquinazolin-4-ylamino)methyl)benzoate (600 mg) as awhite solid. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.92 (d, J=8.0 Hz, 2H),7.80 (d, J=8.4 Hz, 1H), 7.70 (t, J=8.0 Hz, 1H), 7.38-7.33 (m, 5H), 7.22(d, J=7.2 Hz, 1H), 7.02 (d, J=8.0 Hz, 2H), 5.56 (bs, 1H), 4.53 (d, J=4.8Hz, 2H), 3.39 (s, 3H). LCMS Method O: retention time 2.12 min,[M+1]=404.0. HPLC Method B: purity 97.8%, retention time 18.17 min.

Step 3. Preparation of methyl4-((5-phenyl-2-(pyrimidin-5-yl)quinazolin-4-ylamino)methyl)benzoate

To a solution of methyl4-((2-chloro-5-phenylquinazolin-4-ylamino)methyl)benzoate (550 mg, 1.36mmol) in DMF (16 mL) and H₂O (0.5 mL) under nitrogen were addedpyrimidine-5-ylboronic acid pinacol ester (422 mg, 2.04 mmol) andpotassium carbonate (377 mg, 2.72 mmol). The resulting mixture wasdegassed with nitrogen for 15 min and then(1,1′-bis(diphenylphosphino)ferrocene)-palladium (II) chloridedichloromethane complex (50 mg, 0.068 mmol) was added. Upon completionof addition, the reaction mixture was again degassed for 10 min. withnitrogen. The reaction mixture was then heated to 110° C. where itstirred for 12 h. After this time, the reaction mixture was allowed tocool to room temperature. Once at the prescribed temperature, thereaction mixture was quenched by the addition of water and thenextracted with ethyl acetate. The organic layer was washed successivelywith water and brine. The combined organic layers were dried overNa₂SO₄, filtered and concentrated under reduced pressure. The resultingconcentrate was purified by flash column chromatography using 0.5% MeOHin CH₂Cl₂ to afford methyl4-((5-phenyl-2-(pyrimidin-5-yl)quinazolin-4-ylamino)methyl)benzoate (400mg) as an off-white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.62 (s,2H), 9.31 (s, 1H), 7.93-7.86 (m, 4H), 7.54-7.49 (m, 5H), 7.37 (d, J=6.8Hz, 1H), 7.28 (d, J=8.0 Hz, 2H), 5.94 (t, J=4.8 Hz, 1H), 4.71 (d, J=5.2Hz, 1H), 3.85 (s, 3H). LCMS Method C: retention time 2.15 min,[M+1]=448.2. HPLC Method B: purity 98.5%, retention time 9.81 min.

Step 4. Preparation of4-((5-phenyl-2-(pyrimidin-5-yl)quinazolin-4-ylamino)methyl)benzoic acid

To a solution of methyl4-((5-phenyl-2-(pyrimidin-5-yl)quinazolin-4-ylamino)methyl)benzoate (400mg, 0.89 mmol) in MeOH-THF—H₂O (6 mL-6 mL-0.5 mL) was added LiOH (112mg, 2.67 mmol). Upon completion of addition, the reaction mixture washeated to 45° C. where it stirred for 12 h. After this time, thereaction mixture was concentrated under reduced pressure to remove theMeOH and THF and then carefully acidified with 1.5N HCl. The resultingprecipitate was collected by filtration to afford4-((5-phenyl-2-(pyrimidin-5-yl)quinazolin-4-ylamino)methyl)benzoic acid(250 mg) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 12.87 (bs,1H), 9.68 (s, 2H), 9.39 (s, 1H), 8.09 (m, 1H), 7.98 (t, J=8.0 Hz, 1H),7.86 (d, J=8.0 Hz, 2H), 7.53-7.48 (m, 6H), 7.26 (d, J=8.0 Hz, 2H), 6.65(bs, 1H), 4.78 (d, J=5.2 Hz, 2H). LCMS Method O: retention time 1.73min, [M+1]=434.2. HPLC Method B: purity 98.1%, retention time 8.24 min.

Step 5. Example 12

To a solution of4-((5-phenyl-2-(pyrimidin-5-yl)quinazolin-4-ylamino)methyl)benzoic acid(75 mg, 0.17 mmol), EDC-HCl (40 mg, 0.21 mmol), and HOBt (28 mg, 0.21mmol) in DMF (4 mL) was added diisopropylethyl amine (120 μL, 0.69 mmol)followed by NH₄Cl (37 mg, 0.69 mmol). Upon completion of addition, thereaction mixture was stirred at room temperature for 12 h, and thendiluted with ethyl acetate. The organic layer was washed successivelywith water and brine. The organic portion was separated, dried overNa₂SO₄, filtered and then concentrated under reduced pressure. Theresulting concentrate was purified by flash column chromatography using3% MeOH in CH₂Cl₂ to afford Example 12 (25 mg) as an off-white solid. ¹HNMR (400 MHz, DMSO-d₆) δ (ppm): 9.65 (s, 2H), 9.31 (s, 1H), 7.94-7.85(m, 3H), 7.79 (d, J=8.0 Hz, 2H), 7.52-7.49 (m, 5H), 7.36 (m, 2H), 7.17(d, J=8.0 Hz, 2H), 5.89 (t, J=4.8 Hz, 1H), 4.66 (d, J=4.8 Hz, 2H). LCMSMethod O: retention time 1.49 min, [M+1]=433.2. HPLC Method B: purity98.4%, retention time 7.52 min.

Example 16 2-Chloro-5-phenyl-N-(pyridin-2-yl)quinazolin-4-amine

To a suspension of NaH (13 mg, 0.547 mmol) in THF (2 mL) at 0° C. wasadded a solution of 3-aminopyridine (26 mg, 0.273 mmol) in THF (2 mL).Upon completion of addition, the reaction mixture was stirred at 0° C.for 30 min. At the conclusion of this period, a solution of2,4-dichloro-5-phenylquinazoline (75 mg, 0.273 mmol) in THF (2 mL) wasadded. The reaction mixture was allowed to warm to room temperaturewhere it stirred for 16 h. After this time, the reaction mixture wasquenched with a saturated aqueous solution of NH₄C₁, and the resultingsolution was extracted with ethyl acetate. The organic layer was washedsuccessively with water and brine, dried over Na₂SO₄, filtered andconcentrated under reduced pressure. The resulting concentrate waspurified by flash column chromatography using 30% ethyl acetate inpetroleum ether to afford Example 16 (15 mg) as a white solid. ¹H NMR(400 MHz, CDCl₃) δ (ppm): 8.53-8.51 (d, J=8.4 Hz, 1H), 8.11-8.09 (dd,J=4.0, 1.2 Hz, 1H), 7.92-7.88 (m, 2H), 7.82-7.78 (t, J=7.6 Hz, 1H),7.73-7.69 (dt, J=8.0, 1.6 Hz, 1H), 7.62-7.60 (m, 3H), 7.52-7.50 (m, 2H),7.39-7.37 (d, J=7.2 Hz, 1H), 6.97-6.94 (dd, J=7.2, 4.8 Hz, 1H). LCMSMethod M: retention time 1.73 min, [M+1]=333.2. HPLC Method B: purity99.7%, retention time 17.30 min.

Examples 19 Through 58

Examples 19 through 58 were synthesized via similar procedures describedabove. HPLC/MS data for each compound was collected using method E, andthe molecular mass determined by MS (ES) by the formula m/z. Both theretention time and MS data for the examples are listed in Table 1a,wherein MW=molecular weight.

TABLE 1a LCMS Example Structure MW LCMS Data Method 19

346.813 [M + 1] 347.0 Rt: 0.95 min A 20

337.377 [M + 1] 338.3 Rt: 0.88 min D 21

389.452 [M + 1] 390.3 Rt: 0.73 min D 22

326.394 [M + 1] 327.1 Rt: 0.65 min A 23

395.48 [M + 1] 396.3 Rt: 0.86 min D 24

392.456 [M + 1] 393.2 Rt: 0.72 min A 25

407.467 [M + 1] 408.2 Rt: 1.525 min M 26

445.515 [M + 1] 446.2 Rt: 1.477 min M 27

434.536 [M + 1] 435.2 Rt: 1.667 min M 29

419.478 [M + 1] 420.2 Rt: 1.631 min N 30

378.429 [M + 1] 379.2 Rt: 1.359 min M 31

389.452 [M + 1] 390.2 Rt: 1.370 min M 32

404.467 [M + 1] 405.2 Rt: 1.298 min M 34

353.845 [M + 1] 354.2 Rt: 1.675 min O 35

309.793 [M + 1] 310.2 Rt: 1.893 min O 36

367.872 [M + 1] 368.2 Rt: 1.857 min O 37

332.786 [M + 1] 333.2 Rt: 1.888 min N 38

338.814 [M + 1] 339.0 Rt: 1.907 min O 39

353.42 [M + 1] 354.2 Rt: 1.626 min O 40

389.452 [M + 1] 390.2 Rt: 1.810 min O 41

377.842 [M + 1] 378.2 Rt: 2.042 min O 42

345.825 [M + 1] 346.2 Rt: 2.000 min O 43

461.515 [M + 1] 462.2 Rt: 2.138 min Q 45

406.865 [M + 1] 407.2 Rt: 1.656 min Q 46

427.5 [M + 1] 428.2 Rt: 1.622 min O 47

414.461 [M + 1] 415.2 Rt: 2.036 min M 48

414.461 [M + 1] 415.2 Rt: 1.653 min O 50

388.464 [M + 1] 389.2 Rt: 1.605 min O 51

427.5 [M + 1] 428.2 Rt: 1.663 min O 54

364.803 [M + 1] 365.2 Rt: 1.517 min O 55

364.803 [M + 1] 365.2 Rt: 1.530 min O 58

350.777 [M − 1] 349.0 Rt: 3.084 min P

Example 622-(2-methoxypyrimidin-5-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (300 mg, 0.87mmol) in DMF (20 mL) and H₂O (2 mL) under nitrogen was added2-methoxypyrimidin-5-ylboronic acid (199 mg, 1.30 mmol) and potassiumcarbonate (239 mg, 1.73 mmol). The resulting mixture was degassed withnitrogen for 15 min and then tetrakis(triphenylphosphine)palladium (100mg, 0.086 mmol) was added. Upon completion of addition, the reactionmixture was again degassed with nitrogen for 10 min. After this time,the reaction mixture was heated to 90° C. where it stirred for 12 h.After this time, the reaction mixture was allowed to cool to roomtemperature and then quenched by the addition of water. The reactionmixture was extracted with ethyl acetate and the organic layer waswashed successively with water and brine. The combined organic layerswere dried over Na₂SO₄, filtered and concentrated under reducedpressure. The resulting concentrate was purified by preparative HPLC toafford2-(2-methoxypyrimidin-5-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine(205 mg) as an off-white solid. Preparative HPLC Conditions: Column:Sunfire C18 (250×19 mm), Mobile Phase A: 0.1% TFA in H₂O, Mobile PhaseB: CH₃CN, Gradient: 0 to 40% B over 35 min, 100% B for 10 min., FlowRate: 14 mL/min., Retention time: 28 min. ¹H NMR (400 MHz, DMSO-d₆) δ(ppm): 9.50 (s, 2H), 8.27 (d, J=4.7 Hz, 1H), 7.92 (d, J=3.6 Hz, 2H),7.85-7.81 (t, J=8.0 Hz, 1H), 7.60-7.52 (m, 5H), 7.42-7.38 (m, 2H),7.34-7.31 (m, 1H), 4.83 (d, J=4.2 Hz, 2H), 4.04 (s, 3H). LCMS Method O:retention time 1.45 min, [M+1]=421.2. HPLC Method B: purity 98.7%,retention time 5.53 min.

Examples 66 Through 158

Examples 66 through 158 were synthesized via similar proceduresdescribed above. HPLC/MS data for each compound was collected usingmethod E, and the molecular mass determined by MS (ES) by the formulam/z. Both the retention time and MS data for the examples are listed inTable 1b, wherein MW=molecular weight.

TABLE 1b LCMS Example Structure MW LCMS Data Method  66

388.873 [M − 1] 386.8 Rt: 5.82 min L  67

480.967 [M] 478.7 Rt: 5.75 min L  68

387.905 [M] 385.9 Rt: 7.09 min L  69

438.93 [M − 1] 436.9 Rt: 4.67 min L  70

371.862 [M − 1] 369.9 Rt: 6.68 min L  72

388.893 [M] 386.9 Rt: 6.47 min L  74

429.822 [M − 1] 427.8 Rt: 6.83 min L  76

361.824 [M − 1] 359.9 Rt: 5.06 min L  77

361.824 [M − 1] 359.8 Rt: 5.40 min L  84

367.231 [M − 1] 364.9 Rt: 6.09 min L  85

401.772 [M − 1] 399.8 Rt: 5.42 min L  87

384.861 [M − 1] 382.9 Rt: 5.72 min L  88

408.43 [M + 1] 409.2 Rt: 2.031 min Q  89

408.43 [M + 1] 409.2 Rt: 2.035 min Q  92

386.834 [M + 1] 387.0 Rt: 2.102 min O  93

402.899 [M + 1] 403.0 Rt: 2.159 min O  95

458.438 [M + 1] 459.2 Rt: 3.225 min S  96

347.801 [M + 1] 348.2 Rt: 1.706 min O  97

414.811 [M + 1] 415.2 Rt: 2.016 min Q  99

364.803 [M + 1] 365.2 Rt: 2.010 min Q 102

425.458 [M + 1] 426.2 Rt: 3.298 min S 103

428.488 [M + 1] 429.2 Rt: 2.030 min Q 104

441.526 [M + 1] 442.2 Rt: 1.755 min O 105

419.478 [M + 1] 420.2 Rt: 3.957 min R 106

431.917 [M + 1] 432.2 Rt: 1.902 min Q 107

475.544 [M + 1] 476.2 Rt: 1.971 min Q 108

389.881 [M + 1] 390.2 Rt: 2.006 min Q 109

433.508 [M + 1] 434.2 Rt: 2.084 min Q 110

364.803 [M + 1] 365.0 Rt: 1.866 min O 111

408.43 [M + 1] 409.2 Rt: 2.099 min Q 113

399.876 [M] 400.0 Rt: 3.09 min L 114

378.855 [M] 379.0 Rt: 3.68 min L 117

366.867 [M] 366.9 Rt: 3.32 min L 118

389.834 [M] 388.2 Rt: 6.00 min L 119

349.789 [M] 348.1 Rt: 6.48 min L 122

415.796 [M − 1] 414.1 Rt: 6.69 min L 126

339.819 [M − 1] 338.2 Rt: 5.28 min L 127

365.879 [M − 1] 364.2 Rt: 6.30 min L 128

457.01 [M − 1] 455.2 Rt: 5.07 min L 129

402.899 [M − 1] 401.1 Rt: 6.17 min L 130

359.851 [M − 1] 358.2 Rt: 6.46 min L 131

375.851 [M − 1] 374.2 Rt: 6.31 min L 132

359.851 [M − 1] 358.1 Rt: 6.50 min L 133

363.815 [M] 362.1 Rt: 6.16 min L 134

375.851 [M − 1] 374.2 Rt: 6.06 min L 135

375.851 [M − 1] 374.3 Rt: 6.06 min L 136

359.851 [M − 1] 358.2 Rt: 6.57 min L 137

413.823 [M − 1] 412.1 Rt: 6.59 min L 138

405.877 [M + 1] 406.1 Rt: 6.03 min L 139

429.822 [M − 1] 428.1 Rt: 6.76 min L 143

400.784 [M − 1] 399.1 Rt: 6.92 min L 148

414.461 [M + 1] 415.2 Rt: 1.685 min O 149

446.526 [M + 1] 447.0 Rt: 3.991 min S 150

405.451 [M + 1] 406.2 Rt: 1.347 min O 152

404.849 [M + 1] 405.2 Rt: 1.909 min Q 154

524.594 [M + 1] 525.2 Rt: 2.041 min Q 158

432.477 [M + 1] 433.0 Rt: 1.455 min O

Example 159 Tert-butyl5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-ylcarbamate

Step 1 Preparation of tert-butyl 5-bromopyridin-3-ylcarbamate

To 5-bromopyridin-3-amine (2.00 g, 11.5 mmol) in THF (25 mL) was addedsodium hexamethyldisilazide (25.4 mL, 25.4 mmol, 1 M in THF) and thereaction mixture was stirred at room temperature for 20 min.Boc-anhydride (2.52 mL, 15.6 mmol) in THF (10 mL) was added slowly andthe reaction mixture was stirred for an additional 24 h at roomtemperature. 0.1 M HCl (30 mL) was added and the reaction mixture wasextracted with ethyl acetate. The combined organic extracts were washedsuccessively with water and brine. The organic layer was dried, filteredand concentrated under reduced pressure to afford tert-butyl5-bromopyridin-3-ylcarbamate (2.5 g, 81%), which was used withoutfurther purification. LCMS Method 0018: retention time 1.84 min,[M+1]=275.0 ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.82 (s, 1H), 8.57 (d,1H, J=2.4 Hz), 8.30 (d, 1H, J=2 Hz), 8.18 (s, 1H), 1.49 (s, 9H).

Step 2: Preparation of tert-butyl5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ylcarbamate

A mixture of tert-butyl 5-bromopyridin-3-ylcarbamate (0.8 g, 2.9 mmol),bis(pinacolato)diboron (0.82 g, 3.2 mmol) and potassium acetate (0.86 g,8.7 mmol) in 1,4-dioxane (15 mL) was degassed with nitrogen for 15 min.After this time, (1,1′-Bis(diphenylphosphino)ferrocene)palladium (II)chloride dichloromethane complex (0.12 g, 0.1 mmol) was added and themixture was again degassed for 10 min. with nitrogen. Upon completion ofthis period, the reaction mixture was heated in the microwave at 120° C.for 45 min. After this time, the reaction mixture was filtered throughcelite and the filtrate was concentrated under reduced pressure toprovide crude of tert-butyl5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ylcarbamate(1.7 g), which was used without further purification.

Step 3. Example 159

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (1.2 g, 3.4mmol) in 1,4-dioxane (10 mL) and H₂O (2.5 mL) under nitrogen was addedtert-butyl5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ylcarbamate(1.7 g, 5.3 mmol), and potassium carbonate (1.4 g, 10 mmol). The mixturewas degassed with nitrogen for 15 min. and then(1,1′-bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (0.25 mg, 0.3 mmol) was added. Upon completionof addition, the reaction mixture was again degassed for 10 min withnitrogen. After this time, the reaction mixture was stirred at 90° C.for 16 h, and then allowed to cool to room temperature. Once at theprescribed temperature, the reaction mixture was quenched by theaddition of water and then transferred to a separation funnel. Theaqueous layer was extracted with ethyl acetate. The combined organicportions were washed with water and saturated NaCl, dried over Na₂SO₄,filtered and concentrated under reduced pressure to yield a residue. Theresidue was purified by silica gel column chromatography using adichloromethane/methanol mixture to afford Example 159 (0.9 g, 52%yield) as a brown solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.73 (br s,1H); 9.25 (d, 1H, J=2 Hz); 8.95 (s, 1H); 8.76 (s, 1H); 8.25 (d, 1H, J=4HZ); 7.91-7.80 (m, 2H); 7.73 (t, 1H, J=8 Hz); 7.60-7.50 (m, 5H);7.39-7.29 (m, 2H); 7.25 (t, 1H, J=10 Hz); 6.83 (br s, 1H); 4.74 (d, 2H,J=3.6 Hz); 1.54 (s, 9H). LCMS Method W: retention time 2.21 min;[M+1]=505.2; HPLC Method K: purity 97.7%, retention time=15.80 min.

Example 1602-(5-Aminopyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine

To a solution of Example 159 (750 mg, 1.48 mmol) in DCM (5 mL) at 0° C.was added 1.5 M HCl in dioxane (1.5 M). Upon completion of addition, thereaction mixture was stirred for 1 h and then concentrated to yield aresidue. The residue was purified by combiflash using 3% methanol in DCMto give Example 160 (560 mg, 93% yield) as an off white solid. ¹H NMR(400 MHz, DMSO-d₆, δ): 8.84 (s, 1H); 8.24 (d, 1H, J=3.6 Hz): 8.04 (s,1H); 8.00 (s, 1H); 7.89-7.79 (m, 2H); 7.72 (t, 1H, J=7.2 Hz); 7.62-7.48(m, 5H); 7.35-7.22 (m, 3H); 6.78 (s, 1H); 5.47 (s, 2H); 4.73 (d, 12H,J=3.6 Hz); LCMS Method X: retention time 1.91 min, [M+1]=405.2 HPLCMethod A1: purity 99.3%, retention time=6.84 min.

Example 161N-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)acetamide

To a solution of Example 160 (0.2 g, 0.5 mmol) in acetone (20 mL) wasadded acetyl chloride (0.2 mL, 0.55 mmol) and potassium carbonate (0.2g, 1.5 mmol). Upon completion of addition, the reaction mixture wasstirred at room temperature for 4 h. After this time, the reactionmixture was filtered through celite, and the filtrate was concentratedto yield a residue. The residue was diluted with EtOAc and the organicportion was washed with saturated sodium bicarbonate (10 mL). Theorganic layer was dried, and then purified by silica gel columnchromatography using dichloromethane/Methanol as the solvent to obtainExample 161 (180 mg, 82%) as a white solid. ¹H NMR (400 MHz, DMSO-d₆,δ): 10.34 (s, 1H); 9.31 (d, 1H, J=2.4 Hz); 8.96 (d, 2H, J=5.2 Hz), 8.24(d, 1H, J=4.8 Hz), 7.93-7.80 (m, 2H), 7.73 (dt, 1H, J=2.4 Hz, 7.6 Hz),7.60-7.47 (m, 5H), 7.38-7.28 (m, 2H), 7.24 (t, 1H, J=9.2 Hz), 6.85 (brs, 1H), 4.74 (d, 2H, J=4 Hz), 2.13 (s, 3H). LCMS Method W: retentiontime 1.85 min, [M+1]=447.2. HPLC Method A1: purity 98.5%, retentiontime=7.20 min.

Example 162N-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)sulfamide

To a solution of chlorosulfonylisocyanate (0.021 mL, 0.24 mmol) in DCM(4 mL) was added t-BuOH (0.023 mL, 0.24 mmol) at RT. Upon completion ofaddition, the reaction mixture was stirred for 10 min. After this time,TEA was added (0.05 ml, 0.3 mmol), followed by a solution of Example 160(0.1 g, 0.24 mmol) in DCM. The reaction mixture was stirred for anadditional 3 h and then washed with a Na₂CO₃ solution. The aqueous layerwas extracted with ethyl acetate. The combined organic extracts weredried, concentrated under reduced pressure and purified by silica gelcolumn chromatography using dichloromethane/methanol mixture to yieldExample 162 (0.040 g, 34% yield). ¹H NMR (400 MHz, DMSO-d₆, δ): 9.88 (s,1H); 9.30 (s, 1H); 8.61 (br s, 1H); 8.56 (d, 1H, J=2.4 Hz); 8.24 (d, 1H,J=4.4 Hz); 7.91-7.80 (m, 2H); 7.73 (dt, 1H, J=7.6 Hz); 7.61-7.49 (m,5H); 7.38-7.29 (m, 4H); 7.24 (t, 1H, J=5.6 Hz); 6.86 (br t, 1H, J=3.6Hz); 4.74 (d, 2H, J=4 Hz). LCMS Method X: retention time 1.81 min,[M+1]=484.2. HPLC Method A1: purity 97.1%, retention time=7.83 min.

Example 1631-(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)urea

To a solution of Example 160 (0.2 g, 0.5 mmol) in DCM at 0° C. was addedchlorosulfonylisocyanate (0.081 mL, 0.90 mmol). The resulting slurry wasstirred at RT for 4 h and then 2 mL of 1.5 N HCl was added. Uponcompletion of addition, the reaction mixture was heated to 40° C. whereit stirred for an additional 2 h. The resulting solution was neutralizedwith a sat. Na₂CO₃ solution and the aqueous portion was extracted withDCM. The combined organic extracts were dried, concentrated and purifiedby preparative HPLC 5% methanol in dichloromethane to yield Example 163(0.040 g, 18% yield). ¹H NMR (400 MHz, DMSO-d₆, δ): 9.19 (s, 1H); 8.94(s, 1H); 8.83 (s, 1H); 8.76 (d, 1H, J=2.4 Hz); 8.24 (d, 1H, J=4.8 Hz);7.90-7.80 (m, 2H); 7.73 (t, 1H, J=8.4 Hz); 7.60-7.50 (m, 5H); 7.38-7.29(m, 2H); 7.24 (t, 1H, J=5.2 Hz); 6.83 (br t, 1H, J=4 Hz); 6.07 (br s,2H); 4.74 (d, 2H, J=4 Hz). LCMS Method T: retention time 1.43 min,[M+1]=448.0. HPLC Method A1: purity 98.8%, retention time=6.95 min.

Example 1642-(2-Aminopyrimidin-5-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (0.7 g, 2.02mmol) in 1,4-dioxane (30 mL) and H₂O (5 mL) under nitrogen was added2-aminopyrimidin-5-ylboronic ester (670 g, 3.03 mmol), and potassiumcarbonate (0.55 g, 4.04 mmol). Upon completion of addition, the mixturewas degassed with nitrogen for 15 min and then(1,1′-bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (0.147 mg, 0.20 mmol) was added. The reactionmixture was again degassed for 10 min with nitrogen. After this time,the reaction mixture was heated to 90° C. where it stirred for 16 h. Aftthe conclusion of this period, the reaction mixture was allowed to coolto room temperature and then quenched by the addition of water. Thereaction mixture was transferred to a separation funnel and the aqueouslayer was extracted with ethyl acetate. The combined organic portionswere washed with water and saturated NaCl, dried over Na₂SO₄, filteredand concentrated under reduced pressure. The resulting concentrate waspurified by silica gel column chromatography usingdichloromethane/methanol mixture as the eluent to afford Example 164(0.42 g, 52% yield) as a brown solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm):9.20 (s, 2H), 8.23 (d, 1H, J=4.8 Hz), 7.78 (d, 2H, J=2.4 Hz), 7.77-7.70(m, 1H), 7.60-7.57 (m, 5H), 7.34-7.30 (m, 1H), 7.26-7.20 (m, 2H),7.18-7.13 (br s, 2H), 6.76 (br s, 1H), 4.67 (d, 2H, J=4.0 Hz); LCMSMethod U: retention time 1.38 min; [M+1]=406; HPLC Method A1: purity99.5%, retention time=6.74 min.

Example 1655-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyrimidine-2-carbonitrile

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (0.22 g, 0.65mmol) in 1,4-dioxane (10 mL) and H₂O (2 mL) under nitrogen was added2-cyanopyrimidin-5-ylboronic ester (0.22 g, 0.97 mmol), and potassiumcarbonate (0.18 g, 1.30 mmol). Upon completion of addition, the mixturewas degassed with nitrogen for 15 min. After this time,(1,1′-bis(diphenylphosphino)-ferrocene)palladium (II) chloridedichloromethane complex (0.048 mg, 0.06 mmol) was added and the reactionmixture was again degassed with nitrogen for 10 min. After this time,the reaction mixture was stirred heated to 90° C. where it stirred for16 h. At the conclusion of this period, the reaction mixture was allowedto cool to room temperature and then quenched by the addition of water.The reaction mixture was transferred to a separation funnel and theaqueous layer was extracted with ethyl acetate. The combined organicportions were washed with water and saturated NaCl, dried over Na₂SO₄,filtered and concentrated under reduced pressure. The resultingconcentrate was purified by silica gel column chromatography using adichloromethane/methanol mixture as the eluent to afford Example 165(0.13 g, 49% yield) as a brown solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm):9.86 (s, 2H), 8.22 (d, 1H, J=6.4 Hz), 7.94 (dd, 1H, J=1.6 Hz J=8.4 Hz),7.89 (dd, 1H, J=3.2 Hz, J=11.2 Hz), 7.74 (dt, 1H, J=1.6 Hz, 8 Hz),7.63-7.50 (m, 5H), 7.40-7.32 (m, 2H), 7.25 (dd, 1H, J=5.2 Hz, 6.8 Hz),7.08 (br t, 1H, J=4 Hz), 4.76 (d, 2H, J=4.4 Hz). LCMS Method U:retention time 1.85 min; [M+1]=416.0; HPLC Method A4: purity 97.6%,retention time=23.30 min.

Example 1665-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyrimidine-2-carboxamide

To a solution of Example 165 (0.115 g, 0.270 mmol) in THF was added NaOH(0.044 g, 1.1 mmol) and water. Upon completion of addition, the reactionmixture was cooled to 0° C. and hydrogen peroxide (0.037 g, 1.1 mmol)was added dropwise. The reaction mixture was stirred at RT for 2 h andthen concentrated to yield a residue. The residue was diluted with waterand the aqueous phase extracted with ethyl acetate. The combined organicextracts were dried and concentrated. The resulting residue was purifiedby Prep TLC using dichloromethane/methanol mixture as the eluent toyield Example 166 (0.075 g, 63% yield). ¹H NMR (400 MHz, DMSO-d₆, δ):9.82 9s, 2H); 8.35 (d, 1H, J=4 Hz); 3.28 (s, 1H); 7.96 (dd, 1H, J=0.8,8.4 Hz): 7.85 (t, 1H, J=7.2 Hz); 7.74 (dt, 1H, J=1.4, 7.6 Hz); 7.56-7.48(m, 5H); 7.38 (dd, 1H, J=0.8, 7.8 Hz); 7.31-7.22 (m, 2H); 4.75 (d, 2H,J=4 Hz). LCMS Method Y: retention time 1.81 min, [M+1]=434.2. HPLCMethod A1: purity 96.1%, retention time=9.30 min.

Example 1671-Methyl-2-oxo-5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)-1,2-dihydropyridine-3-sulfonamide

Step 1. Preparation of 5-bromo-2-hydroxypyridine-3-sulfonamide

A solution of 5-bromopyridin-2-ol (0.5 g, 2.8 mmol) in chlorosulfonicacid (10 mL) was heated to 150° C. for 16 h. After this time, thereaction mixture was added dropwise to a pre-cooled aqueous ammoniasolution (100 mL) at 0° C. The resulting mixture was stirred for 1 h.The aqueous layer was then extracted with ethyl acetate (150 mL), driedand concentrated to yield a residue. The residue was purified by ISCOchromatography using 3% methanol in DCM to yield5-bromo-2-hydroxypyridine-3-sulfonamide (210 mg). ¹H NMR (400 MHz,DMSO-d₆) δ (ppm): 12.67 (br s, 1H); 8.03 (d, 1H, J=2.8 Hz); 7.98 (d, 1H,J=2.8 Hz); 7.11 (s, 1H). LCMS Method U: retention time 1.85 min;[M+1]=253.0.

Step 2. Preparation of 5-bromo-2-methoxypyridine-3-sulfonamide

To a solution of 5-bromo-2-hydroxypyridine-3-sulfonamide (0.5 g, 1.9mmol) in MeOH/DCM (15 mL, 1:1) at −10° C. was addedtrimethylsilyldiazomethane solution (2 M, 1.97 mL, 3.9 mmol). Uponcompletion of addition, the reaction mixture was concentrated and theresulting residue was purified by column chromatography using methanoland CHCl₃ to 5-bromo-1-methyl-2-oxo-1,2-dihydropyridine-3-sulfonamideyield 5-bromo-1-methyl-2-oxo-1,2-dihydropyridine-3-sulfonamide (280 mg,53% yield) and 5-bromo-2-methoxypyridine-3-sulfonamide (180 mg, 34%yield). Data for5-bromo-1-methyl-2-oxo-1,2-dihydropyridine-3-sulfonamide: ¹H NMR (400MHz, DMSO-d₆, δ): 8.42 (d, 1H, J=2.8 Hz); 7.99 (d, 1H, J=2.8 Hz); 7.14(s, 1H); 3.52 (s, 3H). Data for 5-bromo-2-methoxypyridine-3-sulfonamide:¹H NMR (400 MHz, DMSO-d₆, δ): 8.54 (d, 1H, J=2.4 Hz); 8.17 (d, 1H, J=2.4Hz); 7.51 (s, 1H); 4.00 (s, 3H).

Step 3: Example 167

A stirred solution of5-bromo-1-methyl-2-oxo-1,2-dihydropyridine-3-sulfonamide (0.08 g, 0.3mmol) in dioxane:DMF (6 mL: 1 mL) was degassed for 10 min with argon. Atthe conclusion of this period, Pd(triphenylphosphine)₄ (34 mg, 0.03mmol) and hexamethylditin (0.17 g, 0.53 mmol) were added. The reactionmixture was stirred at room temperature for 16 h. and then2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (0.1 g, 0.3mmol) was added. Upon completion of addition, the reaction mixture washeated to 100° C. where it stirred for an additional 16 h. A precipitatewas formed and the resulting slurry was filtered. The filtrate wasconcentrated and purified by silica gel column chromatography usingdichloromethane/methanol mixture as the eluent to obtain Example 167 (15mg, 13% yield). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.06 (s, 1H); 9.02(s, 1H); 8.25 (d, 1H, J=4 Hz); 7.86-7.78 (m, 2H); 7.73 (dt, 1H, J=1.6,7.6 Hz); 7.60-7.48 (m, 5H); 7.31-7.22 (m, 3H); 7.09 (br s, 2H); 6.79 (t,1H, J=4 Hz); 4.72 (d, 2H, J=4 Hz); 3.72 (s, 3H). LCMS Method U:retention time 1.35 min; [M+1]=499.2; HPLC Method A1: purity 96.2%,retention time=6.10 min.

Example 1682-Amino-5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridine-3-sulfonamide

Step 1. Preparation of 2-amino-5-bromopyridine-3-sulfonamide

To a solution of chlorosulfonic acid (20 mL) at 0° C. was added2-amino-5-bromopyridine (5.0 g, 0.029 mmol) portion wise. Uponcompletion of addition, the reaction mixture was heated to reflux whereit stirred for 16 h. After this time, the reaction mixture was allowedto cool to RT. Once at the prescribed temperature, the reaction mixturewas poured drop wise in to an aqueous ammonium hydroxide solution. Theresulting mixture was extracted with ethyl acetate. The combined organicportions were washed with a brine solution, dried over Na₂SO₄ andconcentrated under reduced pressure to yield2-amino-5-bromopyridine-3-sulfonamide (4.7 g, 65%), which was usedwithout further purification. LCMS Method Y: retention time 0.5 min,[M−1]=250.8.

Step 2. Preparation of2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-sulfonamidewhich was used without further purification

A mixture of 5-bromo-2-aminopyridine-3-sulfonamide (2.0 g, 7.9 mmol),bis(pinacolato)diboron (3.0 g, 12 mmol) and potassium acetate (2.3 g, 23mmol) in 1,4-dioxane (20 mL) was degassed with nitrogen for 15 min.After this time, (1,1′-bis(diphenylphosphino)ferrocene)palladium (II)chloride dichloromethane complex (0.29 g, 0.36 mmol) was added and thereaction mixture was again degassed for 10 min with nitrogen. Thereaction mixture was heated to 100° C. where it stirred for 12 h. At theconclusion of this period, the reaction mixture was filtered throughcelite and the filtrate was concentrated under reduced pressure toprovide2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-sulfonamide(1 g), which was used without further purification. LCMS Method X:retention time 1.29 min; [M+1]=300.

Step 3. Example 168

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (0.20 g, 0.57mmol) in 1,4-dioxane (5 mL) and H₂O (0.55 mL) under nitrogen was added2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-sulfonamide(0.259, 0.800 mmol), and potassium carbonate (0.239 g, 1.70 mmol). Uponcompletion of addition, the reaction mixture was degassed with nitrogenfor 15 min. After this time,(1,1′-bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (0.023 mg, 0.020 mmol) was added and theresulting mixture was again degassed for 10 min with nitrogen. Thereaction mixture was heated to 90° C. where it stirred for 16 h. At theconclusion of this period, the reaction mixture was allowed to cool toroom temperature. Once at the prescribed temperature, the reactionmixture was quenched by the addition of water. The reaction mixture wastransferred to a separation funnel and the aqueous layer was extractedwith ethyl acetate. The combined organic portions were washed with waterand saturated NaCl, dried over Na₂SO₄, filtered and concentrated underreduced pressure. The resulting concentrate was purified by silica gelcolumn chromatography using dichloromethane/methanol mixture as theeluent and further purified by preparative HPLC using 7% methanol indichloromethane as the eluent to afford Example 168 (0.060 g, 22% yield)as an off-white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.14 (d, 1H,J=2.4 Hz); 9.02 (d, 1H, J=2.4 Hz); 8.37 (d, 1H, J=3.6 Hz); 7.87 (dd, 1H,J=1.2, 8.4 Hz): 7.82-7.72 (m, 2H); 7.58-7.47 (br s, 5H), 7.35-7.23 (m,3H); 4.71 (s, 2H). LCMS Method Y: retention time 1.87 min; [M+1]=484.2;HPLC Method A2: purity 98.1%, retention time=12.93 min. Preparative HPLCMethod-I.

Example 169N-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)methanesulfonamide

To a stirred solution of2-(5-aminopyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine(Example 161: 0.12 g, 0.3 mmol) and TEA (0.080 mL, 0.45 mmol) in DCM (10mL) at RT was added methanesulfonyl chloride (0.30 mL, 0.44 mmol)dropwise at 0° C. and the reaction mixture was stirred at RT for 2 h.The reaction mixture was diluted with water and the resulting solutionextracted with DCM. The combined organic extracts were washedsuccessively with water and brine dried, filtered and the filtrateconcentrated. The residue was purified by silica gel columnchromatography using dichloromethane/methanol mixture (98/2) as theeluent to provide Example 169 (65 mg, 45% yield) as an off white solid.¹H NMR (400 MHz, DMSO-d₆, δ): 10.35 (br s, 1H); 9.40 (s, 1H); 8.68 (s,1H), 8.58 (s, 1H), 7.24 (d, 1H, J=3.2 Hz), 7.90-7.82 (m, 2H), 7.73 (dd,1H, J=1.2 Hz, 7.2 Hz), 7.62-7.50 (m, 5H), 7.34-7.30 (m, 2H), 7.23 (t,1H, J=5.2 Hz), 6.85 (t, 1H, J=4 Hz), 4.73 (d, 2H, J=4 Hz), 3.11 (s, 3H).LCMS Method Y: retention time 1.89 min, [M+1]=483.2 HPLC Method A1:purity 97.8%, retention time=6.61 min.

Example 170N-(2-methoxyethyl)-5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridine-3-sulfonamide

Step 1. Preparation of 5-bromopyridine-3-sulfonyl chloride

A mixture of pyridine-3-sulfonic acid (10.3 g, 64.8 mmol), phosphorouspentachloride (20.8 g, 100 mmol) and phosphorous oxychloride (10 mL, 100mmol) was heated at reflux for 4 h. The reaction mixture was allowed tocool to room temperature and evaporated to dryness under reducedpressure. The residue was treated with bromine (6.00 mL, 116 mmol) andheated at reflux for 14 h. The reaction mixture was cooled to 0° C. thenslowly quenched by the addition of ice water. The resulting mixture wasdiluted with ethyl acetate, the organic layer separated and the aqueouslayer extracted further with ethyl acetate. The combined organic layerswere dried over Na₂SO₄ then concentrated to afford5-bromopyridine-3-sulfonyl chloride (5.0 g) as a semi solid, which wasused without further purification.

Step 2. Preparation of 5-bromo-N-(2-methoxyethyl)pyridine-3-sulfonamide

A solution of 5-bromopyridine-3-sulfonyl chloride (1.5 g, 5.8 mmol)) and2-methoxyethanamine (1.3 g, 18 mmol) in THF (40 mL) was stirred at roomtemperature for 16 h. After this time, the resulting reaction mixturewas partitioned between saturated aqueous sodium chloride and ethylacetate. The organic solution was dried and evaporated. The resultingresidue was purified by flash column chromatography using ethylacetate/hexanes to yield5-bromo-N-(2-methoxyethyl)pyridine-3-sulfonamide (460 mg, 27%). LCMSMethod T: Retention time 1.13 min; [M+1]=295, 297.

Step 3. Example 170

A stirred solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (0.15 g, 0.43mmol) in dioxane (10 mL) was degassed for 10 min with argon andPd(TRIPHENYLPHOSPHINE)₄ (0.05 g, 0.043 mmol) and hexamethylditin (0.25g, 0.77 mmol) were added and the reaction mixture stirred at roomtemperature for 16 h. 5-bromo-N-(2-methoxyethyl)pyridine-3-sulfonamide(0.19 g, 0.65 mmol) was added to the reaction mixture and the resultingsolution heated at 100° C. for an additional 16 h. A precipitate formedand the solids were filtered from the reaction mixture and filtrateconcentrated and purified by silica gel column chromatography usingdichloromethane/methanol mixture as the eluent to yield Example 170(0.065 g, 27%) as an off white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm):9.83 (s, 1H), 9.11 (s. 1H), 9.06 (s, 1H), 8.24 (br s. 1H), 8.19 (t, 1H,J=5.6), 7.97-7.92 (m, 1H), 7.88 (t, 1H, J=4), 7.73 (t, 1H, J=8),7.63-7.50 (m, 5H), 7.38-7.30 (m, 2H), 7.25 (t, 1H), 6.96 (br s, 1H),4.76 (d, 2H, J=4.4), 3.34-3.30 (m, 2H), 3.11 (s, 3H), 3.05 (t, 2H,J=5.6). LCMS Method T: retention time 1.61 min; [M+1]=527. HPLC MethodA1: purity 99.4%, retention time=8.17 min.

Example 171 Ethyl2-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridine-3-sulfonamido)acetate

Step 1. Preparation of ethyl 2-(5-bromopyridine-3-sulfonamido)acetate

A solution of 5-bromopyridine-3-sulfonyl chloride (3.5 g, 14 mmol)(described in the synthesis of Example 170) and glycine ethylester (2.1g, 20 mmol), diisopropyl ethyl amine (2.6 g, 20 mmol) in THF (70 mL) wasstirred at room temperature for 16 h. The reaction mixture waspartitioned between saturated aqueous sodium chloride and ethyl acetate.The organic solution was separated, dried and evaporated under reducedpressure. The residue was purified using flash column chromatographyusing ethyl acetate/hexanes as eluent to obtain ethyl2-(5-bromopyridine-3-sulfonamido)acetate (600 mg, 14%). LCMS Method I:retention time 1.31 min; [M+1]=323, 325.

Step 2. Example 171

To a solution of methylethyl 2-(5-bromopyridine-3-sulfonamido)acetate(0.20 g, 0.62 mmol) in dioxane (10 mL) was added hexamethylditin (0.30g, 0.92 mmol) and LiCl (26 mg, 0.62 mmol). The reaction mixture wasdegassed with nitrogen for 10 min and then charged with Tetrakistriphenyl phosphine palladium (68 mg, 0.061 mmol). The reaction mixturewas stirred for 5 h at room temperature under nitrogen atmosphere. Afterthis time, 2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine(0.17 g, 0.50 mmol) in dioxane (2 mL) was added drop wise and thereaction mixture was heated to reflux for 18 h. The reaction mixture wasquenched by the addition of water and extracted with ethyl acetate. Thecombined organic extracts were washed successively with water and brine,dried, filtered and concentrated under reduced pressure. The resultingresidue was purified by flash column chromatography on silica gel using5% methanol in dichloromethane to afford Example 171 (35 mg, 11%) as anoff white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.82 (s, 1H); 9.10(s, 1H); 9.06 (s, 1H); 8.68 (t, 1H, J=6.0 Hz); 8.24 (d, 1H, J=4.8 Hz);7.94 (dd, 1H, J=1.2, 8.0 Hz); 7.86 (t, 1H, 5.6 Hz); 7.73 (dt, 1H, J=1.6,8.0 Hz); 7.62-7.50 (m, 5H); 7.33-7.36 (m, 2H); 7.26-7.23 (m, 1H); 6.96(s, 1H); 4.76 (d, 2H, J=4 Hz); 3.93 (q, 2H, J=7.2 Hz); 3.89 (d, 2H,J=6.0 Hz); 1.04 (t, 3H, J=7.2 Hz). LCMS Method U: retention time 1.65min; [M+1]=555.2; HPLC Method A4: purity 98.9%, retention time=9.15 min.

Example 1722-Methoxy-5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridine-3-sulfonamide

Step 1. Preparation of2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-sulfonamide

A mixture of 5-bromo-2-methoxypyridine-3-sulfonamide (described in thesynthesis of Example 167: 0.15 g, 0.56 mmol), bis(pinacolato)diboron(0.17 g, 0.6 mmol) and potassium acetate (0.22 g, 2.2 mmol) in1,4-dioxane (10 mL) was degassed with nitrogen for 15 min. After thistime, (1,1′-bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (0.036 g, 0.04 mmol) was added and the reactionmixture was again degassed for 10 min. with nitrogen. The reactionmixture was heated in the microwave at 120° C. for 45 min. The reactionmixture was filtered through celite and the filtrate was concentratedunder reduced pressure to provide2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-sulfonamide(0.15 g), which was used without further purification. LCMS Method T:retention time 0.44 min; [M+1]=233.0.

Step 2. Example 172

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (0.19 g, 0.5mmol) in 1,4-dioxane (5 mL) and H₂O (0.55 mL) under nitrogen was added2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-sulfonamide(0.15 g, 0.60 mmol), and potassium carbonate (0.22 g, 1.6 mmol). Thereaction mixture was degassed with nitrogen for 15 min.(1,1′-bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (0.22 mg, 0.02 mmol) was added and the reactionmixture was again degassed for 10 min with nitrogen. The reactionmixture was stirred at 90° C. for 16 h, then allowed to cool to roomtemperature and quenched by the addition of water. The reaction mixturewas transferred to a separation funnel and the aqueous layer extractedwith ethyl acetate. The combined organic portions were washed with waterand saturated NaCl, dried over Na₂SO₄, filtered and concentrated underreduced pressure. The concentrate was purified by column chromatographyto afford Example 172 (0.060 g, 22% yield). ¹H NMR (400 MHz, DMSO-d₆) δ(ppm): 12.78 (br s, 1H); 9.03 (d, 1H, J=2 Hz); 8.66 (s, 1H); 8.24 (d,1H, J=4.8 Hz); 7.86-7.75 (m, 2H); 7.71 (t, 1H, J=7.6 Hz); 7.60-7.46 (m,5H); 7.30-7.20 (m, 3H); 7.07 (br s, 2H); 6.80 (br s, 1H); 4.67 (d, 2H,J=4 Hz). LCMS Method U: retention time 1.32 min; [M+1]=485.0; HPLCMethod A4: purity 97.1%, retention time=5.91 min.

Example 173N-(2-amino-2-oxoethyl)-5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinamide

Step 1. Preparation of ethyl 2-(5-bromonicotinamido)acetate

A solution of 5-bromonicotinic acid (4 g, 0.02 mol) in thionyl chloride(25 mL) was heated under reflux for 4 h. The excess thionyl chloride wasremoved under reduced pressure to provide 5-bromonicotinyl chloridewhich was used without further purification. To 5-bromonicotinylchloride (3.5 g, 13.6 mmol) was added glycine ethylester (2.1 g, 20.3mmol) and diisopropyl ethyl amine (2.6 g, 20.1 mmol) in THF (70 mL) andthe reaction mixture stirred at RT for 16 h. The reaction mixture wasdiluted with EtOAc and washed with brine solution. The combined organiclayers were dried over Na₂SO₄, filtered and concentrated under reducedpressure and the residue was purified by silica gel columnchromatography using 25% EtOAc in hexane to provide ethyl2-(5-bromonicotinamido)acetate 1.2 g (33%) as a brown solid. LCMS MethodT: retention time 1.28 min; [M+1]=288.2

Step 2. Preparation of Example 173

To a solution of N-(2-amino-2-oxoethyl)-5-bromonicotinamide (0.220 g,0.852 mmol) in dioxane (4 mL), was added hexamethylditin (0.50 g, 1.53mmol). The reaction mixture was degassed with nitrogen for 15 min.Pd(triphenylphosphine)₄ (0.098 g, 0.08 mmol) was added and the reactionmixture was stirred at RT for 6 h.2-Chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (0.29 g 0.84mmol) in 1,4-dioxane (3 mL) was added and the resulting mixture wasstirred at 95° C. for 16 h, allowed to cool to room temperature and thenquenched by the addition of water. The reaction mixture was transferredto a separation funnel and the aqueous layer extracted with ethylacetate. The combined organic portions were washed with water andsaturated NaCl, dried over Na₂SO₄, filtered and concentrated underreduced pressure. The concentrate was purified by silica gel columnchromatography using dichloromethane/methanol mixture as the eluent toyield Example 173 (12 mg, 4%) as an off-white solid. ¹H NMR (400 MHz,DMSO-d₆) δ (ppm): 9.76 9s, 1H); 9.21 (s, 1H); 9.16 (s, 1H); 9.14-9.11(m, 1H); 8.24 (d, 1H, J=4.4 Hz); 7.94 (d, 1H, J=4.4 Hz); 7.86 (t, 1H,J=7.6 Hz): 7.73 (dd, 1H, J=7.6, 15.2 Hz); 7.68-7.47 (m, 5H); 7.39-7.30(m, 2H); 7.24 (dd, 1H, J=5.2, 7.6 Hz); 7.10 (br s, 1H); 6.93 (br s, 1H);4.77 (d, 2H, J=4 Hz); 3.90 (d, 2H, J=5.6 Hz). LCMS Method Y: retentiontime 1.70 min; [M+1]=490.2; HPLC Method A1: purity 99.5%, retentiontime=5.73 min.

Example 1742-(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridine-3-sulfonamido)acetamide

Step 1. Preparation of ethyl 2-(5-bromopyridine-3-sulfonamido)acetate

A solution of 5-bromopyridine-3-sulfonyl chloride (3.5 g, 14 mmol) andglycine ethylester (2.1 g, 20 mmol), diisopropyl ethyl amine (2.6 g, 20mmol) in THF (70 mL) was stirred at room temperature for 16 h. Thereaction mixture was partitioned between saturated aqueous sodiumchloride and ethyl acetate. The organic solution was separated, driedand evaporated under reduced pressure. The residue was purified usingflash silica gel column chromatography using ethyl acetate/hexanes toobtain ethyl 2-(5-bromopyridine-3-sulfonamido)acetate (600 mg, 14%);LCMS Method T: retention time 1.31 min; [M+1]=323, 325.

Step 2. Preparation of 2-(5-bromopyridine-3-sulfonamido)acetamide

A solution of ethyl 2-(5-bromopyridine-3-sulfonamido)acetate (0.50 g,1.7 mmol) and ammonia in methanol (2M, 10 mL) was heated to 60° C. in asealed tube for 4 h. The cooled reaction mixture was concentrated underreduced pressure to yield 2-(5-bromopyridine-3-sulfonamido)acetamide(300 mg, 66%), which was used without further purification. ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 8.96 (d, 1H, J=2.4 Hz); 8.90 (d, 1H, J=2 Hz);8.39 (t, 1H, J=2 Hz), 8.21 (br s, 1H), 7.35 (br s, 1H), 7.07 (br s, 1H),3.5 (s, 2H). LCMS Method D: retention time 0.945 min; [M+1]=294, 296.0.

Step 3. Example 174

A stirred solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (0.20 g, 0.57mmol) in dioxane (10 mL) was degassed for 10 min with argon andPd(TRIPHENYLPHOSPHINE)₄ (0.06 g, 0.05 mmol) and hexamethylditin (0.34 g,1.03 mmol) were added and the resulting reaction mixture was stirred atroom temperature for 16 h. 2-(5-bromopyridine-3-sulfonamido)acetamide(0.25 g, 0.86 mmol) was added to the above reaction mixture and thesolution heated at 100° C. for an additional 16 h. A precipitate formedand the solids were filtered from the reaction mixture and filtrateconcentrated and purified by column chromatography to yield Example 174(0.060 g, 20%) as a brown solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.80(s, 1H), 9.11 (s, 1H), 9.05 (s, 1H), 8.25 (d, 1H, J=4.8 Hz), 7.95 (dd,1H, J=1.2 Hz, J=8.4 Hz), 7.86 (t, 1H, J=8.8 Hz), 7.73 (t, 1H, J=4.4 Hz),7.61-7.50 (m, 5H), 7.40-7.32 (m, 3H), 7.26-7.24 (m, 1H), 7.07 (br s,1H), 6.97 (br t, 1H, J=3.6 Hz), 4.76 (d, 2H, J=4 Hz), 3.56 (s, 2H). LCMSMethod Y: retention time 1.77 min; [M+1]=526.0; HPLC Method A1: purity99.2%, retention time=6.709 min.

Example 1752-Methyl-6-(5-phenyl-4-(yridine-2-ylmethylamino)quinazolin-2-yl)imidazo[1,2-a]pyridine-8-sulfonamide

Step 1. Preparation of 2-amino-5-bromopyridine-3-sulfonyl

To a cooled (0° C.) solution of chlorosulfonic acid (58 mL) undervigorous stirring was added 5-bromo-2-pyridinamine (86.7 mmol) portionwise. The reaction mixture was then heated at reflux for 3 h. Uponcooling to room temperature, the reaction mixture was poured over ice(100 g) with vigorous stirring. The resulting yellow precipitate wascollected by suction filtration, washed with cold water and petroleumether to provide 2-amino-5-bromopyridine-3-sulfonyl chloride (18 g, 77%yield) as an orange-yellow solid.

Step 2. Preparation of2-amino-5-bromo-N-tert-butylpyridine-3-sulfonamide

2-amino-5-bromopyridine-3-sulfonyl chloride (15 g, 55 mmol) wasdissolved in THF (125 mL) and at 0° C. t-butylamine (6.5 g, 111 mmol)was added and the reaction mixture was stirred at RT for 2 h. Thereaction mixture was concentrated under reduced pressure to yield2-amino-5-bromo-N-tert-butylpyridine-3-sulfonamide (8.4 g, 49%), whichwas used without further purification. LCMS Method Y: retention time1.70 min, [M−1]=306.0.

Step 3. Preparation of6-bromo-N-tert-butyl-2-methylimidazo[1,2-a]pyridine-8-sulfonamide

To a solution of 2-amino-5-bromo-N-tert-butylpyridine-3-sulfonamide (3.0g, 9.7 mmol) in ethanol (6 mL) was added chloroacetone (3.0 mL, 48 mmol)and the reaction mixture was stirred at 80° C. for 48 h. The solventswere evaporated under reduced pressure and the residue was purified byflash silica gel column chromatography (5% methanol in DCM) to yield6-bromo-N-tert-butyl-2-methylimidazo[1,2-a]pyridine-8-sulfonamide (2.2g, 66%), which was used without further purification. LCMS Method T:retention time 1.33 min; [M+1]=346.64.

Step 4. Preparation of6-bromo-2-methylimidazo[1,2-a]pyridine-8-sulfonamide

6-bromo-N-tert-butyl-2-methylimidazo [1, 2-a] pyridine-8-sulfonamide(1.0 g, 2.8 mmol) was stirred in TFA (6 mL) for 16 h. The TFA wasremoved in vacuo and a saturated solution of NaHCO₃ was added. Theaqueous layer was extracted with DCM, the combined organic portionsdried, filtered and concentrated to yield6-bromo-2-methylimidazo[1,2-a]pyridine-8-sulfonamide (0.45 g, 54%),which was used without further purification. LCMS Method Y: retentiontime 1.44 min; [M+1]=292.16.

Step 5. Example 175

A stirred solution of6-bromo-2-methylimidazo[1,2-a]pyridine-8-sulfonamide (0.20 g, 0.68 mmol)in dioxane (10 mL) was degassed for 10 min with argon and Pd(PPh₃)₄ (0.2g, 0.16 mmol) and hexamethylditin (0.25 mL, 1.2 mmol) were added and thereaction mixture stirred at room temperature for 16 h.2-Chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (0.58 g, 1.68mmol) was added and the reaction mixture heated at 100° C. for anadditional 16 h. A precipitate formed and the solids were filtered fromthe reaction mixture and the filtrate was concentrated and purified bysilica gel column chromatography using dichloromethane/methanol mixtureas the eluent to get pure Example 175 (30 mg, 10%). ¹H NMR (400 MHz,DMSO-d₆) δ (ppm): 9.73 (s, 1H); 8.77 (d, 1H, J=1.2 Hz); 8.28 (d, 1H,J=4.4 Hz); 8.09 (s, 1H); 7.90 (d, 1H, J=8.4 Hz); 7.84 (t, 1H, J=6.8 Hz);7.75 (dt, 1H, J=6 Hz, 7.6 Hz); 7.61-7.50 (m, 6H); 7.43 (s, 1H);7.36-7.25 (m, 3H); 6.85 (br s, 1H0; 4.78 (d, 2H, J=4 Hz); 2.46 (s, 3H).LCMS Method X: retention time 1.59 min; [M+1]=522.2; HPLC Method A1:purity 98.3%, retention time=6.63 min.

Example 176(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)methanol

To a solution of 5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl) nicotinaldehyde (described in Example 191, 1.0 g, 2.4mmol) in ethanol (15 mL) was added NaBH₄ (0.28 g, 7.2 mmol). Thereaction mixture was stirred at RT. A saturated solution of ammoniumchloride was added and the aqueous layer was extracted with ethylacetate. The organic layer was separated, dried, filtered andconcentrated under reduced pressure. The resulting residue was purifiedby silica gel column chromatography using a dichloromethane/methanolmixture as the eluent to provide Example 176 (0.71 g, 71%). ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 9.51 (s, 1H), 8.72 (s, 1H), 8.63 (s, 1H), 8.23(d, 1H, J=4.8 Hz), 7.88 (dd, 1H, J=7.6 Hz, 8.4 Hz), 7.85-7.80 (m, 1H),7.73 (dt, 1H, J=1.2 Hz, 7.6 Hz), 7.61-7.48 (m, 5H), 7.33 (d, 2H, J=19.2Hz), 7.27 (d, 1H, J=14 Hz), 7.23 (dt, 1H, J=1.6, 7.2 Hz), 6.87 (t, 1H,J=4.0 Hz, 1H), 5.47 (t, 1H, J=5.6), 4.75 (d, 2H, J−4 Hz), 4.67 (d, 2H,J=5.6 Hz). LCMS Method U: retention time 1.46 min; [M+1]=420.2; HPLCMethod A4: purity 99.5%, retention time=5.77 min.

Example 1772-(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)propane-1,3-diol

Step 1. Preparation of 2-(5-bromopyridin-3-yl)prop-2-en-1-ol

A microwave vial was charged with 3,5-dibromo pyridine (5.00 g, 21.1mmol), Pd(OAc)₂, (0.185 g, 0.820 mmol),1,3-Bis(diphenylphosphino)propane (0.7 g 1.7 mmol), and1-butyl-3-methylimidazolium tetrafluoroborate (25 mL) under nitrogen atroom temperature. The reaction mixture was degassed three times andallyl alcohol (2.85 g, 49.1 mmol) and triethylamine (4.7 ml, 3.6 mmol)were added. The reaction mixture was heated in microwave reactor at 125°C. for 2 h. After cooling to room temperature, aqueous HCl (20 mL, 10%)was added and the mixture stirred for 1 h. The reaction mixture wastreated with saturated Na₂CO₃ (20 mL) and the aqueous portion extractedwith CH₂Cl₂. The combined organic layers were washed with water andbrine, dried with Na₂SO₄ and evaporated under reduced pressure. Theresulting residue was purified by flash silica gel chromatography (SiO₂,hexane/EtOAc=8/2) to yield 2-(5-bromopyridin-3-yl)prop-2-en-1-ol (1.6 g,36%). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.69 (d, 1H, J=2 Hz), 8.62 (d,1H, J=2.4 Hz), 8.13 (s, 1H), 5.66 (s, 1H), 5.45 (s, 1H), 5.15 (t, 1H,J=5.2 Hz), 4.35 (d, 2H, J=5.2 Hz). LCMS Method T: retention time 0.96min; [M+1]=216.

Step 2. Preparation of 2-(5-bromopyridin-3-yl)propane-1,3-diol

To a stirred solution of 2-(5-bromopyridin-3-yl)prop-2-en-1-ol (0.600 g,2.79 mmol) in tetrahydrofuran (5 mL) at 0° C. under nitrogen was addedborane-methyl sulfide complex (0.85 g, 11 mmol). The reaction mixturewas heated to 25° C. and stirred for 5 h. The reaction mixture wascooled to 0° C. and 1.0 N sodium hydroxide (0.8 mL) was added drop wisefollowed by the addition of hydrogen peroxide (1.0 mL, 35 wt % solutionin water). The reaction mixture was stirred at 0° C. for 2 h thenpartitioned between ethyl acetate and water. The aqueous layer wasextracted with ethyl acetate. The organic portions were combined, washedwith water, aqueous sodium sulfite and brine, dried with Na₂SO₄,filtered, and concentrated under reduced pressure.2-(5-Bromopyridin-3-yl)propane-1,3-diol (0.29 g, 44.7%) was isolated bysilica gel column chromatography using 50% EtOAc in hexanes as a yellowoil. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.53 (d, 1H, J=2 Hz), 8.43 (d,1H, J=4.8 Hz), 4.92 (s, 1H), 4.69 (t, 1H, J=4.4 Hz), 3.71-3.64 (m, 2H),3.62-3.58 (m, 2H), 2.87 (t, J=6.4 Hz). LCMS Method W: retention time0.80 min; [M+1]=232.

Step 3. Preparation of 3-bromo-5-(2,2-dimethyl-1,3-dioxan-5-yl)pyridine

To a solution of 2-(5-bromopyridin-3-yl)propane-1,3-diol (0.12 g, 0.51mmol) in DCM was added 2,2-dimethoxypropane (0.107 g, 1.03 mmol) and acatalytic amount of p-TSA. The mixture was stirred at room temperaturefor 3 h. The reaction mixture was quenched by the addition of sat.NaHCO₃ solution and the organic layer washed successively with water andbrine. The organic layer was concentrated to provide the3-bromo-5-(2,2-dimethyl-1,3-dioxan-5-yl)pyridine (0.1 g, 71.4%), whichwas used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ(ppm): 8.53 (m, 2H), 8.17 (t, 2H, J=2 Hz), 4.00-3.92 (m, 4H), 3.07-3.02(m, 1H), 1.47 (s, 3H), 1.38 (s, 3H).

Step 4. Preparation of3-(2,2-dimethyl-1,3-dioxan-5-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

A mixture of 3-bromo-5-(2,2-dimethyl-1,3-dioxan-5-yl)pyridine (0.10 g,0.37 mmol), bis(pinacolato)diboron (0.112 g, 0.44 mmol) and potassiumacetate (0.145 g, 1.40 mmol) in 1,4-dioxane (8 mL) was degassed withnitrogen for 15 min. (1,1′-Bis(diphenylphosphino)ferrocene)palladium(II) chloride dichloromethane complex (24 mg, 0.03 mmol) was added andthe mixture was again degassed for 10 min. with nitrogen. The reactionmixture was heated in the microwave reactor at 120° C. for 45 min. Afterthis time, the reaction mixture was filtered through celite and thefiltrate was concentrated under reduced pressure to provide crude3-(2,2-dimethyl-1,3-dioxan-5-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine(110 mg) as a brown solid, which was used without further purification.LCMS Method W: retention time 1.46 min; [M+1]=320.2.

Step 5. Preparation of2-(5-(2,2-dimethyl-1,3-dioxan-5-yl)pyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine

To a solution of 2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (80 mg, 0.23 mmol) in 1,4-dioxane (6 mL) and H₂O (0.5mL) under nitrogen was added3-(2,2-dimethyl-1,3-dioxan-5-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine(110 mg, 0.35 mmol), and potassium carbonate (96 mg, 7.0 mmol). Themixture was degassed with nitrogen for 15 min.(1,1′-Bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (12 mg, 0.015 mmol) was added and the reactionmixture was again degassed for 10 min with nitrogen. The reactionmixture was stirred at 90° C. for 16 h, then allowed to cool to roomtemperature and quenched by the addition of water. The reaction mixturewas extracted with ethyl acetate. The combined organic portions werewashed with water and saturated NaCl, dried over Na₂SO₄, filtered andconcentrated under reduced pressure. The resulting residue was purifiedby column chromatography using 20% EtOAc in hexanes to provide2-(5-(2,2-dimethyl-1,3-dioxan-5-yl)pyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine(45 mg, 39%). LCMS Method T: retention time 1.75 min; [M+1]=504.2.

Step 6. Example 177

To a solution2-(5-(2,2-dimethyl-1,3-dioxan-5-yl)pyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine(45 mg, 0.83 mmol) in methanol (5 mL) was added pTSA (30 mg, 0.17 mmol)and the mixture was stirred for 2 h. The reaction was quenched by theaddition of sat. Na₂CO₃ solution and the volatile solvents removed underreduced pressure. The residue was dissolved in ethyl acetate then washedwith water and brine. The organic layer was dried, concentrated andpurified by filter column 80% EtOAc in Hexanes to provide2-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)propane-1,3-diol (18 mg, 44%). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.74(s, 1H), 9.60 (d, 1H, J=2 Hz), 9.56 (d, 1H, J=2 Hz), 8.26 (d, 1H, J=4.8Hz), 7.90 (dd, 1H, J=1.2, 9.2 Hz), 7.83 (t, 1H, J=7.2 Hz), 7.72 (dd, 1H,J=1.8, 7.6 Hz), 7.61-7.50 (m, 5H), 7.38-7.30 (m, 2H), 7.26 (dt, 1H,J=1.2, 8 Hz), 6.80 (br s, 1H), 4.74 (d, 1H, J=4.4 Hz), 4.70 (t, 1H,J=5.2 Hz), 3.85-3.77 (m, 2H), 3.76-3.68 (m, 2H), 3.30-2.95 (m, 1H). LCMSMethod T: retention time 1.40 min; [M+1]=464.2; HPLC Method A4: purity99.4%, retention time=5.48 min.

Example 1786-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyrazine-2-sulfonamide

Step 1. Preparation of 2-(benzylthio)-6-chloropyrazine

To a stirred solution of 2,6-dichloropyrazine (4.50 g, 30.2 mmol) andpotassium carbonate (3.75 g, 27.1 mmol) in DMF (50 mL) was added benzylmercaptane (3.37 g, 27.1 mmol) in DMF (20 mL). The resulting mixture wasstirred for 16 h at room temperature. Water (200 mL) was added to thereaction mixture. The aqueous layer was extracted with ethyl acetate.The organic portions were combined, washed successively with water,aqueous sodium sulfite and brine, dried over anhydrous Na₂SO₄, filtered,and concentrated under reduced pressure to afford2-(benzylthio)-6-chloropyrazine (6.5 g, 97%) as a yellow oil, which wasused without further purification. LCMS Method E: retention time 2.058min; [M+1]=236.6.

Step 2. Preparation of 6-chloropyrazine-2-sulfonyl chloride

2-(Benzylthio)-6-chloropyrazine (5.00 g, 21.2 mmol) was dissolved incarbon tetra chloride and water mixture (200 ml/50 ml). The reactionsolution was purged with chlorine gas at 0° C. for 30 min and dilutedwith DCM. The organic layer was dried, filtered and concentrated underreduced pressure to yield 6-chloropyrazine-2-sulfonyl chloride as abrown oil.

Step 3. Preparation of 6-chloropyrazine-2-sulfonamide

The residue of 6-chloropyrazine-2-sulfonyl chloride from step 1 abovewas dissolved in THF and purged with ammonia gas at −20° C. for 15 min.The resulting mixture was stirred for 16 h at 50° C. in a sealed tube.The organic solvent was removed under reduced pressure and the residuewas purified by column chromatography on silica gel using 2.5% methanolin dichloromethane to afford 6-chloropyrazine-2-sulfonamide (1.6 g, 34%)as white solid. LCMS Method W: retention time 0.638 min; [M+1]=194.0.

Step 4. Example 178

To a stirred solution of 6-chloropyrazine-2-sulfonamide (0.3 g, 1.56mmol) in dioxane (10 mL) was degassed for 10 min with argon. Pd(PPh₃)₄(0.17 g, 0.156 mmol) and hexamethylditin (0.48 mL, 2.3 mmol) were addedand the mixture was stirred at room temperature for 16 h.2-Chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (0.43 g, 1.24mmol) and LiCl (0.16 g, 4.68 mmol) in dioxane (2 mL) were added to thereaction mixture through cannula and heated at 100° C. for an additional16 h. The reaction mixture was concentrated under reduced pressure andwater was added. The aqueous layer was extracted with ethyl acetate, andthe organic extracts washed with brine, dried, filtered and concentratedunder reduced pressure. The residue was purified by columnchromatography using 20% acetone in hexanes then further purified byprep HPLC (method H, Column: Waters SunFire 19×100 mm 5 um C18 andTFA/water, acetonitrile as the eluent) to provide6-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyrazine-2-sulfonamide(35 mg, 9%). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.84 (s, 1H),) 9.24 (s,1H), 8.24 (d, 1H, J=4.8 Hz), 7.98-7.88 (m, 4H), 7.73 (t, 1H, J=7.6 Hz),7.24 (t, 1H, J=5.6 Hz), 7.00 (br s, 1H), 4.77 (d, 2H, J=3.6 Hz). LCMSMethod W: retention time 1.8 min; [M+1]=469.0; HPLC Method A1: purity98.1%, retention time=6.74 min.

Example 1792-(5-(3,5-Dimethylisoxazol-4-yl)pyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine

Step 1. Preparation of 4-(5-bromopyridin-3-yl)-3,5-dimethylisoxazole

To a solution of 3,5-dibromopyridine (0.20 g, 0.85 mmol) in 1,4-dioxane(8 mL) and H₂O (0.55 mL) under nitrogen was added3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole(0.13 g, 0.93 mmol), and potassium carbonate (0.35 g, 2.5 mmol). Thereaction mixture was degassed with nitrogen for 15 min.(1,1′-Bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (62 mg, 0.08 mmol) was added and the reactionmixture was again degassed for 10 min with nitrogen. The reactionmixture was stirred at 95° C. for 16 h, then allowed to cool to roomtemperature and quenched by the addition of water. The reaction mixturewas transferred to a separation funnel and the aqueous layer extractedwith ethyl acetate. The combined organic portions were washed with waterand saturated NaCl, dried over Na₂SO₄, filtered and concentrated underreduced pressure. The residue was purified by column chromatography toprovide 4-(5-bromopyridin-3-yl)-3,5-dimethylisoxazole (0.15 g, 71%) as awhite solid. LCMS Method T: retention time 1.52 min, [M+1]=253.

Step 2. Preparation of3,5-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)isoxazole

A mixture of 4-(5-bromopyridin-3-yl)-3,5-dimethylisoxazole (0.16 g, 0.63mmol), bis(pinacolato)diboron (0.24 g, 0.95 mmol) and potassium acetate(0.25 g, 2.4 mmol) in 1,4-dioxane (10 mL) was degassed with nitrogen for15 min. (1,1′-Bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (0.036 g, 0.05 mmol) was added and the mixturewas again degassed for 10 min. with nitrogen. The reaction mixture washeated in the microwave reactor at 120° C. for 45 min. The reactionmixture was filtered through celite and the filtrate was concentratedunder reduced pressure to provide3,5-dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)isoxazole(0.17 g), which was used without further purification. LCMS Method T:retention time 0.54 min, [M+1]=219.2.

Step 3. Example 179

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (0.15 g, 0.43mmol) in 1,4-dioxane (5 mL) and H₂O (0.55 mL) under nitrogen was added.3,5-Dimethyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)isoxazole(0.16 g, 0.73 mmol), and potassium carbonate (0.24 g, 1.7 mmol). Thereaction mixture was degassed with nitrogen for 15 min. (1,1′-Bis(diphenylphosphino) ferrocene) palladium (II) chloride dichloromethanecomplex (0.043 mg, 0.05 mmol) was added and the reaction mixture wasagain degassed for 10 min with nitrogen. The reaction mixture wasstirred at 95° C. for 16 h, then allowed to cool to room temperature andquenched with water. The reaction mixture was transferred to aseparation funnel and the aqueous layer extracted with ethyl acetate.The combined organic portions were washed with water and saturated NaCl,dried over Na₂SO₄, filtered and concentrated under reduced pressure. Theresidue was purified by silica gel column chromatography usingdichloromethane/methanol mixture as the eluent to provide Example 179(0.08 g, 38.2%) as an off white solid. ¹H NMR (400 MHz, DMSO-d₆) δ(ppm): 9.72 (d, 1H, J=4 Hz), 8.70 (s, 1H), 8.60 (d, 1H, J=2 Hz), 8.26(d, 1H, J=2 Hz), 7.94 (br s, 1H), 7.74 (t, 1H, J=7.2 Hz), 7.57 (dt, 1H,J=2 Hz, 7.6 Hz), 7.52-7.48 (br s, 5H), 7.30-7.27 (m, 1H), 7.18-7.10 (m,2H), 6.70 (br s, 1H), 4.76 (d, 2H, J=4.0 Hz), 2.48 (s, 3H), 2.33 (s,3H). LCMS Method T: retention time 1.82 min; [M+1]=485.2. HPLC MethodA1: purity 98.9%, retention time=7.67 min.

Example 1806-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one

Step 1. Preparation of 6-bromo-1H-imidazo[4,5-b]pyridin-2(3H)-one

A mixture of 5-bromopyridine-2,3-diamine (2 g, 10.6 mmol) and urea (2.5g, 41.6 mmol) was dissolved in DMF and heated to 100° C. for 16 h. Thereaction mixture was diluted with water and extracted with ethylacetate. The organic layer was dried over Na₂SO₄ then concentrated toprovide 6-bromo-1H-imidazo[4,5-b]pyridin-2(3H)-one (0.80 g, 36%) as anoff white solid which was used without further purification. LCMS MethodW: retention time 0.98 min; [M+2]=212, 214.0.

Step 2. Preparation of6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one

A mixture of 6-bromo-1H-imidazo[4,5-b]pyridin-2(3H)-one (0.500 g, 2.35mmol), bis(pinacolato)diboron (0.895 g, 3.53 mmol) and potassium acetate(0.924 g, 9.42 mmol) in 1,4-dioxane (10 mL) was degassed with nitrogenfor 15 min. (1,1′-Bis(diphenylphosphino)ferrocene)palladium (II)chloride dichloromethane complex (0.192 g, 0.23 mmol) was added and thereaction mixture was again degassed for 10 min. with nitrogen. Thereaction mixture was heated in the microwave reactor at 120° C. for 45min. The reaction mixture was filtered through celite and the filtratewas concentrated under reduced pressure to provide6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one(0.3 g, 49%) which was used without further purification. LCMS Method Y:retention time 1.5 min; [M+1]=261.7.

Step 3. Example 180

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (0.25 g, 0.72mmol) in 1,4-dioxane (10 mL) and H₂O (2 mL) under nitrogen was added.6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazo[4,5-b]pyridin-2(3H)-one(0.28 g, 1.1 mmol) and potassium carbonate (0.2 g, 1 mmol). The mixturewas degassed with nitrogen for 15 min.(1,1′-bis(diphenylphosphino)-ferrocene)palladium (II) chloridedichloromethane complex (0.06 mg, 0.07 mmol) was added and the reactionmixture was again degassed for 10 min with nitrogen. The reactionmixture was stirred at 90° C. for 16 h, then allowed to cool to roomtemperature and quenched with water. The reaction mixture wastransferred to a separation funnel and the aqueous layer extracted withethyl acetate. The combined organic portions were washed with water andsaturated NaCl, dried over Na₂SO₄, filtered and concentrated underreduced pressure. The residue was purified by silica gel columnchromatography using dichloromethane/methanol mixture as the eluent toprovide Example 180 (0.038 g, 12% yield) as brown solid. ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 11.14 (br, 1H), 9.06 (s, 1H), 8.25 (d, 1H, J=4.4Hz), 8.20 (s, 1H), 7.86-7.77 (m, 2H), 7.72 (t, 1H, J=8 Hz), 7.60-7.49(m, 5H), 7.31 (d, 1H, J=1.2 Hz), 7.26-7.20 (m, 2H), 6.75 (br s, 1H),4.72 (d, 1H, J=4.0 Hz). LCMS Method T: retention time 1.56 min;[M+1]=446.2.0. HPLC Method A1: purity 99.09%, retention time=5.83 min.

Example 1812-(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)acetonitrile

Step 1. Preparation of 3-bromo-5-chloromethyl-pyridine

To a solution of (5-bromo-pyridin-3-yl)-methanol, (0.500 g, 2.68 mmol)in DCM (10 mL) was added thionyl chloride (0.5 mL) and the resultingsolution was stirred at room temperature for 2 h. The reaction mixturewas quenched by the addition of water and extracted into DCM. Theorganic extracts were washed with brine filtered and concentrated underreduced pressure to provide 3-bromo-5-chloromethyl-pyridine (0.45 g,82%), which was used without further purification.

Step 2. Preparation of 2-(5-bromopyridin-3-yl) acetonitrile

3-Bromo-5-chloromethyl-pyridine (0.45 g; 2.2 mmol) was dissolved in DMF(10 mL). Potassium cyanide (0.21 g, 3.27 mmol) was added and thereaction mixture was stirred at room temperature for 16 h. The reactionmixture was quenched by the addition of water and extracted with ethylacetate. The organic phases were washed with water, brine and dried overNa₂SO₃ filtered and concentrated under reduced pressure. The residue waspurified by silica gel column chromatography using 7% EtOAc in Hexanesto provide 2-(5-bromopyridin-3-yl) acetonitrile (200 mg, 46.5%). ¹H NMR(400 MHz, DMSO-d₆) δ (ppm): 8.68 (d, 1H, J=2 Hz), 8.51 (d, 1H, J=2 Hz),7.88 (t, 1H, J=2 Hz), 3.77 (s, 2H).

Step 3. Preparation of2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)acetonitrile

A mixture of 2-(5-bromopyridin-3-yl)acetonitrile (1.5 g, 7.6 mmol), bis(pinacolato)diboron (2.9 g, 12 mmol) and potassium acetate (2.98 g, 30.0mmol) in 1,4-dioxane (15 mL) was degassed with nitrogen for 15 min.(1,1′-Bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (450 mg, 0.61 mmol) was added and the reactionmixture was again degassed for 10 min. with nitrogen. The reactionmixture was heated in the microwave reactor at 95° C. for 16 h. Thereaction mixture was filtered through celite and the filtrate wasconcentrated under reduced pressure to provide2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)acetonitrile(1.6 g) as brown solid, which was used without further purification.LCMS Method W: retention time 1.34 min; [M+1]=245.2.

Step 4. Example 181

To a solution of 2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (180 mg, 0.52 mmol) in 1,4-dioxane (6 mL) and H₂O(0.5 mL) under nitrogen was added.2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)acetonitrile(190 mg, 0.77 mmol), and potassium carbonate (215 mg, 1.55 mmol). Themixture was degassed with nitrogen for 15 min.(1,1′-bis(diphenylphosphino)-ferrocene)palladium (II) chloridedichloromethane complex (38 mg, 0.52 mmol) was added and the reactionmixture was again degassed for 10 min with nitrogen. The reactionmixture was stirred at 95° C. for 16 h, then allowed to cool to roomtemperature and quenched with water. The reaction mixture wastransferred to a separation funnel and the aqueous layer extracted withethyl acetate. The combined organic portions were washed with water andsaturated NaCl, dried over Na₂SO₄, filtered and concentrated underreduced pressure. The residue was purified by silica gel columnchromatography using 5% methanol in dichloromethane as the eluent toprovide Example 181 (110 mg, 49.6%) as off white solid. ¹H NMR (400 MHz,DMSO-d₆) δ (ppm): 9.60 (s, 1H); 8.80 (s, 1H0; 8.70 (s, 1H); 8.24 (d, 1H,J=4.8 Hz); 7.90 (dd, 1H, J=1.6, 8.4 Hz); 7.84 (t, 1H, J=7.2 Hz); 7.73(dt, 1H, J=1.6, 7.6 Hz); 7.62-7.50 (m, 5H); 7.36-7.30 (m, 2H); 7.23 (dd,1H, J=1.6, 7.2 Hz); 6.89 (t, 1H, J 4 Hz); 4.75 (d, 2H, J=4 Hz); 4.27 (s,2H). LCMS Method Y: retention time 1.94 min; [M−1]=427.0; HPLC MethodA1: purity 99.4%, retention time=6.95 min.

Example 182

2-Amino-5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridine-3-sulfonamide(Example 168, 0.095 g, 0.19 mmol) was dissolved in trimethylorthoformate(10 mL) and refluxed at 110° C. for 16 h. The volatile solvents wereevaporated under reduced pressure and the residue was purified by silicagel column chromatography using 30% acetone in hexanes mixture as theeluent to provide Example 182 (4 mg, 4%) as a white solid. ¹H NMR (400MHz, DMSO-d₆) δ (ppm): 13.10 (br s, 1H); 9.71 (d, 1H, J=2 Hz); 9.11 (d,1H, J=2 Hz); 8.24 (d, 1H, J 4.4 Hz); 8.12 (s, 1H); 7.93 (d, 1H, J=8.4Hz); 7.85 (t, 1H, J=8 Hz); 7.73 (dt, 1H, J 1.2, 8 Hz); 7.61-7.49 (m,5H); 7.33 (dd, 2H, J=8, 10.8 Hz); 7.23 (t, 1H, J=8 Hz); 6.96 (br t, 1H,J=4 Hz); 4.75 (d, 2H, J=8 Hz). LCMS Method W: retention time 1.91 min;[M+1]=494.2; HPLC Method A4: purity 98.0%, retention time=7.65 min.

Example 1832-(5-(1,2,4-Oxadiazol-3-yl)pyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine

Step 1. Preparation ofN-hydroxy-5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinimidamide

To a solution of ethyl5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinonitrile(described in Example 6, 0.10 g, 0.24 mmol) in ethanol (5 mL) was addedhydroxylamine hydrochloride (0.033 g, 0.48 mmol) and potassium carbonate(0.076 g, 0.72 mmol). The reaction mixture was heated to reflux at 80°C. for 16 h. The ethanol solvent was evaporated under reduced pressureand the residue was dissolved in DCM, and washed with water. The organiclayer was dried, filtered and concentrated to provideN-hydroxy-5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinimidamide(0.2 g) which was used without further purification. LCMS Method X:retention time 1.788 min; [M+1]=448.0.

Step 2. Example 183

N-hydroxy-5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinimidamide(0.10 g, 0.22 mmol) was dissolved in trimethylorthoformate (5 mL) andpTSA (cat.) was added. The reaction mixture was refluxed at 100° C. for16 h. The volatile solvents were evaporated under reduced pressure andthe residue was purified by silica gel column chromatography 1.6%methanol in DCM to provide Example 183 (4 mg, 4% yield) as a whitesolid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.83 (s, 1H), 9.37-9.31 (m,2H); 8.25 (d, 1H, J=4 Hz); 7.96 (dd, 1H, J=1.2, 8.4 Hz); 7.87 (dd, 1H,J=6.8, 8.4 Hz); 7.73 (dd, 1H, J=1.6, 7.6 Hz): 7.62-7.50 (m, 5H);7.40-7.33 (m, 2H); 7.24 (dd, 1H, J, =4.8, 6.8 Hz); 6.94 (br s, 1H); 4.77(d, 2H, J=4.4 Hz). LCMS Method Y: retention time 2.03 min; [M+1]=458.2;HPLC Method A4: purity 94.7%, retention time=7.4 min.

Example 1842-(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)acetamide

To a solution of 2-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl) acetonitrile (Example 181) (70 mg, 20.1mmol) in ethanol/H₂O (3/3 mL) was added sodium hydroxide (40 mg, 1.0mmol) The mixture was heated under reflux for 2 h. The reaction mixturewas quenched by the addition of water (5 mL) and extracted with ethylacetate. The organic extracts were washed with saturated brine and driedover anhydrous magnesium sulfate and filtered. The solvent wasevaporated under reduced pressure and the residue was purified by columnchromatography (silica gel. MeOH/DCM, 2.5:97.5) to provide Example 184(32 mg, 44%) as an off white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm):9.50 (s, 1H); 8.68 (s, 1H); 8.59 (s, 1H); 8.25 (d, 1H, J=4.4 Hz); 7.89(dd, 1H, J=1.2, 7.6 Hz); 7.83 (t, 1H, J=7.2 Hz); 7.73 (dt, 1H, J=1.6,7.6 Hz); 7.65 (br s, 1H); 7.60-7.50 (m, 5H); 7.38-7.30 (m, 2H); 7.23 (t,1H, J=6.4 Hz); 7.22 (br s, 1H); 6.84 (br s, 1H); 4.75 (d, 2H, J=4 Hz);3.57 (s, 2H). LCMS Method Y: retention time 1.72 min; [M+1]=447.2; HPLCMethod A4: purity 97.8%, retention time=5.48 min.

Example 1852-(5-(1,3,4-Oxadiazol-2-yl)pyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine

Step 1. Preparation of5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinohydrazide

To a solution of ethyl5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinate(Example 43) (0.2 g, 0.43 mmol) in ethanol (10 mL) was added hydrazinehydrate (0.1 mL, 2.1 mmol). The reaction mixture was heated to reflux at80° C. for 16 h. The ethanol was evaporated under reduced pressure andthe residue was dissolved in DCM and washed with water. The organiclayer was dried and concentrated to provide5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinohydrazide(0.2 g, crude), which was used without further purification. LCMS MethodE: retention time 1.8 min; [M+1]=447.50.

Step 2. Example 185

5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinohydrazide(0.2 g, 0.44 mmol) was dissolved in trimethylorthoformate (5 mL). pTSA(catalytic) was added and the reaction mixture was heated to reflux at110° C. for 16 h. The volatile solvents were evaporated under reducedpressure and the residue was purified by silica gel columnchromatography 1.7% methanol in DCM to provide Example 185 (4 mg, 2%) asa white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.86 (s, 1H), 9.53 (s,1H); 9.33 (s, 1H); 9.31 (s, 1H); 8.25 (br s, 1H); 7.96 (dd, 1H, J=1.2,1.8 Hz); 7.87 (dd, 1H, J=7.2, 8 Hz); 7.74 (dt, 1H, J=1.8 Hz); 7.62-7.50(m, 5H); 7.34 (dd, 2H, J=7.2, 12.8 Hz); 7.25 (dd, 1H, J=4.8, 6.4 Hz);6.95 (t, 1H, J=4 Hz); 4.77 (d, 2H, J=4.4 Hz). LCMS Method Y: retentiontime 1.91 min; [M+1]=458.2; HPLC Method A1: purity 96.7%, retentiontime=6.85 min.

Example 1862-(5-(Oxazol-5-yl)pyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine

Step 1. Preparation of 5-(5-bromopyridin-3-yl)oxazole

To a solution of 5-bromonicotinaldehyde (0.2 g, 1 mmol) in MeOH (5 mL)was added K₂CO₃ (0.3 g, 2 mmol) followed by TOSMIC (0.27 g, 1.39 mmol).The mixture was heated to 85° C. for 2 h. Methanol was evaporated underreduced pressure and the residue was dissolved in DCM then washed withwater. The organic extracts were dried over sodium sulfate, filtered andconcentrated. The residue was purified by silica gel columnchromatography using 2.1% MeOH in DCM as the eluent to provide5-(5-bromopyridin-3-yl)oxazole (0.12 g. 50%). LCMS Method Y: retentiontime 1.39 min; [M+1]=225.0.

Step 2. Preparation of5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)oxazole

A mixture of 5-(5-bromopyridin-3-yl)oxazole (0.10 g, 0.044 mmol),bis(pinacolato)diboron (0.17 g, 0.60 mmol) and potassium acetate (0.129g, 1.3 mmol) in 1,4-dioxane (5 mL) was degassed with nitrogen for 15min. (1,1′-Bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (0.017 g, 0.022 mmol) was added and the mixturewas again degassed for 10 min. with nitrogen. The reaction mixture washeated in the microwave at 100° C. for 16 h. The reaction mixture wasfiltered through celite and the filtrate was concentrated under reducedpressure to provide5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)oxazole(0.1 g), which was used without further purification. LCMS Method W:retention time 1.45 min; [M+1]=273.2.

Step 3. Example 186

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (0.115 g,0.330 mmol) in 1,4-dioxane (6 mL) and H₂O (1.5 mL) under nitrogen wasadded,5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)oxazole(0.10 g, 0.36 mmol) and potassium carbonate (0.136 g, 0.990 mmol). Thereaction mixture was degassed with nitrogen for 15 min.(1,1′-Bis(diphenylphosphino)-ferrocene)palladium (II) chloridedichloromethane complex (0.026 g, 0.033 mmol) was added and the reactionmixture was again degassed for 10 min with nitrogen. The reactionmixture was stirred at 100° C. for 16 h, then allowed to cool to roomtemperature and quenched with water. The reaction mixture wastransferred to a separation funnel and the aqueous layer extracted withethyl acetate. The combined organic portions were washed with water andsaturated NaCl, dried over Na₂SO₄, filtered and concentrated underreduced pressure. The residue was purified by silica gel columnchromatography using 5% methanol in dichloromethane to provide2-(5-(oxazol-5-yl)pyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine(0.015 g) as a brown solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.70 (s,1H); 9.03 (s, 1H); 8.27 (d, 2H, J=3.6 Hz); 8.03 (s, 1H0; 7.77 (t, 1H,J=7.6 Hz); 7.70-7.58 (m, 2H); 7.54-7.47 (m, 5H0; 7.33-7.28 (m, 1H);7.20-7.10 (m, 5H0; 6.82 (br, 1h); 4.80 (d, 2H, J=4.4 Hz). LCMS Method Y:retention time 1.98 min; [M+1]=457.2; HPLC Method A1: purity 98.7%,retention time=7.09 min.

Example 187 Methyl3-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)-1,2,4-oxadiazole-5-carboxylate

To a solution ofN-hydroxy-5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinimidamide(described in Example 183, 1.0 g, 2.2 mmol) in DCE at 0° C. was addedmethyl 2-chloro-2-oxoacetate (0.31 mL, 3.3 mmol). The reaction mixturewas stirred at room temperature for 2 h. Phosphorus oxychloride (1 mL)was added and the reaction mixture was heated to reflux for 1.5 h. Thereaction mixture was quenched by the addition of saturated solution ofNaHCO₃ and extracted with DCM, dried over sodium sulfate andconcentrated. The residue was purified by silica gel columnchromatography using 5% methanol in dichloromethane to provide Example187 (270 mg, 23%) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm):9.85 (s, 1H); 9.34 (s, 1H0; 8.27 (d, 1H, J=5.2 Hz); 7.98 (dd, 1H, J=1.2,8 Hz); 7.87 (t, 1H, J=4.8 Hz); 7.76 (t, 1H, J=3 Hz); 7.63-7.53 (m, 5H0;7.41-7.30 (m, 2H0; 7.24 (t, 1H, J=6 Hz); 6.95 (br s, 1H); 4.77 (d, 2H,J=4 Hz); 4.05 (s, 3H). LCMS Method Y: retention time 2.09 min;[M+1]=516.2; HPLC Method A4: purity 97.4%, retention time=8.77 min.

Example 1883-(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)-1,2,4-oxadiazole-5-carboxamide

To a solution of methyl3-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)-1,2,4-oxadiazole-5-carboxylate(Example 187, 0.080 g, 0.15 mmol) was added ammonia in methanol (10 mL)and the reaction mixture was heated at 60° C. for 4 h. The solvent wasevaporated under reduced pressure to provide Example 188 (0.032 g, 45%)as white solid. ¹H NMR (400 MHz, DMSO-d₆, δ): 9.84 (s, 1H); 9.36 (s,1H0; 9.34 (s, 1H); 8.80 (br s, 1H); 8.35 (br s, 1H); 8.26 (d, 1H, J=4.8Hz); 7.98 (d, 1H, J=8.4 Hz); 7.87 (t, 1H, J=8 Hz); 7.74 (t, 1H, J=8 Hz);7.63-7.50 (m, 3H); 7.41-7.33 (m, 2H); 7.25 (t, 1H, J=7.2 Hz); 6.96 (brt, 1H, J=4 Hz); 4.78 (d, 2H, J=4 Hz). LCMS Method Y: retention time 1.89min, [M+1]=501.2; HPLC Method A1: purity 96.4%, retention time=7.05 min.

Example 1892-(5-(4H-1,2,4-triazol-4-yl)pyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine

Step 1. Preparation of 3-bromo-5-(4H-1,2,4-triazol-4-yl)pyridine

A mixture of 3-bromo-5-amino pyridine (0.30 g, 1.7 mmol) andN,N-diformaylhydrazine (0.15 g, 1.7 mmol) was heated at 150° C. insealed tube for 16 h. A precipitate formed which was dissolved in hotethanol and then filtered. Diethyl ether was added to the filtrate atroom temperature and the slurry was stirred overnight. The resultingsolid was separated and purified by silica gel column chromatographyusing ethyl acetate and hexanes mixture as the eluent to provide3-bromo-5-(4H-1,2,4-triazol-4-yl)pyridine (130 mg, 33% yield) as a whitesolid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.24 (s, 2H); 9.03 (d, 1H, J=2Hz); 8.79 (d, 1H, J=2 Hz); 8.60 (t, 1H, J=2 Hz).

Step 2. Preparation of3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(4H-1,2,4-triazol-4-yl)pyridine

A mixture of 3-bromo-5-(4H-1,2,4-triazol-4-yl)pyridine (0.12 g, 0.50mmol), bis(pinacolato)diboron (0.16 g, 0.60 mmol) and potassium acetate(0.15 g, 1.5 mmol) in 1,4-dioxane (10 mL) was degassed with nitrogen for15 min. (1,1′-Bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (0.043 g, 0.05 mmol) was added and the resultingmixture was again degassed for 10 min. with nitrogen. The reactionmixture was heated in the microwave reactor at 120° C. for 45 min. Afterthis time, the reaction mixture was filtered through celite and thefiltrate was concentrated under reduced pressure to provide3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(4H-1,2,4-triazol-4-yl)pyridine(150 mg), which was used without further purification.

Step 3. Example 189

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (180 mg, 0.5mmol) in 1,4-dioxane (6 mL) and H₂O (1 mL) under nitrogen was added3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(4H-1,2,4-triazol-4-yl)pyridine(150 mg, 0.700 mmol) and potassium carbonate (215 mg, 1.50 mmol). Uponcompletion of addition, the mixture was degassed with nitrogen for 15min and then. (1,1′-bis(diphenylphosphino)ferrocene)palladium (II)chloride dichloromethane complex (0.041 g, 0.050 mmol) was added. Thereaction mixture was again degassed for 10 min with nitrogen. At theconclusion of this period, the reaction mixture was stirred at 90° C.for 16 h, allowed to cool to room temperature and then quenched withwater. The reaction mixture was transferred to a separation funnel andthe aqueous layer was extracted with ethyl acetate. The combined organicportions were washed with water and saturated NaCl, dried over Na₂SO₄,filtered and concentrated under reduced pressure. The resulting residuewas purified by preparative TLC using 5% methanol in dichloromethane toafford Example 189 (6 mg, 3% yield) as a brown solid. ¹H NMR (400 MHz,DMSO-d₆) δ (ppm): 9.70 (s, 1H), 9.34 (s, 2H), 9.07 (s, 1H), 8.97 (s,1H), 8.22 (d, 1H, J=4.4 Hz), 7.93 (dd, 1H, J=1.2, 8.4 Hz), 7.86 (t, 1H,J=6 Hz), 7.73 (dt, 1H, J=1.6, 7.6 Hz), 7.50-7.62 (m, 5H); 7.36-7.32 (m,2H); 7.23 (t, 1H, J=5.6 Hz), 6.97 (t, 1H, J=4 Hz), 4.79 (d, 2H, J=4.0Hz). LCMS Method Y: retention time 1.79 min; [M−1]=455.2; HPLC MethodA3: purity 98.9%, retention time=13.5 min.

Example 190 Methyl3-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)propanoate

To a solution of (E)-methyl3-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)acrylate(Example 191, prepared in a similar manner to the procedure describedbelow, 0.3 g, 6.3 mmol) in ethanol (7 mL) was added 10%palladium-on-carbon (100 mg). Upon completion of addition, the reactionmixture was stirred at RT under hydrogen for 16 h. After this time, thereaction mixture was filtered through celite, and the solvent wasevaporated under reduced pressure. The resulting residue was purified bysilica gel column chromatography using methanol in DCM (2:98) as theeluent to provide Example 190 (180 mg, 60% yield). ¹H NMR (400 MHz,DMSO-d₆) δ (ppm): 9.47 (s, 1H), 8.63-8.57 (m, 2H), 8.23 (br s, 1H), 7.87(d, 1H, J=6.8 Hz), 7.82 (t, 1H, J=6.8 Hz), 7.72 (dt, 1H, J=2, 7.6 Hz),7.63-7.49 (m, 5H), 7.36-7.28 (m, 2H), 7.23 (dd, 1H, J=5.2, 6.8 Hz), 6.83(t, 1H, J=4.4 Hz), 4.73 (d, 2H, J=2 Hz), 3.00 (t, 2H, J=7.6 Hz), 2.76(t, 2H, J=7.6 Hz). LCMS Method W: retention time 2.17 min; [M+1]=476.2;HPLC Method A1: purity 98.7%, retention time=7.10 min.

Example 191 (E)-methyl3-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)acrylate

Step 1. Preparation of5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinaldehyde

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (2 g, 5.7mmol) in 1,4-dioxane (40 mL) and H₂O (8 mL) under nitrogen was added5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinaldehyde (1.48 g,6.30 mmol), and potassium carbonate (2.39 g, 17.0 mmol). Upon completionof addition, the reaction mixture was degassed with nitrogen for 15 minand then (1,1′-bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (0.46 mg, 0.050 mmol) was added. The reactionmixture was again degassed for 10 min with nitrogen. At the conclusionof this period, the reaction mixture was stirred at 90° C. for 16 h,then allowed to cool to room temperature and quenched by the addition ofwater. The reaction mixture was transferred to a separation funnel andthe aqueous layer was extracted with ethyl acetate. The combined organicportions were washed with water and saturated NaCl, dried over Na₂SO₄,filtered and concentrated under reduced pressure. The resultingconcentrate was purified by silica gel column chromatography using 2.7%MeOH in DCM as eluent to afford5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinaldehyde(1.8 g, 100% yield) as an off-white solid. LCMS Method Y: retention time1.99 min; [M+1]=418.4.

Step 2. Example 191

To a solution of5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinaldehyde(250 mg, 0.60 mmol) in THF (15 mL) was added methyl(triphenylphosphoranylidine)acetate (300 mg, 0.9 mmol). The resultingsolution was stirred at room temperature for 16 h. After this time, thesolvent was removed under reduced pressure to yield a residue. Theresidue was purified by silica gel column chromatography using 20%EtOAc, hexane as the eluent to provide Example 191 (0.18 g, 63%). ¹H NMR(400 MHz, DMSO-d₆) δ (ppm): 9.57 (s, 1H), 8.31 (d, J=4.8, 1H), 8.15 (d,J=8.4 Hz, 1H), 8.04-7.89 (m, 1H), 7.92-7.84 (m, 2H), 7.63-7.55 (m, 5H),7.51-7.43 (m, 2H), 7.37 (t, J=5.6 Hz, 1H), 7.00 (d, J=16 Hz, 1H), 4.93(d, J=4 Hz, 2H), 3.79 (s, 3H). LCMS Method Y: retention time 2.15 min;[M+1]=474.1; HPLC Method A1: purity 99.0%, retention time=7.85 min.

Example 1923-(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)propanamide

A solution of Example 190 (0.1 g, 0.2 mmol) in NH₃ (2.0 M in MeOH, 5 mL)was stirred at room temperature in a sealed vessel for 30 min. Afterthis time, the solid formed was collected by filtration and washed withice cooled methanol. The solid was further purified by silica gel columnchromatography using 5% methanol in DCM as the eluent to provide Example192 (35 mg, 35%). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.45 (s, 1H); 8.55(s, 1H); 8.24 (d, 1H, J=4 Hz); 7.88 (dd, 1H, J=1.2, 8.0 Hz): 7.80 (t,1H<J=8 Hz); 7.72 (dt, 1H, J=1.2, 8 Hz); 7.60-749 (m, 5H); 7.40-7.30 (m,2H); 7.29 (dd, 1H, J=1.2, 7.2 Hz); 7.23 (dd, 1H, J=5.2, 6.8 Hz); 6.84(t, 1H, 3.2 Hz); 4.73 (d, 2H, 4 Hz); 2.95 (t, 2H, J=7.6 Hz); 2.48 (t,2H, 7.6 Hz). LCMS Method W: retention time 1.64 min; [M+1]=461.2; HPLCMethod A1: purity 99.1%, retention time=5.76 min.

Example 193 Methyl3-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)propanoate

Step 1. Preparation of (E)-methyl3-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl) acrylate

A solution of trimethyl phosphonoacetate (0.225 g 1.00 mmol) in THF (20mL) was added 95% sodium hydride (0.050 g, 2.0 mmol). Upon thecompletion of addition, the mixture was stirred at 0° C. for 30 min andthen 5-phenyl-4-(pyridin-2-ylmethylamino)quinazoline-2-carbaldehyde(Example 212, prepared in a similar manner to the procedure describedbelow, 0.340 g, 1.00 mmol) was added to the reaction mixture. Theresulting mixture was stirred at room temperature for 14 h. After thistime, the reaction mixture was quenched with saturated aqueous ammoniumchloride solution (50 mL) and extracted with ethyl acetate. The organiclayer was washed with saturated brine, dried over anhydrous magnesiumsulfate, and filtrated. The filtrate was concentrated and the resultingresidue was subjected to silica gel column chromatography using 5% MeOHin chloroform as the eluent to provide (E)-methyl3-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl) acrylate (0.30g, 72%) as a brown solid. LCMS Method V: retention time 1.94 min;[M+1]=411.2.

Step 2. Example 193

To a solution of (E)-ethyl3-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl) acrylate (0.150g, 0.370 mmol) in MeOH (25 mL) was added 10% palladium-on-carbon (50mg). The mixture is stirred at room temperature under hydrogen for 14 h.After this time, the mixture was filtered to provide Example 193 (110mg, 73%). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.21 (d, 1H, J=4.4 Hz);7.76-7.66 (m, 3H); 7.55-7.45 (m, 5H); 7.24-7.19 (m, 3H); 6.65 (br s,1H); 4.54 (d, 2H, J=4.4 Hz); 3.60 (s, 3H0; 3.06 (t, 2H, J=6 Hz); 2.82(t, 2H, J=6 Hz). LCMS Method Y: retention time 1.87 min; [M+1]=399.4;HPLC Method A1: purity 94.0%, retention time=6.32 min.

Example 1945-(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)-1,3,4-oxadiazole-2-carboxamide

Step 1. Preparation of methyl5-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)-1,3,4-oxadiazole-2-carboxylate

To a solution of5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinohydrazide(from Example 185, 0.30 g, 0.66 mmol) in DCM at 0° C. was added methyl2-chloro-2-oxoacetate (0.062 mL, 0.66 mmol) and potassium carbonate(0.273 g, 1.90 mmol). Upon completion of addition, the mixture wasstirred at RT for 16 h. After this time, water was added and the mixturewas extracted into DCM, dried and concentrated. The resulting residuewas dissolved in DCM. Triflic anhydride (0.187 mL, 1.1 mmol) andpyridine (0.149 mL, 1.8 mmol) were added and the resulting mixture wasstirred at RT for 16 h. At the conclusion of this period, the reactionmixture was quenched with water and extracted with DCM (100 mL). The DCMlayer was washed with water and brine. Chromatographic purificationprovided methyl5-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)-1,3,4-oxadiazole-2-carboxylate(270 mg, 78% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm):9.81 (s, 1H), 9.17 (s, 1H), 9.09 (s, 1H), 8.24 (d, J=4.4 Hz, 1H), 7.94(d, J=7.2 Hz, 1H), 7.86 (t, J=7.6 Hz, 1H), 7.75-7.72 (t, J=7.6 Hz, 3H),7.59-7.51 (m, 5H), 7.34 (d, J=7.2 Hz, 2H), 7.24 (t, J=6.4 Hz, 1H), 6.98(t, J=3.2 Hz, 1H), 4.77 (d, J=4.0 Hz, 2H). LCMS Method Q: retention time1.39 min; [M+1]=514.5; HPLC Method B: purity 98.1%, retention time=8.74min.

Step 2. Example 194

A solution of the methyl5-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)-1,3,4-oxadiazole-2-carboxylate(0.0700 g, 0.136 mmol) in NH₃ (2.0 M in MeOH, 10 mL) was heated at 60°C., in a sealed vessel for 4 h. After this time, the reaction mixturewas allowed to cool to room temperature and the solvent was evaporatedunder reduced pressure to provide the crude product. The crude productwas recrystallized from EtOAc/hexanes to provide Example 194 (0.06 g,99% yield). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.81 (s, 1H), 9.17 (s,1H), 9.09 (s, 1H), 8.24 (d, J=4.4 Hz, 1H), 7.94 (d, J=7.2 Hz, 1H), 7.86(t, J=7.6 Hz, 1H), 7.75-7.72 (t, J=7.6 Hz, 3H), 7.59-7.51 (m, 5H), 7.34(d, J=7.2 Hz, 2H), 7.24 (t, J=6.4 Hz, 1H), 6.98 (t, J=3.2 Hz, 1H), 4.77(d, J=4.0 Hz, 2H). LCMS Method Q: retention time 1.39 min; [M+1]=499.50.HPLC Method B: purity 98.1%, retention time=8.74 min.

Example 1952-(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)propan-2-ol

To a solution of methyl5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinate (fromExample 43, 0.30 g, 0.67 mmol) in THF (10 mL) was added methyl magnesiumiodide (3.3 mL, 10 mmol) at 0° C. under nitrogen atmosphere. Upon thecompletion of addition, the reaction mixture was stirred at roomtemperature for 16 h. After this time, the reaction mixture was quenchedwith the addition of water and then extracted with ethyl acetate (50mL). The combined organic extracts were washed successively with waterand brine. The organic layer was dried, filtered and concentrated. Theresulting residue was purified by column chromatography on silica gel(5% methanol in dichloromethane) to afford Example 195 (0.090 g, 30%yield) as an off white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.51(s, 1H), 8.81 (s, 1H), 8.79 (s, 1H), 8.25 (d, 1H, J=4.4 Hz), 7.92 (d,1H, J=8.4 Hz), 7.85 (dt, 1H, J=7.2, 8 Hz), 7.74 (m, 1H), 7.60-7.51 (m,5H), 7.34-7.31 (m, 2H), 7.29-7.22 (m, 1H), 7.24 (t, 1H, J=4.8, 7.6 Hz),6.80 (s, 1H), 5.36 (s, 1H), 4.75 (d, 2H, J−4 Hz), 1.51 (s, 6H). HPLCMethod B: purity 99.0%, retention time=7.26 min; LCMS Method E:retention time 1.8 min; [M+1]=447.50.

Example 196(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)methylisopropylcarbamate

Step 1. Preparation of(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)methanol

To a solution of 5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl) nicotinaldehyde (from example 191, 1.0 g, 2.4 mmol) inethanol (15 mL) was added NaBH₄ (0.28 g, 7.19 mmol). Upon completion ofaddition, the reaction mixture was stirred at RT for 4 h. After thistime, a saturated solution of ammonium chloride was added and theresulting mixture was extracted into ethyl acetate. The organic layerwas separated, dried, filtered and concentrated under reduced pressureto yield a residue. The residue was purified by silica gel columnchromatography using 2% methanol in DCM as the eluent to provide pure(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)methanol(0.71 g, 71% yield). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.51 (s, 1H),8.72 (s, 1H), 8.63 (s, 1H), 8.23 (d, 1H, J=4.8 Hz), 7.88 (dd, 1H, J=7.6Hz, 8.4 Hz), 7.85-7.80 (m, 1H), 7.73 (dt, 1H, J=1.2 Hz, 7.6 Hz),7.61-7.48 (m, 5H), 7.33 (d, 2H, J=19.2 Hz), 7.27 (d, 1H, J=14 Hz), 7.23(dt, 1H, J=1.6, 7.2 Hz), 6.87 (t, 1H, J=4.0 Hz, 1H), 5.47 (t, 1H,J=5.6), 4.75 (d, 2H, J−4 Hz), 4.67 (d, 2H, J=5.6 Hz). LCMS Method U:retention time 1.46 min; [M+1]=420.2; HPLC Method A2: purity 99.5%,retention time=5.77 min.

Step 2. Example 196

To a solution of(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)methanol(0.050 g, 0.12 mmol) in DCM (2 mL) was added DMAP (0.014 g, 0.12 mmol)followed by isopropylisocyanate (0.010 g, 012 mmol) at 0° C. Upon thecompletion of addition, the reaction mixture was slowly heated to 45° C.where it stirred for 8 h. At the conclusion of this period, the reactionmixture was washed with water and extracted with ethyl acetate. Thecombined organic extracts were dried, filtered, concentrated underreduced pressure to yield a residue. The residue purified by silica gelcolumn chromatography (2% MeOH in DCM) to provide Example 196 (30 mg,50% yield). ¹H NMR (400 MHz, DMSO-d₆, δ): 9.59 (s, 1H); 8.75 (s, 1H);8.70 (s, 1H); 8.24 (d, 1H, J=4.8 Hz); 7.88 9dd, 1H, J=1.2, 8 Hz); 7.84(t, 1H, J=7.2 Hz); 7.73 (dt, 1H, J=1.6, 7.6 Hz); 7.60-7.49 (m, 5H);7.38-7.29 (m, 3H); 7.23 (dd, 1H, J=1.6, 7.2 Hz); 6.87 (br s, 1H); 5.18(br s, 1H); 4.75 (d, 2H, J=4 HZ); 3.72-3.60 (m, 1H); 1.08 (d, 6H, J=6.4Hz). LCMS Method Y: retention time 2.00 min, [M+1]=505.4; HPLC MethodA1: purity 98.9%, retention time=8.12 min.

Example 1972-Methyl-1-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)propan-1-ol

To a solution of5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinaldehyde(from example 191, 0.15 g, 0.35 mmol) in THF at −78° C. was addedisopropyl magnesium chloride solution (2 M in THF, 10 eq). Uponcompletion of addition, the reaction mixture was allowed to reach roomtemperature. Once at the prescribed temperature, the reaction mixturewas stirred for 16 h. After this time, the reaction mixture was quenchedwith a saturated solution of ammonium chloride (2 mL) and then extractedwith ethyl acetate. The combined organic layers were dried, concentratedunder reduced pressure, and purified by silica gel column chromatography(2% MeOH in DCM) to yield racemic Example 197 (20 mg, 12% yield). Theracemate was separated into the corresponding enantiomers using chiralHPLC to provide the pure Enantiomer 1 (4 mg) and Enantiomer 2 (3.5 mg),respectively. CHIRAL HPLC: (CHIRAL PAK IC (250×4.6) mm, 5 micron; mobilephase (85% hexane, 15% ethanol; flow rate: 1 ml/min}. Enantiomer-1: ¹HNMR (400 MHz, DMSO-d₆, δ): 9.51 (s, 1H); 8.69 (s, 1H); 8.60 (s, 1H);8.26 (d, 1H, J=4.4 Hz); 7.90 (d, 1H, J=7.6 Hz); 8.55 (t, 1H, J=7.2 Hz);7.73 (dt, 1H, J=1.6, 7.6 Hz); 7.61-7.50 (m, 4H); 7.38-7.30 (m, 2H); 7.24(t, 1H, J=9.2 Hz); 6.81 (br s, 1H); 5.42 (d, 1H, J=4.4 Hz); 4.74 (d, 2H,J=4 Hz); 4.45 (t, 1H, J=4.8 Hz); 2.00-2.90 (m, 1H); 0.92 (d, 3H, J=6.4Hz); 0.82 (t, 3H, J=6.4 Hz). LCMS Method T: retention time 1.78 min,[M+1]=462.2; HPLC Method A1: purity 99.0%, retention time=6.93 min.CHIRAL HPLC: retention time 19.78 {CHIRAL PAK IC (250×4.6) mm, 5 micron;mobile phase (hexane (85), Ethanol (15); Flow rate: 1 ml/min}.Enantiomer-2: ¹H NMR (400 MHz, DMSO-d₆, δ): 9.51 (s, 1H); 8.69 (s, 1H);8.60 (s, 1H); 8.26 (d, 1H, J=4.4 Hz); 7.90 (d, 1H, J=7.6 Hz); 8.55 (t,1H, J=7.2 Hz); 7.73 (dt, 1H, J 1.6, 7.6 Hz); 7.61-7.50 (m, 4H);7.38-7.30 (m, 2H); 7.24 (t, 1H, J=9.2 Hz); 6.81 (br s, 1H); 5.42 (d, 1H,J=4.4 Hz); 4.74 (d, 2H, J=4 Hz); 4.45 (t, 1H, J=4.8 Hz); 2.00-2.90 (m,1H); 0.92 (d, 3H, J=6.4 Hz); 0.82 (t, 3H, J=6.4 Hz). LCMS Method T:retention time 1.78 min, [M+1]=462.2; HPLC Method A1: purity 96.9%,retention time=6.93 min. CHIRAL HPLC: retention time 22.02 {CHIRAL PAKIC (250×4.6) mm, 5 micron; mobile phase (hexane (85), Ethanol (15); Flowrate: 1 ml/min}.

Example 1982-(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-ylsulfonyl)acetamide

Step 1. Preparation of methyl 2-(5-bromopyridin-3-ylthio)acetate

To a solution of sodium hydride (0.518 g, 21.0 mmol) in DMF (5 mL) at 0°C. was added dropwise a solution of methylthioglycolate (2 g, 18 mmol)in DMF (6 mL). Upon completion of addition, the reaction mixture wasstirred at RT for 30 min. After this time, a solution of3,5-dibromopyridine (4.46 g, 18 mmol) in DMF (10 mL) was added dropwise.The resulting reaction mixture was allowed stir at RT for 16 h. At theconclusion of this period, the reaction mixture was quenched by theaddition of ice and the resulting slurry was extracted with ethylacetate. The combined organic layers were dried and concentrated underreduced pressure. The resulting residue was purified by silica gelcolumn chromatography (1.5% methanol in DCM) to yield methyl2-(5-bromopyridin-3-ylthio)acetate (1.2 g, 24% yield). LCMS Method A:retention time 1.49 min; [M+1]=262.

Step 2. Preparation of methyl 2-(5-bromopyridin-3-ylsulfonyl)acetate

To a solution of methyl 2-(5-bromopyridin-3-ylthio)acetate (1.2 g, 4.6mmol) in 3:1 MeOH:H₂O (12 mL) was added oxone (2.8 g, 4.6 mmol). Uponcompletion of addition, the reaction mixture was stirred at RT for 5 h.At the conclusion of this period, the reaction mixture was concentratedunder reduced pressure and then extracted with DCM. The combined organiclayers were dried and concentrated under reduced pressure to yield aresidue. The residue was purified by silica gel column chromatography(1.5% methanol in DCM) to yield methyl2-(5-bromopyridin-3-ylsulfonyl)acetate (0.6 g, 46% yield). ¹H NMR (400MHz, DMSO-d6, δ): 9.11 (d, 1H, J=2 Hz); 9.02 (d, 1H, J=2 Hz); 8.57 (t,1H, J=2 Hz); 4.95 (s, 2H); 3.63 (s, 3H). LCMS Method T: retention time1.12 min; [M+1]=294.0.

Step 3. Preparation of 2-(5-bromopyridin-3-ylsulfonyl)acetamide

To a solution of methyl 2-(5-bromopyridin-3-ylsulfonyl)acetate (0.2 g,0.67 mmol) was added 5% ammonia in methanol (10 mL). Upon completion ofaddition, the reaction mixture was stirred at 60° C. for 4 h. After thistime, the reaction mixture was allowed to cool to room temperature. Onceat the prescribed temperature, the reaction mixture was concentratedunder reduced pressure to afford2-(5-bromopyridin-3-ylsulfonyl)acetamide (0.2 g) as a white solid. LCMSMethod W: retention time 0.92 min; [M−1]=277.0.

Step 4. Preparation of2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ylsulfonyl)acetamide

A mixture 2-(5-bromopyridin-3-ylsulfonyl)acetamide (0.2 g, 0.7 mmol),bis(pinacolato)diboron (0.27 g, 1 mmol) and potassium acetate (0.2 g,2.1 mmol) in 1,4-dioxane (10 mL) was degassed with nitrogen for 15 min.After this time, (1,1′-bis(diphenylphosphino)ferrocene)palladium (II)chloride dichloromethane complex (0.028 g, 0.035 mmol) was added and theresulting mixture was again degassed for 10 min. with nitrogen. Thereaction mixture was then heated in the microwave at 100° C. for 16 h.At the conclusion of this period, the reaction mixture was filteredthrough celite and the filtrate was concentrated under reduced pressureto provide2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ylsulfonyl)acetamide(0.170 g), which was used without further purification.

Step 5. Example 198

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (from example1, step 4, 0.182 g, 0.52 mmol) in 1,4-dioxane (6 mL) and H₂O (1.2 mL)under nitrogen was added2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-ylsulfonyl)acetamide(0.170 g, 0.57 mmol), and potassium carbonate (0.215 g, 1.56 mmol). Uponcompletion of addition, the reaction mixture was degassed with nitrogenfor 15 min. After this time,(1,1′-bis(diphenylphosphino)-ferrocene)palladium (II) chloridedichloromethane complex (0.042 g, 0.052 mmol) was added. The resultingmixture was again degassed with nitrogen for 10 min. At the conclusionof this period, the reaction mixture was stirred at 100° C. for 16 h,then allowed to cool to room temperature and quenched by the addition ofwater. Upon the completion of addition, the reaction mixture wastransferred to a separation funnel and the aqueous layer was extractedwith ethyl acetate. The combined organic portions were washed with waterand saturated NaCl, dried over Na₂SO₄, filtered and concentrated underreduced pressure. The resulting concentrate was purified by columnchromatography to afford Example 198 (0.020 g, 8% yield). ¹H NMR (400MHz, DMSO-d₆, δ): 9.89 (s, 1H); 9.17 (s, 1H); 9.14 (s, 1H); 8.25 (s,1H); 7.96 (dd, 1H, J=1.6, 4.4 Hz); 7.88 (dd, 1H, J=7.2, 8.4 Hz); 7.73(dd, 1H, J=2, 7.6 Hz); 7.61-7.50 (m, 5H); 7.45 (br s, 1H); 7.39-7.33 (m,2H); 7.24 (t, 1H, J=2.4 Hz); 6.96 (br s, 1H); 4.77 (d, 2H, J=4 Hz); 4.49(s, 2H). LCMS Method Y: retention time 1.83 min, [M−1]=509.0; HPLCMethod A1: purity 96.2%, retention time=6.79 min.

Example 1992-Methyl-2-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)propanenitrile

Step 1. Preparation of 3-bromo-5-chloromethyl-pyridine

To a solution of (5-bromo-pyridin-3-yl)-methanol (0.5 g, 2.68 mmol) inDCM (10 mL) was added thionyl chloride (0.5 mL). The resulting solutionwas stirred at room temperature for 2 h. After this time, the reactionmixture was quenched with water and extracted into DCM. The organicextracts were washed with brine filtered and concentrated under reducedpressure to give 3-bromo-5-chloromethyl-pyridine (0.45 g, 82%), whichwas used in the next step without further purification.

Step 2. Preparation of 2-(5-bromopyridin-3-yl) acetonitrile

Potassium cyanide (0.21 g, 3.27 mmol) was added to a solution of3-bromo-5-chloromethyl-pyridine (0.45 g; 2.18 mmol) in DMF (10 mL). Uponcompletion of addition, the reaction mixture was stirred at roomtemperature for 16 h. After this time, the reaction mixture was quenchedwith water and extracted with ethyl acetate. The organic phase waswashed with water and brine, dried over Na₂SO₄, filtered and evaporated.The resulting residue was purified by silica gel column chromatography(10% ethyl acetate in hexane) to provide 2-(5-bromopyridin-3-yl)acetonitrile (200 mg, 46.5%). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.68(d, 1H, J=2 Hz), 8.51 (d, 1H, J=2 Hz), 7.88 (t, 1H, J=2 Hz), 3.77 (s,2H).

Step 3. Preparation of 2-(5-bromopyridin-3-yl)-2-methylpropanenitrile

To a suspension of NaH (95%, 0.17 g, 7.1 mmol) in THF was added asolution of 2-(5-bromopyridin-3-yl)acetonitrile (0.7 g, 3.0 mmol) in THF(5 mL) at 0° C. and the resulting reaction mixture stirred at RT for 30min. At the conclusion of this period, methyl iodide (0.66 mL, 8.9 mmol)was added and then stirring continued for an additional 16 h. After thistime, the reaction mixture was quenched by the addition of saturatedammonium chloride solution and then extracted into ethyl acetate. Thecombined organic portions were concentrated under reduced pressure andthe resulting residue was purified by flash column chromatography (15%ethyl acetate in hexanes) to yield2-(5-bromopyridin-3-yl)-2-methylpropanenitrile (0.35 g, 56%). ¹H NMR(400 MHz, DMSO-d₆) δ (ppm): 8.67 (d, 1H, J=2 Hz), 8.45 (d, 1H, J=2 Hz),7.73 (t, 1H, J=2 Hz), 2.44 (s, 3H), 2.28 (s, 3H).

Step 4. Preparation of2-methyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)propanenitrile

A mixture of 2-(5-bromopyridin-3-yl)-2-methylpropanenitrile (0.4 g, 1.77mmol), bis(pinacolato)diboron (0.67 g, 2.65 mmol) and potassium acetate(0.69 g, 7.04 mmol) in 1,4-dioxane (15 mL) was degassed with nitrogenfor 15 min. After this time,(1,1′-bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (0.11 g, 0.15 mmol) was added. The reactionmixture was again degassed for 10 min with nitrogen and then heated inthe microwave at 120° C. for 45 min. At the conclusion of this period,the reaction mixture was filtered through celite and the filtrate wasconcentrated under reduced pressure to provide2-methyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)propanenitrile(0.53 g), which was used without further purification.

Step 5. Example 199

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (from example1, step 4, 0.4 g, 1 mmol) in 1,4-dioxane (15 mL) and H₂O (1 mL) undernitrogen was added2-methyl-2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)propanenitrile(0.5 g, 2 mmol) and potassium carbonate (0.48 g, 3.5 mmol). Uponcompletion of addition, the mixture was degassed with nitrogen for 15min. At the conclusion of this period, (1,1′-bis(diphenylphosphino)ferrocene)palladium (II) chloride dichloromethanecomplex (85 mg, 0.11 mmol) was added and the reaction mixture was againdegassed with nitrogen for 10 min. After this time, the reaction mixturewas stirred at 95° C. for 16 h. At the conclusion of this period, thereaction mixture was allowed to cool to room temperature and thenquenched by the addition of water. Upon completion of addition, thereaction mixture was transferred to a separation funnel and the aqueouslayer was extracted with ethyl acetate. The combined organic portionswere washed with water and saturated NaCl, dried over Na₂SO₄, filteredand concentrated under reduced pressure. The resulting residue waspurified by column chromatography (2% methanol in dichloromethane) toafford Example 199 (0.38 g, 72% yield) as an off-white solid. ¹H NMR(400 MHz, DMSO-d₆) δ (ppm): 9.61 (s, 1H), 8.92 (s, 1H), 8.88 (s, 1H),8.24 (d, 1H, J=4.4 Hz), 7.93 (dd, 1H, J=1.2 Hz, 4.4 Hz), 7.84 (t, 1H,J=8 Hz), 7.73 (dt, 1H, J=1.6, 8 Hz), 7.63-7.50 (m, 5H), 7.36-7.30 (m,2H), 7.24 (t, 1H, J=5.6 Hz), 6.84 (br s, 1H), 4.75 (d, 2H, J=4.0 Hz),1.84 (s, 6H). LCMS Method Y: retention time 2.04 min; [M+1]=457.0; HPLCMethod A1: purity 99.1%, retention time=8.39 min.

Example 2002-(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)propanamide

Step 1. Preparation of 2-(5-bromopyridin-3-yl)propanenitrile

To a suspension of NaH (95%, 113 mg, 4.70 mmol) in DMF was added asolution of 2-(5-bromopyridin-3-yl)acetonitrile (from example 199, 0.8g, 4 mmol) in DMF. Upon completion of addition, the reaction mixture wasstirred at RT for 30 min. After this time, methyl iodide (0.3 mL, 4mmol) was added and the stirring continued for an additional 4 h. At theconclusion of this period, the reaction mixture was quenched by additionof saturated ammonium chloride solution and then extracted into ethylacetate. The combined organic portions were concentrated under reducedpressure and the resulting residue was purified by flash columnchromatography (30% EtOAc in hexanes) to yield racemic2-(5-bromopyridin-3-yl)propanenitrile (200 mg, 24%). ¹H NMR (400 MHz,CDCL₃) δ (ppm): 8.67 (d, 1H, J=2 Hz); 8.53 (d, 1H, J=5 Hz); 7.88 (t, 1H,J=5 Hz); 3.94 (q, 1H, J=7.6 Hz); 1.69 (d, 3H, J=7.6 Hz). LCMS Method Y:retention time 1.54 min; [M+1]=212.6.

Step 2. Preparation of2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)propanenitrile

A mixture of 2-(5-bromopyridin-3-yl)propanenitrile (0.1 g, 0.5 mmol),bis(pinacolato)diboron (0.18 g, 0.70 mmol) and potassium acetate (0.19g, 1.9 mmol) in 1,4-dioxane (8 mL) was degassed with nitrogen for 15min. After this time, (1,1′-bis(diphenylphosphino)ferrocene)palladium(II) chloride dichloromethane complex (28 mg, 0.038 mmol) was added andthe resulting mixture was again degassed for 10 min. with nitrogen. Atthe conclusion of this period, the reaction mixture was heated in themicrowave at 120° C. for 45 min. After this time, the reaction mixturewas filtered through celite and the filtrate was concentrated underreduced pressure to provide racemic2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)propanenitrile(0.12 g), which was used without further purification. LCMS Method Y:retention time 1.83 min; [M+1]=258.8.

Step 3. Preparation of 2-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)propanenitrile

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (from example1, step 4, 0.12 g, 0.5 mmol) in 1,4-dioxane (8 mL) and H₂O (0.55 mL)under nitrogen was added2-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)propanenitrile(0.120 g, 0.4 mmol) and potassium carbonate (0.14 g, 1 mmol). Theresulting mixture was degassed with nitrogen for 15 min. After thistime, (1,1′-bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (0.26 mg, 0.036 mmol) was added and the reactionmixture was again degassed with nitrogen for 10 min. At the conclusionof this period, the reaction mixture was stirred at 95° C. for 16 h. Thereaction mixture was then allowed to cool to room temperature. Once atthe prescribed temperature, the reaction mixture was quenched by theaddition of water and then transferred to a separation funnel. Theaqueous layer was extracted with ethyl acetate. The combined organicportions were washed with water and saturated NaCl, dried over Na₂SO₄,filtered and concentrated under reduced pressure. The resultingconcentrate was purified by silica gel column chromatography using 1%methanol in DCM to afford racemic2-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)propanenitrile (95 mg, 63% yield) as an offwhite solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.60 (s, 1H), 8.80 (d,1H, J=2 Hz); 8.77 (s, 1H); 8.26 (d, 1H, J=6 Hz); 7.92 (dd, 1H, J=1.2,6.8 Hz); 7.85 (t, 1H, J=6.8 Hz); 7.73 (dt, 1H, J=1.6, 7.6 Hz); 7.58-7.52(m, 5H); 7.34-7.32 (m, 2H); 7.24 (t, 1H, 7.2 Hz); 6.86 (t, 1H, J=4 Hz);4.76 (d, 2H, J=4.4 Hz); 4.59 (q, 1H, J=7.2 Hz); 1.68 (d, 3H, 7.2 Hz).LCMS Method Y: retention time 1.68 min, [M+1]=443.2.

Step 4. Preparation of2-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)propanoicacid

To a solution of racemic of 2-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl) propanenitrile (0.08 g, 0.18 mmol) inethanol/water (3:3 mL) was added solid NaOH (52 mg, 1.1 mmol). Uponcompletion of addition, the reaction mixture was heated at 95° C. for 16h. After this time, the reaction mixture allowed to cool to RT and thenwater was added (5 mL). Upon completion of addition, 1.0 N HCl was addedto the reaction mixture to adjust the pH to 6-7. Once at the prescribedpH, the aqueous portion was extracted with ethyl acetate. The combinedorganic extracts were dried, filtered and concentrated under reducedpressure to yield racemic2-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)propanoicacid (32 mg, 39% yield).

Step 5. Example 200

To a solution of racemic2-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)propanoicacid (0.08 g, 0.2 mmol) in DMF (1.5 mL) was added EDCI (0.04 g, 0.2 mL),HOBt (0.028 g, 0.20 mmol) and DIPEA (0.2 mL, 0.7 mmol) followed byammonium chloride (0.03 g, 0.7 mmol). The reaction mixture was stirredat room temperature for 2 h. After this time, the reaction mixture waswashed and then extracted with ethyl acetate. The combined organicextracts were dried, filtered and concentrated under reduced pressure.The resulting residue was purified by flash silica gel columnchromatography (5% methanol in dichloromethane) to obtain racemicExample 200 (35 mg, 43% yield) as an off-white solid. The enantiomerswere separated by Chiral HPLC (CHIRAL HPLC: CHIRAL PAK IC (250×4.6) mm,5 micron; mobile phase 85% hexane, 15% ethanol; Flow rate: 1 ml/min}).Enantiomer-1: ¹H NMR (400 MHz, DMSO-d₆, δ): 9.50 (s, 1H); 8.70 (s, 1H);8.65 (s, 1H); 8.25 (d, J=4.8 Hz, 1H), 7.91 (dd, J=1.2 Hz, 8.4 Hz, 1H),7.84 (t, 7.2 Hz, 1H), 7.72 (dt, J=1.6 Hz, 7.6 Hz, 1H), 7.62-7.50 (m, 6Hz), 7.36-7.30 (m, 2H), 7.23 (dd, J=5.2 Hz, 6.2 Hz, 1H), 6.98 (s, 1H),6.83 (brs, 1H), 4.74 (d, J=4 Hz, 2H), 3.78 (t, J=7.7 Hz, 1H), 1.44 (d,J=7.2 Hz, 3H). LCMS Method Y: retention time 1.78 min; [M+1]=461.0; HPLCMethod A1: purity 99.8%, retention time=6.04 min. CHIRAL HPLC: retentiontime 15.43 {CHIRAL PAK IC (250×4.6) mm, 5 micron; mobile phase 85%hexane, 15% ethanol; Flow rate: 1 ml/min}. Enantiomer-2: ¹H NMR (400MHz, DMSO-d₆, δ): 9.50 (s, 1H); 8.70 (s, 1H); 8.65 (s, 1H); 8.25 (d,J=4.8 Hz, 1H), 7.91 (dd, J=1.2 Hz, 8.4 Hz, 1H), 7.84 (t, 7.2 Hz, 1H),7.72 (dt, J=1.6 Hz, 7.6 Hz, 1H), 7.62-7.50 (m, 6 Hz), 7.36-7.30 (m, 2H),7.23 (dd, J=5.2 Hz, 6.2 Hz, 1H), 6.98 (s, 1H), 6.83 (brs, 1H), 4.74 (d,J=4 Hz, 2H), 3.78 (t, J=7.7 Hz, 1H), 1.44 (d, J=7.2 Hz, 3H). LCMS MethodY: retention time 1.78 min; [M+1]=461.0; HPLC Method A1: purity 99.6%,retention time=6.06 min. CHIRAL HPLC: retention time 19.08 {CHIRAL PAKIC (250×4.6) mm, 5 micron; mobile phase 85% hexane, 15% ethanol; Flowrate: 1 ml/min}.

Example 201 Methyl5-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)-1,3,4-oxadiazole-2-carboxylate

To a solution of5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinohydrazide(from example 185, 0.3 g, 0.66 mmol) in DCM (3 mL) at 0° C. was addedmethyl 2-chloro-2-oxoacetate (0.062 mL, 0.66 mmol) and potassiumcarbonate (0273 g, 1.90 mmol). Upon completion of addition, the reactionmixture was stirred at RT for 16 h. After this time, water was added (2mL) and the reaction mixture was extracted into DCM. The combinedorganic portions were dried and concentrated under reduced pressure. Theresulting residue was dissolved in DCM (3 mL) andtrifluoromethanesulfonic anhydride (0.19 mL, 1.1 mmol) and pyridine(0.149 mL, 1.80 mmol) were added. Upon completion of addition, thereaction mixture was stirred at RT for 16 h. At the conclusion of thisperiod, the reaction mixture was quenched by the addition of water andthen extracted with DCM. The combined organic portions were washedsuccessively with water and brine, dried, filtered and concentratedunder reduced pressure to yield a residue. The residue was purifiedusing flash column chromatography (2% methanol in dichloromethane) toyield Example 201 (270 mg, 35% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) δ (ppm): 9.87 (s, 1H0; 9.36 (s, 1H0; 9.32 9s, 1H); 8.26 (d, 1H,J=4.4 Hz), 7.98 (dd, 1H, J=1.2, 8.4 Hz); 7.87 (dd, 1H, J=1.4, 4 Hz);7.74 (dt, 1H, J=1.6, 7.6 Hz); 7.62-7.50 (m, 5H); 7.39-7.31 (m, 2H); 7.24(dd, 1H, J=5.2, 6.8 Hz); 6.95 (br t, 1H, J=4.4 Hz); 4.77 (d, 2H, J=4Hz); 4.05 (s, 3H). LCMS Method Y: retention time 2.07 min; [M+1]=516.0;HPLC Method A1: purity 96.4%, retention time=8.75 min.

Example 2021-(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)ethanol

To a solution of5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinaldehyde(from example 191, 0.3 g, 0.7 mmol) in THF (5 mL) at 0° C. was addedmethylmagnesium bromide solution (3 M in THF, 0.7 mL, 2 mmol). Uponcompletion of addition, the reaction mixture was stirred at roomtemperature for 5 h. After this time, the reaction mixture was quenchedby the addition of saturated solution of ammonium chloride (2 mL) andthen extracted into ethyl acetate. The combined organic layers weredried, filtered concentrated to yield a residue. The residue purified bycolumn chromatography to yield racemic Example 202 (20 mg, 7% yield),which was separated into the corresponding enantiomers by chiral HPLC{CHIRAL PAK IC 250×4.6 mm, 5 micron; mobile phase 85% hexane, 15%ethanol; Flow rate: 1 ml/min} to provide pure Enantiomer 1 (11 mg) andEnantiomer 2 (12 mg), respectively. Enantiomer 1: ¹H NMR (400 MHz,DMSO-d₆, δ): 9.50 (d, 1H, J=2 Hz); 8.73 (s, 1H); 8.65 (d, 1H, J=2 Hz);8.24 (d, 1H, J=4.8 Hz); 7.90 (dd, 1H, J 1.2, 8.4 Hz); 7.83 (dd, 1H,J=7.2, 8.4 Hz); 7.71 (dt, 1H, J=1.6, 7.6 Hz); 7.60-7.49 (m, 5H);7.38-7.27 (m, 2H); 7.23 (dd, 1H, J=3.2, 6.8 Hz); 6.82 (br t, 1H, J=4Hz); 5.45 (d, 2H, J=4 Hz); 4.92 (t, 1H, J=3.6 Hz); 4.74 (d, 2H, J=4 Hz);1.45 (d, 3H, J=6.8 Hz). LCMS Method V: retention time 1.60 min,[M+1]=434.2; HPLC Method A1: purity 99.8%, retention time=6.30 min.CHIRAL HPLC: retention time 16.27 {CHIRAL PAK IC (250×4.6) mm, 5 micron;mobile phase 85% hexane, 15% ethanol; Flow rate: 1 ml/min}. Enantiomer2: ¹H NMR (400 MHz, DMSO-d₆, δ): 9.50 (d, 1H, J=2 Hz); 8.73 (s, 1H);8.65 (d, 1H, J=2 Hz); 8.24 (d, 1H, J=4.8 Hz); 7.90 (dd, 1H, J=1.2, 8.4Hz); 7.83 (dd, 1H, J=7.2, 8.4 Hz); 7.71 (dt, 1H, J=1.6, 7.6 Hz);7.60-7.49 (m, 5H); 7.38-7.27 (m, 2H); 7.23 (dd, 1H, J=3.2, 6.8 Hz); 6.82(br t, 1H, J=4 Hz); 5.45 (d, 2H, J=4 Hz); 4.92 (t, 1H, J=3.6 Hz); 4.74(d, 2H, J=4 Hz); 1.45 (d, 3H, J=6.8 Hz). LCMS Method T: retention time1.61 min, [M+1]=434.2; HPLC Method A1: purity 96.8%, retention time=6.23min. CHIRAL HPLC: retention time 21.02 {CHIRAL PAK IC (250×4.6) mm, 5micron; mobile phase 85% hexane, 15% ethanol; Flow rate: 1 ml/min}.

Example 2034-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)thiazol-2-amine

Step 1. Preparation of2-(1-ethoxyvinyl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine

To 2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (1.0 g,2.88 mmol) was added 1,4-dioxane (15 mL) and the resulting solutiondegassed with nitrogen. Pd(TPP)₂Cl₂ (0.202 g, 0.288 mmol) andtributyl(1-ethoxyvinyl)stannane (5.2 g, 14 mmol) were added under anitrogen stream and the reaction mixture was heated to 90° C. where itstirred for 16 h. After this time, the reaction mixture was allowed tocool to room temperature. Once at the prescribed temperature, thereaction mixture was concentrated under reduced pressure and theresulting residue was purified by neutral alumina column chromatography(20% ethyl acetate, hexane) to yield2-(1-ethoxyvinyl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (940mg, 85% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.23(d, 1H, J=4.4 Hz), 7.75-7.85 (m, 2H), 7.70 (dt, 1H, J=2, 7.6 Hz),7.45-7.58 (m, 5H), 7.20-7.30 (m, 3H), 6.61 (br s, 1H), 4.61 (s, 1H),4.60 (d, 2H, J=4 Hz), 3.94 (q, 2H, J=6.8 Hz), 1.40 (t, 3H, J=6.8 Hz).LCMS Method Y: retention time 1.952 min, [M+1]=383.2.

Step 2. Preparation of2-bromo-1-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)ethanone

N-bromosuccinimide (0.55 g, 3.1 mmol) was added to 1,4-dioxane/water(3:1) (20 mL).2-(1-Ethoxyvinyl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine(0.59 g, 1.5 mmol) was then added in small portions at 0° C. Uponcompletion of addition, the reaction mixture was stirred at roomtemperature for 20 min. After this time, water was added and the aqueousportion was extracted twice with DCM. The combined organic layers weredried, filtered and evaporated under reduced pressure to yield2-bromo-1-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)ethanone(600 mg, 69% purity by LCMS), which was used without furtherpurification. LCMS Method Y: retention time 1.996 min, [M+1]=433.

Step 3. Example 203

To a solution of2-bromo-1-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)ethanone(75 mg, 0.17 mmol) in ethanol (7 mL) was added thiourea (14 mg, 0.17mmol) and the reaction mixture heated to 70° C. for 1 h. After thistime, the ethanol was evaporated under reduced pressure and DCM (25 mL)was added. Upon the completion of addition, the organic portion waswashed with 10% sodium bicarbonate solution and the aqueous layer wasextracted with DCM (2×20 mL). The combined organic phases were dried andevaporated under reduced pressure to yield a residue. The residue waspurified by silica gel chromatography (8% methanol in dichloromethane)to provide Example 203 (25 mg, 35%) as a black semi-solid. ¹H NMR (400MHz, DMSO-d₆, δ): 8.24 (d, 1H, J=4.8 Hz); 7.80-7.67 (m, 3H); 7.45-7.59(m, 6H); 7.20-7.30 (m, 3H); 7.07 (s, 2H); 6.56 (br s, 1H); 4.65 (d, 2H,J=4.4 Hz). LCMS Method V: retention time 1.59 min, [M+1]=411.2; HPLCMethod A1: purity 97.6%, retention time=6.52 min.

Example 204(4-Aminopiperidin-1-yl)(3-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)-1,2,4-oxadiazol-5-yl)methanone

Step 1. Preparation of tert-butyl1-(3-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)-quinazolin-2-yl)pyridin-3-yl)-1,2,4-oxadiazole-5-carbonyl)piperidin-4-ylcarbamate

To a solution of methyl3-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)-1,2,4-oxadiazole-5-carboxylate(from example 187, 0.2 g, 0.38 mmol) in ethanol (10 mL) was added4-(Boc-amino)piperidine (0.389 g, 1.90 mmol). Upon completion ofaddition, the reaction mixture was heated to 80° C. where it stirred for16 h. At the conclusion of this period, the ethanol was evaporated andthe resulting residue was purified by flash silica gel columnchromatography (1.6% methanol in DCM) to yield tert-butyl1-(3-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)-1,2,4-oxadiazole-5-carbonyl)piperidin-4-ylcarbamate(0.1 g, 38% yield) as yellow solid. LCMS Method T: retention time 2.08min; [M+1]=684.2.

Step 2. Example 204

To a solution of tert-butyl1-(3-(5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)-1,2,4-oxadiazole-5-carbonyl)piperidin-4-ylcarbamate(0.1 g, 0.1 mmol) in ether (3 mL) was added ether HCl (2 mL). Thereaction mixture was stirred at RT for 16 h. After this time, aprecipitate formed and the solution was decanted from the reactionmixture. The resulting solid was recrystallized from ether to yieldExample 204 (0.022 g, 26% yield). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm):9.54 (s, 1H), 8.26 (d, 1H, J=4 Hz); 7.96 (dd, 1H, J=1.2, 8 Hz); 7.87(dd, 1H, J=7.2, 8 Hz); 7.72 (dd, 1H, J=1.6, 7.6 Hz); 7.63-7.50 (m, 2H);7.39-7.33 (m, 2H); 7.25 (t, 1H, J=5.6 Hz); 6.95 (br s, 1H); 4.77 (d, 2H,J=2 Hz); 4.30 (br d, 1H, J=12 Hz); 4.02 (br d, 1H, J=12 Hz); 3.40-3.36(m, 1H); 3.21-3.13 (m, 1H); 3.04-2.95 (m, 1H); 1.95-1.80 (m, 2H);1.43-1.28 (m, 2H). LCMS Method T: retention time 1.65 min; [M+1]=584.2;HPLC Method A1: purity 96.1%, retention time=6.08 min.

Example 2051-(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)cyclopropanecarbonitrile

Step 1. Preparation of 1-(5-bromopyridin-3-yl)cyclopropanecarbonitrile

A suspension of 7 mL NaOH (50/50 w/w in H₂O) was charged with2-(5-bromopyridin-3-yl)acetonitrile (from example 199: 0.36 g, 1.9mmol). 1-Bromo-2-chloroethane (0.29 g, 2.01 mmol) was added followed bya catalytic amount of benzyl triethylammonium chloride (5 mg). Thereaction mixture was stirred for 20 h at 60° C. and then poured intowater. The resulting solution was extracted into ethyl acetate. Thecombined organic extracts were washed successively with water and brine,dried over Na₂SO₄ filtered and then concentrated to yield1-(5-bromopyridin-3-yl)cyclopropanecarbonitrile (0.25 g, 41%), which wasused without further purification. ¹H NMR (400 MHz, CDCL₃) δ (ppm): 8.49(d, 1H, J=2 Hz); 7.78 (d, 1H, J=4 Hz); 3.94 (q, 2H, J=7.6 Hz); 1.69 (d,3H, J=7.6 Hz). LCMS Method Y: retention time 1.54 min; [M+1]=212.6.

Step 2. Preparation of1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)cyclopropanecarbonitrile

A mixture of 1-(5-bromopyridin-3-yl)cyclopropanecarbonitrile (0.25 g,1.1 mmol), bis(pinacolato)diboron (0.31 g, 1.2 mmol) and potassiumacetate (0.44 g, 4.5 mmol) in 1,4-dioxane (8 mL) was degassed withnitrogen for 15 min. After this time,(1,1′-bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (94 mg, 0.12 mmol) was added and the reactionmixture was again degassed for 10 min with nitrogen. The reactionmixture was then heated in the microwave reactor at 120° C. for 45 min.At the conclusion of this period, the reaction mixture was filteredthrough celite and the filtrate was concentrated under reduced pressureto provide1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)cyclopropanecarbonitrile(0.28 g), which was used without further purification. LCMS Method Y:retention time 1.83 min; [M+1]=258.8.

Step 3. Example 205

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (from example1, step 4, 0.12 g, 0.34 mmol) in 1,4-dioxane (8 mL) and H₂O (0.55 mL)under nitrogen was added1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)cyclopropanecarbonitrile(0.12 g, 0.37 mmol), and potassium carbonate (0.15 g, 1.11 mmol). Thereaction mixture was degassed with nitrogen for 15 min. (1,1′-Bis(diphenyphosphino) ferrocene)palladium (II) chloride dichloromethanecomplex (27 mg, 0.037 mmol) was added and the reaction mixture was againdegassed for 10 min with nitrogen. The reaction mixture was stirred at95° C. for 16 h, then allowed to cool to room temperature and quenchedby the addition of water. The reaction mixture was transferred to aseparation funnel and the aqueous layer extracted with ethyl acetate.The combined organic portions were washed with water and saturated NaCl,dried over Na₂SO₄, filtered and concentrated under reduced pressure. Theresulting residue was purified by column chromatography (2% methanol inDCM) to afford Example 205 (85 mg, 55% yield) as an off-white solid. ¹HNMR (400 MHz, DMSO-d₆) δ (ppm): 9.57 (s, 1H), 8.80 (d, 1H, J=2 Hz); 8.77(s, 1H); 8.26 (d, 1H, J=6 Hz); 7.92 (dd, 1H, J=1.2, 6.8 Hz); 7.85 (t,1H, J=6.8 Hz); 7.73 (dt, 1H, J=1.6, 7.6 Hz); 7.58-7.52 (m, 5H);7.34-7.32 (m, 2H); 7.24 (t, 1H, 7.2 Hz); 6.86 (t, 1H, J=4 Hz); 4.75 (d,2H, J=4.4 Hz); 1.90 (dd, 2H, J=4.8, 8 Hz); 1.90 (dd, 2H, J=4.8, 8 Hz).LCMS Method V: retention time 1.78 min, [M+1]=455.2; HPLC Method A1:purity 97.7%, retention time=7.75 min.

Example 2062-(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)ethanesulfonamide

Step 1. Preparation oftert-butyl(diphenylphosphoryl)methylsulfonylcarbamate

To a solution of tert-butyl methylsulfonylcarbamate (2 g, 10 mmol) inTHF (25 mL) at −78° C. was added LDA (2 M in THF, 15.4 mL, 30.7 mmol).Upon completion of addition, the reaction mixture stirred for 10 min andthen diphenylphosphinic chloride (2.42 g, 10.2 mmol) was added drop wiseto the reaction at −78° C. After 90 min, water (100 mL) was added andthe reaction mixture was diluted with ethyl acetate (250 mL). Theaqueous layer was adjusted to pH 5 with 5% aqueous HCl. The whiteprecipitate that formed was filtered and the solid dried in vacuo togive tert-butyl(diphenylphosphoryl)methylsulfonylcarbamate (2.9 g, 72%yield) as a white solid.

Step 2. Preparation of (E)-tert-butyl2-(5-(5-phenyl-4-(pyridin-2-ylmethylamino) quinazolin-2-yl)pyridin-3-yl) vinylsulfonylcarbamate

A solution of tert-butyl {[(diphenylphosphoryl)methyl]sulfonyl}carbamate(0.400 g, 1.01 mmol) in N,N-dimethylformamide (20 mL) was added 95%sodium hydride (0.06 g, 2 mmol) and the reaction mixture was stirred at0° C. for 1 h.5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinaldehyde(from example 191: 0.505 g, 1.21 mmol) was added to the reactionmixture, and the resulting mixture was stirred at room temperature for18 h. Saturated aqueous ammonium chloride solution (100 mL) was added tothe reaction mixture, and the resulting mixture was extracted with ethylacetate. The combined organic layers were washed with saturated brine,dried over anhydrous magnesium sulfate, and filtered. The filtrate wasconcentrated, and the resulting residue was subjected to silica gelcolumn chromatography (CHCl₃-MeOH 95:5). The resulting material wascrystallized from CH₂Cl₂-hexane to give the (E)-tert-butyl2-(5-(5-phenyl-4-(pyridin-2-ylmethylamino) quinazolin-2-yl)pyridin-3-yl) vinylsulfonylcarbamate (0.450 g, 62% yield) as a brownsolid. LCMS Method Y: retention time 1.90 min; [M+1]=595.4.

Step 3. Example 206

To a solution of (E)-tert-butyl 2-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)vinylsulfonylcarbamate (0.210 g, 0.410 mmol) in MeOH (10mL) was added 10% palladium-on-carbon (20 mg) and the reaction mixturestirred at RT under a hydrogen atmosphere for 14 h. The reaction mixturewas filtered and. the filtrate was concentrated under reduced pressureto yield a residue. Trifluoroacetic acid (15 mL) was added to theresidue and the reaction mixture was stirred at room temperature for 2h. After this time, the reaction mixture was concentrated under reducedpressure, sodium bicarbonate solution was added, and the resultingmixture was extracted with ethyl acetate. The combined organic layerswere washed with saturated brine, dried over anhydrous magnesiumsulfate, and filtered. The filtrate was concentrated, and the resultingresidue was subjected to silica gel column chromatography (CHCl₃-MeOH95:5) followed by recrystallization (CHCl₃-hexane) to give Example 206(0.115 g, 65%) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.49(br s, 1H), 8.63 (brm, 2H), 8.27 (m, 1H), 7.91-7.82 (m, 2H), 7.74 (m,1H), 7.59-7.55 (m, 5H), 7.28-7.21 (m, 1H), 6.95 (m, 2H), 6.82 (brs, 1H),4.75 (d, J=4.0 Hz, 2H), 3.42 (t, J=5.6 Hz, 2H), 3.21 (t, J=8 Hz, 2H).LCMS Method Y: retention time 1.59 min; [M+1]=497.2; HPLC Method A1:purity 99.6%, retention time=7.96 min.

Example 2071-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)cyclopropanecarbonitrile

Step 1. Preparation of3-(1-cyanocyclopropanecarboxamido)biphenyl-2-carboxamide

To a solution of 1-cyanocyclopropanecarboxylic acid (0.75 g, 7 mmol) inDCM (40 mL) was added HATU (3.5 g, 10 mmol) and DIPEA (3.4 mL, 20 mmol).After stirring at room temperature for 1 h,3-aminobiphenyl-2-carboxamide (from example 218: 1 g, 5 mmol) was addedand the reaction mixture stirred for an additional 16 h. The reactionmixture was washed with water and the organic phase dried, filtered,concentrated under reduced pressure and purified by silica gelchromatography (60% ethyl acetate in hexanes) to provide3-(1-cyanocyclopropanecarboxamido)biphenyl-2-carboxamide (0.75 g, 74%yield) as a white solid. LCMS Method T: retention time 1.53 min;[M+1]=306.2.

Step 2. Preparation of1-(4-oxo-5-phenyl-3,4-dihydroquinazolin-2-yl)cyclopropanecarbonitrile

To a solution 3-(1-cyanocyclopropanecarboxamido)biphenyl-2-carboxamide(0.7 g, 2 mmol) in methanol was added saturated aqueous Na₂CO₃ (23 mmol)and the reaction mixture stirred at 80° C. for 30 min. The reactionmixture was concentrated under reduced pressure and the resultingresidue was diluted with ethyl acetate then washed with water. Theorganic extracts were dried, concentrated and purified by silica gelchromatography (4% MeOH in DCM) to yield1-(4-oxo-5-phenyl-3,4-dihydroquinazolin-2-yl)cyclopropanecarbonitrile(0.65 g, 99% yield) as a white solid. LCMS Method T: retention time1.810 min; [M+1]=288.2.

Step 3. Example 207

To a solution of1-(4-oxo-5-phenyl-3,4-dihydroquinazolin-2-yl)cyclopropanecarbonitrile)(0.15 g, 0.52 mmol) in acetonitrile (3 mL) at room temperature was addedDBU (0.25 g, 1.6 mmol) and BOP (0.3 g, 0.7 mmol) and the reactionmixture stirred for 30 min. Aminomethylpyridine (0.1 ml, 0.93 mmol) wasadded and the resulting reaction mixture stirred for an additional 16 h.The reaction mixture was concentrated under reduced pressure and theresulting residue was purified by silica gel column chromatography (2%MeOH in DCM) to give Example 207 (0.05 g, 25% yield) as a white solid.¹H NMR (400 MHz, DMSO-d₆, δ): 8.23 (s, 1H); 7.82-7.62 (m, 3H); 7.60-7.46(m, 5H); 7.21-7.28 (m, 3H); 6.76 (t, 1H, J=4 Hz); 4.52 (d, 2H, J=4 Hz);1.78-1.74 (m, 4H). LCMS LC-MS Method V: retention time 1.80 min,[M+1]=378.2; HPLC Method A1: purity 95.2%, retention time=8.75 min.

Example 208N-((5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)methyl)methanesulfonamide

Step 1. Preparation of2-(5-(aminomethyl)pyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine

To a solution of5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)nicotinonitrile(from example 183: 200 mg, 0.48 mmol) in 5% ammonia in methanol (5 mL)was added Ra—Ni (catalytic) and the resulting slurry was stirred underhydrogen atmosphere for 16 h. After this time, the reaction mixture wasfiltered and the filtrate was concentrated under reduced pressure toyield2-(5-(aminomethyl)pyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine(0.1 g, 50% yield), which was used without further purification.

Step 2. Example 208

To a stirred solution of2-(5-(aminomethyl)pyridin-3-yl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine(0.1 g, 0.2 mmol) and TEA (0.063 mL, 0.46 mmol) in DCM (3 mL) was addedmethanesulfonyl chloride (0.24 mL, 0.3 mmol) drop wise at 0° C. Thereaction mixture was stirred for 1 h and then quenched by the additionof water (1 mL). The resulting solution was extracted with DCM. Thecombined organic extracts were washed successively with water and brineand dried, over Na₂SO₄, filtered and the filtrate concentrated underreduced pressure. The resulting residue was chromatographed on silicagel (MeOH/DCM, 2:98) to provide Example 208 (40 mg, 34%). ¹H NMR (400MHz, DMSO-d₆, δ): 9.56 (s, 1H); 8.79 (s, 1H); 8.69 (s, 1H); 8.25 (d, 1H,J=4 Hz); 7.91 (dd, 1H, J=1.6, 4 Hz); 7.84 (t, 1H, J=8 Hz); 7.80-7.70 (m,2H); 7.61-7.50 (m, 5H); 7.38-7.30 (m, 2H); 7.25 (br s, 1H); 6.85 (s,1H); 4.76 (d, 2H, J=4 Hz); 4.35 (s, 2H); 2.98 (s, 3H). LCMS Method T:retention time 1.52 min; [M+1]=497.2; HPLC Method A1: purity 98.5%,retention time=6.42 min.

Example 209 Ethyl5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)isoxazole-3-carboxylate

A solution of ethyl5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)-4,5-dihydroisoxazole-3-carboxylate(from example 215, see the procedure describe below, 0.30 g, 0.66 mmol),DDQ (0.06 g, 0.3 mmol) in toluene (15 mL) was heated at 75° C. for 16 h.After this time, the reaction mixture was concentrated under reducedpressure and the resulting residue was purified by ISCO chromatography(40% ethyl acetate in hexanes) to obtain Example 209 (0.075 g, 25%yield) as an off white solid. ¹H NMR (400 MHz, DMSO-d₆, δ): 8.30 (s,1H); 8.21 (s, 1H); 7.99-7.87 (m, 3H); 7.73 (dt, 1H, J=1.6, 7.6 Hz);7.63-7.48 (m, 6H); 7.40-7.32 (m, 2H); 7.24 (dd, 1H, J=5.6, 7.2 Hz); 7.03(br s, 1H); 4.71 (d, 2H, J=4 Hz). LCMS Method T: retention time 1.81min; [M+1]=423.2; HPLC Method A1: purity 99.3%, retention time=7.31 min.

Example 210 Ethyl4-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)thiazole-2-carboxylate

2-Bromo-1-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)ethanone(from example 203: 0.5 g, 1 mmol) was dissolved in ethanol (20 mL) andethyl thiooxamate (0.15 g, 1.2 mmol) was added. The reaction mixture wasstirred at 70° C. for 1 hour. The ethanol was evaporated under reducedpressure and the resulting residue was dissolved in DCM (25 mL). Theorganic portion was washed with 10% sodium bicarbonate solution and theaqueous layer was extracted with DCM (2×20 mL). The combined organicphases were dried and evaporated under reduced pressure. The resultingresidue was purified by ISCO chromatography (30% ethyl acetate inhexanes) to yield Example 210 (0.13 g, 24% yield). ¹H NMR (400 MHz,DMSO-d₆, δ): 8.94 (s, 1H); 8.24 (d, 1H, J=4 Hz); 7.96 (d, 1H, J=8.8 Hz);7.87 (t, 1H, J=8 Hz); 7.74 (t, 1H, J=8 Hz); 7.50-7.60 (m, 5H); 7.30-7.36(m, 2H); 7.25 (t, 1H, J=6 Hz); 6.95 (br s, 1H); 4.75 (d, 2H, J=4 Hz);4.47 (q, 2H, J=7.2 Hz); 1.41 (t, 3H, J=7.2 Hz). LCMS Method W: Retentiontime 2.243 min, [M+1]=468.2; HPLC Method A1: purity 94.4%, retentiontime=7.522 min.

Example 211 Tert-butyl4-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)piperidine-1-carboxylate

Step 1. Preparation of tert-butyl 4-(2-carbamoylbiphenyl-3-ylcarbamoyl)piperidine-1-carboxylate

To a solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid(2.4 g, 10 mmol) in DCM (40 mL) was added HATU (5.3 g, 14 mmol) andDIPEA (3.6 mL, 28 mmol) and the reaction mixture was stirred at roomtemperature for 1 h. 3-Aminobiphenyl-2-carboxamide (from Example 218)(1.5 g, 7.07 mmol) was added and the resulting mixture stirred for anadditional 16 h. The reaction mixture was washed with water, the organicportion dried, filtered and concentrated under reduced pressure. Theresulting residue was purified by ISCO chromatography (50% ethyl acetatein hexanes) to yield tert-butyl 4-(2-carbamoylbiphenyl-3-ylcarbamoyl)piperidine-1-carboxylate (1.0 g, 22% yield) as a white solid. LCMSMethod T: retention time 1.71 min; [M+1]=423.0.

Step 2. Preparation of tert-butyl4-(4-oxo-5-phenyl-3,4-dihydroquinazolin-2-yl)piperidine-1-carboxylate

To a solution tert-butyl4-(2-carbamoylbiphenyl-3-ylcarbamoyl)piperidine-1-carboxylate (1.0 g,2.4 mmol) in methanol was added NaOMe (2.6 mL, 25% in MeOH, 12.3 mmol).The resulting reaction mixture was stirred at RT for 14 h. After thistime, the reaction mixture was concentrated under reduced pressure andthe resulting residue was diluted with ethyl acetate and then washedwith water. The organic portion was dried, concentrated under reducedpressure to yield a residue. The residue was purified by ISCOchromatography (30% EtOAc in hexanes) to yield tert-butyl4-(4-oxo-5-phenyl-3,4-dihydroquinazolin-2-yl)piperidine-1-carboxylate(0.60 g, 67% yield) as a white solid. LCMS Method W: retention time 2.07min; [M+1]=422.2.

Step 3. Example 211

To a solution of tert-butyl4-(4-oxo-5-phenyl-3,4-dihydroquinazolin-2-yl)piperidine-1-carboxylate(0.6 g, 1 mmol) in acetonitrile (20 mL) at room temperature was addedDBU (0.45 g, 2.96 mmol) and BOP (0.98 g, 2.22 mmol). The reactionmixture was stirred for 30 min and then aminomethylpyridine (0.24 g 2.22mmol) was added. The resulting solution was stirred for an additional 16h. The reaction mixture was then concentrated under reduced pressure andthe resulting residue was purified by silica gel chromatography (20%EtOAc in hexanes) to provide Example 211 (0.32 g, 45% yield) as a whitesolid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.20 (br s, 1H); 7.86-7.68 (m,3H); 7.60-7.52 (m, 5H), 7.32-7.17 (m, 3H), 6.64 (br, 1H), 4.60 (br s,2H), 4.04 (br d, 2H, J=8.8 Hz), 3.03-2.79 (br m, 3H), 1.94 (br t, 2H,J=13.6 Hz), 1.72 (dd, 2H, J=11.2 Hz, J=20 Hz), 1.43 (s, 9H). LCMS MethodW: retention time 1.80 min, [M+1]=475.2; HPLC Method A1: purity 97.4%,retention time=8.08 min.

Example 212 (Z)-methyl2-amino-3-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)acrylate

Step 1. Preparation of methyl 2,2-diethoxyacetimidate

To a stirred solution of diethoxyacetonitrile (5 g, 38.75 mmol) in drymethanol (80 mL) was added 1 mL of a 20% solution of sodium methoxide.After the addition, the reaction mixture was stirred at RT for 24 h,quenched with solid CO₂, and then concentrated. The resulting residuewas diluted with water and extracted with chloroform. The organic layerwas washed with brine and dried over Na₂SO₄ to yield methyl2,2-diethoxyacetimidate (6 g, 96%). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm):7.95 (s, 1H), 4.82 (s, 1H), 3.66 (s, 3H), 3.49 (q, 4H, J=7.2 Hz);1.16-1.13 (t, 3H, J=7.2 Hz).

Step 2. Preparation of 5-chloro-2-(diethoxymethyl)quinazolin-4(3H)-one

To a stirred solution of 6-chloro anthranilic acid (6 g, 34.97 mmol) inEtOH (60 mL) under nitrogen atmosphere was added 1.5 equivalent of TEA(14 mL, 104.9 mmol). Upon completion of addition, the mixture was heatedto 50° C. where it stirred for 30 min. After this time, a methyl2,2-diethoxyacetimidate (6 g, 41.96 mmol) in ethanol solution was addedthrough syringe and the resulting mixture was heated to reflux where itstirred for 24 h. At the conclusion of this period, the reaction mixturewas cooled to RT and the volatiles were evaporated. The resultingresidue was diluted with water, extracted with DCM and washed with brinesolution. The crude product was purified by column chromatography (25%ethyl acetate in hexane) to provide5-chloro-2-(diethoxymethyl)quinazolin-4(3H)-one (7 g, 60% yield). LCMSMethod W: retention time 1.5 min; [M+1]=283.

Step 3. Preparation of 2-(diethoxymethyl)-5-phenylquinozoline-4(3H)one

To a solution of 5-chloro 2-(diethoxymethyl)quinozoline-4(3H)-one (5 g,17.68 mmol) in a dioxane-water mixture (45:15 mL) was added phenylboronic acid (2.8 g, 22.9 mmol) and potassium carbonate (7.32 g, 53.05mmol). The reaction mixture was degassed with nitrogen for 30 min andthen tetrakis triphenyl phosphine palladium (2.04 g, 1.76 mmol) wasadded. The resulting mixture was heated to reflux where it stirred for24 h. At the conclusion of this period, the reaction mixture was cooledto RT, concentrated and then diluted with water. The resulting mixturewas filtered through celite, washed with DCM and then extracted withDCM. The organic layer was dried over Na₂SO₄, diluted with ethylacetate, washed with water and brine, and then dried over Na₂SO₄. Thecrude product was purified by silica gel chromatography (25% ethylacetate in hexane) to provide2-(diethoxymethyl)-5-phenylquinozoline-4(3H)one (4.5 g, 78% yield). LCMSMethod V: retention time 1.62 min; [M+1]=325.0.

Step 4. Preparation of2-(diethoxymethyl)-5-Phenyl-N-(pyridinyl-2-methyl)quinozoline-4-amine

To a solution of 2-(diethoxymethyl)-5-Phenylquinozoline-4(3H)one (5 g,15.4 mmol) in acetonitrile (50 mL) under nitrogen atmosphere was addedBOP reagent (10.25 g, 23.12 mmol) followed by DBU (6.3 mL, 46.2 mmol).The reaction mixture was stirred at RT for an hour and then a solutionof 2-aminomethyl pyridine (2.5 mL, 23.12 mmol) in acetonitrile wasadded. The resulting mixture was stirred at RT under nitrogen for 20 h.After this time, the solution was concentrated under reduced pressureand diluted with water. The aqueous solution was extracted with ethylacetate and then washed with brine solution. The crude product waspurified using silica gel chromatography (23% ethyl acetate in hexane)to provide2-(diethoxymethyl)-5-Phenyl-N-(pyridinyl-2-methyl)quinozoline-4-amine(3.3 g, 52%). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.21- (s, 1H),7.80-7.75 (m, 2H), 7.72-7.19 (m, 1H), 7.55-747 (m, 5H), 7.29-7.21 (m,3H), 6.72 (s, 1H), 5.33 (s, 1H), 4.58 (d, 2H, J=4 Hz); 3.77-3.60 (m,4H), 1.17-1.13 (t, 6H, J=6.8 Hz). LCMS Method V: retention time 1.69min; [M+1]=415.0.

Step 5. Preparation of5-phenyl-4-(pyridin-2-ylmethylamino)quinazoline-2-carbaldehyde

To a solution of2-(diethoxymethyl)-5-phenyl-N-(pyridinyl-2-methyl)quinozoline-4-amine (3g, 7.24 mmol) in 1,4 dioxane (30 mL) under nitrogen atmosphere was addedHCl (30 mL, 6M). The resulting mixture was heated at 90′C for 4 h. Afterthis time, the mixture was cooled to ambient temperature and thenconcentrated under reduced pressure. This mixture was diluted withwater, neutralized with solid Na₂CO₃ and then extracted with DCM. Theorganic layer was dried with sodium sulphate and evaporated underreduced pressure to yield5-phenyl-4-(pyridin-2-ylmethylamino)quinazoline-2-carbaldehyde (1.5 g,42%). LCMS Method V: retention time 1.70 min; [M+1]=340.0.

Step 6. Preparation of (Z)-methyl2-(benzyloxycarbonylamino)-3-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)acrylate

To a solution of5-phenyl-4-(pyridin-2-ylmethylamino)quinazoline-2-carbaldehyde (0.9 g, 3mmol) in THF (10 mL) was added methyl2-benzyloxycarbonylamino-2(dimethoxyphosphinyl)acetate (0.96 g, 2.9mmol) followed by tetramethyguanidine (0.66 mL. 5.3 mmol). The resultingsolution was stirred at RT for 3 h. After this time, the reactionmixture was diluted with ethyl acetate, washed successively with waterand brine, dried over Na₂SO₄, filtered then and concentrated underreduced pressure. The resulting residue was purified by silica gelchromatography (30% ethyl acetate in hexane) to yield (Z)-methyl2-(benzyloxycarbonylamino)-3-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)acrylate(0.7 g (48% yield). LCMS Method V: retention time 1.94 min; [M+1]=546.0.

Step 7. Example 212

To a solution of (Z)-methyl2-(benzyloxycarbonylamino)-3-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)acrylate(0.4 g, 0.7 mmol) in MeOH (7 mL) was added 10% palladium-on-carbon (40mg). Upon completion of addition, the reaction mixture was stirred at RTunder an atmosphere of hydrogen for 20 h. After this time, the reactionmixture was filtered through celite and the filtrate was evaporatedunder reduced pressure. The resulting residue was purified bychromatography on silica gel (23% ethyl acetate in hexane) to yieldExample 212 (0.3 g, 88% yield). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.21(d, 1H, J 4.4 Hz); 7.72-7.68 (m, 3H), 7.54-7.45 (m, 5H), 7.25-7.21 (m,2H), 7.14 (d, 1H, J 6 Hz); 5.97 (s, 1H), 4.55 (d, 2H, J=2.8 Hz), 3.84(s, 1H). LCMS Method V: retention time 1.74 min; [M+1]=412.0; HPLCMethod A2: purity 97.7%, retention time=8.90 min.

Example 2135-(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)-1,3,4-oxadiazol-2-amine

Step 1. Preparation of 5-bromonicotinohydrazide

To a solution methyl 5-bromonicotinate (5 g, 23 mmol) in ethanol (40 mL)was added hydrazine hydrate (6 mL, 115 mmol). The reaction mixture wasrefluxed at 90° C. for 4 h. After this time, the reaction mixture wasevaporated to dryness and then redissolved in ethyl acetate. The organiclayer was washed with water, dried and evaporated to yield5-bromonicotinohydrazide (3.4 g, 72%). LCMS Method T: retention time0.573 min; [M+1]=216.0, 218.0.

Step 2. Preparation of 5-(5-bromopyridin-3-yl)-1,3,4-oxadiazol-2-amine

To a solution 5-bromonicotinohydrazide (2 g, 9 mmol) in dioxane (48 mL)was added sodium bicarbonate (0.78 g, 9.2 mmol) and 20 mL of water. Thereaction mixture was allowed to stir for 10 min. and then cynogenbromide (1.17 g, 10 mmol) was added. The resulting clear solution wasallowed to stir overnight at ambient temperature. At the conclusion ofthis period, a pinkish precipitate was collected by filtration to yield5-(5-bromopyridin-3-yl)-1,3,4-oxadiazol-2-amine (3.4 g, 72% yield). LCMSMethod Y: retention time 1.43 min; [M+1]=239.0, 241.0.

Step 3. Preparation of5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-1,3,4-oxadiazol-2-amine

A mixture of 5-(5-bromopyridin-3-yl)-1,3,4-oxadiazol-2-amine (0.2 g, 0.8mmol), bis(pinacolato)diborone (0.28 g, 1.0 mmol) and potassium acetate(0.25 g, 2.5 mmol) in 1,4-dioxane (8 mL) was degassed with nitrogen for15 min. After this time, (1,1′-bis(diphenylphosphino)ferrocene)palladium(II) chloride dichloromethane complex (0.055 g 0.06 mmol) was added andthe reaction mixture was again degassed for 10 min. with nitrogen. Thereaction mixture was then heated in a microwave at 120° C. for 45 min.At the conclusion of this period, the reaction mixture was filteredthrough celite and the filtrate was concentrated under reduced pressureto provide crude5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-1,3,4-oxadiazol-2-amine(0.3 g), which was used without further purification.

Step 4. Example 213

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (from example1, step 4, 0.2 g, 0.5 mmol) in 1,4-dioxane (5 mL) and H₂O (0.55 mL)under nitrogen was added5-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-1,3,4-oxadiazol-2-amine(0.2 g, 0.7 mmol) and potassium carbonate (0.24 g, 1.7 mmol). Thereaction mixture was degassed with nitrogen for 15 min. After this time,(1,1′-bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (0.047 g, 0.050 mmol) was added and the reactionmixture was again degassed for 10 min with nitrogen. At the conclusionof this period, the reaction mixture was stirred at 90° C. for 16 h, andthen allowed to cool to room temperature. Once at the prescribetemperature, the reaction mixture was quenched by the addition of water.The reaction mixture was then transferred to a separation funnel and theaqueous layer was extracted with ethyl acetate. The combined organicportions were washed with water and saturated NaCl, dried over Na₂SO₄,filtered and concentrated under reduced pressure. The resulting residuewas purified by silica gel column chromatography (5% methanol indichloromethane) afford Example 213 (0.067 g, 10% yield) as an off-whitesolid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.71 (s, 1H); 9.11 (s, 2H);8.25-8.23 (m, 1H0; 7.92 (d, 1H<J=8 Hz); 7.86 (t, 1H, J=8 Hz); 7.73 (t,1H, J=8 Hz); 7.60-7.50 (m, 5H), 7.46 (br s, 2H); 7.37-7.31 (m, 2H); 7.22(t, 1H, J=4 Hz); 6.93 (br s, 1H); 4.76 (d, 2H, J=4 Hz). LCMS Method W:retention time 1.80 min; [M+1]=473.2; HPLC Method A4: purity 95.9%,retention time=6.11 min.

Example 2144-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)thiazole-2-carboxamide

A solution of ethyl4-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)thiazole-2-carboxylate(from example 210, 90 mg, 0.19 mmol) in NH₃ (2.0 M in MeOH, 5 mL) wasstirred at RT in a sealed vessel for 30 min. The solid formed wasfiltered and washed with ice cooled methanol. The solid was furtherpurified by preparative HPLC (Method S) to provide Example 214 (35 mg,42% yield). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.79 (s, 1H); 8.26 (s,1H); 8.22 (s, 1H); 7.97 (br s, 1H); 7.90-7.81 (m, 2H); 7.73 (dt, 1H,J=2, 7.6 Hz); 7.61-7.49 (m, 5H); 7.32-7.30 (m, 2H); 7.26-7.20 (m, 1H);6.77 (t, 1H, J=4.8 Hz); 4.73 (d, 2H, J=4.8 Hz). LCMS Method W: retentiontime 1.85 min; [M+1]=439.2; HPLC Method A1: purity 95.2%, retentiontime=6.26 min. Preparative HPLC Method: S.

Example 2151-(5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)-4,5-dihydroisoxazol-3-yl)butan-1-one

Step 1. Preparation of5-phenyl-N-(pyridin-2-ylmethyl)-2-vinylquinazolin-4-amine

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (0.5 g, 1.44mmol) in 1,4-dioxane (10 mL) was added Pd(TPP)₂Cl₂ (0.101 g, 0.144 mmol)and tributylvinyltin (2.285 g, 7.20 mmol) under a nitrogen stream. Uponcompletion of addition, the reaction mixture was heated to reflux at 90°C. for 16 h. After this time, the reaction mixture was allowed to coolto room temperature and then concentrated under reduced pressure. Theresulting residue was purified by silica gel column chromatography (20%ethyl acetate, hexane) to yield5-phenyl-N-(pyridin-2-ylmethyl)-2-vinylquinazolin-4-amine (0.38 g, 78%yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.22 (dd,1H, J=4.8 Hz), 7.76 (d, 1H, J=1.6 Hz), 7.75 (s, 1H), 7.70 (dt, 1H, J=2Hz, 8 Hz), 7.45-7.56 (m, 5H), 7.20-7.28 (m, 3H), 6.72 (dd, 1H, J=10.4Hz, 17.2 Hz), 6.64 (t, 1H, J=3.6 Hz), 6.56 (dd, 1H, J=1.6 Hz, 17.2 Hz),5.67 (d, 1H, J=10.4 Hz), 4.62 (d, 2H, J=4.0 Hz). LCMS Method T:retention time 1.500 min; [M+1]=339.2; HPLC Method A2: purity 98.1%,retention time=8.74 min.

Step 2. Preparation of (Z)-ethyl 2-chloro-2-(hydroxyimino)acetate

To a solution of glycine ester hydrochloride (2 g, 14 mmol) in 3 mLwater was added conc. HCl (1.2 mL). Upon completion of addition, theresulting solution was cooled to −5° C. and then a solution of sodiumnitrite (1 g, 14 mmol) in water (1.4 mL) was added. The resultingmixture was stirred at 0° C. for 10 min and then another solution ofsodium nitrite (1 g, 14 mmol) in water (1.4 mL) was added. The resultingmixture was stirred at 0° C. for 45 min. At the conclusion of thisperiod, a brine solution was added. The reaction mixture was extractedwith ether, dried and evaporated under reduced pressure to yield(Z)-ethyl 2-chloro-2-(hydroxyimino)acetate (1.6 g, 76%), was taken tothe next step immediately without further purification.

Step 3. Example 215

A solution of 5-phenyl-N-(pyridin-2-ylmethyl)-2-vinylquinazolin-4-amine(0.4 g, 1 mmol), (Z)-ethyl 2-chloro-2-(hydroxyimino)acetate (0.534 g,3.54 mmol) and triethylamine (0.358 g, 3.54 mmol) in DCM (10 mL) wasstirred at room temperature for 16 h. After this time, the reactionmixture was concentrated under reduced pressure to yield a residue. Theresidue was purified by ISCO chromatography (30% ethyl acetate inhexane) to yield Example 215 (0.2 g, 38% yield) as an off-white solid.¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.21 (d, 1H, J=4 Hz), 7.88-7.80 (m,2H), 7.68 (dd, 1H, J=1.6 Hz, 8.0 Hz), 7.60-7.47 (m, 5H), 7.32 (dd, 1H,J=2.4, 6.0 Hz), 7.25-7.20 (m, 2H), 6.78 (br s, 1H), 5.74 (dd, 1H, J=8,12 Hz), 4.54 (dd, 2H, J=4, 6.8 Hz), 4.31 (q, 2H, J=8.0 Hz), 3.73 (dd,1H, J=8, 17.6 Hz), 3.60 (dd, 1H, J=5.6, 17.2 Hz), 1.30 (t, 3H, J=7.2Hz). LCMS Method W: retention time 2.033 min; [M+1]=454.4; HPLC MethodA2: purity 95.1%, retention time=8.65 min.

Example 2164-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)but-3-yn-1-ol

A solution of 2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine(from example 1, step 4, 0.3 g, 0.9 mmol) and homopropargyl alcohol(0.07 mL, 1 mmol) in acetonitrile (10 mL) was degassed with nitrogen andthen Pd(TPP)₂Cl₂ (0.060 g, 0.085 mmol), triethylamine (0.4 mL, 4 mmol)and CuI (0.016 g, 0.080 mmol) were added. The resulting reaction mixturewas heated at 60° C. for 16 h. After this time, the reaction mixture wasfiltered through celite. The resulting filtrate was diluted with ethylacetate and then washed successively with water and brine. The organiclayer was dried, filtered and concentrated under reduced pressure toyield a residue. The residue was purified by silica gel chromatography(2% methanol in hexanes) to yield Example 216 (0.15 g, 46% yield) as anoff-white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.18 (br s, 1H);7.88 (t, 1H, J=8 Hz); 7.77-7.72 (m, 2H); 7.60-7.48 (m, 5H); 7.38-7.30(m, 3H); 7.26-7.22 (m 1H); 4.62 (d, 2H, J 4 Hz); 3.66 (t, 2H, 6.8 Hz);2.67 (t, 2H, J=6.8 Hz). LCMS Method W: retention time 1.72 min;[M+1]=381.2; HPLC Method A1: purity 98.5%, retention time=6.03 min.

Example 2172-((5-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)pyridin-3-yl)methylsulfonyl)acetamide

Step 1. Preparation of methyl 2-((5-bromopyridin-3-yl)methylthio)acetate

To a solution of 3-bromo-5-(chloromethyl)pyridine (from example 199,(1.2 g, 5.8 mmol) in acetonitrile (15 mL) was added K₂CO₃ (0.97 g, 7.0mmol) followed by methyl 2-mercaptoacetate (0.57 mL, 6.4 mmol). Theresulting solution was stirred at room temperature for 16 h. After thistime, the reaction mixture was filtered and the filtrate was dilutedwith ethyl acetate and washed with water. The organic portion was dried,filtered and concentrated under reduced pressure. The resulting residuewas purified by silica gel chromatography (30% ethyl acetate in hexane)to yield methyl 2-((5-bromopyridin-3-yl)methylthio)acetate (1.2 g, 80%yield). LCMS Method Y: retention time 1.66 min; [M+1]=276.0.

Step 2. Preparation of 2-((5-bromopyridin-3-yl)methylthio)acetamide

A solution of methyl 2-((5-bromopyridin-3-yl)methylthio)acetate (1.2 g,4.5 mmol) in NH₃ (2.0 M in MeOH, 40 mL) was heated at 80° C. in a sealedvessel for 2 h. After this time, the reaction mixture was allowed tocool to room temperature and then the solvent was evaporated underreduced pressure. The resulting residue was recrystallized fromEtOAc/hexanes to provide 2-((5-bromopyridin-3-yl)methylthio)acetamide(0.8 g, 72% yield). LCMS Method W: retention time 1.08 min; [M+1]=263.0.

Step 3. Preparation of 2-(5-bromopyridin-3-yl)methylsulfonyl)acetamide

To a solution of 2-((5-bromopyridin-3-yl)methylthio)acetamide (0.8 g,3.0 mmol) in MeOH:H₂O (30:10 mL) was added Oxone® (2.5 g, 3.9 mmol). Theresulting reaction mixture was stirred at room temperature for 2 h.After this time, the solvent was evaporated and the resulting residuewas dissolved in EtOAc and washed with water. The organic portion wasconcentrated to provide 2-(5-bromopyridin-3-yl)methylsulfonyl)acetamide(0.6 g, 67%). LCMS Method T: retention time 0.68 min; [M+1]=293.

Step 4. Preparation of2-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylsulfonyl)acetamide

A mixture of 2-(5-bromopyridin-3-yl)methylsulfonyl)acetamide (10.3 g,1.00 mmol), bis(pinacolato)diboron (0.337 g, 1.30 mmol) and potassiumacetate (0.3 g, 3.0 mmol) in 1,4-dioxane (10 mL) was degassed withnitrogen for 15 min. After this time,(1,1′-bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (0.066 mg, 0.08 mmol) was added and the reactionmixture was again degassed for 10 min. with nitrogen. The reactionmixture was heated in the microwave reactor at 120° C. for 45 min. Atthe conclusion of this period, the reaction mixture was filtered throughcelite and the filtrate was concentrated under reduced pressure toprovide2-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylsulfonyl)acetamide(440 mg) as a brown solid, which was used without further purification.

Step 5. Example 217

To a solution of2-chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (from example1, step 4, 0.3 g, 0.9 mmol) in 1,4-dioxane (10 mL) and H₂O (2 mL) undernitrogen was added2-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methylsulfonyl)acetamide(0.3 g, 0.9 mmol), and potassium carbonate (0.36 g, 2.6 mmol). Thereaction mixture was degassed with nitrogen for 15 min and then(1,1′-bis(diphenylphosphino)ferrocene)palladium (II) chloridedichloromethane complex (0.07 g, 0.08 mmol) was added. The reactionmixture was again degassed for 10 min with nitrogen and then stirred at90° C. for 16 h. At the conclusion of this period, the reaction mixturewas allowed to cool to room temperature and then quenched by theaddition of water. The reaction mixture was transferred to a separationfunnel and the aqueous layer was extracted with ethyl acetate. Thecombined organic portions were washed with water and saturated NaCl,dried over Na₂SO₄, filtered and concentrated under reduced pressure. Theresulting concentrate was purified by preparative TLC (5% methanol indichloromethane) to provide Example 217 (100 mg, 22% yield) as an offwhite solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 9.62 (s, 1H); 9.84 (s,1H); 8.84 (s, 1H); 8.23 (br s, 1H); 7.92-7.88 (m, 1H); 7.85 (t, 2H, J=4Hz); 7.72 (t, 1H, J=8 Hz); 7.60-7.50 (m, 6H); 7.40-7.28 (m, 2H); 7.22(t, 1H, J=8 Hz); 6.85 (br s, 1H); 4.85 (s, 2H); 4.73 (d, 2H, J=4 HZ);4.06 (s, 2H). LCMS Method W: retention time 1.70 min; [M+1]=525.2; HPLCMethod A2: purity 99.5%, retention time=5.91 min.

Example 2185-Phenyl-N-(pyridin-2-ylmethyl)-2-(2,2,5-trimethyl-1,3-dioxan-5-yl)quinazolin-4-amine

Step 1. Preparation of 3-aminobiphenyl-2-carbonitrile

To a solution of 2-amino-6-bromobenzonitrile (5 g, 0.025 mmol) intoluene (70 mL) was added KOAc (5 g, 0.05 mmol), phenylboronic acid(4.27 g, 0.035 mmol) and cat. Pd(TPP)₂Cl₂. The reaction mixture washeated to 115° C. for 16 h. After this time, the reaction mixture wasfiltered and the volatiles were evaporated to yield as residue. Theresidue was purified by column chromatography (1% EtOAc in hexanes) toprovide 3-aminobiphenyl-2-carbonitrile (3.2 g, 65% yield) as lightyellow solid. LCMS Method Z: retention time 3.65 min; [M+]=195.2.

Step 2. Preparation of 3-aminobiphenyl-2-carboxamide

A solution of 3-aminobiphenyl-2-carbonitrile (4 g, 20 mmol) in ethanol(20 mL) and aqueous NaOH (8 g, 200 mmol) was heated at 100° C. in themicrowave reactor for 1 h 30 min. After this time, the ethanol wasevaporated under reduced pressure and the resulting residue wasextracted with ethyl acetate. The organic extracts were concentratedunder reduced pressure to yield a residue. The residue was purified bysilica gel chromatography (50% EtOAc in hexane) to give3-aminobiphenyl-2-carboxamide (3.1 g, 72% yield) as a brown solid. ¹HNMR (400 MHz, DMSO-d₆) δ (ppm): 7.40-7.30 (m, 5H), 7.15 (br s, 1H), 7.11(t, 1H, J=8 Hz), 6.72 (dd, 1H, J=0.8, 8 Hz), 6.52 (dd, 1H, J=0.8, 8 Hz),5.13 (s, 1H). LCMS Method W: retention time 1.28 min; [M+1]=213.0.

Step 3. Preparation ofN-(2-carbamoylbiphenyl-3-yl)-2,2,5-trimethyl-1,3-dioxane-5-carboxamide

To a solution of the commercially available2,2,5-trimethyl-1,3-dioxane-5-carboxylic acid (0.6 g, 4 mmol) in DCM (30mL) was added HATU (1.8 g, 4.7 mmol) and DIPEA (1.6 mL, 23.5 mmol). Thereaction mixture was stirred at room temperature for 1 h. After thistime, 3-aminobiphenyl-2-carboxamide (0.6 g, 2.35 mmol) was added and theresulting solution was stirred for 16 h. At the conclusion of thisperiod, the reaction mixture was washed with water, dried, filtered andconcentrated under reduced pressure. The resulting residue was purifiedby silica gel chromatography (25% ethyl acetate in hexanes) to yieldN-(2-carbamoylbiphenyl-3-yl)-2,2,5-trimethyl-1,3-dioxane-5-carboxamide(0.25 g, 24% yield) as a white solid. LCMS Method Y: retention time 1.69min; [M+1]=367.2.

Step 4. Preparation of5-phenyl-2-(2,2,5-trimethyl-1,3-dioxan-5-yl)quinazolin-4(3H)-one

To a solutionN-(2-carbamoylbiphenyl-3-yl)-2,2,5-trimethyl-1,3-dioxane-5-carboxamide(0.23 g, 0.62 mmol) in methanol was added NaOMe (0.25 mL, 25% in MeOH,1.2 mmol) and the reaction mixture stirred at 50° C. for 1 h. After thistime, the reaction mixture was concentrated and the resulting residuewas diluted with ethyl acetate then washed with water. The organicportion was dried and concentrated under reduced pressure to yield aresidue. The residue was purified by silica gel chromatography (30%ethyl acetate in hexanes) to yield pure5-phenyl-2-(2,2,5-trimethyl-1,3-dioxan-5-yl)quinazolin-4(3H)-one (0.2 g,91% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 11.49(br s, 1H), 7.77 (t, 1H, J=8 Hz), 7.64 (d, 1H, J=8 Hz), 7.36-7.28 (m,5H), 7.21 (d, 1H, J=8 Hz), 4.27 (d, 2H, J=12 Hz), 3.91 (d, 2H, J=12 Hz),1.40 (s, 3H), 1.35 (d, 6H, 10.2 Hz). LCMS Method W: retention time 2.01min; [M+1]=351.

Step 5. Example 218

To a solution of5-phenyl-2-(2,2,5-trimethyl-1,3-dioxan-5-yl)quinazolin-4(3H)-one (0.22g, 0.62 mmol) in acetonitrile (10 mL) at room temperature was added DBU(0.24 g, 1.57 mmol) and BOP reagent (0.36 g, 0.81 mmol). The reactionmixture was stirred for 30 min and then aminomethylpyridine (0.11 mL,1.1 mmol) was added. The resulting solution was stirred for 16 h. Afterthis time, the reaction mixture was concentrated under reduced pressureand the resulting residue was purified by silica gel chromatography (30%EtOAc in hexanes) to give Example 219 (0.18 g, 67% yield) as a whitesolid. ¹H NMR (400 MHz, DMSO-d₆, δ): 8.26 (br s, 1H); 7.80-7.69 (m, 3H);7.59-7.45 (m, 5H); 7.27-7.20 (m, 3H); 6.53 (br s, 1H); 4.55 (d, 2H, J=4Hz); 4.31 (d, 2H, J=7.6 Hz); 3.79 (d, 2H, J=7.6 Hz); 1.38 (d, 6H, J=4.8Hz); 1.33 (s, 3H). LCMS Method W: retention time 2.37 min, [M+1]=441;HPLC Method A1: purity 96.7%, retention time=6.87 min.

Example 2192-Methyl-2-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)propane-1,3-diol

5-Phenyl-N-(pyridin-2-ylmethyl)-2-(2,2,5-trimethyl-1,3-dioxan-5-yl)quinazolin-4-amine(from example 218, 0.1 g, 0.23 mmol) was dissolved in ether (2 mL). Upondissolution, M HCl in ether (5 mL) was added and the resulting mixturewas stirred at RT for 4 h. After this time, the resulting solution wasneutralized with sat. NaHCO₃ solution. The ether was evaporated and theaqueous layer residue was extracted in ethyl acetate. The organicextracts were dried and evaporated. The resulting residue was purifiedby silica gel column chromatography (2% methanol in dichloromethane) toyield Example 219 (56 mg, 62% yield). ¹H NMR (400 MHz, DMSO-d₆, δ): 8.24(br s, 1H); 7.80-7.63 (m, 3H); 7.54-7.44 (m, 5H); 7.24-7.20 (m, 3H);6.56 (br s, 1H); 4.57 (s, 2H), 4.56 (d, 2H, J=6 Hz); 3.77 (d, 4H, J=6Hz); 1.23 (s, 3H). LCMS Method W: retention time 1.77 min, [M+1]=401;HPLC Method A1: purity 95.14%, retention time=9.78 min.

Example 2203-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)isoxazole-5-carboxamide

Step 1. Preparation of(E)-5-phenyl-4-(pyridin-2-ylmethylamino)quinazoline-2-carbaldehyde

A solution of5-phenyl-4-(pyridin-2-ylmethylamino)quinazoline-2-carbaldehyde (fromexample 212, 0.62 g, 1.8 mmol), hydroxylamine hydrochloride (0.19 g, 2.8mmol) and sodium acetate (0.30 g, 3.7 mmol) in water (10 mL) was heatedat 100° C. for 30 min. After this time, the reaction mixture was allowedto cool to RT and then extracted with DCM (2×50 mL). The combinedorganic portions were concentrated under reduced pressure and theresulting residue was purified by silica gel chromatography (0.8% MeOHin DCM) to provide(E)-5-phenyl-4-(pyridin-2-ylmethylamino)quinazoline-2-carbaldehyde (0.4g, 60% yield) as a yellow solid. LCMS Method W: retention time 1.703min, [M+1]=356.2.

Step 2. Preparation of methyl3-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)isoxazole-5-carboxylate

To a solution of(E)-5-phenyl-4-(pyridin-2-ylmethylamino)quinazoline-2-carbaldehyde oxime(0.32 g, 0.90 mmol) and methylpropriolate (0.227 g, 2.70 mmol) inacetonitrile was added CrO₂ (magtrieve) (0.75 g, 9.0 mmol). The reactionmixture was heated at 80° C. for 2 h. After this time, the reactionmixture was allowed to cool to RT. Once at the prescribed temperature,the reaction mixture was diluted with ethyl acetate and filtered throughcelite. The filtrate was evaporated under reduced pressure and theresulting residue was purified by silica gel chromatography (1.5% MeOHin DCM) to provide methyl3-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)isoxazole-5-carboxylate(120 mg, 30% yield) as an off white solid. LCMS Method W: retention time2.185 min, [M+1]=438.2.

Step 3. Example 220

A solution of3-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)isoxazole-5-carboxylate(90 mg, 0.199 mmol) in NH₃ (2.0 M in MeOH, 5 mL) was heated at 60° C. ina sealed vessel for 8 h. After this time, the reaction mixture wasallowed to cool to room temperature and the solvent was evaporated underreduced pressure. The resulting residue was purified by preparative HPLC(Method S) to provide Example 220 (35 mg, 42% yield). ¹H NMR (400 MHz,DMSO-d₆, δ): 8.45 (s, 1H); 8.21 (s, 1H); 8.05 (s, 1H); 7.92-7.85 (m,2H); 7.73 (dt, 1H, J=1.2, 7.6 Hz); 7.67 (s, 1H); 7.60-7.49 (m, 5H);7.40-7.30 (m, 3H); 7.24 (t, 1H, J=5.6 Hz); 7.00 (t, 1H, J=4 Hz); 4.69(d, 2H, J=4 Hz). LCMS Method W: Retention time 1.74 min, [M+1]=423.2;HPLC Method A1: purity 99.3%, retention time=6.78 min.

Example 221N-((1-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)cyclopropyl)methyl)methanesulfonamide

Step 1. Preparation of2-(1-(aminomethyl)cyclopropyl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine

To a solution of1-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)cyclopropanecarbonitrile(Example 207, 0.6 g, 2 mmol) in 7 M ammonia methanol (10 mL) was addedRa—Ni (200 mg). The resulting slurry was stirred under hydrogenatmosphere for 16 h. After this time, the reaction mixture was filteredand filtrate was concentrated under reduced pressure to yield2-(1-(aminomethyl)cyclopropyl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine(380 mg, 63% yield), which was used without further purification.

Step 2. Example 221

To a stirred solution of2-(1-(aminomethyl)cyclopropyl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine(60 mg, 0.16 mmol) and TEA (0.05 ml, 0.43 mmol) in DCM (5 mL) was addedmethanesulfonyl chloride (0.015 mL, 0.18 mmol) dropwise at 0° C. Thereaction mixture was allowed to reach RT where it stirred for 2 h. Afterthis time, the reaction mixture was quenched with water and thenextracted with EtOAc. The combined organic extracts were washedsuccessively with water and brine, dried, and filtered. The filtrate wasconcentrated under reduced pressure to yield a residue. The residue waspurified by silica gel chromatography (15% EtOAc, hexane) to provideExample 221 (25 mg, 36% yield) as a solid. ¹H NMR (400 MHz, DMSO-d₆, δ):8.25 (d, 1H, J=4.4 Hz); 7.80-7.68 (m, 3H); 7.60-7.43 (m, 5H); 7.27-7.15(m, 3H); 6.95 (t, 1H, J=6 Hz), 6.53 (s, 1H), 4.54 (d, 2H, J=4 Hz), 3.54(d, 2H, J=6.4 Hz), 2.99 (s, 3H), 1.30 (d, 2H, J=2.4 Hz, 1.01 (d, 2H,J=2.4 Hz). LCMS Method V: retention time 1.77 min, [M+1]=460.0; HPLCMethod A1: purity 99.1%, retention time=6.29 min.

Example 222N-((1-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)cyclopropyl)methyl)sulfamide

To a solution chlorosulfonylisocyanate (0.03 mL, 0.2 mmol) in DCM (1 mL)was added t-BuOH (0.16 mL, 0.21 mmol) at 0° C. The reaction mixture wasstirred for 10 min. After this time, the reaction mixture was added to amixture of2-(1-(aminomethyl)cyclopropyl)-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (from example 221, 80 mg, 0.21 mmol) and TEA (0.043ml, 0.42 mmol) in DCM at 0° C. The resulting reaction mixture wasstirred for an additional 3 h at room temperature. At the conclusion ofthis period, the reaction mixture was quenched with water (15 mL) andthen extracted with DCM. The combined organic extracts were washedsuccessively with water and brine, dried with Na₂SO₄, filtered andconcentrated under reduced pressure to yield a residue. TFA (2 mL) wasadded to the residue and the resulting reaction mixture was stirred for2 h and then concentrated in vacuo. The resulting residue was dilutedwith EtOAc (20 mL) and washed successively with saturated NaHCO₃ andbrine, dried over Na₂SO₄ filtered and the solvent was removed underreduced pressure. The resulting residue was purified by silica gelchromatography (5% MeOH in DCM) to yield Example 222 (25 mg, 27% yield).¹H NMR (400 MHz, DMSO-d₆, δ): 8.24 (dd, 1H, J=1.2 Hz, 7.2 Hz); 7.67-7.80(m, 3H); 7.58-7.43 (m, 5H); 7.28-7.16 (m, 3H); 6.63 (s, 2H), 6.53 (br s,1H), 6.48-6.43 (m, 1H), 4.52 (d, 2H, J=4 Hz), 3.45 (d, 2H, J=7.6 Hz),1.28 (d, 2H, J=4 Hz), 1.02 (d, 2H, J=4 Hz). LCMS Method W: retentiontime 1.93 min, [M+1]=461.2; HPLC Method A1: purity 96.5%, retentiontime=5.91 min.

Example 2234-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)piperidine-1-sulfonamide

Step 1. Preparation of5-phenyl-2-(piperidin-4-yl)-N-(pyridin-2-ylmethyl)quinazolin-4-amine

Tert-butyl4-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)piperidine-1-carboxylate(Example 211, 0.2 g 0.4 mmol) was dissolved in 10 mL HCl (2 M in ether).The reaction mixture stirred at RT for 16 h. After this time, thesolvent was removed under reduced pressure. The resulting residue wasneutralized with sat. NaHCO₃ and the aqueous phase was extracted intoDCM. The combined organic extracts were concentrated under reducedpressure and the resulting residue was purified by recrystallizationwith EtOAc to yield5-phenyl-2-(piperidin-4-yl)-N-(pyridin-2-ylmethyl)quinazolin-4-amine(0.13 g, 76% yield). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.21 (d, 1H,J=4.0 Hz), 7.77-7.66 (m, 3H), 7.58-7.40 (m, 5H), 7.30-7.15 (m, 3H), 6.57(br s, 1H), 4.56 (d, 2H, J=4.0 Hz), 3.05 (d, 2H, J=12.0 Hz), 2.80-2.70(m, 1H), 2.60 (t, 2H, J=8.0 Hz), 1.95-1.80 (m, 2H), 1.80-1.65 (m, 2H).LCMS Method W: retention time 1.43 min, [M+1]=396.2; HPLC Method A1:purity 96.4%, retention time=9.00 min.

Step 2. Example 223

To a solution chlorosulfonylisocyanate (0.035 g, 0.25 mmol) in DCM (5mL) was added t-BuOH (0.019 g, 0.25 mmol) at RT. The reaction mixturewas stirred for 10 min and then TEA (0.038 g, 0.37 mmol) was addedfollowed by5-phenyl-2-(piperidin-4-yl)-N-(pyridin-2-ylmethyl)quinazolin-4-amine(0.1 g, 0.3 mmol) in DCM. The resulting reaction mixture was stirred foran additional 3 h. After this time, the reaction mixture was dilutedwith water and then extracted in EtOAc. The combined organic extractswere dried and concentrated under reduced pressure to yield a residue.The residue was treated with etherial HCl (4 ml, 2 M solution). Theresulting solution was concentrated under reduced pressure and theresulting residue was purified by recrystallization using EtOAc to yieldExample 223 (0.038 g, 32% yield). ¹H NMR (400 MHz, DMSO-d₆) δ (ppm):8.20 (s, 1H), 7.80-7.66 (m, 3H), 7.58-7.43 (m, 5H), 7.27 (d, 1H, J=8.0Hz), 7.24-7.18 (m, 2H), 6.73 (br s, 2H), 6.65 (t, 1H, J=4.0 Hz), 4.58(d, 1H, J=8.0 Hz), 3.55 (d, 2H, J=12.0 Hz), 2.81-2.64 (m, 3H), 2.10-2.04(m, 2H), 2.00-1.86 (m, 2H). LCMS Method V: retention time 1.62 min,[M+1]=475; HPLC Method A1: purity 98.7%, retention time=6.26 min.

Example 2245-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)isoxazole-3-carboxamide

A solution of the ethyl5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)isoxazole-3-carboxylate(from example 209, 0.075 g, 0.17 mmol) in NH₃ (2.0 M in MeOH, 5 mL) washeated at 60° C. in a sealed vessel for 16 h. After this time, thereaction mixture was allowed to cool to room temperature. Once at theprescribed temperature, the solid formed was filtered and washed withice cooled methanol to provide Example 224 (31 mg, 44% yield). ¹H NMR(400 MHz, DMSO-d₆) δ (ppm): 8.29 (s, 1H), 8.21 (d, 1H, J=2 Hz),7.87-7.95 (m, 3H), 7.73 (dt, 1H, J=1.6, 8 Hz), 7.45-7.64 (m, 5H), 7.37(dt, 2H, J=1.6, 6.8 Hz, 2H), 7.25 (dd, 1H, J=6.0, 7.2 Hz), 4.70 (d, 2H,J=4 Hz). LCMS Method W: retention time 1.817 min; [M+1]=423.2; HPLCMethod A1: purity 99.3%, retention time=7.31 min.

Examples 225 to 322

Examples 225 to 322 were synthesized via similar procedures describedabove. HPLC/MS data for each compound was collected using methods E-Z1and the molecular mass determined by MS (ES) by the formula m/z. Boththe retention time and MS data for Examples 225 to 322 are listed inTable 1c, wherein MW=molecular weight.

TABLE 1c LCMS Example Structure MW LCMS Data Method 225

432.477 [M + 1] 433.0  Rt 1.86 min  E 226

447.491 [M + 1] 448.0  Rt 1.50 min  O 227

389.452 [M + 1] 390.0  Rt 1.58 min  O 228

446.503 [M + 1] 447.0  Rt 1.49 min  O 229

536.528 [M + 1] 537.0  Rt 1.73 min  O 230

468.53  [M + 1] 469.0  Rt 1.41 min  O 231

405.451 [M + 1] 406.2  Rt 2.50 min  Z1 232

405.451 [M + 1] 406.2  Rt 2.58 min  Z1 233

427.498 [M + 1] 428.2  Rt 3.12 min  Z1 234

419.478 [M + 1] 420.2  Rt 2.56 min  Z1 235

448.479 [M + 1] 449.2  Rt 1.89 min  Y 236

467.542 [M + 1] 468.2  Rt 1.98 min  Y 237

482.557 [M + 1] 483.2  Rt 1.99 min  Y 238

360.839 [M + 1] 361.20 Rt 1.55 min  T 239

497.568 [M + 1] 498.2  Rt 1.48 min  T 240

364.803 [M + 1] 365.2  Rt 2.05 min  T 241

376.839 [M + 1] 377.2  Rt 2.14 min  T 242

512.583 [M + 1] 513.2  Rt 1.80 min  Y 243

431.489 [M + 1] 432.2  Rt 2.40 min  Z1 244

431.489 [M + 1] 432.2  Rt 2.40 min  Z1 245

471.552 [M + 1] 472.2  Rt 2.68 min  Z1 246

445.515 [M + 1] 446.2  Rt 2.50 min  Z1 247

445.515 [M + 1] 446.2  Rt 2.53 min  Z1 248

489.568 [M + 1] 490.2  Rt 2.59 min  Z1 249

485.579 [M + 1] 486.2  Rt 2.84 min  Z1 250

473.568 [M + 1] 474.2  Rt 2.87 min  Z1 251

461.515 [M + 1] 462.2  Rt 2.52 min  Z1 252

502.609 [M + 1] 503.2  Rt 2.57 min  Z1 253

489.568 [M + 1] 490.2  Rt 2.63 min  Z1 254

514.62  [M + 1] 515.2  Rt 2.58 min  Z1 255

514.62  [M + 1] 515.2  Rt 2.58 min  Z1 256

523.649 [M + 1] 524.2  Rt 3.24 min  Z1 257

523.649 [M + 1] 524.2  Rt 3.23 min  Z1 258

495.595 [M + 1] 496.2  Rt 3.13 min  Z1 259

514.6  [M + 1] 515.2  Rt 2.99 min  Z1 260

514.6  [M + 1] 515.2  Rt 3.04 min  Z1 261

537.632 [M + 1] 538.2  Rt 3.05 min  Z1 262

495.595 [M + 1] 496.2  Rt 2.96 min  Z1 263

509.622 [M + 1] 510.2  Rt 3.10 min  Z1 264

507.606 [M + 1] 508.2  Rt 3.01 min  Z1 265

509.622 [M + 1] 510.2  Rt 3.09 min  Z1 266

557.665 [M + 1] 558.2  Rt 3.23 min  Z1 267

449.479 [M + 1] 450.2  Rt 2.54 min  Z1 268

507.606 [M + 1] 508.2  Rt 2.99 min  Z1 269

511.595 [M + 1] 512.2  Rt 2.50 min  Z1 270

467.542 [M + 1] 468.2  Rt 2.53 min  Z1 271

498.556 [M + 1] 499.2  Rt 2.03 min  W 272

482.557 [M + 1] 483.2  Rt 1.91 min  W 273

468.53  [M + 1] 469.2  Rt 1.52 min  T 274

520.625 [M + 1] 521.2  Rt 1.76 min  T 275

492.572 [M + 1] 493.4  Rt 1.73 min  Y 276

486.521 [M + 1] 487.2  Rt 1.95 min  W 277

584.689 [M + 1] 585.2  Rt 1.83 min  T 278

556.635 [M + 1] 557.2  Rt 1.56 min  T 279

386.877 [M + 1] 387.2  Rt 2.17 min  Y 280

468.53  [M + 1] 469.2  Rt 1.84 min  Y 281

463.53  [M + 1] 464.2  Rt 3.16 min  Z1 282

465.478 [M + 1] 466.2  Rt 3.00 min  Z1 283

476.529 [M + 1] 477.2  Rt 2.74 min  Z1 284

496.603 [M + 1] 497.2  Rt 3.34 min  Z1 285

518.609 [M + 1] 519.2  Rt 3.17 min  Z1 286

470.525 [M + 1] 471.2  Rt 2.97 min  Z1 287

518.609 [M + 1] 519.2  Rt 3.16 min  Z1 288

428.488 [M + 1] 429.2  Rt 3.01 min  Z1 289

508.594 [M + 1] 509.2  Rt 1.58 min  T 290

468.53  [M + 1] 469.2  Rt 1.42 min  T 291

455.513 [M + 1] 456.2  Rt 1.86 min  Y 292

447.488 [M + 1] 448.2  Rt 1.36 min  W 293

486.521 [M + 1] 485.0  Rt 1.93 min  Y 294

536.528 [M + 1] 537.0  Rt 1.96 min  T 295

524.637 [M + 1] 523.2  Rt 2.10 min  Y 296

469.518 [M + 1] 470.2  Rt 1.64 min  T 297

482.557 [M + 1] 483.2  Rt 1.66 min  T 298

482.557 [M + 1] 483.2  Rt 1.65 min  T 299

461.558 [M + 1] 462.2  Rt 1.78 min  T 300

360.839 [M + 1] 361.0  Rt 1.87 min  T 301

388.893 [M + 1] 389.2  Rt 1.98 min  T 302

510.61  [M + 1] 511.2  Rt 1.79 min  T 303

510.61  [M + 1] 511.2  Rt 1.79 min  T 304

460.53  [M + 1] 461.0  Rt 1.78 min  Y 305

469.518 [M + 1] 470.0  Rt 1.72 min  W 306

433.504 [M + 1] 434.2  Rt 1.60 min  V 307

447.491 [M + 1] 447.9  Rt 1.79 min  Y 308

500.475 [M + 1] 499.0  Rt 1.75 min  V 309

498.556 [M + 1] 499.2  Rt 1.83 min  W 310

414.811 [M + 1] 415.0  Rt 2.16 min  T 311

498.556 [M + 1] 499.2  Rt 1.87 min  W 312

498.556 [M + 1] 499.2  Rt 1.64 min  V 313

395.456 [M + 1] 396.2  Rt 1.43 min  T 314

536.528 [M + 1] 537.2  Rt 2.05 min  T 315

536.528 [M + 1] 537.2  Rt 2.05 min  T 316

484.53  [M + 1] 485.2  Rt 1.69 min  Y 317

419.499 [M + 1] 418.0  Rt 1.73 min  Y 318

501.582 [M + 1] 502.2  Rt 1.58 min  V 319

579.672 [M + 1] 580.2  Rt 1.87 min  W 320

601.697 [M + 1] 600.2  Rt 2.16 min  W 321

587.714 [M + 1] 588.2  Rt 1.865 min V 322

474.578 [M + 1] 475.2  Rt 1.84 min  W

Example 3234-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)thiazole-2-sulfonamide

Step 1. Preparation of ethyl 2-(benzylthio)thiazole-4-carboxylate

To a solution of ethyl 2-bromothiazole-4-carboxylate (2.0 g, 8.40 mmol)in DMF (15 mL) was added K₂CO₃ (1.16 g, 8.40 mmol) followed by benzylmercaptan (1.07 g, 8.40 mmol) in DMF (5 mL) over 20 min. Upon completionof addition, the reaction mixture was stirred at RT for 16 h. After thistime, the reaction mixture was diluted with water and extracted inEtOAc. The combined organic layers were dried over Na₂SO₄, filtered andconcentrated under reduced pressure. The resulting concentrate waspurified by silica gel chromatography (10% EtOAc in hexane) to provideethyl 2-(benzylthio)thiazole-4-carboxylate (2.0 g, 87% yield). ¹H NMR(400 MHz, DMSO-d₆) δ (ppm): 8.42 (s, 1H); 7.47-45 (m, 2H); 7.36-7.28 (m,3H); 4.52 (s, 2H); 4.31 (q, 2H, J=7.2 Hz); 1.31 (t, 3H, J=7.2 Hz).

Step 2. Preparation of ethyl2-(N-tert-butylsulfamoyl)thiazole-4-carboxylate

A solution of ethyl 2-(benzylthio)thiazole-4-carboxylate (2.0 g, 7.10mmol) in CCl₄/H₂O (100/10 mL) was cooled to 0-5° C. Chlorine gas wasbubbled through the solution for 30 min. After this time, the excesschlorine gas was evaporated by flushing with a stream of nitrogen. Thereaction mixture was then diluted with dichloromethane and washed withbrine. The combined organic layers were dried over Na₂SO₄, filtered andconcentrated to yield the crude sulfonyl chloride. The crude sulfonylchloride was dissolved in THF (50 mL) followed by the addition oftert-butyl amine (10 mL) in sealed tube. The contents of the tube wereheated to 60° C. for 16 h. At the conclusion of this period, thevolatiles were evaporated. The resulting residue was washed with waterand extracted into EtOAc. The combined organic layers were dried overNa₂SO₄, filtered and concentrated to provide ethyl2-(N-tert-butylsulfamoyl)thiazole-4-carboxylate (1.8 g, 90% yield) asoff white solid. ¹H NMR (400 MHz, DMSO-d₆) δ (ppm): 8.78 (s, 1H); 8.0(br s, 1H); 4.34 (q, 2H, J=7.2 Hz); 1.31 (t, 3H, J=7.2 Hz); 1.18 (s,9H).

Step 3. Preparation of ethyl2-(N-tert-butylsulfamoyl)thiazole-4-carboxylate

To a solution of ethyl 2-(N-tert-butylsulfamoyl)thiazole-4-carboxylate(1.8 g, 6.1 mmol) in 50 mL THF-EtOH (1:1) was added LiOH (0.07 g, 18.3mmol). The resulting mixture was stirred for 4 h. After this time, thereaction mixture was neutralized with HCl (1.0 M, aq), diluted withwater and then extracted into EtOAc. The combined organic layers weredried over Na₂SO₄, filtered and concentrated to provide ethyl2-(N-tert-butylsulfamoyl)thiazole-4-carboxylate (1.6 g, 99% yield) as awhite solid. LCMS Method V: retention time 0.93 min; [M+1]=263.0.

Step 4. Preparation of2-(N-tert-butylsulfamoyl)-N-(2-carbamoylbiphenyl-3-yl)thiazole-4-carboxamide

To a solution of 2-(N-tert-butylsulfamoyl)thiazole-4-carboxylic acid(0.56 g, 2.1 mmol) in DCM (50 mL) was added HATU (1.41 g, 2.8 mmol) andDIPEA (1.04 ml, 5.6 mmol). The reaction mixture was stirred at roomtemperature for 1 h and then 3-aminobiphenyl-2-carboxamide (from example218, 0.3 g, 1.4 mmol) was added. The resulting solution was stirred foran additional 16 h. After this time, the reaction mixture was washedwith water, dried, filtered and concentrated under reduced pressure toyield a residue. The residue was purified by silica gel chromatography(30% EtOAc in hexane) to provide2-(N-tert-butylsulfamoyl)-N-(2-carbamoylbiphenyl-3-yl)thiazole-4-carboxamide(0.1 g, 17% yield) as white solid. LCMS Method V: retention time 1.85min; [M+1]=459.2.

Step 5. Preparation of(N-tert-butyl-4-(4-hydroxy-5-phenylquinazolin-2-yl)thiazole-2-sulfonamide

To a solution2-(N-tert-butylsulfamoyl)-N-(2-carbamoylbiphenyl-3-yl)thiazole-4-carboxamide(0.11 g, 0.24 mmol) in methanol (10 mL) was added NaOMe (0.25 ml, 25% inMeOH, 1.2 mmol). The resulting mixture was stirred at RT for 16 h. Afterthis time, the reaction mixture was concentrated, diluted with ethylacetate and washed with water. The combined organic layers were driedover Na₂SO₄, filtered and concentrated under reduced pressure. Theresulting residue was purified by silica gel chromatography (40% EtOAcin hexane) to provide(N-tert-butyl-4-(4-hydroxy-5-phenylquinazolin-2-yl)thiazole-2-sulfonamide(0.10 g, 100% yield) as a white solid. LCMS Method V: retention time2.01 min; [M+1]=441.2.

Step 6. Preparation of5-phenyl-N-(pyridin-2-ylmethyl)-2-(2,2,5-trimethyl-1,3-dioxan-5-yl)quinazolin-4-amine

To a solution of5-phenyl-2-(2,2,5-trimethyl-1,3-dioxan-5-yl)quinazolin-4(3H)-one (0.22g, 0.62 mmol) in MeCN (10 mL) at room temperature was added DBU (0.24 g,1.57 mmol) and BOP reagent (0.36 g, 0.81 mmol). Upon completion ofaddition, the reaction mixture was stirred for 30 min.Aminomethylpyridine (0.11 ml, 1.13 mmol) was added and the resultingmixture was stirred for an additional 16 h. After this time, thereaction mixture was concentrated and purified by silica gel columnchromatography (2% MeOH in DCM) to provide5-phenyl-N-(pyridin-2-ylmethyl)-2-(2,2,5-trimethyl-1,3-dioxan-5-yl)quinazolin-4-amine(0.18 g, 68% yield) as a white solid. LCMS Method V: retention time 2.21min, [M+1]=531.2.

Step 7. Example 323

A solution ofN-tert-butyl-4-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)thiazole-2-sulfonamide(0.05 g 0.10 mmol) in TFA (10 mL) was heated at 50° C. for 8 h. Afterthis time, the TFA was evaporated off under reduced pressure to yield aresidue. The residue was made basic by the addition of 10% sodiumbicarbonate solution and then extracted into DCM. The combined organiclayers were dried over Na₂SO₄, filtered and concentrated under reducedpressure. The resulting residue was purified by recrystallization usingDCM/hexane to provide Example 323 (30 mg, 78% yield) as a brownishyellow solid. ¹H NMR (400 MHz, DMSO-d₆, δ): 8.80 (s, 1H); 8.25 (s, 1H);8.19 (br s, 1H); 7.90-7.80 (m, 2h); 7.65 (dt, 1H, J=1.6, 6.8 Hz);7.60-7.48 (m, 5H); 7.32-7.20 (m, 3H); 6.78 (t, 1H, J=4 Hz); 4.71 (d, 2H,J=4 Hz). LCMS Method R: retention time 1.65 min, [M+1]=472.8; HPLCMethod A1: purity 95.8%, retention time=12.5 min.

Example 3245-(5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)thiazole-2-sulfonamide

Step 1. Preparation of 2-(benzylthio)-5-bromothiazole

To a solution of 2,5-dibromothiazole (2.0 g, 8.23 mmol) in DMF (15 mL)was added K₂CO₃ (1.16 g, 8.40 mmol) followed by benzyl mercaptan (1.07g, 8.40 mmol) in DMF (10 mL) over a period of 20 min. The reactionmixture was stirred at RT for over night. After this time, the reactionmixture was diluted with water and extracted in EtOAc. The combinedorganic layers were dried over Na₂SO₄, filtered and concentrated underreduced pressure. The resulting crude product was purified by silica gelchromatography (0.2% EtOAc in hexane) to yield2-(benzylthio)-5-bromothiazole (2.3 g, 97.5% yield) as a brown solid. ¹HNMR (400 MHz, DMSO-d₆, δ): 7.56 (s, 1H); 7.25-7.36 (m, 5H); 4.39 (s,2H). ¹H LCMS Method V: Retention time 2.319 min, [M+1]=286.

Step 2. Preparation of 5-bromo-N-tert-butylthiazole-2-sulfonamide

A solution of 2-(benzylthio)-5-bromothiazole (2.3 g 8.00 mmol) wasdissolved in CCl₄/H₂O (100/10 mL) and then cooled to 0-5° C. Chlorinegas was bubbled through the reaction mixture for 30 min. After thistime, the excess chlorine gas was evaporated by flushing the reactionmixture with a stream of nitrogen. The reaction mixture was diluted withdichloromethane and washed with brine. The combined organic layers weredried over Na₂SO₄, filtered and concentrated to provide the crudesulfonyl chloride. The crude sulfonyl chloride was dissolved in THF (50mL) and then tert-butyl amine (10 mL) was added in sealed tube. Thecontents of the tube were heated to 60° C. for 16 h. After this time,the volatiles were evaporated and washed with water and extracted intoEtOAc. The combined organic layers were dried over Na₂SO₄, filtered andconcentrated. The resulting residue was purified by silica gelchromatography (10% EtOAc/hexane) to provide5-bromo-N-tert-butylthiazole-2-sulfonamide (1.0 g, 41.5% yield) as awhite solid. NMR (400 MHz, DMSO-d₆, δ): 8.41 (s, 1H); 8.17 (s, 1H); 1.25(s, 9H). LCMS Method V: Retention time 1.861 min, [M−1]=297.

Step 3. Preparation ofN-tert-butyl-5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)thiazole-2-sulfonamide

To a stirring suspension of 5-bromo-N-tert-butylthiazole-2-sulfonamide(0.50 g, 1.67 mmol) in 1,4-dioxane (10 mL) was added lithium chloride(0.210 g, 5.03 mmol), followed by hexamethylditin (0.820 g, 2.50 mmol).After degassing with nitrogen, Pd(TPP)₄ (0.19 g, 0.16 mmol) was added.The resultant suspension was stirred for over night at RT.2-Chloro-5-phenyl-N-(pyridin-2-ylmethyl)quinazolin-4-amine (0.46 g, 1.33mmol) was dissolved in 1,4-dioxane (3 mL) and then added to the reactionmixture. Upon completion of addition, the reaction mixture was heated at90° C. for 24 h. After this time, the solvent was evaporated, water wasadded and the mixture was extracted with DCM. The combined organiclayers were dried over Na₂SO₄, filtered and concentrated. The resultingresidue was purified by recrystallization with ethyl acetate and furtherpurified by preparative HPLC (method H) to provideN-tert-butyl-5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)thiazole-2-sulfonamide(32 mg, 4.2%) as a yellow solid. LCMS Method V: Rt 2.47 min;[M+1]=531.2; HPLC Method A1: purity 97.3%, retention time=10.89 min.

Step 4. Example 324

A solution ofN-tert-butyl-5-(5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl)thiazole-2-sulfonamide(0.03 g 0.05 mmol) in TFA (5 ml) was heated at 80° C. for 8 h. Afterthis time, the TFA was evaporated. The reaction mixture was basifiedwith 10% sodium bicarbonate solution and then extracted in DCM. Thecombined organic layers were dried over Na₂SO₄, filtered andconcentrated to yield a residue. The residue was purified byrecrystallization with DCM/hexane to provide Example 324 (23 mg, 86%yield) as a brownish yellow solid. ¹H NMR (400 MHz, DMSO-d₆, δ): 8.68(s, 1H); 8.21 (s, 1H); 8.19 (br s, 1H); 7.83-7.80 (m, 2h); 7.62 (dt, 1H,J=1.6, 6.8 Hz); 7.61-7.49 (m, 5H); 7.32-7.28 (m, 2H); 7.23-7.20 (m, 1H);6.94 (t, 1H, J=4 Hz); 4.68 (d, 2H, J=4 Hz). LCMS Method T: Rt 1.63 min;[M+1]=475.0; HPLC Method A1: purity 99.0%, retention time=8.05 min.

It is noted that the proceeding examples, while illustrative of thepresent invention, are not in sequential order and some example numbersmay be missing.

Utility

In general, compounds of the present invention, such as particularcompounds disclosed in the preceding examples, have been shown toinhibit the K_(v)1 subfamily of voltage-gated K+ channels (for example,by displaying % inhibition values ≧29%, preferably ≧30%, more preferably≧40%, even more preferably ≧50%, at 0.3 micromolar concentration in anassay such as those set forth below). By displaying activity asinhibitors of the K_(v)1 subfamily of voltage-gated K+ channels,compounds of the present invention are expected to be useful in thetreatment of human diseases associated with the K_(v)1 subfamily ofvoltage-gated K+ channels.

Assays to determine the degree of activity of a compound as an I_(Kur)inhibitor are well known in the art and are described in references suchas J. Gen. Physiol., 101(4):513-543 (April 1993), and Br. J. Pharmacol.,115(2):267-274 (May 1995).

Assays to determine the degree of activity of a compound as an inhibitorof other members of the K_(v)1 subfamily are also well known in the art.For example, inhibition of K_(v)1.1, K_(v)1.2 and K_(v)1.3 can bemeasured using procedures described by Grissmer, S. et al., Mol.Pharmacol., 45(6):1227-1234 (June 1994); inhibition of K_(v)1.4 can bemeasured using procedures described by Petersen, K. R. et al., PflugersArch., 437(3):381-392 (February 1999); inhibition of K_(v)1.6 can bemeasured using procedures described by Bowlby, M. R. et al., J.Neurophysiol. 73(6):2221-2229 (June 1995); and inhibition of K_(v)1.7can be measured using procedures described by Kalman, K. et al., J.Biol. Chem., 273(10):5851-5857 (Mar. 6, 1998).

Compounds of the present invention were tested in one of the assaysdescribed immediately above and the results shown in Table 2 below wereobtained.

TABLE 2 Kv 1.5 Example (% inhibition at 0.3 uM) 7 95.7 22 60.4 29 65.331 98.2 32 53.1 38 61.3 40 59.8 42 96.4 46 98.7 50 96.1 97 98.7 105 98.7107 50.3 108 98.1 110 51.8 111 61.5 130 96.2 134 98.4 137 55.6

Find below in Table 3 data for disclosed compounds (See U.S. Pat. No.7,713,983). It is believed that this data demonstrates the unexpectedability of the compounds of the present invention to significantlyincrease the inhibition of the K_(v)1 subfamily of voltage-gated K+channels.

TABLE 3 Kv 1.5 Compound (% inhibition at 0.3 uM) Replicates Example 57820.5 ± 2.3  2 U.S. Pat. No. 7,713,983 Example 580 5.3 ± 5.1 2 U.S. Pat.No. 7,713,983 Example 68 8.5 ± 6.9 2 U.S. Pat. No. 7,713,983 Example 825.6 ± 3.8 2 U.S. Pat. No. 7,713,983

In addition, compounds of the present invention, such as particularcompounds disclosed in the preceding examples, were evaluated for theireffectiveness as inhibitors of kinase receptor activity. The compoundswere tested in the assay(s) set forth below for inhibition of kinaseactivity and results are shown in Table 4. Based on the results, it isbelieved that the compounds of the present invention, such as particularcompounds disclosed in the preceding examples, are not effective ininhibiting kinase receptor activity and therefore would not be effectiveas inhibitors or modulators of kinase receptor activity.

Caliper Kinase Assay

The analyses were performed in U-bottom 384-well plates. The final assayvolume was 30 μl prepared from 15 μl additions of enzyme and substrates(fluoresceinated peptide and ATP) and test compounds in assay buffer (20mM HEPES pH 7.4, 10 mM MgCl₂, 0.015% Brij35 and 4 mM DTT). The reactionwas initiated by the combination of purified protein kinase withsubstrates and test compounds. The reaction was incubated at roomtemperature for 60 min. and terminated by adding 30 μl of 35 mM EDTA toeach sample. The reaction mixture was analyzed on the Caliper LABCHIP®3000 (Caliper, Hopkinton, Mass.) by electrophoretic separation of thefluorescent substrate and phosphorylated product. Inhibition data werecalculated by comparison to no enzyme control reactions for 100%inhibition and vehicle-only reactions for 0% inhibition. The ATP wasused at a final concentration equivalent to the Km and the peptidesubstrate concentration was 1.5 μM. Dose response curves were generatedto determine the concentration required to inhibit 50% of kinaseactivity (IC₅₀). Compounds were dissolved at 10 mM in dimethylsulfoxide(DMSO) and evaluated at eleven concentrations. IC₅₀ values were derivedby non-linear regression analysis.

TABLE 4 LLE LLE LLE LLE Flt3 GSK3B IGF1R IKKE LLE IRAK-4 LLE IRAK1 LLEmAurA LLE PIM1 LLE_ABL1 LLE_AURORA-B (IC50, (IC50, (IC50, (IC50, (IC50,(IC50, (IC50, (IC50, (% INH, (IC50, Example uM) uM) uM) uM) uM) uM) uM)uM) 50 uM) uM) 1 — 50.00 — 50.00 50.00 50.00 — — — 50.00 7 — 50.00 — —50.00 — — — — — 19 10.11 5.15 17.58 50.00 18.69 — 39.84 33.81 32.37 —LLE_(—) LLE_(—) LLE_(—) LLE_(—) LLE_(—) LLE_(—) LLE_(—) LLE_(—) LLE_(—)LLE_(—) BMX BTK CDK2E CDK5 CDK5/p25 CK1A1 CK2A1 CK2A2 IGF1R IRAK1 (IC50,(IC50, (IC50, (IC50, (IC50, (IC50, (IC50, (IC50, (IC50, (IC50, ExampleuM) uM) uM) uM) uM) uM) uM) uM) uM) uM) 1 50.00 50.00 50.00 — — — — — —50.00 7 50.00 50.00 50.00 — — — — 50.00 — — 19 — 19.17 50.00 50.00 50.0050.00 50.00 25.52 17.58 — LLE_(—) LLE_(—) LLE_(—) LLE_(—) LLE_(—)LLE_(—) LLE_(—) LLE_(—) LLE_(—) LLE_(—) ITK JAK1 JAK2 JAK3 Lck LYNAmAurA PIM1 PLK1 SRC (IC50, (IC50, (IC50, (IC50, (IC50, (IC50, (IC50,(IC50, (IC50, (IC50, Example uM) uM) uM) uM) uM) uM) uM) uM) uM) nM) 150.00 — 23.87 50.00 50.00 50.00 — — — — 7 50.00 — 50.00 50.00 50.0050.00 — — — — 19 — 50.00 17.79 23.84 — — 39.84 33.81 50.00 50.00LLE_TAK1 LLE_TBK1 LLE_TEC LLE_TPL2 CAL LLE_TXK LLE_TYK2_887 (IC50,(IC50, (IC50, (IC50, (IC50, (IC50, Example uM) uM) uM) uM) uM) uM) 150.00 50.00 50.00 — 50.00 50.00 7 — — 50.00 — — 50.00 19 — — — 11.90 —50.00

In view of the foregoing, it is believed that compounds of the presentinvention show unexpected advantages over compounds previously disclosedin the art. It is believed that compounds of the present inventiondemonstrate a desirable combination of K_(v)1 subfamily inhibitoryactivity and minimal potency against kinases or Na+ ion channel. Inaddition, it is believed that Example 7 demonstrates a desirablecombination of K_(v)1 subfamily inhibitory activity and pharmacologicalcharacteristics including a surprisingly low degree of brain penetrationacross species in combination with indications of high efficacy andimproved safety criteria, for example, improved ion channel selectivityas measured by hERG and Na+ ion channel studies.

Compounds within the scope of the present invention inhibit the K_(v)1subfamily of voltage-gated K+ channels, and as such are believed to beuseful in the treatment and/or prevention of various disorders: cardiacarrhythmias, including supraventricular arrhythmias, atrial arrhythmias,atrial flutter, atrial fibrillation, complications of cardiac ischemia,and use as heart rate control agents; angina pectoris including reliefof Prinzmetal's symptoms, vasospastic symptoms and variant symptoms;gastrointestinal disorders including reflux esauphagitis, functionaldispepsia, motility disorders (including constipation and diarrhea), andirritable bowel syndrome; disorders of vascular and visceral smoothmuscle including asthma, chronic obstructive pulmonary disease, adultrespiratory distress syndrome, peripheral vascular disease (includingintermittent claudication), venous insufficiency, impotence, cerebraland coronary spasm and Raynaud's disease; inflammatory and immunologicaldisease including inflammatory bowel disease, rheumatoid arthritis,graft rejection, asthma. chronic obstructive pulmonary disease, cysticfibrosis and atherosclerosis; cell proliferative disorders includingrestenosis and cancer (including leukemia); disorders of the auditorysystem; disorders of the visual system including macular degenerationand cataracts; diabetes including diabetic retinopathy, diabeticnephropathy and diabetic neuropathy; muscle disease including myotoniaand wasting; peripheral neuropathy; cognitive disorders; migraine;memory loss including Alzheimer's and dementia; CNS mediated motordysfunction including Parkinson's disease, and ataxia; epilepsy; andother ion channel mediated disorders.

As inhibitors of the K_(v)1 subfamily of voltage-gated K+ channelscompounds of the present invention are believed to be useful to treat avariety of further disorders including resistance by transplantation oforgans or tissue, graft-versus-host diseases brought about by medullaossium transplantation, rheumatoid arthritis, systemic lupuserythematosus, Hashimoto's thyroiditis, multiple sclerosis, myastheniagravis, type I diabetes uveitis, juvenile-onset or recent-onset diabetesmellitus, posterior uveitis, allergic encephalomyelitis,glomerulonephritis, infectious diseases caused bypathogenicmicroorganisms, inflammatory and hyperproliferative skindiseases, psoriasis, atopical dermatitis, contact dermatitis, eczematousdermatitises, seborrhoeis dermatitis, Lichen planus, Pemphigus, bullouspemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides,erythemas, cutaneous eosinophilias, Lupus erythematosus, acne, Alopeciaareata, keratoconjunctivitis, vernal conjunctivitis, uveitis associatedwith Behcet's disease, keratitis, herpetic keratitis, conical cornea,dystrophia epithelialis comeae, comeal leukoma, ocular pemphigus,Mooren's ulcer Scleritis, Graves' opthalmopathy, Vogt-Koyanagi-Haradasyndrome, sarcoidosis, pollen allergies, reversible obstructive airwaydisease, bronchial asthma, allergic asthma, intrinsic asthma, extrinsicasthma, dust asthma, chronic or inveterate asthma, late asthma andairway hyper-responsiveness, bronchitis, gastric ulcers, vascular damagecaused by ischemic diseases and thrombosis, ischemic bowel diseases,inflammatory bowel diseases, necrotizing enterocolitis, intestinallesions associated with thermal burns and leukotriene B4-mediateddiseases, Coeliaz diseases, proctitis, eosinophilic gastroenteritis,mastocytosis, Crohn's disease, ulcerative colitis, migraine, rhinitis,eczema, interstitial nephritis, Good-pasture's syndrome,hemolytic-uremic syndrome, diabetic nephropathy, multiple myositis,Guillain-Barre syndrome, Meniere's disease, polyneuritis, multipleneuritis, mononeuritis, radiculopathy, hyperthroidism, Basedow'sdisease, pure red cell aplasia, aplastic anemia, hypoplastic anemia,idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia,agranulocytosis, pernicious anemia, megaloblastic anemia,anerythroplasia, osteoporosis, sarcoidosis, fibroid lung, idiopathicinterstitial pneumonia, dermatomyositis, leukoderma vulgaris, ichthyosisvulgaris, photoallergic sensitivity, cutaneous T cell lymphoma,arteriosclerosis, atherosclerosis, aortitis syndrome, polyarteritisnodosa, myocardosis, scleroderma, Wegener's granuloma, Sjögren'ssyndrome, adiposis, eosinophilic fascitis, lesions of gingiva,periodontium, alveolar bone, substantia osses dentis,glomerulonephritis, male pattern alopecia or alopecia senilis bypreventing epilation or providing hair germination and/or promoting hairgeneration and hair growth, muscular dystrophy; Pyoderma and Sezary'ssyndrome, Addison's disease, ischemia-reperfusion injury of organs whichoccurs upon preservation, transplantation or ischemic disease,endotoxin-shock, pseudomembranous colitis, colitis caused by drug orradiation, ischemic acute renal insufficiency, chronic renalinsufficiency, toxinosis caused by lung-oxygen or drugs, lung cancer,pulmonary emphysema, cataracta, siderosis, retinitis, pigentosa, senilemacular degeneration, vitreal scarring, corneal alkali burn, dermatitiserythema multiforme, linear IgA ballous dermatitis and cementdermatitis, gingivitis, periodontitis, sepsis, pancreatitis, diseasescaused by environmental pollution, aging, carcinogenis, metastatis ofcarcinoma and hypobaropathy, disease caused by histamine orleukotriene-C4 release, Behcet's disease, autoimmune hepatitis, primarybiliary cirrhosis sclerosing cholangitis, partial liver resection, acuteliver necrosis, necrosis caused by toxin, viral hepatitis, shock, oranoxia, B-virus hepatitis, non-A/non-B hepatitis, cirrhosis, alcoholiccirrhosis, hepatic failure, fulminant hepatic failure, late-onsethepatic failure, “acute-on-chronic” liver failure, augention ofchemotherapeutic effect, cytomegalovirus infection, HCMV infection,AIDS, cancer, senile dementia, trauma, and chronic bacterial infection.

The compounds of the present invention are suspected antiarrhythmicagents which are useful in the prevention and treatment (includingpartial alleviation or cure) of arrhythmias. As inhibitors of K_(v)1.5,compounds within the scope of the present invention are particularlyuseful in the selective prevention and treatment of supraventriculararrhythmias such as atrial fibrillation, and atrial flutter. By“selective prevention and treatment of supraventricular arrhythmias” ismeant the prevention or treatment of supraventricular arrhythmiaswherein the ratio of the prolongation of the atrial effective refractoryperiod to the prolongation of the ventricular effective refractoryperiod is greater than 1:1. This ratio can also be greater than 4:1,even greater than 10:1. In addition, the ratio may be such thatprolongation of the atrial effective refractory response period isachieved without significantly detectable prolongation of theventricular effective refractory period.

In addition, the compounds within the scope of the present inventionblock I_(Kur), and thus may be useful in the prevention and treatment ofall I_(Kur)-associated conditions. An “I_(Kur)-associated condition” isa disorder which may be prevented, partially alleviated or cured by theadministration of an I_(Kur) blocker. The K_(v)1.5 gene is known to beexpressed in stomach tissue, intestinal/colon tissue, the pulmonaryartery, and pancreatic beta cells. Thus, administration of an I_(Kur)blocker can provide useful treatment for disorders such as: refluxesauphagitis, functional dispepsia, constipation, asthma, and diabetes.Additionally, K_(v)1.5 is known to be expressed in the anteriorpituitary. Thus, administration of an I_(Kur) blocker can stimulategrowth hormone secretion. I_(Kur) inhibitors can additionally be usefulin cell proliferative disorders such as leukemia, and autoimmunediseases such as rheumatoid arthritis and transplant rejection.

The present invention thus provides methods for the prevention ortreatment of one or more of the aforementioned disorders, comprising thestep of administering to a subject in need thereof an effective amountof at least one compound of the formula I, Ia, Ib, and/or Ic, preferablycompounds exemplified in the examples, more preferably, Examples 7, 22,29, 31, 32, 38, 40, 42, 46, 50, 97, 105, 107, 108, 110, 111, 130, 134and 137, even more preferably, Examples 7, 32, and 101, still even morepreferably, Examples 7 and 101. Other therapeutic agents such as thosedescribed below may be employed with the inventive compounds in thepresent methods. In the methods of the present invention, such othertherapeutic agent(s) may be administered prior to, simultaneously withor following the administration of the compound(s) of the presentinvention.

Dosage and Formulation

The present invention also provides pharmaceutical compositionscomprising at least one of the compounds of the formula I, Ia, Ib,and/or Ic, preferably compounds exemplified in the examples, morepreferably, Examples 7, 22, 29, 31, 32, 38, 40, 42, 46, 50, 97, 105,107, 108, 110, 111, 130, 134 and 137, even more preferably, Examples 7,32, and 101, still even more preferably, Examples 7 and 101, or saltsthereof capable of preventing or treating one or more of theaforementioned disorders in an amount effective therefor, and apharmaceutically acceptable vehicle or diluent. The compositions of thepresent invention may contain other therapeutic agents as describedbelow, and may be formulated, for example, by employing conventionalsolid or liquid vehicles or diluents, as well as pharmaceuticaladditives of a type appropriate to the mode of desired administration(for example, excipients, binders, preservatives, stabilizers, flavors,etc.) according to techniques such as those well known in the art ofpharmaceutical formulation.

The compounds of the formula I, Ia, Ib, and/or Ic, preferably compoundsexemplified in the examples, more preferably, Examples 7, 22, 29, 31,32, 38, 40, 42, 46, 50, 97, 105, 107, 108, 110, 111, 130, 134 and 137,even more preferably, Examples 7, 32, and 101, still even morepreferably, Examples 7 and 101, may be administered by any suitablemeans, for example, orally, such as in the form of tablets, capsules,granules or powders; sublingually; bucally; parenterally, such as bysubcutaneous, intravenous, intramuscular, or intrastemal injection orinfusion techniques (e.g., as sterile injectable aqueous or non aqueoussolutions or suspensions); nasally such as by inhalation spray;topically, such as in the form of a cream or ointment; or rectally suchas in the form of suppositories; in dosage unit formulations containingnon toxic, pharmaceutically acceptable vehicles or diluents. The presentcompounds may, for example, be administered in a form suitable forimmediate release or extended release. Immediate release or extendedrelease may be achieved by the use of suitable pharmaceuticalcompositions comprising the present compounds, or, particularly in thecase of extended release, by the use of devices such as subcutaneousimplants or osmotic pumps. In the case where the compounds of formula I,Ia, Ib, and/or Ic, preferably compounds exemplified in the examples,more preferably, Examples 7, 22, 29, 31, 32, 38, 40, 42, 46, 50, 97,105, 107, 108, 110, 111, 130, 134 and 137, even more preferably,Examples 7, 32, and 101, still even more preferably, Examples 7 and 101,are being administered to prevent or treat arrhythmias, the compoundsmay be administered to achieve chemical conversion to normal sinusrhythm, or may optionally be used in conjunction with electricalcardioconversion.

Exemplary compositions for oral administration include suspensions whichmay contain, for example, microcrystalline cellulose for imparting bulk,alginic acid or sodium alginate as a suspending agent, methylcelluloseas a viscosity enhancer, and sweeteners or flavoring agents such asthose known in the art; and immediate release tablets which may contain,for example, microcrystalline cellulose, dicalcium phosphate, starch,magnesium stearate and/or lactose and/or other excipients, binders,extenders, disintegrants, diluents and lubricants such as those known inthe art. The compounds of formula I, Ia, Ib, and/or Ic, preferablycompounds exemplified in the examples, more preferably, Examples 7, 22,29, 31, 32, 38, 40, 42, 46, 50, 97, 105, 107, 108, 110, 111, 130, 134and 137, even more preferably, Examples 7, 32, and 101, still even morepreferably, Examples 7 and 101, may also be delivered through the oralcavity by sublingual and/or buccal administration. Molded tablets,compressed tablets or freeze-dried tablets are exemplary forms which maybe used. Exemplary compositions include those formulating the presentcompound(s) with fast dissolving diluents such as mannitol, lactose,sucrose and/or cyclodextrins. Also included in such formulations may behigh molecular weight excipients such as celluloses (AVICEL®) orpolyethylene glycols (PEG). Such formulations may also include anexcipient to aid mucosal adhesion such as hydroxy propyl cellulose(HPC), hydroxy propyl methyl cellulose (HPMC), sodium carboxy methylcellulose (SCMC), maleic anhydride copolymer (e.g., Gantrez), and agentsto control release such as polyacrylic copolymer (e.g., Carbopol 934).Lubricants, glidants, flavors, coloring agents and stabilizers may alsobe added for ease of fabrication and use.

Exemplary compositions for nasal aerosol or inhalation administrationinclude solutions in saline which may contain, for example, benzylalcohol or other suitable preservatives, absorption promoters to enhancebioavailability, and/or other solubilizing or dispersing agents such asthose known in the art.

Exemplary compositions for parenteral administration include injectablesolutions or suspensions which may contain, for example, suitable nontoxic, parenterally acceptable diluents or solvents, such as mannitol,1,3 butanediol, water, Ringer's solution, an isotonic sodium chloridesolution, or other suitable dispersing or wetting and suspending agents,including synthetic mono- or diglycerides, and fatty acids, includingoleic acid.

Exemplary compositions for rectal administration include suppositorieswhich may contain, for example, a suitable non irritating excipient,such as cocoa butter, synthetic glyceride esters or polyethyleneglycols, which are solid at ordinary temperatures, but liquefy and/ordissolve in the rectal cavity to release the drug.

Exemplary compositions for topical administration include a topicalcarrier such as Plastibase (mineral oil gelled with polyethylene).

The effective amount of a compound of the present invention may bedetermined by one of ordinary skill in the art, and includes exemplarydosage amounts for an adult human of from about 0.001 to 100 mg/kg ofbody weight of active compound per day, which may be administered in asingle dose or in the form of individual divided doses, such as from 1to 4 times per day. It will be understood that the specific dose leveland frequency of dosage for any particular subject may be varied andwill depend upon a variety of factors including the activity of thespecific compound employed, the metabolic stability and length of actionof that compound, the species, age, body weight, general health, sex anddiet of the subject, the mode and time of administration, rate ofexcretion, drug combination, and severity of the particular condition.Preferred subjects for treatment include animals, most preferablymammalian species such as humans, and domestic animals such as dogs,cats and the like, subject to the aforementioned disorders.

The compounds of the present invention may be employed alone or incombination with each other and/or other suitable therapeutic agentsuseful in the treatment of the aforementioned disorders or otherdisorders, including: other antiarrhythmic agents such as Class I agents(e.g., propafenone), Class II agents (e.g., carvadiol and propranolol),Class III agents (e.g., sotalol, dofetilide, amiodarone, azimilide andibutilide), Class IV agents (e.g., diltiazem and verapamil), 5HTantagonists (e.g., sulamserod, serraline and tropsetron), anddronedarone; calcium channel blockers (both L-type and T-type) such asdiltiazem, verapamil, nifedipine, amlodipine and mybefradil;Cyclooxygenase inhibitors (i.e., COX-1 and/or COX-2 inhibitors) such asaspirin, indomethacin, ibuprofen, piroxicam, naproxen, CELEBREX®, VIOXX®and NSAIDs; anti-platelet agents such as GPIIb/IIIa blockers (e.g.,abciximab, eptifibatide and tirofiban), P2Y12 antagonists (e.g.,clopidogrel, cangrelor, ticlopidine and CS-747), P2Y1 antagonists,thromboxane receptor antagonists (e.g., ifetroban), aspirin, and PDE-IIIinhibitors (e.g., dipyridamole) with or without aspirin; diuretics suchas chlorothiazide, hydrochlorothiazide, flumethiazide,hydroflumethiazide, bendroflumethiazide, methylchlorothiazide,trichloromethiazide, polythiazide, benzthiazide, ethacrynic acidtricrynafen, chlorthalidone, furosemide, musolimine, bumetanide,triamtrenene, amiloride, and spironolactone; anti-hypertensive agentssuch as alpha adrenergic blockers, beta adrenergic blockers, calciumchannel blockers, diuretics, renin inhibitors, ACE inhibitors, (e.g.,captropril, zofenopril, fosinopril, enalapril, ceranopril, cilazopril,delapril, pentopril, quinapril, ramipril, lisinopril), A II antagonists(e.g., losartan, irbesartan, valsartan), ET antagonists (e.g.,sitaxsentan, atrsentan and compounds disclosed in U.S. Pat. Nos.5,612,359 and 6,043,265), Dual ET/AII antagonist (e.g., compoundsdisclosed in WO 00/01389), neutral endopeptidase (NEP) inhibitors,vasopepsidase inhibitors (dual NEP-ACE inhibitors) (e.g., omapatrilatand gemopatrilat), nitrates, and combinations of such anti-hypertensiveagents; antithrombotic/thrombolytic agents such as tissue plasminogenactivator (tPA), recombinant tPA, tenecteplase (TNK), lanoteplase (nPA),factor VIIa inhibitors, factor Xa inhibitors (such as razaxaban), XIainhibitors, thromin inhibitors (e.g., hirudin and argatroban), PAI-1inhibitors (i.e., inactivators of tissue plasminogen activatorinhibitors), α2-antiplasmin inhibitors, streptokinase, urokinase,prourokinase, anisoylated plasminogen streptokinase activator complex,and animal or salivary gland plasminogen activators; anticoagulants suchas warfarin and heparins (including unfractionated and low molecularweight heparins such as enoxaparin and dalteparin); HMG-CoA reductaseinhibitors such as pravastatin lovastatin, atorvastatin, simvastatin,NK-104 (a.k.a. itavastatin, or nisvastatin or nisbastatin) and ZD-4522(a.k.a. rosuvastatin, or atavastatin or visastatin); othercholesterol/lipid lowering agents such as squalene synthetaseinhibitors, fibrates, and bile acid sequestrants (e.g., QUESTRAN®);antipoliferative agents such as cyclosporin A, TAXOL®, FK 506, andadriamycin; antitumor agents such as TAXOL®, adriamycin, epothilones,cisplatin and carboplatin; anti-diabetic agents such as biguanides(e.g., metformin), glucosidase inhibitors (e.g., acarbose), insulins,meglitinides (e.g., repaglinide), sulfonylureas (e.g., glimepiride,glyburide and glipizide), biguanide/glyburide combinations (i.e.,GLUCOVANCE®), thiozolidinediones (e.g., troglitazone, rosiglitazone andpioglitazone), PPAR-gamma agonists, aP2 inhibitors, and DP4 inhibitors;thyroid mimetics (including thyroid receptor antagonists) (e.g.,thyrotropin, polythyroid, KB-130015, and dronedarone); Mineralocorticoidreceptor antagonists such as spironolactone and eplerinone; growthhormone secretagogues; anti-osteoporosis agents (e.g., alendronate andraloxifene); hormone replacement therapy agents such as estrogen(including conjugated estrogens in premarin), and estradiol;antidepressants such as nefazodone and sertraline; antianxiety agentssuch as diazepam, lorazepam, buspirone, and hydroxyzine pamoate; oralcontraceptives; anti-ulcer and gastroesophageal reflux disease agentssuch as famotidine, ranitidine, and omeprazole; anti-obesity agents suchas orlistat; cardiac glycosides including digitalis and ouabain;phosphodiesterase inhibitors including PDE III inhibitors (e.g.,cilostazol), and PDE V inhibitors (e.g., sildenafil); protein tyrosinekinase inhibitors; steroidal anti-inflammatory agents such asprednisone, and dexamethasone; and other anti-inflammatory agents suchas ENBREL®. The combinations can be co-formulated or in the form of kitspackaged to provide appropriate dosages for co-administration.

The above other therapeutic agents, when employed in combination withthe compounds of the present invention, may be used, for example, inthose amounts indicated in the Physicians' Desk Reference (PDR) or asotherwise determined by one of ordinary skill in the art.

Publications and references, including but not limited to patents andpatent applications, cited in this specification are herein incorporatedby reference in their entirety in the entire portion cited as if eachindividual publication or reference were specifically and individuallyindicated to be incorporated by reference herein as being fully setforth. Any patent application to which this application claims priorityis also incorporated by reference herein in the manner described abovefor publications and references.

While this invention has been described with an emphasis upon particularembodiments, it will be obvious to those of ordinary skill in the artthat variations in the particular compounds and methods may be used andthat it is intended that the invention may be practiced otherwise thanas specifically described herein. Accordingly, this invention includesall modifications encompassed within the spirit and scope of theinvention as defined by the claims that follow.

What is claimed is:
 1. A compound, wherein the compound is

or salt thereof.
 2. A pharmaceutical composition comprising atherapeutically effective amount of the compound of claim 1 or saltthereof.
 3. The pharmaceutical composition of claim 2, furthercomprising at least one other therapeutic agent, wherein the othertherapeutic agent is selected from anti-arrhythmic agents, calciumchannel blockers, anti-platelet agents, anti-hypertensive agents, antithrombotic/anti thrombolytic agents, anti-coagulants, HMG-CoA reductaseinhibitors, anti diabetic agents, thyroid mimetics, mineralocorticoidreceptor antagonists, and cardiac glycosides.
 4. A method of treatingarrhythmia comprising administering to a patient in need thereof aneffective amount of the compound of claim
 1. 5. A method of controllingheart rate comprising administering to a patient in need thereof aneffective amount of the compound of claim
 1. 6. A compound, wherein thecompound is

or salt thereof.
 7. A pharmaceutical composition comprising atherapeutically effective amount of the compound of claim 6 or saltthereof.
 8. The pharmaceutical composition of claim 7, furthercomprising at least one other therapeutic agent, wherein the othertherapeutic agent is selected from anti-arrhythmic agents, calciumchannel blockers, anti-platelet agents, anti-hypertensive agents, antithrombotic/anti thrombolytic agents, anti-coagulants, HMG-CoA reductaseinhibitors, anti diabetic agents, thyroid mimetics, mineralocorticoidreceptor antagonists, and cardiac glycosides.
 9. A method of treatingarrhythmia comprising administering to a patient in need thereof aneffective amount of the compound of claim
 6. 10. A method of controllingheart rate comprising administering to a patient in need thereof aneffective amount of the compound of claim
 6. 11. A compound, wherein thecompound is

or salt thereof.
 12. A pharmaceutical composition comprising atherapeutically effective amount of the compound of claim 11 or saltthereof.
 13. The pharmaceutical composition of claim 12, furthercomprising at least one other therapeutic agent, wherein the othertherapeutic agent is selected from anti-arrhythmic agents, calciumchannel blockers, anti-platelet agents, anti-hypertensive agents, antithrombotic/anti thrombolytic agents, anti-coagulants, HMG-CoA reductaseinhibitors, anti diabetic agents, thyroid mimetics, mineralocorticoidreceptor antagonists, and cardiac glycosides.
 14. A method of treatingarrhythmia comprising administering to a patient in need thereof aneffective amount of the compound of claim
 11. 15. A method ofcontrolling heart rate comprising administering to a patient in needthereof an effective amount of the compound of claim 11.